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agents for HIV-associated invasive fungal infections. 
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Fungal infections cause an estimated 13 million life-threatening infections and 1.6 
million deaths annually.  The burden of invasive fungal infections (IFIs) reflects 
immunocompromise resulting from the rise in HIV/AIDS and iatrogenic 
immunosuppressive therapy.  Cryptococcal meningoencephalitis and disseminated 
talaromycosis are archetypal conditions to illustrate the unmet medical need of IFIs.  
The optimum treatment regimens for cryptococcal meningoencephalitis and 
disseminated talaromycosis are unclear.  As an alternative to serial clinical trials, PK-
PD approaches offer enhanced efficiency, reduced cost and reduced risk to patients.  
Asides from PK parameters, additional factors that may influence treatment 
response include the host response to infection. 
This thesis begins with an overview of the historical context of antifungal PK-PD, the 
wide-ranging factors that influence it and methods of measuring and modelling it.  
Following this, a population PK model of fluconazole in cryptococcal 
meningoencephalitis quantifies the variability of fluconazole penetration into 
cerebrospinal fluid (CSF) in 43 patients.  Simulations predict a low probability of PK-
PD target attainment at widely used dosages of fluconazole.  A meta-analysis of 
studies reporting clinical outcomes from fluconazole monotherapy demonstrates 
only minor improvements in PD and clinical outcomes with escalating dosage.  A 
second PK model describes the population PK of amphotericin B deoxycholate 
(DAmB) in 42 patients treated for cryptococcal meningoencephalitis.  Inter-patient 
variability in DAmB PK is modest and unlikely to account for variability in clinical 
outcome.  A meta-analysis of trials reporting clinical outcomes from DAmB 
monotherapy suggests that DAmB dosage explains most heterogeneity in CSF 
sterility, but not mortality outcomes.  A third population model assesses the PK of 
liposomal amphotericin B (LAmB) administered as a single high dose to 32 patients 
with cryptococcal meningoencephalitis within an ongoing clinical trial.  A bridging 
study is performed from murine data to predict PD outcome in humans following 
high dose LAmB regimens, using the posterior PK parameters derived from the 
population PK model.  This analysis supports the dose of LAmB being used in the 
trial. 
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Using data from 76 clinical trial patients, a population PK-PD model of itraconazole 
in disseminated talaromycosis is constructed.  While the model describes 
considerable variability in the PK of both itraconazole and its active metabolite, 
hydroxyitraconazole, a relationship between PK and PD cannot be demonstrated.  
This study suggests that the trial failed to demonstrate the non-inferiority of 
itraconazole versus DAmB due to a PK failure, the overwhelming majority of 
patients failing to mount adequate itraconazole exposure. 
Finally, an immunophenotyping study is presented, describing networks of immune 
biomarkers in the CSF of patients with cryptococcal meningoencephalitis.  
Phagosomal function in whole blood is measured.  Data are analysed from serial 
samples taken during the first 14 days of treatment.  A proinflammatory immune 
signature is associated with increased phagosomal activity in monocyte populations 
and may contribute to favourable PD and clinical outcomes in cryptococcal 
meningoencephalitis. 
In conclusion,  pharmacometric analysis has been a neglected area of research, 
particularly in mycology.  This work demonstrates that PK-PD tools can de-risk 
efforts to optimise antifungal treatment regimens, enhance the efficiency of those 






1.1 Antimicrobial pharmacokinetic and pharmacodynamic analyses are 
essential for the future of modern medicine 
1.1.1 A brief history of antimicrobial drug discovery 
The discovery of arsphenamine in 1909 and penicillin in 1928 marked the 
beginning of the antibiotic revolution, which transformed modern medicine and 
indeed society as a whole by contributing to huge gains in average life expectancy 
and encouraging medical, surgical, oncological and obstetric advances that would 
previously not have been imaginable.1,2  These discoveries heralded an era of 
intensive research into not only anti-bacterial compounds, but also those active 
against important viral and fungal pathogens – the so-called ‘golden age’ of 
antimicrobial discovery.3  In 1943, streptomycin was discovered from actinomycetes 
in soil, inspiring several pharmaceutical companies to concentrate efforts on 
screening soil samples for further antimicrobial compounds from the 1940s to the 
1960s.  This was highly successful, ultimately producing many of the antimicrobial 
drugs still in use today.3,4  When the yield of these phenotypic screening methods 
for natural products declined, medicinal chemistry and molecular genetics 
approaches were employed to enhance the utility of existing compounds.5  Later, 
more sophisticated high throughput screening methods were aimed at the 
discovery of novel synthetic antimicrobial compounds.3,5,6  Unfortunately, these 
were not nearly as productive as the early discovery approaches had been and 
widespread divestment in antimicrobial research followed.7,8 
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1.1.2 The critical importance of dose selection 
Interest in antimicrobial PK-PD arose soon after the discovery of 
antimicrobial drugs, with early observations that the efficacy of some antibiotics 
(e.g. penicillin) is determined by the duration of drug exposure, while for others 
(e.g. streptomycin), the rate of bactericidal activity depends on peak drug 
concentration.9,10  Summary PK measures such as the maximum drug concentration 
(Cmax), the area under the concentration-time curve (AUC) and the duration of drug 
exposure in a dosing interval can be expressed relative to the minimum inhibitory 
concentration (MIC) of the infecting organism.  These PK-PD indices – Cmax/MIC, 
AUC/MIC and T/MIC - have been determined using dose-fractionation studies for 
virtually every antimicrobial class in use today and related to their efficacy in-vitro 
or in animal models.  Moreover, the magnitude of PK-PD indices predictive of 
therapeutic efficacy in preclinical studies generally correlates well with the 
magnitude of PK-PD index required for efficacy in human therapy and thereby 
enables results to be bridged to humans.11,12  Only in the past two decades, 
however, has the inclusion of PK-PD analysis in drug development been formally 
endorsed by the US FDA13 and the EMA.14  Prior to this, many antimicrobial agents 
were developed and brought to market without detailed preclinical 
pharmacometric analyses.  For this reason, the recommended dosing regimen for 
many antimicrobial drugs is based on experience and habit rather than quantitative 
methods to optimise dosage or treatment schedule.11,15,16  This raises the risk of 
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supratherapeutic levels and potential toxicity, and/or subtherapeutic levels leading 
to low efficacy and encouraging the selection of resistant microbial strains.  
Indeed, simultaneous with the stalling of antimicrobial drug discovery has 
been the inexorable rise of antimicrobial resistance (AMR), which has reached 
critical levels worldwide.17-19  AMR threatens to undo progress made towards many 
of the Sustainable Development Goals and is on course to cause 10 million annual 
deaths worldwide by 2050.20  Low- and middle-income countries are forecast to be 
hardest hit and a reduction in annual global gross domestic product of 3.8% by 2050 
is predicted.21  A number of initiatives have been launched to search for and develop 
new antimicrobial agents22 and innovative commercial incentive schemes have 
arisen.23  While waiting for these strategies to bear fruit, it is clear that the current 
antimicrobial armamentarium must be preserved and utilised optimally.  Post 
marketing PK-PD analyses present a method for scientifically designing or re-
designing antimicrobial treatment regimens to select dosages that generate 
therapeutic drug levels and achieve optimal PD effect, whilst minimising the risk of 
toxicity and the selection of resistant organisms.24  In addition, PK-PD analyses are 
increasingly employed to refine dosing regimens for special populations including 
children,25,26 people with renal impairment27 and obese patients,28 and to assess the 




1.2 The optimised use of antifungal drugs is an area of urgent priority 
1.2.1 The global burden of invasive fungal infections 
Fungal infections cause enormous global morbidity and mortality, including 
an estimated 13 million life-threatening infections and 1.6 million deaths annually.29  
This is comparable to estimated annual deaths from tuberculosis30 and four-fold the 
number caused by malaria.31  Invasive fungal infections (IFIs) rarely occur in patients 
with intact immune systems, and the current burden of IFIs is largely reflective of 
immunocompromise resulting from the rise over recent decades in HIV/AIDS and 
iatrogenic immunosuppressive therapy.  Despite the burden of suffering they inflict, 
fungal infections have historically been neglected by the research and funding 
community compared with bacterial or viral infectious diseases.32,33  Between 2000 
and 2017, funding from public and philanthropic actors in the G20 countries was 
US$ 1.7 billion for mycology – almost forty times less than funding for virology (US$ 
62.9 billion), sixteen times less than funding for bacteriology (US$ 27.3 billion) and 
seven times less than funding for parasitology (US$ 11.5 billion).34  The need for 
greater investment in the identification and management of IFIs is clear, and 
nowhere more so than in HIV-infected populations.35  Despite great progress having 
been made with antiretroviral coverage globally, this has been insufficient to reduce 
mortality from IFIs.36  While fewer patients are presenting to HIV services for the 
first time with advanced immunosuppression, this has been offset by increased 




1.2.2 Cryptococcal meningoencephalitis and talaromycosis 
Of the major HIV-associated mycoses, cryptococcal meningoencephalitis 
and disseminated talaromycosis are archetypal conditions to illustrate the unmet 
medical need of IFIs and they are the focus of this thesis.  Cryptococcal 
meningoencephalitis is a preventable and treatable infection that is nevertheless 
associated with devastating morbidity and mortality.  It is caused by the ubiquitous 
basidiomycete yeasts Cryptococcus neoformans and Cryptococcus gattii.37  Among 
PLHIV there are estimated to be 223,000 incident cases of cryptococcal 
meningoencephalitis per year, and 181,000 deaths.38  Cryptococcal 
meningoencephalitis is the most common fungal brain infection worldwide and the 
second most frequent cause of HIV-associated mortality after tuberculosis.38,39  The 
vast burden of disease resides in low- and middle-income countries (LMICs),38 
where mortality even with the best available antifungal treatment regimen and 
even in a clinical trial setting is 24% at ten weeks.40  In 2018 cryptococcal meningitis 
received just 0.2% (7.7 million USD) of available relevant research and development 
funding, compared with 17% (684.6 million USD) of funding directed towards R&D 
for tuberculosis and 16% (663.4 million USD) for malaria.41    
Talaromycosis is caused by the dimorphic fungus Talaromyces marneffei.  T. 
marneffei grows as a mould at 25 degrees Celcius and as a yeast at 37 degrees 
Celcius.42  It is endemic to tropical Southeast Asia and in particular Vietnam, 
Thailand, Laos, Cambodia, Myanmar, Southern China, Hong Kong, Taiwan and 
Northwestern India.43  In these regions, talaromycosis accounts for up to 15% of 
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AIDS-related hospital admissions.44,45   Mortality from treated disseminated 
infection with T. marneffei is as high as 30 – 40%.42,46,47  
Cryptococcal meningoencephalitis and talaromycosis share some sombre 




Both cryptococcal meningoencephalitis and disseminated talaromycosis are 
uniformly fatal without treatment.46,48 
Both cryptococcal meningoencephalitis and disseminated talaromycosis 
disproportionately affect patients in LMICs.38,42 
Incidence of both cryptococcal meningoencephalitis and disseminated 
talaromycosis has failed to decrease in PLHIV despite wider access to ART.36,47 
Limited treatment options exist for both cryptococcal meningoencephalitis 
and disseminated talaromycosis, particularly in LMICs.36,49 
The first line antifungal in both cases (amphotericin B deoxycholate) is 
associated with severe, life-threatening toxicity.50-56 
 
 
1.2.3 The antifungal armamentarium is sorely limited 
Clinical outcomes from IFIs are unacceptably poor and failure to achieve 50 
percent treatment success is common.35  Just four antifungal drug classes are 
currently licensed for the treatment of human mycoses.  The polyenes (such as 
amphotericin B deoxycholate (DAmB) and liposomal amphotericin B (LAmB)) 
disrupt fungal cell membrane integrity.  The pyrimidine analogue 5-flourocytosine 
(5-FC) was originally developed as an anti-cancer drug and acts by inhibiting DNA 
Box 1-1: Epidemiological similarities between cryptococcal meningoencephalitis 
and talaromycosis 
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synthesis.  Azole drugs (for example fluconazole, itraconazole and voriconazole) 
inhibit lanosterol 14-α-demethylase, thereby blocking the synthesis of ergosterol, a 
key component of the fungal cell wall.  Echinocandins inhibit (1-3)-β-D-glucan 
synthase, also interfering with cell wall formation.  Of note, Cryptococcus spp. are 
intrinsically resistant to echinocandins57-59 and T. marneffei displays limited 
sensitivity to this class of antifungals while in yeast form.60  Echinocandins are not 
recommended for either infection, so just three antifungal drug classes are available 
for their treatment. 
For cryptococcal meningoencephalitis, the reality in the majority of settings 
that bear the greatest burden of disease is that the only drug available for patients 
is fluconazole.  The reason that neither polyenes or flucytosine are routinely 
administered in LMICs is multifactorial and includes lack of access to those drugs, 
challenges in administration and managing drug-induced toxicity, and concerns 
related to drug-drug interactions.36,61  Fluconazole monotherapy is a wholly 
inadequate treatment strategy for cryptococcal meningoencephalitis, associated 
with between 40% and 70% mortality.62-65  Since fluconazole is fungistatic rather 
than fungicidal, patients who survive an episode of cryptococcal 
meningoencephalitis must continue taking this drug for at least 12 months or until 
immune reconstitution.52  Moreover, with current dosing strategies, fluconazole 
monotherapy promotes the expansion of azole-resistant subpopulations during 
treatment.66,67  Primary resistance to amphotericin B has not been reported and 
cases of secondary resistance are vanishingly rare.68-70  While primary resistance of 
 26 
Cryptococcus spp. to flucytosine is uncommon,71 the development of secondary 
resistance on treatment in up to 57% of cases precludes its use in monotherapy.72 
Novel treatment options for IFIs are urgently required.  The antifungal 
development pipeline has been characterised by slow progress for several decades.  
However, several novel agents are currently progressing through development 
(table 1.1).  Of particular note are: APX001 and APX2096, of the novel Gwt1 inhibitor 
class of antifungals that demonstrate synergy with fluconazole; VT-1129 and 
VT1598 (Mycovia), tetrazole agents that demonstrate enhanced selectivity for 
fungal over mammalian cytochrome P450 enzymes compared with conventional 
azoles; T-2307 (Appili Therapeutics), an allylamine that inhibits mitochondrial 
membrane potential; and MAT2203 (Matinas), an encochleated formulation of 
amphotericin B that can be administered orally.  A modified-release formulation of 
flucytosine is the subject of an ongoing project run by the Drugs for Neglected 
Diseases Initiative (DNDi).73 
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Table from 36   
CME: Cryptococcal meningoencephalitis; PK: pharmacokinetic; PD: pharmacodynamic; AmB: amphotericin B; BID: bis in die (twice per day); IV: intravenous; FDA: Food 
and Drug Administration. QIDP: Qualified Infectious Disease Product. 
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1.2.4 Antifungal pharmacokinetic-pharmacodynamic analysis is a neglected but 
vital field 
The volume and scope of progress in antifungal drug development is both 
welcome and long overdue.  It will likely be some years before this progress 
translates to expanded formularies available to treat IFIs in the clinical setting.  In 
the meantime, it is paramount that the antifungal drugs currently available are 
used optimally.  Despite over half a century of experience with both amphotericin 
B deoxycholate and flucytosine in the treatment of cryptococcal 
meningoencephalitis, the best regimen remains unclear.  Numerous clinical trials 
have been conducted to investigate different dosages and treatment strategies 
using the limited drugs available for both cryptococcal meningoencephalitis and 
talaromycosis.40,50,62,74-77  PK-PD analysis offers a more precise mechanism to 
understand the relationship between drug dosages, metabolism and antifungal 
effect.  This understanding can then be harnessed, and dosage regimens 
manipulated in hypothetical scenarios to explore the impact of such 
manipulations on PD outcome.  Compared with serial clinical trials, PK-PD 
approaches offer vastly enhanced efficiency, reduced cost and most importantly, 
reduced risk to patients. 
In summary, there is a pressing need to optimise the use of antifungal 
drugs through improved understanding of their PK-PD, for several reasons: 
1. Current treatment strategies for IFIs are inadequate, as evidenced by 
unacceptably poor clinical outcomes. 
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2. There is an exceptionally limited antifungal armamentarium available 
for the treatment of IFIs and those drugs that are available must be 
preserved through optimal use. 
3. The practice of conducting serial clinical trials to answer questions of 
dosage without PK-PD support is inefficient in terms of time and cost, 
and potentially risky for trial participants. 
 
1.3 Factors that influence antifungal pharmacokinetics  
The key to successful antimicrobial pharmacotherapy is the attainment of 
effective drug concentrations at the target site, which in turn is influenced by the 
pharmacological properties of the drug, the pathology inflicted by the disease 
itself, and the physiology of the patient concerned.  An understanding of these 
variables and their interrelatedness is central to designing treatment regimens 
that capitalise on the opportunity for therapeutic success.   
 
1.3.1 Pharmacological characteristics that influence treatment success 
Elucidation of the pharmacological properties of antifungal agents has 
historically been lacking, compromising the development of optimised antifungal 
treatment regimens.78  Several antifungal drugs exhibit nonlinear or highly 
variable PK to the extent that therapeutic drug monitoring (TDM) is indicated to 
avoid under- or over-dosing.79  In addition, PK profiles in the bloodstream may not 
reflect those at the site of infection.  This discordance in the shape of 
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concentration-time profiles between physiological compartments is termed 
hysteresis (see 80).  In human cryptococcal meningitis, plasma concentrations of 
fluconazole may be lower than, equivalent to or higher than those in the central 
nervous system (CNS) and this relationship can fluctuate during the course of 
treatment.81  In rodent models, liposomal amphotericin B,82,83 amphotericin B 
deoxycholate84 and caspofungin85 persist in tissues longer than their plasma levels 
would indicate, which provides a potential explanation for the persistence of 
antifungal activity despite negligible plasma levels.   
The physicochemical properties of a drug directly influence the attainment 
and maintenance of therapeutic concentrations at the site of infection.  These 
properties include the molecular weight of the compound, its lipophilicity, protein 
binding and affinity for relevant efflux pumps.  They are highly variable and are 
inconsistent between and within drug classes.  The physicochemical properties of 
antifungals that influence PK-PD are summarised, with reference to CNS 
penetration, in table 1.2.
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Correlation of measurable 
CNS concentration with 
biological activity 
References 
Fluconazole 309  2.17 0.5 10 No Good 80,86-90 
Itraconazole 705  6.99 4.9 98 Yes Poor 80,87-90 
Voriconazole 349  2.56 2.1 58 No Good/ variable 80,88-90 
Posaconazole 700  6.1 4.4 99 Yes Poor 80,88-90 
Isavuconazole 718  -3.33 3.6 99 No Good 80,88-92 
DAmB 924 <0.4 0.95 -2.8 >95 No Poor 80,88-90,93,94 
LAmB 924 0.05 - 0.08 0.95 -2.8 >95 Contentious Poor 80,88-90,94-96 
ABLC 924 1.6 – 11 0.95 -2.8 >95 No Poor 80,88-90,94 
ABCD 924 0.12 – 0.14 0.95 -2.8 >95 No Poor 80,88-90,94 
5FC 120  -0.89 -2.34 5 No Good 80,87-90 
Caspofungin 1093  -2.8 -3.88 98 No Good 80,88-90,97,98 
Micafungin 1140  -3.8 -1.62 98 No Good 80,88-90,97,98 
Anidulafungin 1291  0.21 -3.32 98 No Good 89,98,99 
Table adapted from 100
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1.3.2 Pathological determinants of drug concentrations at the site of infection 
The pathological changes induced by IFIs exhibit huge inter- and intra-
individual heterogeneity.  Aspergillus has a predilection to angioinvasion and 
causes infarction and haemorrhage as it spreads haematogenously, usually from 
the primary site of the lungs to the brain and less commonly to other organs 
including the skin, kidneys, heart and liver.101,102  The clinical manifestations of 
aspergillosis are related to underlying immune status and in particular 
neutropenia.101  Invasive candidiasis may spread haematogenously to cause 
endophthalmitis, endocarditis, osteomyelitis or a range of other deep organ 
infections.  Alternatively, Candida may be directly inoculated from a foreign 
device, for example to the peritoneum from a peritoneal dialysis catheter or 
following abdominal surgery.103   Pathogenic species of Cryptococcus are strongly 
neurotropic and tend to disseminate to the CNS from the primary infection site of 
the lungs (where infection may be asymptomatic).104-106  It is thought that 
talaromycosis is acquired through inhalation of environmental conidia, which then 
disseminate systemically through the reticuloendothelial system.42  The 
partitioning of antifungal agents from the bloodstream to these organ sites is 
highly variable and this augments the PK variability presented by plasma profiles 
alone.  Furthermore, at the sub-organ level, infected tissue compartments may be 
pharmacologically distinct.  In the example of cryptococcal meningoencephalitis, 
there are multiple sub-compartments within the CNS such as the meninges, the 
cerebrospinal fluid (CSF), the brain parenchyma and the ventricles.  Within the 
brain parenchyma itself, large cryptococcomas are common.104,107  Concentrations 
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of antifungal agents in CNS compartments may therefore differ markedly from one 
compartment to another, as well as from levels measured in plasma. 
Pathophysiological considerations are key to understanding whether a drug is 
likely to reach therapeutic levels at the site of infection.  
 
1.3.3 Attainment of target drug concentrations depends on the patient being 
treated 
 The impact of patient characteristics such as age, renal function, liver 
function, weight and body mass on PK has long been recognised.  Through its 
impact on the function of multiple organ systems, critical illness can cause 
profound alterations in drug exposure.  Since IFIs predominantly affect persons 
who are severely immunosuppressed, many of these patients are critically unwell 
- either with advanced HIV infection, following organ transplantation or as a 
consequence of immunosuppressive chemotherapy.  In addition, these patients 
are frequently subject to significant polypharmacy, raising the risk of drug-drug 
interactions.   The effect of critical illness on antifungal drug exposure has been 
described in multiple clinical studies encompassing all antifungal drug classes in 
clinical use.108-113  However, since physicochemical properties of antifungal agents 
are inconsistent within drug classes, the impact of critical illness on PK cannot be 
generalised at the class level.  Fluconazole AUC increases with deteriorating renal 
function in critical illness until renal replacement therapy is required, at which 
point the AUC is lower than that in patients with normal renal function.114  
Isavuconazole PK parameters, in contrast, are reported to be similar across 
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different patient populations regardless of disease or physiological status.115  
Micafungin AUC decreases by approximately 40% in patients admitted to intensive 
care facilities116 and in patients with HIV infection,117 compared with healthy 
volunteers.27  Anidulafungin AUC is 22% lower in critically ill patients118  than it is 
in healthy volunteers.27  Model-simulated AUC values for amphotericin B 
deoxycholate are comparable between healthy volunteers and patients living with 
advanced HIV.119,120  In general, PK variability increases in critically ill patients, 
whose physiology is hugely heterogeneous, adding further potential compromise 
to the efficacy of empiric dosing of antifungals in this patient group.121  This 
variability results from altered drug clearance mechanisms – critically ill patients 
may have increased or decreased renal clearance; they may undergo renal 
replacement therapy or extracorporeal membrane oxygenation – as well as 
changes in volume of distribution caused by shifts in fluid balance including those 
caused by fluid resuscitation and oedema.  In certain populations, food availability 
may be problematic, which can have a significant impact on antifungal 
bioavailability – for example in the case of voriconazole122 and itraconazole.123,124  
Clearly, PK parameters cannot be assumed to be equivalent between healthy 
volunteers and the majority of patients suffering IFIs; population-specific analyses 
are key to optimising therapy. 
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1.4 Non-pharmacological factors that influence antifungal 
pharmacodynamics 
The study of pharmacodynamics concerns the relationship between the 
concentration of a drug at its site of action, and its associated effect.  While 
infection site PK is influenced by the physicochemical, pathophysiological and 
patient factors outlined above, the attainment of specific antifungal drug 
concentrations at the site of infection does not necessarily result in a predictable 
PD response.  Asides from PK, PD is influenced by factors specific to both the host 
and the infecting pathogen itself. 
 
1.4.1 The host response to invasive fungal infection 
 Many IFIs – for example cryptococcosis, talaromycosis, aspergillosis and 
histoplasmosis – are primarily acquired through inhalation of environmental 
conidia.  In the setting of immune dysfunction and particularly defects in cell-
mediated immunity, such as those induced by advanced HIV or 
immunosuppressive therapy, inhalation of fungal spores results in disseminated 
disease with multi-organ involvement.104,125 
 
1.4.1.1 Macrophages can be instrumental in both clearance and propagation of 
infection 
The host immune response to pathogenic fungi is complex and requires 
coordination between multiple innate and adaptive immune mechanisms.126,127  In 
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the case of cryptococcal infection, inhaled cryptococcal spores are phagocytosed 
by alveolar macrophages, which present the first line of immune defence.128  After 
phagocytosis, macrophages undergo rapid maturation with acidification and 
lysosomal fusion.129-131  This triggers the release of proinflammatory cytokines and 
chemokines, regulates antigen presentation to T-cells, and promotes the 
recruitment of monocytes and neutrophils to the site of infection.132,133  The aim 
of this process is sterilization or containment of infection within a granuloma.126  
However, cryptococcal cells can survive and replicate within host macrophages 
owing to a combination of the antioxidant properties of the cryptococcal 
capsule,134 permeabilization of the phagolysosome,135 and cryptococcal 
degradation of urea to CO2 and ammonia to limit phagolysosomal 
acidification.136,137  Similarly, conidia of T. marneffei are phagocytosed by alveolar 
macrophages,138 but are able to survive intracellularly thanks in part to Mp1p, a 
mannoprotein and virulence factor in the fungal cell wall.139 
The effect of macrophage activity is therefore not straightforward, being 
involved in control of infection, as well as persistence and dissemination of 
disease.126,140  Dominance of intracellular cryptococcal proliferation early in 
infection appears to protect host tissues from damage on one hand, while also 
hindering effective immune responses by reducing pro-inflammatory immune 
signalling.141,142  Evidence for the apparently conflicting roles of macrophages in 
cryptococcal disease is summarised in table 1.3. 
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Table 1.3: The conflicting roles of macrophages in cryptococcal meningoencephalitis 
Macrophage role Evidence Reference(s) 
Macrophages benefit the immune response to cryptococcal disease 
 Macrophages appear 
to be required to 
control fungal burden 
Macrophage depletion leads to uncontrolled 
cryptococcal proliferation (models using zebrafish 
and rats) 
141,143 
Alveolar macrophage activation is associated with 
intrapulmonary cryptococcal clearance 
144,145 
Macrophage 
depletion leads to 
host death 
Mortality was universal and occurred within days 
in setting of macrophage depletion in an animal 
model of cryptococcal meningoencephalitis  
146 
Cryptococci have 
evolved to evade 
phagocytosis 
The large cryptococcal cell capsule protects from 







better host outcomes 
This is evident in experimental animal 
cryptococcosis models 




Macrophages contribute to the pathogenesis of cryptococcal disease 




The majority of cryptococci become intracellular 
in the first hours of infection 
141,156 
Cryptococcal cells can survive in the intracellular 
environment 
135,157 
Early intracellular cryptococcal proliferation drives 
increases in fungal burden (models using zebrafish 





cryptococcal cells  
Macrophage depletion late in infection protects 
against dissemination of infection in experimental 
cryptococcosis in mice 
158 
Cryptococcal cells can be transferred from one 




1.4.1.2 T helper lymphocyte responses determine macrophage polarisation 
Additional insight into the opposing roles of macrophages in cryptococcal 
disease can be found in studies of their activation pathways (figure 1.1).  Classically 
activated, pro-inflammatory (M1) macrophages are associated with clearance of 
fungal burden, whereas alternative (M2) macrophage activation is associated with 
cryptococcal proliferation and dissemination.161,162  Macrophage polarisation 
towards M1 or M2 phenotypes is itself stimulated by cytokines released by T 
helper lymphocytes, dendritic cells and natural killer cells and depends on a 
delicate balance between Th1- and Th2-type immune responses.126,163  The burden 
of cryptococcal disease in people living with HIV (PLHIV) is plain evidence of the 
importance of a healthy CD4+ T helper cell count in the immunological control of 
this infection.38  The CD4+ T-cell predominance observed in blood and CSF in 
healthy persons164  is replaced by CD8+ T-cells in PLHIV.154,165  In in-vitro and animal 
experiments, effective immune responses are characterised by a predominance of 
Th1-type responses, with IFN-γ and TNF-α/β secretion, classical macrophage 
activation and associated inflammation.149,166-169  Murine experiments using 
antibody neutralisation or genetic interference to decrease the levels of Th1-type 
cytokines such as IL-12,170 IL-18171 and IFN-γ172 have demonstrated decreased 
survival from cryptococcal infection compared with wild-type animals.  
Intriguingly, lack of TNF-α does not appear to influence mouse survival, but 
administration of TNF-α confers a survival advantage.173  
Clinical data also support the benefit of Th1-type responses.  Decreased 
Th1-type responses in peripheral blood with reduced levels of IL-12 and IFN-γ 
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independently predict 14-day mortality from HIV-associated cryptococcal 
meningoencephalitis.153  In CSF, decreased levels of proinflammatory cytokines 
such as IL-5, IL-6, granulocyte-colony stimulating factor and IFN-γ are associated 
with higher fungal burden and slower clearance of infection.154,155,174  Low levels 
of CSF IFN-γ are also predictive of early mortality in HIV-associated cryptococcal 
meningoencephalitis.154  Conversely, increased release of the Th1-type cytokines 
IL-4, IL-6, IL-8, IL-17, IFN-γ and TNF-α in CSF have been associated with mortality 
benefit.152,155,175 
In contrast to Th1-type responses, Th2-type responses are characterised 
by IL-4, IL-10 and IL-13 cytokine predominance with alternative (M2) macrophage 
activation.150,151,169  Immune responses with Th2 predominance are associated 
with poor clinical outcomes in murine studies of cryptococcal 
meningoencephalitis,176 increased levels of IL-4170 and IL-13150 being inversely 
proportional to survival.  The association between increased Th2-type responses 
and decreased survival has not been replicated in clinical samples from patients 
with HIV-associated cryptococcal meningoencephalitis.154,175  Whether the 
difference in this observation between murine and clinical studies relates to 
intrinsic differences between murine and human immune systems, or is a function 
of the dynamism of CSF cytokine profiles over time during cryptococcal infection 
of the CNS (the temporal study of which is unmatched in murine and human 
investigations), is not clear.175 
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Figure 1.1: Model of the adaptive immune response to Cryptococcus neoformans  
 
* indicates that the association of this cytokine/ chemokine with the indicated outcome has been 
demonstrated in clinical samples (as opposed to purely pre-clinical experiments).
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Autopsy studies corroborate preclinical and clinical findings that a 
coordinated, pro-inflammatory, Th1-type response with classical macrophage 
activation is a beneficial immune reaction to cryptococcal meningoencephalitis.  
Post mortem, immunocompetent patients display typical inflammatory 
granuloma at the initial site of infection in the lungs, composed of dense 
aggregates of epithelioid macrophages and multinucleated giant cells containing 
numerous intracytoplasmic yeasts.106,177  In the brain and spinal cord, there is 
prominent T-cell lymphocytic infiltration with granulomatous inflammation.106  In 
contrast, autopsy studies of patients with HIV-associated cryptococcal 
meningoencephalitis demonstrate that in general, while inflammatory cells 
(predominantly macrophages) are present, they are few in number and are not 
epithelioid.106  T-cells are scant and there is evidence of reduced antigen 
presentation.177  In the lung, cryptococci are not contained within granulomas but 
are widely distributed both intra- and extracellularly.177  In some cases there is 
massive proliferation of cryptococci in expanded alveoli, interstitial tissue and 
capillaries.177  In the CNS too, a coordinated inflammatory response is lacking in 
patients with advanced HIV; T-cells are focally distributed and are not associated 
with either C. neoformans cells or macrophages.106   
Taken together, these findings have generated interest in the potential 
role of IFN-γ, a key adaptive Th1-type cytokine, as an adjunct to antifungal therapy 
for HIV-associated cryptococcal meningoencephalitis.  Inoculation of mice with an 
experimental strain of C. neoformans that produces IFN-γ resulted in the 
production of Th1-type cytokines in lungs, classical macrophage activation and 
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reduced pulmonary fungal burden.178,179  Macrophages isolated from these mice 
were fungistatic against C. neoformans ex vivo.179  Two clinical trials have 
demonstrated that administration of IFN-γ in combination with amphotericin-B 
therapy promotes an inflammatory response, increases fungal clearance from CSF 
and produces a trend towards improved survival.174,180  Further work is needed to 
target and select those patients most likely to benefit from this immune adjuvant 
- likely those with minimal endogenous IFN-γ responses.181  Another promising 
approach is the use of monoclonal antibodies directed against cryptococcal 
capsular polysaccharide.  One such antibody, 18B7, has completed a phase I 
clinical trial.182  In contrast, and in keeping with the beneficial role of inflammatory 
immune responses, a trial of the anti-inflammatory glucocorticoid dexamethasone 
as adjunctive therapy in HIV-associated cryptococcal meningitis was stopped early 
after showing no evidence of benefit and a trend towards increased mortality.183  
Patients in the adjunctive dexamethasone arm had more rapid declines in CSF-
concentrations of the pro-inflammatory Th1-cytokine TNF-α over the first week of 
therapy.184  
 
1.4.2 Characteristics of the infecting strain 
1.4.2.1 Genotypic heterogeneity in fungal pathogens 
IFIs do not result from infection with homogeneous strains of fungus.  
Rather, there is considerable pathogen variability both between and within 
patients.  Molecular typing techniques have delineated five lineages of C. 
neoformans: VNI, VNII and VNB (which encompasses two distinct subdivisions 
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VNBI and VNBII)185 are molecular types of C. neoformans var. grubii; VNIV 
corresponds to C. neoformans var. neoformans, and VNIII is the hybrid of var. 
grubii and var. neoformans.186-188  Evidence suggests that an association between 
genotype, phenotype and virulence potential is likely.189-192  Data from Botswana 
demonstrate significantly increased capsule thickness and cell diameter in VNBI 
isolates than either VNI or VNBII isolates, with worse mortality outcomes among 
patients infected with VNBI strains.192  In Uganda, VNIII strains were found to be 
more strongly associated with mortality than other strains.189  At the sub-lineage 
level, further clinical associations have been identified.  Sequence type 5 strains of 
VNI isolated in Southeast Asia infect HIV seronegative patients significantly more 
frequently than they infect PLHIV.190,191  In addition, better clinical outcomes from 
cryptococcal meningoencephalitis have been observed following infection with 
the VNIa-93 sub-clade which predominates in Uganda and Malawi, than with the 
VNIa-4 and VNIa-5 sub-clades which are common in Southeast Asia.193 
Within an individual patient’s infection there is also evidence of strain 
heterogeneity.  Numerous clinical studies of infection with C. neoformans have 
shown that temporally distinct single-colony isolates from within the same 
episode of cryptococcosis or during relapse of infection represent different 
genotypes,  suggesting that cases can be caused by infection with genetically 
distinct genotypes occurring in the environment.67,194-197  With inadequate 
treatment such as that provided by fluconazole in monotherapy, genotypic 




1.4.2.2 Phenotypic heterogeneity in invasive pathogenic fungi 
 Numerous pathogens are known to display phenotypic differences 
between individual cells of genetic clonality.  Phenotypic heterogeneity enables 
adaptation to environmental stressors and the re-establishment of cell 
populations, and is essential to species survival.198  It may also augment the 
virulence of a microbial population through enhanced pathogenicity or drug 
tolerance.199  The clinical significance of microbial phenotypic heterogeneity has 
been extensively studied in mycobacteria200-202 and other pathogenic bacteria.203-
205  The same concept applies to fungi, in which alterations in morphology can 
promote growth in vivo, mediate tissue damage, and enable evasion of host 
immune factors and recruitment of immune cells.206-208 
Several Cryptococcus virulence factors have been characterised 
experimentally.  These include induction of the cryptococcal polysaccharide 
capsule, production of melanin, production of extracellular vesicles, urease 




Table 1.4: Phenotypic virulence attributes of Cryptococcus neoformans 
Virulence attribute Mechanism of pathogenic action References  
Extracellular capsule 
production 
Interferes with phagocytosis 209,210 
Promotes intracellular survival 129 
Disrupts antigen processing and presentation 133 
Protects against ROS 134 
Induces macrophage apoptosis 211 
Downregulates Th1 responses 212,213 
Induces soluble markers of Th2 responses 213-215 
Facilitates cryptococcal dissemination 
 
216,217 
Melanin deposition Impedes phagocytosis of encapsulated cryptococcal 
cells 
218,219 
Protects against ROS 220,221 
Increases antifungal tolerance  222,223 





Transport proteins associated with virulence 225 
Promote encapsulation of cryptococci 226 227 228 
Involved in melanin incorporation into cell wall 
 
229 
Urease activity Promotes alternative macrophage polarization 230 
Increases phagolysosomal pH, possibly fostering 
dormancy and persistence 
137,231 




Thermotolerance Fundamental to establishing clinical infection 
 
234 
Titan cell formation Evasion of phagocytosis 235,236 
Generation of genotypically heterogeneous daughter 
cells with varying propensity for immune evasion and 
drug resistance 
237,238 




1.5 Assessing antifungal pharmacodynamics 
Factors related to antifungal PK, host immunity and pathogen 
characteristics can be important sources of heterogeneity in PD response.  Several 
established methods and models exist to assess and predict PD response. 
 
1.5.1 Dynamic in vitro pharmacokinetic-pharmacodynamic models 
1.5.1.1 Time-kill curves for in vitro pharmacodynamic experiments 
 Time-kill experiments are performed in vitro to record the response of a 
microbial population to drug exposure over time.  This enables estimation of 
growth rate, death rate and the rate of emergence of resistance in a population.  
Antimicrobial drug concentrations in growth media can be altered over the course 
of an experiment or can remain static throughout.  Various doses and drug 
combinations can be compared in terms of their PD effect.  Time-kill experiments 
have been employed to investigate fungicidal activity for a range of antifungal 
compounds, including those pertinent to the treatment of cryptococcal 
meningoencephalitis and talaromycosis: amphotericin B,240-243 flucytosine,243,244 
fluconazole,242,245 itraconazole245,246 and combinations of these agents.243 
 
1.5.1.2 Hollow fibre infection models 
 The hollow fibre infection model (HFIM) is a dynamic in vitro model that 
enables simulation of PK profiles that mimic those observed in human studies.  
Two circuits are run in parallel, one of which represents the luminal PK 
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compartment, the other the extracapillary PD compartment, containing 
pathogens and/or cells.  Drug-containing nutrient media is pumped through the 
luminal compartment, which includes porous hollow fibres.  The flow rate in the 
luminal compartment is sufficient to result in equilibration of drug concentrations 
between the hollow fibres and the surrounding extracapillary space.  Drug 
exposure of pathogens in the extracapillary compartment is controlled by altering 
the drug concentration in the nutrient media entering the capillary compartment.  
Drug-containing broth is removed from the circuit into a waste reservoir and 
replaced with fresh media at a rate proportional to the clearance rate observed 
for that drug/s in humans.   
 Using HFIMs it is possible to assess the impact of changes in drug exposure 
on microbial growth, microbial kill and the emergence of resistance.  For example, 
a HFIM has been used demonstrate that when a wild-type laboratory strain of C. 
neoformans (H99) is exposed to low concentrations of fluconazole, any reduction 
in fungal burden is offset by the emergence of resistant subpopulations that are 
able to grow on agar containing 32 to 64 mg/litre of fluconazole.66  
 
1.5.2 Animal models for the assessment of antifungal pharmacodynamics 
 Fungal disease models in animals differ in a number of fundamental ways 
to in vitro models.  Central advantages and disadvantages of in vitro and in vivo 
infection models are outlined in table 1.5.  Two animal models of cryptococcal 
meningoencephalitis have been developed.  In the murine model, C. neoformans 
is inoculated either via inhalation to the respiratory tract,247 or by intravenous 
 49 
injection.248,249  Predictable disseminated infection with encephalitis follows.84  
The volume of CSF in mice is too small to sample for quantitative cryptococcal 
cultures, however tissue homogenates can be used to generate PD read-outs 
following animal sacrifice.  In the rabbit model of cryptococcal 
meningoencephalitis, both CSF and brain tissue samples can be used to quantify 
fungal burden.  The former can be sampled serially to enable a PD profile to be 
examined in response to different dosing strategies and to mimic the seral CSF 
sampling possible in clinical trials of cryptococcal meningoencephalitis therapy.250  
By using animal models to demonstrate PD effect at the site of activity intended 
in human therapy (such as the CNS), drug penetration and efficacy at the infection 




Table 1.5: Attributes of in vitro and animal pharmacodynamic studies 
In vitro PD studies Animal PD studies 
Can precisely control pathogen drug 
exposure 
Can study infection in specific body sites 
In hollow fibre models, can closely mimic 
human PK profiles  
Can evaluate host factors including immune 
response and protein binding 
Can frequently resample PK and PD 
compartments 
Can mimic human route of infection or 
dissemination of disease: inhalation, 
haematogenous, etc. 
Can estimate ‘pure’ PK/PD target without 
interference of host factors 
Refinement of models of particular diseases 
can yield robust and highly reproduceable 
experiments 
Sophisticated models, for example of the 
BBB, can be used to study cellular 
mechanisms of pathogenesis as well as 
predict drug penetration into body 
compartments 
PD readout can be the same as used in 
human patients – for example fungal burden 
in plasma or CSF 
Can account for heterogeneity in fungal 
virulence in response to host factors  
 Cause of death can be uncertain, not reliable 
models for assessing IFI-associated mortality 
PD: pharmacodynamic; PK: pharmacokinetic; CSF: cerebrospinal fluid; BBB: blood-brain barrier; IFI: 
invasive fungal infection 
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1.5.3 Clinical pharmacodynamic measurements 
1.5.3.1 Minimum inhibitory concentrations, minimum inhibitory concentration 
breakpoints, and epidemiological cutoff values 
While the study of genotypic and phenotypic heterogeneity between 
pathogenic strains of fungi provides valuable insights into pathogen-host 
interactions and the establishment of clinical infection, their relevance in the 
setting of antifungal therapy is not clear.  In other words, if pathogenic fungi are 
subject to sufficient drug exposure, does this supersede the clinical impact of any 
virulence factors that may be present?  Characterising strains according to their 
minimum inhibitory concentration (MIC) can function to capture microbial 
heterogeneity as it relates to the drugs available for treatment.  The MIC of an 
antifungal agent to a particular organism is defined as the lowest concentration 
(in mg/L) of the drug that inhibits fungal growth.251  MICs from clinical isolates 
assist in guiding therapy by indicating the susceptibility or resistance of an 
organism to an antimicrobial agent.  In this way, the genotypic and phenotypic 
particularities of a strain are placed in context of whether they influence the 
strain’s susceptibility to treatment.  This analysis can be done on an individual 
patient level.   
The classification of antimicrobials into time-dependent versus AUC- or 
Cmax-dependent PD effect conventionally uses the MIC of the infecting strain as 
the denominator in each PK-PD index (thus, time/MIC, AUC/MIC and Cmax/MIC).  
This approach has undoubtedly improved understanding of antimicrobial dosing.  
Over time, the interpretation of MICs has evolved to consider MIC breakpoints, 
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which are used to predict whether a microorganism is likely to respond in vivo to 
clinically relevant drug concentrations at the site of infection.252  In the 
determination of MIC breakpoints, data such as known MIC distributions, 
resistance determinants, in vivo PK/PD indices and clinical outcomes are 
considered.  By comparing the MIC of a particular strain to the consensus MIC 
breakpoint, drug-tolerant or resistant isolates can be identified.  For antifungal 
agents, MIC breakpoints are exceptionally difficult to determine due to the paucity 
of clinical PK and outcome data.252  An alternative MIC-based measure 
circumvents this lack of clinical information by aiming to estimate the in vitro 
efficacy of drugs: the epidemiological cutoff value (ECV).  While they are unable to 
predict clinical success, ECVs can be used to predict drug-tolerant or resistant 
isolates in situations where a given agent has known activity against the fungal 
pathogen of interest, but sufficient data to establish MIC breakpoints do not exist.  
ECVs can be used for resistance surveillance at a population level.253,254  
 
1.5.3.2 Drawbacks of using minimum inhibitory concentrations 
Each of the assessments defined above place a high degree of confidence 
in MIC as a reliable and stable measurement.  In reality, there are significant 
shortcomings to the use of MIC and MIC-derived measures to optimise 
therapeutic strategy.  Firstly, MIC results have repeatedly been shown to vary 
between assays and laboratories.255-257  Studies of inter-assay variability in yeast 
MIC have revealed considerable differences between visual methods, which are 
prone to observer bias, and spectrophotometric methods, which are more 
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objective by design.258,259  For example, agreement between Etest and 
microdilution methods for testing itraconazole MICs against 9 strains of 
filamentous fungi vary from 0% to 100%.260  Furthermore, agreement between 
antifungal MIC testing methods can depend on the fungal strain being examined 
and the growth medium used.  Secondly, PK-PD indices that utilise MIC tend to 
assume a single static MIC value for the infecting organism of the patient being 
treated.  This overlooks the fact that a patient may be infected with a number of 
microbial subpopulations simultaneously, the MICs of which may vary – or be 
‘heteroresistant’.67  Thirdly, MICs for an individual patient’s infection are often 
read a number of days following sample acquisition and treatment initiation, so 
that the result will not necessarily reflect the organisms currently causing 
pathology since these may have adapted in response to drug pressure.67,261  
Finally, the only pharmacodynamically active portion of drug is that which is not 
protein-bound.  Protein binding varies considerably between anti-infective 
compounds and different patient populations may have different levels of plasma 
proteins available for binding, depending on their physiological state.  Protein 
binding can be linear or non-linear, can alter according to the drug concentration 
in plasma and can have a significant impact on the exposure of pathogens to drug 
at the infection site.  It is frequently only unbound drug that partitions to sites such 
as the CNS,100 the skin and skeletal muscles.261  Since PK-PD indices tend to use 
total, rather than unbound, drug concentration, this represents another limitation 
of the use of MICs in this context. 
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1.5.3.3 Dynamic clinical biomarkers 
An alternative PD measure is to use a dynamic biomarker that is associated 
with clinical outcome.  Examples in mycology include galactomannan for invasive 
aspergillosis and 1,3-β-D-glucan for disseminated candidiasis and invasive 
aspergillosis.  For cryptococcal meningoencephalitis, early fungicidal activity (EFA) 
(i.e. a linear regression of log10 colony forming units (CFU)/mL of CSF vs. time) is 
routinely used as a primary endpoint for Phase II clinical studies and a secondary 
endpoint in Phase III trials.40,74,262  This PD endpoint has been validated as a 
surrogate marker for mortality in multiple clinical studies, and EFA targets have 
been defined.  Specifically, a pooled analysis of individual-level CSF data from 738 
subjects suggests that an EFA of <0.20 Log10 CFU/mL/day versus >= 0.20 Log10 
CFU/mL/day is associated with a hazard ratio for 18-week mortality of 1.60 (95% 
CI, 1.25 – 2.04, p=0.002).263   A combined analysis of 501 ART-naïve patients 
demonstrated similarly that EFA values > 0.2 Log10CFU/mL/day were associated 
with the greatest probability of survival.264 
 
1.6 Pharmacokinetic-pharmacodynamic modelling 
1.6.1 Introduction to pharmacokinetic-pharmacodynamic modelling 
For the reasons outlined above, the prediction and evaluation of antifungal 
PK and PD is complex.  Inter- and intra-individual variability in each contributing 
factor expands this complexity.79,265  Nevertheless, the relationship between the 
concentration of a drug at its effect site and its PD effect is invariably better 
aligned than the relationship between the dose of a drug and its PD effect.  
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Antifungal PK-PD analyses provide supportive evidence that therapeutic effects 
are the result of drug exposure, are predictable and can be exploited for 
therapeutic benefit.  Ideally, the information required to establish robust 
pharmacokinetic-pharmacodynamic (PK-PD) targets at the site of infection 
includes all of the points listed in box 1.2.   
 
 Adapted from 100 
 
Using this information, data can be modelled using a variety of approaches 
to predict clinical PK parameters and their association with PD outcomes.  Classical 




1. Principal PK parameter of interest, depending on whether drug activity is determined by 
maximum concentration (Cmax), area under the curve (AUC), or time above a given 
therapeutic threshold. 
2. Drug susceptibility/ minimum inhibitory concentration (MIC) of the infecting fungus. 
3. Magnitude of the PK-PD index required, in terms of the unbound concentration of drug 
that is sufficient to exert PD effect on the target organism. 
4. Histopathology of site(s) of disease. 
5. Rate constant describing the movement of drug from the circulation to the site of 
infection. 
6. Rate constant(s) describing the movement of drug within anatomical sub-compartments 
of interest. 
7. Rate constant(s) describing the elimination of drug from the target site. 
8. Rate constant(s) describing the clearance of drug from the body. 
9. Time-dependent differences in plasma and tissue drug concentrations (hysteresis). 
10. PK parameters associated with toxicity in measurable physiological compartments (usually 
the systemic circulation). 
11. Clinical and physiological covariates that influence the PK of the drug in question. 
12. Population-level variability in each of these factors. 
 
Box 1-2: Desirable information for the accurate setting of PK-PD targets for fungal 
infection 
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a model comprised of theoretical, though not necessarily physiologically relevant, 
compartments.  Physiologically based PK (PBPK) modelling (the ‘bottom-up’ 
approach) is a complementary technique that starts by considering the 
pharmacology of a drug at the organ or tissue level.266  PK modelling provides a 
means of describing the statistical distribution of PK parameter estimates, so that 
sources of variability in those estimates can be explored through the examination 
of clinical covariates such as body size, weight and renal function.  In addition, the 
effect of attributes of special populations can be explored – for example, ECMO in 
children267 or renal replacement therapy in critically ill patients268 - as can the 
influence of food269 and genetic polymorphisms on the PK of a drug.270   Population 
PK models derive mean parameter estimates, describe inter-individual variability 
and calculate residual variability as a sum of intra-individual variability, 
measurement error and model bias.261  
 
1.6.2 Parametric versus non-parametric models 
A number of established mathematical methods for population PK 
modelling exist.  These can be broadly categorised into parametric and non-
parametric modelling approaches.  Parametric approaches assume that PK 
parameter values – for example volume, intercompartmental rate constants and 
clearance – have a Gaussian or log-normal distribution across the population.261,271  
Mean values are calculated for each PK parameter, as well as standard deviations 
to describe inter- and intra-individual variability, inter-occasion variability and 
residual variability.  Overall parameter distributions are described in terms of 
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‘fixed effects’ (the mean parameter values) and ‘random effects’ (the standard 
deviations).  Thus, parametric models are ‘mixed effects’ models and they enable 
a view of population PK that is constrained to assumptions made regarding the 
shape of PK parameter distributions prior to analysis of the PK data.  The 
NONMEM programme (Icon plc) is the original example of software designed to 
perform parametric nonlinear mixed effects modelling. 
In contrast, non-parametric PK modelling approaches apply no constraints 
to the parameter distributions whatsoever.271  It is frequently the case that 
cohorts of patients comprise multiple subpopulations that handle drugs 
differently; for example, fast and slow metabolisers.  Neither Gaussian nor log-
normal distributions are able to describe such subpopulations, since in those cases 
the model PK parameter distributions are discrete rather than continuous.271,272  
Non-parametric approaches represent an attempt to estimate the precise, 
discrete PK parameter distributions for each patient under study.  These models 
estimate the population distribution – which may contain multiple discrete spikes, 
rather than being a smooth continuous line – and reinforce it with up to as many 
support points as there are patients in the dataset.  Each support point in a non-
parametric model is a set of estimates for all discrete parameter values in the 
model, as well as a normalised estimate of the likelihood of that set of estimates 
in the population.271,273  In principle, non-parametric methods more closely 
approximate the ideal (but impossible) scenario of having access to each patient’s 
true PK parameter values in the population, than do parametric methods.261  This 
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is because non-parametric models are built from the data rather than imposing 
any assumptions about the shape of the population distribution.   
 
1.6.3 Pmetrics software for non-parametric pharmacokinetic-pharmacodynamic 
modelling 
Non-parametric methods were initially described in the early 1980s274,275 
and were refined and improved over the following two decades.276,277  The leading 
software for nonparametric unconstrained population modelling is Pmetrics,273 an 
R package that encompasses Non-Parametric Adaptive Grid (NPAG) software.  The 
NPAG software creates nonparametric population PK models consisting of 
discrete support points as described.  NPAG models are mixed effects models, the 
(unconstrained) parameter values representing the random effects and the error 
model representing the fixed effects.273  The error model comprises a polynomial 
equation to describe assay variance, plus one of either gamma, a multiplier of 
assay variance, or lambda, which is the additive term for assay variance.273,278  
Gamma and lambda are terms to account for extra process noise related to the 
parameter estimate, including errors in dosing and observation times.278  NPAG is 
able to accurately identify PK outliers and subpopulations, as well as simulate 
populations in which dosing regimens have been manipulated to estimate PK in 
theoretical scenarios.273  The simulator uses Monte-Carlo simulation to sample 
new sets of parameter values from the user-selected distributions described in the 
chosen PK-PD model.278 
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1.6.4 Pharmacokinetic-pharmacodynamic modelling of antifungal drugs 
Many of the antifungal drugs in common use today - including 
amphotericin B, 5-FC, fluconazole and itraconazole - were developed before the 
routine use of modern PD approaches in drug development.  Antifungal dosage 
guidelines are frequently based on experience rather than having a basis in PK-PD 
science.  Pharmacometric tools offer an opportunity to evaluate established 
dosing practices and assess the likelihood, on a population level, that target PK 
parameters are being reached without undue risk of toxicity.  Clinical attributes of 
the population under study can be interrogated for their influence on the 
attainment of target PK parameters.  PD measures such as the MIC of the 
pathogen, the burden of infection (measured, for example, using quantitative 
cultures or described dynamically using EFA), and mortality outcomes, can be 
incorporated in PK-PD models.  Hypothetical scenarios can be simulated to predict 
outcomes in response to changes in dosing strategy. 
PK-PD modelling approaches have been applied to a range of clinical 
questions in antifungal therapeutics.  Population PK models have been built from 
preclinical investigations of micafungin279 and anidulafungin,280 with Monte Carlo 
simulation used to bridge the results to neonatal populations at risk of Candida 
meningoencephalitis.  Population PK modelling has been used to advocate for 
TDM of voriconazole79,281 and against the necessity of TDM for isavuconazole.282  
A combination approach using PBPK modelling and incorporating published in vivo 
data has been used to predict drug-drug interactions with itraconazole.283  
Preclinical experiments using mouse and rabbit models of cryptococcal 
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meningoencephalitis demonstrated the non-inferior efficacy of abbreviated 
polyene regimens83,84 and provided the basis for two large cryptococcal 
meningoencephalitis phase III clinical trials.  The first was Antifungal Combinations 
for Treatment of Cryptococcal Meningitis in Africa (ACTA), which demonstrated 
the non-inferiority of one week of DAmB (1 mg/kg/day) plus flucytosine (100 
mg/kg/day) followed by 7 days of fluconazole (1200 mg/day) versus regimens 
based on two weeks of DAmB, in terms of ten week mortality14 and one year 
mortality.57  The second trial is the ongoing AMBITION trial, which exploits the 
relative safety of LAmB and is designed to evaluate induction therapy with a single 
high dose of LAmB (10 mg/kg) plus 14 days of fluconazole (1200 mg/day) and 
flucytosine (100 mg/kg/day).58   
 
1.7 Conclusion 
 The management of IFIs is an area of unmet medical need.  Treatment 
options are profoundly limited, particularly in LMICs which bear the vast burden 
of HIV-associated IFIs.  Cryptococcal meningoencephalitis and talaromycosis are 
model diseases to study in this regard, since mortality from both conditions is high, 
treatment regimens are suboptimal and PK-PD methodologies have not been 
extensively applied to attempt to address the issue of poor treatment outcomes 
in either disease.  In addition, the role of host immune responses in clinical 
outcomes from HIV-associated IFIs requires further clarification, in particular 
phagocyte function.
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1.8 Research objectives and overview of chapters 
The overarching objective of this PhD is to describe the clinical PK-PD of 
currently available antifungal drugs for cryptococcal meningoencephalitis and 
talaromycosis.  As described, this is both essential and challenging.  Essential, 
because without a detailed understanding of the PK-PD of antifungal agents we 
use to treat these life-threatening infections, we cannot be certain that we are 
using those agents optimally and thereby maximising the likelihood of patient 
survival.  Challenging, because PK-PD studies of drugs already in clinical use are 
limited by the inability to explore substantially different dosages and dosage 
regimens and confounded by pathophysiological alterations in the patients 
concerned.  Nevertheless, these challenges also present opportunities because 
the activity of drugs can be assessed in the patient population in which they are 
most needed. 
Chapters 2, 3 and 4 describe the population PK of antifungals in common 
use for cryptococcal meningoencephalitis.  In chapter 2, the important question 
of the variability in CNS penetration of fluconazole is addressed.  PK parameters 
derived from the population PK model are related to wild-type MIC distributions 
of fluconazole against C. neoformans and a meta-analysis of clinical trials reporting 
outcomes from the treatment of cryptococcal meningoencephalitis with 
fluconazole monotherapy is performed.  Chapter 2 provides the pharmacological 
explanation for the long-recognised inadequacy of fluconazole monotherapy for 
cryptococcal meningoencephalitis.  Chapter 3 describes a PK model of 
amphotericin B deoxycholate (DAmB), which is contextualised within a meta-
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analysis of clinical trials that report outcomes from the treatment of cryptococcal 
meningoencephalitis with DAmB monotherapy.  Chapter 3 demonstrates the 
limitations of relying on CSF sterility as a surrogate for mortality outcomes in 
cryptococcal meningoencephalitis and suggests additional contributors to death 
from cryptococcal meningoencephalitis.  Chapter 4 describes the population PK of 
liposomal amphotericin B (LAmB) used in a novel regimen for cryptococcal 
meningoencephalitis, administered as a single high dose.  A previously published 
PD model derived from murine data served as the basis for a bridging study that 
related PD outcomes in mice to those that would be expected in hypothetical 
human patients, using the posterior predictions from the clinical PK model and 
performing Monte Carlo simulations of various doses of LAmB.  The necessity and 
limitations of this approach are discussed. 
In chapter 5, the population PK and PD of itraconazole are described, based 
on data from a clinical trial that compared itraconazole to DAmB for talaromycosis.  
Itraconazole has an active metabolite, hydroxyitraconazole, so a model was 
constructed that accounted for the PK and PD of both agents.  The analysis 
suggests that the failure of itraconazole to satisfy non-inferiority against DAmB in 
the clinical trial resulted from overwhelmingly low itraconazole PK parameters 
across the population.  It provides a real-world example of the importance of a 
comprehensive consideration of PK-PD factors in a clinical drug trial before trial 
initiation, or at a minimum during the early stages of trial roll out. 
Finally, chapter 6 considers the role of the host response in the outcome 
of cryptococcal meningoencephalitis.  In keeping with the findings of chapter 3, 
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chapter 6 cautions against an overreliance on traditional PD biomarkers such as 
CSF sterility or fungicidal activity as indicators of mortality outcomes.  A 
coordinated, proinflammatory immune response with associated increases in the 
phagosomal activity of neutrophils and monocytes is shown to correlate with 
favourable outcomes in terms of reduced CSF fungal burden at baseline, reduced 
lumbar puncture opening pressure and reduced mortality, in addition to increased 
EFA.  More generally, chapter 6 demonstrates the importance of considering non-
pharmacological factors in our attempts to understand patients’ response to IFIs 
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Robust population pharmacokinetic (PK) data for fluconazole are scarce.  
The variability of fluconazole penetration into the central nervous system (CNS) is 
not known.  A fluconazole PK study was conducted in 43 patients receiving oral 
fluconazole (usually 800 mg q24h) in combination with amphotericin B 
deoxycholate (1 mg/kg q24h) for cryptococcal meningoencephalitis.  A 4-
compartment PK model was developed, and Monte Carlo simulations performed 
for a range of fluconazole dosages.  A meta-analysis of trials reporting outcomes 
of cryptococcal meningoencephalitis patients treated with fluconazole 
monotherapy was performed.  Adjusted for bioavailability, the PK parameter 
means (standard deviation, SD) were: clearance, 0.72 (0.24) litres/hour; volume of 
the central compartment, 18.07 (6.31) litres; volume of CNS compartment, 32.07 
(17.60) litres; first-order rate constant from central to peripheral compartment, 
12.20 (11.17) hours-1; from peripheral to central compartment, 18.10 (8.25) hours-
1; from central to CNS compartment 35.43 (13.74) hours-1; from CNS to central 
compartment 28.63 (10.03) hours-1. Simulations of area under concentration-time 
curve resulted in median (interquartile range) values 1143.2 (988.4 – 1378.0) 
mg.h/litre in plasma and 982.9 (781.0 – 1185.9) mg.h/litre in cerebrospinal fluid 
(CSF) after a dosage of 1200mg q24h.  The mean simulated ratio of 
AUCCSF:AUCplasma was 0.89 (SD 0.44).  The recommended dosage of fluconazole for 
cryptococcal meningoencephalitis induction therapy fails to attain the PD target 
in respect to the wild-type MIC distribution of C. neoformans.  The meta-analysis 
 66 
suggested modest improvements in both CSF sterility and mortality outcomes 
with escalating dosage.  This study provides the pharmacodynamic rationale for 
the long-recognised fact that fluconazole monotherapy is an inadequate induction 




 Mortality from cryptococcal meningitis remains unacceptably high.  More 
than 90% of the estimated 223,100 annual incident cases of cryptococcal 
meningitis occur in Sub-Saharan Africa and Asia-Pacific regions.38  The most 
effective regimen for induction is amphotericin B deoxycholate and 
flucytosine.40,74  However, access to these drugs is limited in many regions where 
the burden of cryptococcal meningitis is greatest.36,284,285  In these settings, high-
dose fluconazole is used for induction monotherapy, despite consistent evidence 
of reduced survival in comparison with other agents and combinations.62,65,286 
 Fluconazole was discovered by Pfizer Inc. (Sandwich, UK) in 1978.287  The 
objective was to discover an orally bioavailable agent for the treatment of invasive 
mycoses with a lower propensity to develop resistance than flucytosine.287  
Fluconazole inhibits cytochrome P450-dependent demethylation of lanosterol in 
the ergosterol biosynthetic pathway.288  The ratio of the area under the 
concentration-time curve (AUC) to the minimum inhibitory concentration (MIC) is 
the pharmacodynamic (PD) index that best links drug exposure of fluconazole with 
the observed antifungal effect.248,289 
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 Successful antimicrobial therapy within the central nervous system 
depends on the achievement of effective drug concentrations within relevant sub-
compartments that include the cerebrum, meninges and CSF.290  Fluconazole has 
a low molecular weight (approximately 300g/mol), is weakly protein bound and is 
not known to be a substrate for central nervous system (CNS) efflux pumps.88,89  
Its ability to partition from the endovascular compartment into the CNS has been 
established in laboratory animal models291,292 and clinical studies.293,294  
Brain:plasma penetration ratios up to 1.33 have been reported in humans.294  
However, there is a surprising paucity of population pharmacokinetic (PK) data for 
fluconazole in all clinical contexts.  Furthermore, the extent and variability of 
penetration into the CNS is not known.   
  The primary aim of this study was to quantify the extent and variability of 
CNS penetration of fluconazole in adults with cryptococcal meningitis.  We 
developed a population PK model that quantified the inter-individual variability in 
drug exposure in plasma and cerebrospinal fluid (CSF).  We investigated the impact 
of a range of clinically relevant covariates on fluconazole PK.  Monte Carlo 
simulation was used to assess the implications of PK variability in terms of 
achieving fluconazole PD targets.  Finally, we conducted a meta-analysis of clinical 




2.4 Materials and Methods 
2.4.1 Clinical pharmacokinetic studies 
 Patients from whom plasma and CSF samples were obtained for this PK 
study have been described previously.262  Adult patients were initially recruited 
from a multi-centre randomised controlled trial of adjuvant dexamethasone in 
HIV-associated cryptococcal meningitis.  The trial is reported elsewhere (n=3, 
International Standard Registered Clinical Number 59144167).183  Following the 
early cessation of this trial, patients were recruited from a prospective descriptive 
study at the same sites (n=40). Study sites were The Hospital for Tropical Diseases 
in Ho Chi Minh City, Vietnam, and Masaka General Hospital, Uganda. The study 
protocols were approved by the relevant institutional review boards and 
regulatory authorities at each trial site and by the Oxford University Tropical 
Research Ethics Committee. 
 Fluconazole was administered orally.  Where conscious level did not 
enable oral administration, fluconazole was administered via nasogastric tube.  
The majority of patients received 800mg fluconazole q24h.  Two patients received 
one-off doses of 400mg q24h.  Two received one-off doses of 600mg q24h.  One 
patient’s regimen of 800mg fluconazole q24h was escalated to 1200mg q24h for 
6 days from day 8 of treatment.  All patients received combination therapy with 
amphotericin B deoxycholate 1mg per kg per day, infused over 5-6 hours. 
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2.4.2 Measurement of fluconazole concentrations 
Fluconazole concentrations were measured using a validated LC/MS/MS 
methodology (1260 Agilent UPLC coupled to an Agilent 6420 Triple Quad mass 
spectrometer, Agilent Technologies UK Ltd, Cheshire, UK).  Fluconazole was 
extracted by protein precipitation; 300 µl of cold methanol containing the internal 
standard fluconazole-D4 at 0.625 mg/L (TRC, Canada) was added to 10 µl of 
sample (plasma or CSF). The solution was vortex mixed for 5 seconds and filtered 
through a Sirocco precipitation plate (Waters Ltd, Cheshire, UK). One hundred fifty 
µl of supernatant was transferred to a 96-well auto sampler plate, and 3 µL were 
injected on an Agilent ZORBAX C18 RRHD (2.1 X 50mm, 1.8 µm) (Agilent 
Technologies UK Ltd, Cheshire, UK).  
Chromatographic separation was achieved using a gradient consisting of 
70% A:30% B (0.1% formic acid in water as mobile phase A and 0.1% formic acid 
in methanol as mobile phase B).  The organic phase was increased to 100% over 
90 seconds, with additional 90 seconds of equilibration.   
The mass spectrometer was operated in multiple reaction monitoring scan 
mode in positive polarity. The precursor ions were 307.11 m/z and 311.1 m/z for 
fluconazole and internal standard, respectively. The product ions for fluconazole 
were 220.1 m/z and 238.1 m/z; for the internal standard 223.2 m/z and 242.1 m/z. 
The source parameters were set as follows: capillary voltage 4000 V, gas 
temperature 300°C and nebulizer gas 15 lb/in2.  The standard curve for fluconazole 
encompassed the concentration range 1-120 mg/L and was constructed using 
blank matrix. The limit of quantitation was 1 mg/L.  In plasma, the intra-day 
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coefficient of variation (CV) was <3.4% and the inter-day CV was <6.7%, over the 
concentration range 1-90 mg/L.  In CSF, the intra-day CV was <5.2% and the inter-
day CV was <5.3% over the same concentration range. 
 
2.4.3 Population pharmacokinetic modelling 
The concentration-time data for fluconazole in plasma and CSF were 
analysed using the non-parametric adaptive grid (NPAG) algorithm of the program 
Pmetrics273 version 1.5.0 for R statistical package 3.1.1.  The initial PK 
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3. 𝑑𝑑𝑑𝑑(3)
𝑑𝑑𝑑𝑑
= 𝐾𝐾𝐾𝐾𝐾𝐾 ∗ 𝑋𝑋(2) −  𝐾𝐾𝐾𝐾𝐾𝐾 ∗ 𝑋𝑋(3)  
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6. 𝑌𝑌(2) =  𝑋𝑋(3)/𝑉𝑉𝐾𝐾𝑉𝑉𝐾𝐾 
Where equations (1), (2), (3) and (4) describe the rate of change in amount of drug 
in milligrams (mg) in the gut, central, CSF and peripheral compartment, 
respectively.  Ka is the absorption rate constant from the gut to the central 
compartment. X(1), X(2), X(3) and X(4) are the amount of fluconazole (mg) in the 
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gut, central (c), CSF (s) and peripheral compartments (p), respectively.  Kcp, Kpc, 
Kcs and Ksc represent first-order transfer constants connecting the various 
compartments.  SCL is the first-order clearance of drug (L/h) from the central 
compartment.  V is the volume of the central compartment.  The CSF 
compartment (X(3)) has an apparent CSF volume (Vcns), given in litres.  
 Model error was attributed separately to process noise (including errors in 
sampling times or dosing) and assay variance.  Process noise was modelled using 
lambda, an additive error term.  The data were weighted by the inverse of the 
estimated assay variance.   
The data for some patients indicated that they had taken fluconazole at an 
undocumented time prior to study enrolment, since there was detectable drug in 
the first PK sample.  To accommodate this, non-zero initial conditions of all four 
compartments were estimated in the structural model.  A switch was coded 
whereby the parameterised estimate of each initial condition was multiplied by a 
binary covariate equal to 1 where fluconazole was detected in the first PK sample, 
or 0 where no fluconazole was detected in the first PK sample.  
 
2.4.4 Population pharmacokinetic covariate screening 
 The impact of patent weight, BMI, sex, ethnicity and baseline eGFR on the 
PK of fluconazole were investigated.  Bidirectional stepwise multivariate linear 
regression was employed to assess the relationship between each covariate and 
the Bayesian estimates for volume of distribution and clearance from the central 
compartment from the standard population PK model.  Covariates that were 
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retained with significant multivariate p-values (≤0.05) in the regression model 
were explored individually.  The relationship between retained continuous 
covariates and Bayesian estimates of PK parameters was explored using univariate 
linear regression.  The difference between Bayesian estimates of volume and 
clearance according to categorical covariates (sex and ethnicity) was compared 
using the Mann-Whitney test.   
 
2.4.5 Population pharmacokinetic model diagnostics 
The fit of the model to the data was assessed by visual inspection of 
diagnostic scatterplots displaying observed-versus-predicted values before and 
after the Bayesian step.  Linear regression was performed and the coefficient of 
determination, intercept and regression slope noted for each model.  In addition, 
the log-likelihood value, Akaike Information criterion (AIC), mean weighted error 
(a measure of bias) and bias-adjusted, mean weighted squared error (a measure 
of precision) were calculated and compared for each model. 
 
2.4.6 Monte Carlo Simulation and calculation of probability of target attainment 
 Monte Carlo simulation (n = 5000) was performed in Pmetrics.273  The 
support points from the final joint density were used.  For the simulations, the 
initial conditions of all compartments were defaulted to zero.  Fluconazole was 
administered at a range of dosages: 400mg q24h, 800mg q24h, 1200mg q24h and 
2000mg q24h.  The plasma and CSF AUC for fluconazole was calculated using 
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trapezoidal approximation after the sixth dose, from 144 to 168 hours after 
treatment initiation.  
Wild type fluconazole MIC data were obtained from a previously published 
collection of 5,733 C. neoformans isolates estimated using Clinical and Laboratory 
Standards Institute (CLSI) methodology.295  The modal MIC was 4mg/L (1,629 of 
5,733 strains; 28%).  Almost half of strains had MICs ≥ 4mg/L (2,834 of 5,733 
strains; 49%).  The epidemiological cut-off value for C. neoformans versus 
fluconazole was 8mg/L.  This collection of strains included molecular types VNI to 
VNIV and the pattern of MIC distribution was comparable across all molecular 
types.295 The proportion of simulated patients that would achieve a previously 
published plasma AUC/MIC target of 389.3 was determined.  This target was 
defined as the magnitude of drug exposure required for fungal stasis (defined as 
prevention of progressive fungal growth) in a murine study that employed CLSI 
methodology.248  To our knowledge, no CSF PK/PD target has been defined in 
preclinical or clinical studies of fluconazole for cryptococcal meningitis.  In the 
present study, the probability of attaining this plasma PK/PD target was examined 
at each simulated fluconazole dose. 
 
2.4.7 Meta-analysis of clinical outcome data 
 The AUC/MIC target used in the probability of target attainment analysis 
was derived from murine studies.  To enhance clinical relevance, we sought PD 
data from humans.  The PD data from patients in the present PK study are 
confounded by the co-administration of amphotericin B deoxycholate.  For this 
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reason, a search for clinical trials of fluconazole monotherapy for cryptococcal 
meningitis was performed.  The electronic databases Pubmed and Medline were 
searched on 31st January 2018 using the terms “fluconazole” and “cryptococcal 
meningitis”.  Preclinical studies and case reports were excluded.  To reduce 
potential heterogeneity, only studies of HIV-positive participants were included in 
the meta-analysis.  Baseline variables were chosen a priori for extraction from the 
studies if they had previously been determined to have a significant impact on 
clinical outcome.  These were mental status, CSF fungal burden and patient 
age.286,296  Where it was not reported, baseline CSF fungal burden was 
extrapolated from CSF cryptococcal antigen titre according to a correlation 
published by Jarvis et al.286 
 For consistency with the literature, we collected data on clinical outcomes 
commonly presented in cryptococcal meningitis trials: CSF sterility at 8-10 weeks, 
2-week mortality and 10-week mortality.  Mixed-effects meta-analysis adjusted 
for fluconazole dosage was performed.  Fungal burden in CSF, CD4 count and 
proportion of patients with reduced Glasgow Coma Score (GCS) at baseline were 
explored to assess the degree to which these modifiers accounted for inter-study 
heterogeneity in clinical outcome.   The mixed-effects model took the form: 
𝜃𝜃𝑖𝑖 = 𝛽𝛽0 + 𝛽𝛽1𝑍𝑍𝑖𝑖1 + ⋯+ 𝛽𝛽1𝑍𝑍𝑖𝑖𝑖𝑖 + 𝑢𝑢𝑖𝑖 
where 𝜃𝜃𝑖𝑖 is the corresponding (unknown) true effect of the 𝑖𝑖th study, 𝑍𝑍𝑖𝑖𝑖𝑖 is the 
value of the 𝑗𝑗th moderator variable for the 𝑖𝑖th study and 𝑢𝑢𝑖𝑖 are study-specific 
random effects such that 𝑢𝑢𝑖𝑖~𝑁𝑁(0, 𝜏𝜏2). Here, 𝜏𝜏2 denotes the amount of residual 
heterogeneity, estimated using the DerSimonian-Laird estimator.297  Additional 
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model parameters were estimated via weighted least squares with weights 
relative to the estimated 𝜏𝜏2.  The null hypothesis 𝐻𝐻0: 𝜏𝜏2 = 0 was tested using 





A total of 43 patients (23 from Vietnam and 20 from Uganda) were 
recruited over an 11-month period between January and November 2016.  
Twenty-two patients (52%) were female.  The overall median (range) age was 33 
years (20 – 73 years), weight 48 kg (32 – 68 kg), body mass index 18 kg/m2 (12 – 
25 kg/m2), creatinine at enrolment 70 µmol/L (37 – 167 µmol/L) and estimated 
glomerular filtration rate using the Cockcroft Gault equation 84.8 mL/min/1.73m2 
(35.4 – 146.7 mL/min/1.73m2).  The baseline creatinine concentration was 
significantly lower in Vietnamese patients than in Ugandan patients (median 56 
versus 79 µmol/L; p-value 0.02).  However, this did not manifest as a significant 
difference in eGFR due to different age, sex and weight profiles between the two 
patient populations.  There were no statistically significant differences between 
ethnic groups for other demographic variables.  The demographic data are shown 
by ethnicity and for the study population as a whole in table 2.1.   
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Table 2.1: Patient demographics 
Demographic or clinical 
characteristic Vietnam Uganda Combined p-value† 
Sex a (Male:Female) 13:10 8:12 23:20  















20 - 73 0.75 















32 – 68 0.23 















12 - 25 0.73 















37 - 167 0.02 















35.4 – 146.7 0.10 
a n = 43; b n = 31; c n = 41; d n = 35; e n = 33 
† p-value for difference between Vietnam and Uganda by Mann-Whitney test of significance. 
BMI: Body Mass Index; eGFR: estimated Glomerular Filtration Rate, by Cockcroft-Gault equation. 
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2.5.2 Pharmacokinetic data 
 The final dataset included 312 plasma observations and 52 CSF 
observations from the Vietnamese cohort.  From the Ugandan cohort, the dataset 
included 196 plasma observations and 115 CSF observations.  A single CSF 
observation from 1 Ugandan patient was excluded because no fluconazole was 
detectable in an isolated sample after 13 days of therapy.  This was inconsistent 
with results from other patients and could not be verified.  The mean number of 
plasma samples and CSF samples per patient was 11.8 and 3.9, respectively.  
Figure 2.1 shows the raw plasma and CSF concentration-time profiles from study 
participants.  
 
Figure 2.1: Fluconazole concentrations in 43 patients 
Black diamonds represent plasma concentrations.  White triangles represent CSF concentrations.
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2.5.3 Population pharmacokinetic analysis 
 The final mathematical model was a linear model comprised of an 
absorption compartment, central compartment, peripheral compartment and CSF 
compartment.  The fit of the final model to the clinical data was acceptable.  The 
mean parameter estimates better fitted the data than medians, and were used to 
calculate Bayesian estimates of drug exposure for each individual patient.  A linear 
regression of the observed-versus-predicted fluconazole concentrations in plasma 
after the Bayesian step was given by: observed fluconazole concentration = 
1.03*predicted fluconazole concentration + 0.27; r2 = 0.80.  For the observed-
versus-predicted fluconazole concentrations in CSF, the linear regression was 
given by observed fluconazole concentration = 1.03*predicted fluconazole 
concentration - 0.07; r2 = 0.81 (Figure 2.2 and table 2.2).  The mean weighted 
population bias for fluconazole concentrations in plasma and CSF was 0.20 and -
0.30, respectively.  The bias-adjusted population imprecision in plasma and CSF 
was 2.21 and 1.55, respectively.  The population PK parameter estimates for the 
final model are shown in table 2.3. 
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Figure 2.2: Scatter plots showing observed versus predicted values for the chosen 
population pharmacokinetic model after the Bayesian step 
 
A: Population predicted concentration of fluconazole in plasma.  R2 = 0.49; intercept = 2.89 (95% 
CI 0.51 – 5.27), slope = 0.89 (95% CI 0.82 – 0.97) 
B:  Individual posterior predicted concentration of fluconazole in plasma.  R2 = 0.80; intercept = 
0.27 (95% CI -1.08 – 1.62); slope = 1.03 (95% CI 0.98 – 1.07) 
C: Population predicted concentration of fluconazole in CSF.  R2 = 0.46; intercept = 3.39 (95% CI -
0.09– 6.87), slope = 1.03 (95% CI 0.87 – 1.2) 
D:  Individual posterior predicted concentration of fluconazole in CSF.  R2 = 0.81; intercept = -0.07 
(95% CI -1.97 – 1.84); slope = 1.03 (95% CI 0.95 – 1.10) 
 
Circles, dashed lines, and solid lines represent individual observed-predicted data points, line of 
identity, and the linear regression of observed-predicted values, respectively. All observed and 
predicted fluconazole concentrations in mg/L. FLC: fluconazole; CI: Confidence Interval. 
 80 










Linear regression of observed-predicted 
values for each patient 
p-value†  R2, a Intercept Slope 
Model 1 Plasma -2451 4928 0.20 2.21 0.80 0.27 1.03 0.56 
 CSF -0.30 1.55 0.81 -0.07 1.03 
Model 2 Plasma -2413 4854 0.36 2.38 0.80 0.01 1.03 
 CSF -0.41 1.81 0.80 0.89 1.01 
 
Model 1 did not include any covariates.  Model 2 incorporated a function to scale the volume of distribution in central compartment to patient weight. 
AIC: Akaike Information criterion. 
a Relative to the regression line fitted for the observed versus predicted values after the Bayesian step. 
† Comparison of the joint distribution of population parameter values for each model.
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Table 2.3: Population parameter estimates from the final 4-compartment 
pharmacokinetic model 
Parameter Mean Median Standard deviation 
Ka (h-1) 8.78 1.73 11.98 
SCL/F (L/h) 0.72 0.65 0.24 
Volumec /F(L) 18.07 17.41 6.31 
Kcp (h-1) 12.20 8.36 11.17 
Kpc (h-1) 18.10 18.34 8.25 
ICgut (mg) 34.67 49.99 22.74 
ICcentral (mg) 35.86 49.98 19.67 
ICCNS (mg) 31.06 49.96 23.47 
ICperipheral (mg) 34.29 49.96 13.21 
Kcs (h-1) 35.43 42.55 13.74 
Ksc (h-1) 28.63 29.04 10.03 
Volumecns /F(L) 32.07 30.49 17.60 
 
SCL: clearance; Volumec: volume of distribution in central compartment; F: bioavailability; Kcp: 
first-order rate constant from the central to peripheral compartment; Kpc, first-order rate constant 
from peripheral to central compartment; IC: initial conditions in respective compartments; Kcs: 
first-order rate constant from the central to CNS compartment; Ksc, first-order rate constant from 
CNS to central compartment; Volumecns: volume of distribution in CNS compartment. 
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2.5.4 Covariate investigation 
 Multivariate linear regression of each subject’s covariates versus the 
Bayesian posterior parameter values revealed a weak relationship between 
patient weight and estimated volume of distribution (slope 0.22, 95% confidence 
interval for the slope -0.06 to 0.51, p-value 0.05).  Incorporation of weight into the 
PK model was therefore explored.  However, values for log likelihood, Akaike 
information criterion (AIC) and population bias and imprecision were comparable 
between the two models.  The simple base model was therefore used to describe 
the data and for the subsequent simulations.  The model comparisons and the fit 
to data are summarized in table 2.2.  
 There was no relationship between the Bayesian estimates of clearance 
and volume, and ethnicity or sex in the base model.  The mean (95% CI) clearance 
was 0.74 liters/hour (0.64 – 0.83) and 0.71 liters / hour (0.59 – 0.82) for 
Vietnamese and Ugandan patients, respectively; p= 0.51.  The mean (95% CI) 
volume was 16.88 liters (14.33 – 19.44) and 19.44 liters (16.88 – 22.0) for 
Vietnamese and Ugandan patients, respectively; p= 0.16.  In males, the mean (95% 
CI) clearance was 0.79 liters /hour (0.67 – 0.90).  In females, clearance was 0.66 
liters / hour (0.57 – 0.75); p= 0.09.  In males, the mean (95% CI) volume was 18.07 
liters (15.47 – 20.67).  In females, volume was 18.07 liters / hour (15.41 – 20.73); 
p= 0.97.   
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2.5.5 Fluconazole penetration into the CSF 
 There was large variability in the AUCs generated from each patient’s 
posterior estimates.  The 38 patients who received 800mg fluconazole q24h had a 
median (IQR) AUC144-168 of 945.4 (799.2 – 1139.8) mg.h/L in plasma and 784.2 
mg.h/L (615.9 – 879.4) in CSF.  From these posterior estimates, the mean ratio of 
AUCCSF:AUCplasma was 0.82 (standard deviation 0.22).  
Monte Carlo simulation was used to estimate the distribution of drug 
exposure for dosages of 400mg, 800mg, 1200mg and 2000mg q24h of fluconazole 
(figure 2.3).  PK variability was marked, both in plasma and CSF.  After 
administration of a dosage of 1200mg fluconazole q24h, median (IQR) simulated 
plasma AUC144-168 was 1143.2 mg.h/L (988.4 – 1378.0) and CSF AUC144-168 was 
982.9 mg.h/L (781.0 – 1185.9).  The mean simulated ratio of AUCCSF:AUCplasma was 
0.89 (SD 0.44).  
 
 84 
Figure 2.3: AUC distributions in 5,000 simulated patients at escalating fluconazole 
dosages 
 
Light grey bars indicate simulated plasma AUC144-168.  Dark grey bars indicate simulated CSF AUC144-
168. 
 
2.5.6 Probability of target attainment analysis 
 Monte Carlo simulation was used to predict the probability of achieving a 
total drug AUC:MIC ratio of ≥ 389.3 in plasma.  This PD target was shown in a 
murine model of cryptococcal meningitis to be associated with a stasis endpoint 
(i.e. no net change in fungal density at the end of the experiment compared with 
that at treatment initiation).248  Only 61% of simulated patients receiving 1200mg 
fluconazole q24h achieved this PD target when the MIC of the infecting strain was 
2.0 mg/L.  For MICs ≥ 4.0mg/L, < 1% of simulated patients administered 1200mg 
q24h achieved the PD target (figure 2.4). 
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Figure 2.4: Probability of pharmacodynamic target attainment in plasma as a 
function of isolate MIC and fluconazole dosage 
 
Each line represents the proportion of 5000 simulated patients that achieve the PD target at the 
respective dosage of fluconazole.  The PD target was a plasma AUC/MIC ratio ≥ 389.3.  Bars show 
the proportion of WT strains of C.neoformans at the indicated MIC.  
 
2.5.7 Meta-analysis of clinical outcome data 
 A systematic review identified 163 relevant manuscripts, of which 11 were 
duplicates.  After reviewing titles and abstracts, 28 studies were deemed 
potentially relevant for inclusion in the meta-analysis.  Detailed examination of 
these studies resulted in the ultimate inclusion of 12 papers describing clinical 
outcomes from cryptococcal meningitis treated with fluconazole monotherapy.  In 
total, 28 patients in 1 study received 200mg fluconazole q24h,64 19 patients in 2 
studies received 400mg fluconazole q24h,65,298 97 patients in 3 studies 800mg 
q24h,299-301 113 patients in 4 studies 1200mg q24h,62,300-302 and 1 study described 
outcomes of 16 patients on 1600mg301 and 8 patients on 2g fluconazole q24h.301  
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All included patients were HIV positive.  Baseline characteristics and reported 
clinical outcomes are presented in Table 2.4. 
The final model suggests that the combination of dose and baseline fungal 
burden explains the total heterogeneity in the estimated proportion of patients 
with sterile CSF after 10 weeks of treatment (P-value for residual heterogeneity 
0.64).  However, there was not a significant relationship between dose and CSF 
sterility at 8-10 weeks (p-value 0.45).  After adjustment for dose, the test for 
residual heterogeneity in both 2 and 10-week mortality was not significant (p-
value 0.70 and 0.22, respectively), indicating that dose alone adequately explained 
total heterogeneity in mortality outcomes at both time points.  For both 2 and 10-
week mortality outcomes, there was a non-significant trend towards reduced 
mortality with escalating dosage (Figure 2.5). 
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Table 2.4: Baseline characteristics and clinical outcomes from trial data of fluconazole monotherapy, by dosing regimen 
Fluconazole 









CSF sterility, fraction 






mortality (%) Reference 
200 Uganda 28 33 (range 23-50) 43 Mean 73 . 4/8 (50) 2 months 10/25 (40) 16/25 (64) Mayanja-Kizza 1998 64 
400 USA 14 mean 38(SE 2) 0 Mean 44 (SE 13) 4§ 6/14 (43) 10 weeks NR 4/14 (29) Larsen 1990 298 
400 South Africa 5 39 (37-51) 60 41 5.53 NR NR NR 3/4 (75) Bicanic 2007 65 
800 Malawi 58 32 (29-39) 24 37 (11-58) . NR NR 17/58 (29) 33/58 (57) Rothe 2013 299 
800 Uganda 30 35 (30-38) 33 7 (3-17) 5.7 NR NR 11/30 (37) 18/30 (60) Longley 2008 300 
800 USA 9 35 100 8 4.8§ 1/9 (11) 10 weeks NR 8/9 (89) Milefchik 2008 301 
1200 Malawi 47 35 (32-40) 24 36 (17-62) . NR NR 16/47 (34) 26/47 (55) Gaskell 2014 301 
1200 Uganda 30 33 (28-42) 60 14 (4-33) 5.9 NR NR 6/27 (22) 13/27 (48) Longley 2008 300 
1200 USA 16 40 100 36 3.5§ 6/16 (37.5) 10 weeks NR 10/16 (62.5) Milefchik 2008 301 
1200 Malawi 20 36.5 (range 27-71) 40 25 (range 1-66) 5.30 1/20 (5) 2 weeks 7/19 (37) 11/19 (58) Nussbaum 2010 62 
1600 USA 16 35 100 33 3§ 10/16 (62.5) 10 weeks NR 6/16 (37.5) Milefchik 2008 301 
2000 USA 8 36 100 35 2.4§ 5/8 (62.5) 10 weeks NR 3/8 (37.5) Milefchik 2008 301 
 
*Median (interquartile rage) unless otherwise specified.  §: Extrapolated from cryptococcal antigen titre.  CSF: Cerebrospinal fluid.  SE: Standard error.  CFU: Colony-
forming units. 
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Figure 2.5: Meta-analysis of clinical trials of fluconazole monotherapy showing 
dose-adjusted effects on A) 2-week mortality and B) 10-week mortality. 
 
Right hand column provides observed and estimated proportions of patients dead at 2 weeks. 
 
 





 Fluconazole is the only drug available for induction therapy for 
cryptococcal meningitis in many regions of the world where the incidence of 
disease is highest.  An accumulating body of evidence suggests that fluconazole is 
a suboptimal agent for this indication.303  While this has long been recognised, an 
explanation for the relatively poor efficacy of fluconazole is absent.  This study 
presents a uniquely comprehensive clinical dataset describing the PK of 
fluconazole.  It provides robust estimates of CNS penetration and the variability of 
those estimates.  A high degree of CNS partitioning has been observed in previous 
clinical studies with fluconazole.294,304  Distribution into the CNS is facilitated by 
low molecular weight, low protein binding and moderate lipophilicity.86,88  
Fluconazole has proven activity against Cryptococcus neoformans.305,306  This study 
provides further understanding as to why, despite these attributes, fluconazole is 
an inferior agent for induction monotherapy for cryptococcal meningitis 
compared with amphotericin B deoxycholate.62,65,286 
 In contrast to previous studies of fluconazole PK,28,307,308 our data do not 
suggest a significant relationship between fluconazole clearance and creatinine 
clearance, nor between patient weight and volume of distribution.  The reason for 
this is not immediately clear but may relate to the relatively narrow range of 
creatinine clearance in our population, and the fact that the vast majority of 
patients in our cohort had low body weight, with the range of this covariate also 
being relatively narrow. 
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The PK model suggests that current regimens of fluconazole are 
inadequate for induction therapy for cryptococcal meningitis.  This has routinely 
been ascribed to the overly simplistic notion that fluconazole is a fungistatic agent.  
Our analyses provide further insight into the limitations of this drug.  Previous 
estimates of fluconazole CNS:plasma partition ratios have ranged from 0.52 to 
1.33.36,293,294,304,309  We have extended these estimates by rigorously quantifying 
the marked variability in the CSF PK.  This variability has consequences at both 
microbiological and clinical levels.  Suboptimal exposure of fluconazole promotes 
the expansion of intrinsically resistant cryptococcal subpopulations present at the 
initiation of therapy.310  In addition, the evolution of C. neoformans during therapy 
to become increasingly triazole resistant has been demonstrated in clinical 
studies.311,312  To be clinically effective, adequate concentrations of drug must be 
present at the site of infection for long enough to exert antimicrobial effect on 
both susceptible and resistant subpopulations.  The present analysis 
demonstrates the challenges in achieving that aim.   
At recommended fluconazole dosages of 1200mg q24h, the probability of 
PD target attainment (PTA) bisects the MIC distribution of WT C. neoformans 
isolates.  This is consistent with the findings of Sudan et al.248  Approximately half 
of patients will fail therapy because they are not able to generate the drug 
exposure required to prevent progressive fungal growth.  Since clinical PK-PD 
targets are not available for fluconazole in cryptococcal meningitis, we have used 
a target derived from a murine study.248  This assumes that CNS partitioning is the 
same in mice and humans.  The cerebrum:plasma AUC ratio in the murine study 
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was 46.9%.248  It is conceivable that this is in keeping with our CSF:plasma AUC 
ratio of 82%, though clearly it would be preferable to have clinical PK-PD targets 
defined.  Furthermore, the PK-PD target we used was derived from plasma data 
and it would have been preferable to additionally aim for a PK-PD target in CSF.  
One additional challenge in achieving adequate drug exposure at the site of 
infection, which we were unable to account for, is the role of protein binding.  
Fluconazole is approximately 10% protein bound in plasma (Table 1.2).  Our data 
reflect total fluconazole concentrations and it is possible that a portion of 
measured drug was protein bound and inactive, which raises the risk that PTA was 
slightly lower than our predictions suggest.  Nevertheless, our PTA analysis is 
supported by the 53% 10-week mortality outcomes for patients receiving 1200mg 
fluconazole q24h, estimated in the meta-analysis.  Importantly, such PTA analyses 
are based on an AUC/MIC of 389.3, which is more than an order of magnitude 
greater than the AUC/MIC ratio required for Candida albicans.289  
Progressive escalation of the dosage of fluconazole is not likely to be an 
effective strategy for improving cryptococcal meningitis induction therapy.  The 
drug exposure required to reliably treat isolates with MICs ≥ 4.0mg/L is difficult to 
achieve and potentially toxic.  Our meta-analysis suggests that escalating dosages 
of fluconazole do not increase the proportion of patients with sterile CSF at 10 
weeks.  Dosages of 2000mg q24h do not appear to significantly improve 10-week 
mortality outcomes in comparison to 1200mg q24h.  The ACTG study 
(https://clinicaltrials.gov/show/NCT00885703) is investigating the use of higher 
dosages of fluconazole (1600mg and 2000mg q24h) for the treatment of 
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cryptococcal meningitis in HIV-infected individuals and results are pending.  The 
addition of flucytosine to high-dose fluconazole (≥ 1200mg q24h) for cryptococcal 
meningitis increases antifungal activity and improves mortality outcomes,62,301 
suggesting that combination therapy is required to optimise antifungal activity in 
fluconazole-containing regimens. 
In summary, this study provides part of the pharmacodynamic rationale for 
the long-recognised fact that fluconazole monotherapy is an ineffective induction 
regimen for cryptococcal meningitis.  We have developed a fluconazole population 
PK model that suggests that approximately half of patients with cryptococcal 
meningitis caused by WT strains of C. neoformans will be undertreated by 
currently recommended dosages of fluconazole for induction therapy.  In doing so 
we have addressed a knowledge gap regarding the reason for the inferiority of this 
drug for cryptococcal meningitis.  There is a pressing need for improved provision 
of affordable combination treatments and development of more effective drugs. 
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3 Amphotericin B Deoxycholate in adults with Cryptococcal 
meningoencephalitis; a Population Pharmacokinetic Model 
and Meta-Analysis of Outcomes 
 
3.1 Declaration regarding presentation of published work within 
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pharmacokinetic model and meta-analysis of outcomes of amphotericin B 
deoxycholate use in adults with cryptococcal meningoencephalitis. Antimicrobial 
agents and chemotherapy. 2018 Jul 1;62(7). 
As the first author of this publication, I curated the data for analysis, 
constructed and validated the PK model, simulated hypothetical dosing regimens, 
performed a probability of target attainment (PTA) analysis and performed meta-
analyses of clinical outcomes.  I wrote the first draft of the manuscript and all co-
authors approved the final version for publication.  All co-authors have granted 
their permission for this published manuscript to be re-formatted and included in 
this postgraduate thesis – see appendix A. 
The published manuscript is copyrighted to Stott et al. 2018 as an open 




There is a limited understanding of the population pharmacokinetics (PK) 
and pharmacodynamics (PD) of amphotericin B deoxycholate (DAmB) for 
cryptococcal meningoencephalitis (CME).  A PK study was conducted in n=42 
patients receiving DAmB 1 mg/kg q24h.  A 2-compartment PK model was 
developed.  Patient weight influenced clearance and volume in the final structural 
model.  Monte Carlo simulations estimated drug exposure associated with various 
DAmB dosages.  A search was conducted for trials reporting outcomes of CME 
patients treated with DAmB monotherapy and a meta-analysis was performed.  
The PK parameter means (standard deviation) were: clearance, 0.03 (0.01) x 
weight + 0.95 (0.02) litres/hour; volume, 0.89 (0.90) x weight + 1.54 (1.13) litres; 
first-order rate constant from central to peripheral compartment, 7.12 (6.50) 
hours-1; from peripheral to central compartment, 12.13 (12.50) hours-1. The meta-
analysis suggested that DAmB dosage explained most of the heterogeneity in 
cerebrospinal fluid (CSF) sterility, but not in mortality outcomes. Simulations of 
area under concentration-time curve (AUC144-168) resulted in median (interquartile 
range) values 5.83 mg.h/litre (4.66-8.55), 10.16 (8.07-14.55) and 14.51 (11.48-
20.42), with dosages of 0.4, 0.7 and 1.0 mg/kg q24h respectively.  DAmB PK is 
described adequately by a linear model that incorporates weight on clearance and 
volume. Inter-patient PK variability is modest and unlikely to be responsible for 
variability in clinical outcome. There is discordance between the impact that drug 
exposure has on CSF sterility and on mortality outcomes, which may be due to 
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Cryptococcal meningoencephalitis is a leading infectious cause of 
morbidity and mortality worldwide, with approximately 223,100 incident cases 
and 181,100 deaths annually.38  Ten week mortality for patients receiving the 
current standard-of-care is 24-31%.74,75,174,286  There have been no new antifungal 
agents developed for use in LMICs in the last 3 decades.  Given the paucity of new 
agents, one important strategy for improving clinical outcomes is a better 
understanding and use of currently available compounds.   
Amphotericin B (AmB) is a polyene antifungal agent with broad spectrum 
activity against yeasts and moulds, as well as some parasites.  AmB was initially 
isolated from a streptomycete and described in 1955.313 AmB was the first 
therapeutic option for treatment of lethal invasive fungal diseases such as 
cryptococcal meningoencephalitis.314,315 Amphotericin B deoxycholate (DAmB) is 
the most potent formulation of AmB on a mg-mg basis316,317 and is a mainstay for 
the treatment of cryptococcal meningoencephalitis.   
Clinical studies have progressively examined escalating dosages of 
0.4mg/kg q24h63,318, 0.7mg/kg q24h77,319,320 and 1.0mg/kg q24h74 of DAmB for 
cryptococcal meningoencephalitis. The primary motivation of these studies was 
identification of the dosage that induces maximal antifungal activity.  A regimen 
of 1.0 mg/kg q24h in combination with flucytosine for seven days is currently 
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recommended for induction therapy.52 DAmB dosages approaching 1.0 mg/kg 
q24h are associated with increased rates of cerebrospinal fluid (CSF) sterilisation75 
and improved mortality.74,262,286 However, the broad clinical utility of DAmB is 
compromised by dose-limiting toxicities that include infusional reactions, 
phlebitis, nephrotoxicity and anaemia.53,321  A detailed understanding of the 
therapeutic index for each DAmB dosage level is lacking.  
 Herein, we describe the development of a population pharmacokinetic 
model of DAmB.  In addition, a meta-analysis of clinical trials of DAmB 
monotherapy was performed to estimate the contribution of various DAmB 
dosages to the observed heterogeneity in study outcomes. Finally, Monte Carlo 
simulations were performed to estimate the mean, median and dispersion of drug 
exposures that are associated with microbiological and clinical outcomes from 
DAmB monotherapy. 
 
3.2 Materials and Methods 
3.2.1 Clinical Pharmacokinetic Studies 
Plasma samples were obtained from adults with HIV associated 
cryptococcal meningoencephalitis. Patients were initially recruited from a 
multicentre randomised controlled trial of adjuvant treatment with 
dexamethasone in HIV-associated cryptococcal meningoencephalitis reported 
elsewhere (n=3, International Standard Registered Clinical Number 59144167).183 
Following the early cessation of this trial, they were recruited from a prospective 
descriptive study at the same sites (n=39). Patients were recruited in 2 sites: The 
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Hospital for Tropical Diseases in Ho Chi Minh City Vietnam, and Masaka General 
Hospital, Uganda.  The study protocols were approved by the relevant institutional 
review boards and regulatory authorities at each trial site and by the Oxford 
University Tropical Research Ethics Committee.  
The protocol for the randomised controlled trial has been described 
previously.322  Patients had HIV infection, a syndrome consistent with cryptococcal 
meningoencephalitis, and laboratory evidence of cryptococcal infection (positive 
India ink staining of CSF, culture of Cryptococcus spp. from CSF or blood, or 
cryptococcal antigen (CrAg) detected in CSF on CrAg lateral flow assay).262  Patients 
who were pregnant, had renal failure, had gastrointestinal bleeding, had received 
more than 7 days of anti-cryptococcal antifungal therapy, were already taking 
corticosteroids, or required corticosteroid therapy for co-existing conditions were 
excluded.  The inclusion and exclusion criteria for the prospective descriptive 
study were identical to those of the clinical trial.  Patients received 1 mg/kg DAmB 
once daily by intravenous infusion over 5-6 hours, as well as 800mg fluconazole 
per day.  Two patients recruited during the clinical trial received dexamethasone 
according to the following regimen: 0.3mg/kg/day intravenously (IV) for week 1, 
0.2mg/kg/day IV for week 2, then orally 0.1mg/kg/day for week 3, 3mg/day week 
4, 2mg/day week 5, 1mg/day week 6, then stop.  For the first five patients enrolled, 
blood samples were obtained immediately prior to intravenous DAmB infusion, 
and then at 1, 2, 4, 8, 12, 16, 20 and 24. The results for these patients informed a 
subsequent sampling strategy defined using optimal design theory such that 
patients were sampled pre-dose, then at 1, 2, 4, 8, 12 and 24 hours after the 
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initiation of infusion.  PK sampling occurred on treatment days 1 or 2, and 7.  
Whenever patients had lumbar punctures performed for other clinical indications 
such as raised intracranial pressure, paired plasma samples were collected for 
subsequent PK analysis.  Therefore, additional sparse samples were taken up to 
17 days after initial dosing.  Quantitative fungal counts were determined for each 
lumbar puncture, as described previously.320 
 
3.2.2 Measurement of Amphotericin B Concentrations 
Amphotericin B concentrations in plasma were measured using high-
performance liquid chromatography (HPLC) with a Shimadzu Prominence HPLC 
system (Shimadzu, Milton Keynes, UK).  Amphotericin B was extracted by protein 
precipitation.  A total of 300 µL of methanol that contained piroxicam 2 mg/L 
(Sigma Aldrich, Dorset, UK) as internal standard was added to 100 µL of matrix.  
Samples were vortexed for 5 seconds and then centrifuged at 13,000 x g for 3 
minutes.  
One hundred-fifty µL of supernatant was removed and placed in a 96-well 
plate, to which 50 µL of water was added.  A 50µL aliquot was injected onto a 
Kinetex 5µ XB-C18 liquid chromatography column (Phenomenex, Macclesfield, 
UK).  Chromatographic separation was achieved using a gradient with the starting 
conditions of 75% A:25% B (0.1% formic acid in water as mobile phase A and 0.1% 
formic acid in acetonitrile as mobile phase B).  Mobile phase B was increased to 
80% over five minutes and then reduced to starting conditions for two minutes of 
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equilibration.  Amphotericin B and internal standard were detected using UV 
detection at wavelengths of 406nm and 385nm; they eluted after 4.1 and 4.6 
minutes, respectively.  
The standard curve for amphotericin B encompassed the concentration 
range 0.05- 8.0 mg/L and was constructed using blank matrix.  The limit of 
quantitation was 0.05 mg/L.  The coefficient of variation was <9.3% over the 
concentration range 0.05-8 mg/L. The intra- and inter-day variation was <7.9%. 
 
3.2.3 Population Pharmacokinetic Modelling 
A PK model was fitted to the data using the non-parametric adaptive grid 
(NPAG) algorithm of the program Pmetrics273 version 1.5.0 for R statistical package 
3.1.1.  The data were weighted by the inverse of the estimated assay variance.  
Both two- and three-compartment models were tested, with zero-order 
intravenous input and first-order elimination from the central compartment.  The 
two-compartment model took the following form: 
a) 𝑑𝑑𝑑𝑑(1)
𝑑𝑑𝑑𝑑
= 𝑅𝑅(1) − �𝑆𝑆𝑆𝑆𝑆𝑆
𝑉𝑉
+ 𝐾𝐾12� ∗ 𝑋𝑋(1) +  𝐾𝐾21 ∗ 𝑋𝑋(2) 
b) 𝑑𝑑𝑑𝑑(2)
𝑑𝑑𝑑𝑑
= 𝐾𝐾12 ∗ 𝑋𝑋(1) −  𝐾𝐾21 ∗ 𝑋𝑋(2) 
c) 𝑌𝑌(1) = 𝑑𝑑(1)
𝑉𝑉
 
Where equations (a) and (b) describe the rate of change of the amount of drug 
(mg) in the central and the peripheral compartments, respectively. X(1) and X(2) 
are the amount of AmB in milligrams (mg) in the central (c) and peripheral (p) 
compartments respectively.  R(1) is the intravenous infusion of DAmB into the 
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central compartment. SCL is the first-order clearance of drug (L/h) from the central 
compartment. V is the volume of the central compartment.  K12 and K21 are the 
first-order inter-compartmental rate constants.  Equation (c) is the model output, 
with Y(1) representing the concentration of amphotericin B in the central 
compartment.  The three-compartment model contained an additional equation 
to connect the third compartment to the second compartment in series: 
d) 𝑑𝑑𝑑𝑑(3)
𝑑𝑑𝑑𝑑
= 𝐾𝐾23 ∗ 𝑋𝑋(2) −  𝐾𝐾32 ∗ 𝑋𝑋(3) 
An initial condition was estimated to accommodate detectable drug in the 
first PK sample from those patients who received a dose of DAmB at an 
undocumented time before study enrolment.  The non-zero initial conditions of 
X(1) and X(2) were estimated by assigning the respective parameters in the 
structural model (not shown in the equations above).  A switch was coded 
whereby a parameterised estimate of the initial condition was multiplied by a 
binary covariate equal to 1 where the first PK sample was drawn after a dose of 
DAmB, or 0 where this represented a pre-dose sample.  
 Once the standard model was fitted (Model 1), the effects of patient 
weight, baseline eGFR and patient ethnicity on the PK of DAmB were investigated.  
Bidirectional stepwise multivariate linear regression of each subject’s covariates 
versus the Bayesian posterior parameter values revealed a significant (P< 0.05) 
relationship between both weight and eGFR with estimated PK parameters.  
Univariate linear regression was employed, firstly to assess the relationship 
between patient weight and the Bayesian estimates for both clearance and 
volume.  Since a positive relationship was observed between weight and both PK 
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parameters, the population PK model was re-fitted to the data (Model 2) with 
incorporation of the following equations to describe (e) clearance (SCL), and (f) 
volume (V), as functions of patient weight (Wt): 
e) 𝑆𝑆𝑆𝑆𝑆𝑆 = 𝐼𝐼𝑉𝑉𝐼𝐼_𝐾𝐾 + (𝑊𝑊𝐼𝐼 ∗ 𝑆𝑆𝑆𝑆_𝐾𝐾) 
f) 𝑉𝑉 = 𝐼𝐼𝑉𝑉𝐼𝐼_𝑣𝑣 + (𝑊𝑊𝐼𝐼 ∗ 𝑆𝑆𝑆𝑆_𝑣𝑣) 
Where Int is the intercept and Sl the slope of the linear regression describing the 
relationship between weight and clearance or volume, and the intercept and slope 
for each of these PK parameters is parameterised separately. Thus, equation (a) 
of the structural model was replaced with: 
a.2)  𝑑𝑑𝑑𝑑(1)
𝑑𝑑𝑑𝑑
= 𝑅𝑅(1) − �𝐼𝐼𝐼𝐼𝑑𝑑𝑐𝑐+ (𝑊𝑊𝑑𝑑∗𝑆𝑆𝑙𝑙𝑐𝑐)
𝐼𝐼𝐼𝐼𝑑𝑑𝑣𝑣+ (𝑊𝑊𝑑𝑑∗𝑆𝑆𝑙𝑙𝑣𝑣)
 + 𝐾𝐾12� ∗ 𝑋𝑋(1) +  𝐾𝐾21 ∗ 𝑋𝑋(2). 
In addition, a power function was explored to describe the relationship 
between weight and clearance.  In this model (Model 3), clearance was 
parameterised and scaled with weight to the exponent 0.75.  This exponent has 
previously been demonstrated to usefully scale for size.323,324  A linear relationship 
was maintained between volume and weight.  Thus, in Model 3, equation (a) was 
replaced with:  
a.3)  𝑑𝑑𝑑𝑑(1)
𝑑𝑑𝑑𝑑
= 𝑅𝑅(1) − �𝑆𝑆𝑆𝑆𝑆𝑆 ∗  𝑊𝑊𝑑𝑑^0.75
𝑉𝑉∗𝑊𝑊𝑑𝑑
 + 𝐾𝐾12� ∗ 𝑋𝑋(1) +  𝐾𝐾21 ∗ 𝑋𝑋(2).  
Univariate linear regression was similarly employed to assess the 
relationship between eGFR and the Bayesian estimates for clearance and volume. 
A weaker but nevertheless positive association was demonstrated. Consequently, 
a further structural model was fitted to the data (Model 4), with the following 
equation (g) explored to describe clearance (SCL): 




Where eGFR is the estimated glomerular filtration rate calculated for each patient 
by the Cockcroft-Gault equation and med_eGFR is the population median 
estimated glomerular filtration rate.  In Model 4, equation (a) was replaced with: 
a.4)  𝑑𝑑𝑑𝑑(1)
𝑑𝑑𝑑𝑑






 + 𝐾𝐾12� ∗ 𝑋𝑋(1) +  𝐾𝐾21 ∗ 𝑋𝑋(2). 
To explore whether there were significant differences between the model 
predicted PK parameters in Vietnamese and Ugandan patients, Bayesian estimates 
of volume of distribution and clearance from the central compartment were 
compared using a Mann-Whitney test and a Student’s t-test respectively.  Since 
no significant relationship between ethnicity and DAmB PK was apparent, this 
variable was not incorporated in the final model. 
The fit of the model to the data was assessed using a linear regression of 
observed-versus-predicted values before and after the Bayesian step.  The 
coefficient of determination of the linear regression was noted in combination 
with the intercept and slope of the regression for each model. Model comparison 
was achieved through calculation of the log-likelihood value, the Akaike 
Information criterion (AIC), the mean weighted error (a measure of bias), and the 
bias-adjusted, mean weighted squared error (a measure of precision).  To verify 
the ability of the final model to predict observed concentrations with acceptable 
accuracy, a visual predictive check (VPC) of the data was performed.  For the VPC, 
the covariance matrix in Pmetrics was utilised to simulate 1000 patients 
administered DAmB on a mg per kg basis.  Simulated weight was limited to the 
range observed in our clinical cohort.  
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3.2.4 Meta-analysis of clinical outcome data 
The pharmacodynamic data from patients enrolled in the present clinical 
trial are confounded by the co-administration of fluconazole.262  Therefore, a 
search was performed for clinical trials of treatment for cryptococcal 
meningoencephalitis with at least one arm comprised of adult patients receiving 
DAmB monotherapy.  For consistency, included trials were limited to those that 
recruited HIV-positive patients.  Baseline clinical variables with demonstrated 
ability to predict patient mortality were selected a-priori and extracted from the 
studies; namely altered mental status, patient age and baseline CSF fungal 
burden.286,296  To aid meaningful trial comparison, baseline fungal burden and 
baseline CSF cryptococcal antigen titre were extrapolated from one another 
where they were not explicitly reported in the study, applying a correlation 
presented by Jarvis et al.286  
We collated a variety of clinical trial outcomes based on those that were 
commonly reported across trials of DAmB monotherapy: documented CSF sterility 
during trial follow-up, mortality at 2 weeks and, where possible, mortality at 10 
weeks.  Meta-analysis was performed on each outcome using a dose-adjusted 
random effects model to account for the baseline heterogeneity in the included 
studies. We included dose as a moderator variable in the model to assess the 
degree to which it explained heterogeneity in clinical outcome.325  The resulting 
mixed-effects model took the form: 
𝜃𝜃𝑖𝑖 = 𝛽𝛽0 + 𝛽𝛽1𝑑𝑑𝑑𝑑𝐾𝐾𝑑𝑑𝑖𝑖 + 𝑢𝑢𝑖𝑖  
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Where 𝛽𝛽0 and 𝛽𝛽1 are the model parameters intercept and dose respectively; 𝑑𝑑𝑑𝑑𝐾𝐾𝑑𝑑𝑖𝑖 
is the dose given in the 𝑖𝑖th study, assuming study-specific random effects; and 
𝑢𝑢𝑖𝑖~𝑁𝑁(0, 𝜏𝜏2), where 𝜏𝜏2 is the amount of residual heterogeneity among the true 
effects 𝜃𝜃𝑖𝑖 that is not accounted for by dose. We calculated to what extent dose as 
a moderator influenced the true average effect, and estimated the corresponding 
proportions of each outcome measure. 
 
3.2.5 Monte Carlo Simulations 
Monte Carlo simulations were performed in Pmetrics.273  Model 2 was 
used.  Amphotericin B deoxycholate was administered on a mg/kg basis and 
infused over 5.5 hours.  The initial condition of the central and peripheral 
compartment was defaulted to zero.  The weight-based dosage of DAmB was 
converted to an absolute dosage by multiplying by the simulated patient’s weight.  
This process served to mimic the bedside drug administration in the original 
clinical trial, in which dosing was planned on a mg/kg basis but the absolute dose 
that was ultimately administered was determined by the patient’s weight.  
Drug exposure was quantified using the DAmB AUC.316,317,326  The 
simulated AUC for each patient was estimated 144 to 168 hours post therapy 
initiation.  Simulations were performed to estimate the AUC that resulted from 
dosages administered in clinical trials of DAmB monotherapy for which PD 





A total of 42 patients (22 from Vietnam and 20 from Uganda) were 
recruited over an 11-month period between January and November 2016.  Twenty 
two patients (52 %) were female. The overall median (range) age was 33 years (20 
– 73 years), weight 48 kg (32 – 68 kg) and body mass index 18 kg/m2 (12 – 25 
kg/m2), creatinine at enrolment 69 µmol/L (37 – 167 µmol/L) and estimated 
glomerular filtration rate using the Cockcroft Gault equation 76.7 mL/min/1.73m2 
(35.4 – 146.7 mL/min/1.73m2). The demographic data are shown by ethnicity and 
overall in table 3.1. There were no statistically significant differences between 
ethnic groups in any demographic variable.
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Table 3.1: Patient demographics 
Demographic or clinical 
characteristic 






Sex a (Male:Female) 12:10 8:12 20:22  















20 - 73 
0.75† 















32 – 68 
0.21† 















12 - 25 
0.73∆ 















37 - 167 
0.06† 















35.4 – 146.7 
0.19† 
a n = 42 
b n = 28 
c n = 39 
d n = 33 
e n = 26 
 
† Mann-Whitney test of significance 
∆ Unpaired t test of significance 




3.3.2 Pharmacokinetic data 
 The final dataset included 282 of 312 total observations from the 
Vietnamese cohort and 197 of 241 total observations from the Ugandan cohort 
(mean 11.4 samples per patient, range 6-18). In total, 74 plasma samples were 
excluded because of absent information on the time PK samples were drawn.  





Figure 3.1: Amphotericin B serum concentrations in 42 patients 
 
Patients received 1.0 mg/kg of amphotericin B deoxycholate (DAmB), infused over 5-6 hours. 
 
3.3.3 Population pharmacokinetic models 
 Initial exploration of structural models revealed that a two-compartment 
model fitted the data better than a three-compartment model.  Specifically, the 
three-compartment structural model resulted in a more negative log likelihood 
value (-55.5 versus -42.8) and higher AIC (127.3 versus 101.9).  Accordingly, 
subsequent model development was based on a two-compartment base model.  
Model 1 was a standard two-compartment model without inclusion of 
covariates. Linear regressions of the Bayesian estimates of clearance and volume 
(derived from the mean population PK parameter values from Model 1) with 
weight and estimated glomerular filtration rate (eGFR) as covariates are presented 
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in Figures 2a and 2b, respectively. A relationship was apparent between patient 
weight and both estimated clearance (slope 1.2, 95% confidence interval for 
estimate of slope 0.51 to 1.88, p=0.002) and estimated volume of the central 
compartment, (slope 1.08, 95% CI 0.05 to 2.11; p<0.001).  Similarly, linear 
regression described a positive relationship between eGFR and estimated 
clearance (slope of linear regression 0.01, 95% CI for the slope 0 to 0.02, p<0.001) 
and volume (slope 0.67, 95% CI 0.36 to 0.98, p<0.001). These covariates were 
incorporated into the structural model as follows: Model 2 incorporated weight as 
a covariate with a linear term for clearance; Model 3 incorporated weight as a 
covariate with a non-linear term for clearance and Model 4 incorporated both 
weight and baseline renal function as covariates in the equations, with linear 
clearance.  Population PK parameter estimates for all 4 models are shown in table 
3.2.  There were no statistically significant differences in estimated clearance and 
volume from the standard model (Model 1) according to ethnicity.  The mean (95% 
CI) clearance was 2.03 litres/h (1.69 – 2.38) and 2.24 litres/h (1.91 – 2.56) for 
Vietnamese and Ugandan patients, respectively; p-value 0.37.  The mean (95% CI) 
volume was 33.55 litres (17.96 – 49.13) and 63.93 litres (40.98 – 86.88) for 
Vietnamese and Ugandan patients, respectively; p-value 0.09.  
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Figure 3.2: Linear regression of the relationship between (A) patient weight and (B) estimated glomerular filtration rate and Bayesian posterior 














Circles are Bayesian estimates from each patient. Solid line: linear regression.
R2=0.32. Clearance = 0.05*weight – 0.2 R2=0.12. Volume = 1.08*weight – 24.8 
A 
R2=0.36. Volume = 0.67*weight – 31.13 
B 
R2=0.17. Clearance = 0.01*weight + 1.03 
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Table 3.2: Parameter estimates for the initial and modified two-compartment 
pharmacokinetic models 
Parameter and model Mean Median Standard 
deviation 
Model 1 
   
SCL (L/h) 2.19 2.46 0.77 
Vc (L) 27.77 13.88 28.06 
K12 (h-1) 3.84 2.16 6.57 
K21 (h-1) 1.14 0.32 3.06 
IC (mg) 10.16 2.55 9.00 
Model 2 
   
SCLslope (L/h/kg) 0.03 0.03 0.01 
SCLintercept (L/h) 0.67 0.57 0.01 
Vcslope (L/kg) 0.82 0.36 0.80 
Vcintercept (L) 1.76 1.99 1.29 
K12 (h-1) 5.36 3.83 6.76 
K21 (h-1) 9.92 0.46 12.27 
IC (mg) 20.29 6.03 27.75 
Model 3 
   
SCL (L/h/kg) 0.12 0.12 0.04 
Vc (L/kg) 1.40 0.51 1.75 
K12 (h-1) 1.69 0.50 4.09 
K21 (h-1) 8.31 0.27 12.32 
IC (mg) 30.10 7.87 40.56 
Model 4 
   
SCLslope (L/h) 0.01 0.01 0.01 
SCLintercept (L/h) 1.50 1.31 0.74 
Vcslope (L) 1.26 0.52 1.39 
Vcintercept (L) 1.64 0.01 2.96 
K12 (h-1) 3.86 0.73 7.74 
K21 (h-1) 11.24 0.40 13.44 
IC (mg) 26.15 6.17 26.76 
 
SCL: Clearance; Vc: Volume of distribution in central compartment; K12: first-order rate constant 
from the central to peripheral compartment; K21, first-order rate constant from peripheral to 
central compartment; IC: initial condition.
 112 
 For all 4 two-compartment models the fit of the model to the data was 
acceptable.  The model diagnostics are presented in table 3.3.  The coefficient of 
determination of a linear regression of observed-versus-predicted plots after the 
Bayesian step was 0.72, 0.74, 0.69 and 0.73 for Models 1, 2, 3 and 4, respectively.  
The intercept and slope approximated 0 and 1 respectively for each regression 
(table 3.3).  The mean parameter values predicted the observed values better than 
the medians. The measures of population bias and imprecision were comparable 
between the models, with bias -0.85, -0.34, -0.23 and -0.43 and imprecision 3.13, 
2.97, 2.16 and 3.29 for Models 1, 2, 3 and 4 respectively. The more positive log 
likelihood value and lower Akaike information criterion (AIC) for Model 2 implied 
that the inclusion of weight as a covariate explained a portion of the observed 
variance.  
 











Linear regression of observed-
predicted values for each 
patient 
R2, a Intercept Slope 
Model 1 -56.3 1137 124.8 -0.85 3.13 0.72 0.08 0.97 
Model 2 -42.8 1251 101.9 -0.34 2.97 0.74 0.01 1.01 
Model 3 -102.7 577 221.7 -0.23 2.16 0.69 0.00 1.04 
Model 4 -43.1 1704 102.7 -0.43 3.29 0.73 0.01 1.02 
 
Model 2 included a linear function to scale DAmB clearance to patient weight. 
Model 3 included a non-linear function to scale DAmB clearance to patient weight. 
Model 4 included a function to scale DAmB clearance to patient weight and eGFR. 




The model that incorporated an exponential term for clearance (Model 3) 
decreased the log likelihood value and increased the AIC (table 3.3).  The inclusion 
of eGFR in Model 4 failed to increase the log likelihood value or reduce the AIC 
further.  In addition, there was no statistically significant difference between 
Model 1 and either Model 3 or Model 4; the latter models were therefore rejected. 
Model 2 was chosen as the final model.  Observed-versus-predicted plots for the 
population and Bayesian posterior values in the final model are shown in figure 
3.3.  Figure 3.4 shows a visual predictive check (VPC) of the final model.  
 
Figure 3.3: Scatter plots showing observed versus predicted values for the chosen 
population pharmacokinetic model after the Bayesian step (model 2) 
 
R2=0.17       R2=0.74 
Intercept = 0.18 (95% CI 0.03 – 0.32)  Intercept = 0.01 (95% CI -0.04 – 0.07) 
Slope = 0.89 (95% CI 0.70 – 1.09)   Slope = 1.01 (95% CI 0.95 – 1.07) 
 
Circles, dashed lines, and solid lines represent individual observed-predicted data points, 
line of identity, and the linear regression of observed-predicted values, respectively. All 
observed and predicted amphotericin B concentrations in mg/L. AmB: Amphotericin B; CI: 
Confidence Interval. 
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Figure 3.4: Visual predictive check of the final model 
 
Black circles indicate observed DAmB concentrations.  The continuous lines represent the 5th, 50th 
and 95th percentiles of DAmB concentrations in 1000 simulated patients.  In total, 83.4% of 
observed DAmB concentrations fall within the 5th and 95th percentiles estimated by the final model, 
indicating adequate model fit. 
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3.3.4 Meta-analysis of clinical outcome data 
 Five clinical trials that included a DAmB monotherapy arm were identified.  
There was one trial in which 63 patients received 0.4 mg/kg q24h63, 3 in which a 
combined 208 patients received 0.7 mg/kg q24h77,319,320 and 1 in which 99 patients 
received 1.0 mg/kg q24h.74  An additional study that reported clinical outcomes in 
untreated cryptococcal meningoencephalitis patients was also included.  The 
baseline variables and clinical outcomes of these study arms are summarised in 
table 3.4.  Due to the small number of studies, we were unable to adjust for 
baseline variables that may have had an impact on outcome measures (age, CD4 
cell count, baseline level of consciousness, baseline fungal burden and baseline 
cryptococcal antigenaemia).  The forest plots of the dose-adjusted random effects 
model are shown in figure 3.5.  The model suggests that dose adjustment accounts 
for 77% of the heterogeneity in CSF sterility (p=0.007) but did not have a significant 
impact on the heterogeneity in either 2- or 10-week mortality outcomes (33%, p= 
0.139 and 39%, p=0.092 respectively).  
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NR NR Saag et al, 
NEJM 
199263 ≈ 4.2 
0.7 mg/kg 
q24h 
Thailand 16 34 9 1/16 (6) 5.63 (5.19 – 
5.97) 



















USA 179 37 18 18/179 
(10) 












Vietnam 99 28 18 31/97 (32) 5.91 (5.49 – 
6.48) 
NR 52/99 (53) 25/99 (25) 44/99 (44) All anaemia 62/99 
(63). Grade 3-4±: 
46/99 (46) 
All 54/99 (55). 
Gr 3-4: 20/99 
(20) 




LOC: level of consciousness; no.: number; CFU: Colony Forming Units; NR: not reported; CSF: cerebrospinal fluid; CrAg: cryptococcal antigen. NEJM : New England Journal 
Of Medicine.  * Reported in.77  Italic text indicates value extrapolated from available data.  ± Grade 3-4 anaemia defined as haemoglobin <8 g/dL.  ̂  Grade 3-4 hypokalaemia 
defined as <2.5 mmol/L.
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Figure 3.5: Meta-analysis of clinical trials of DAmB monotherapy showing dose adjusted effects on A) CSF sterility, B) Mortality at 2 weeks and 
C) Mortality at 10 weeks 
A) 
 
Tau value for unadjusted model: 4.22.  Tau value for 
dose-adjusted model: 0.98.  Dose adjustment accounts 
for (4.22 – 0.98)/4.22 = 77% of heterogeneity in clinical 





Tau value for unadjusted model: 1.90.  Tau value for 
dose-adjusted model: 1.28.  Dose adjustment accounts 
for (1.90 – 1.28)/1.90 = 33% of heterogeneity in clinical 




Tau value for unadjusted model: 9.0.  Tau value for dose-
adjusted model: 4.93.  Dose adjustment accounts for 
(9.00 – 4.93)/9.00 = 45% of heterogeneity in clinical 
outcome. P-value for dose adjustment 0.07. 
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3.3.5 Monte Carlo simulations 
 Monte Carlo simulations (n = 5,000) were performed from the final 
population PK model. This enabled exploration of the consequences of the 
population PK variability, quantified in the final model, on plasma DAmB 
concentrations in a simulated population receiving the dosage regimens for which 
clinical trial outcome data were available. The median (interquartile range) AUC144-
168 was 5.91 mg/L*h (4.96 – 9.33 mg/L*h) for patients receiving DAmB 0.4 mg/kg 
q24h, 10.21 mg/L*h (8.51 – 15.72 mg/L*h) for 0.7 mg/kg q24h and 14.61 mg/L*h 
(12.14 – 22.03 mg/L*h) for 1.0mg/kg q24h. The AUC144-168 distributions from the 
simulations are shown in figure 3.6. 
 
Figure 3.6: AUC distributions based on Monte Carlo simulations 
 
Simulated dosing regimens are 0.4, 0.7 and 1.0 mg/kg q24h. Medians, 25th and 75th percentiles 






 We conducted a PK study in HIV positive adults with cryptococcal 
meningoencephalitis in regions of high disease burden, and developed a 
population PK model that enabled the extent of interpatient variability to be 
quantified.  We described the PK of DAmB using a 2-compartment PK model with 
intravenous (IV) infusion and first-order clearance of drug from the central 
compartment.  Simulated AUCs reveal relatively modest PK variability, suggesting 
that the frequently poor clinical outcomes are not the result of significant PK 
variability.  The relationship between weight and drug clearance suggests that 
weight accounts for a portion of the observed variance.  Dosage adjustment on 
the basis of weight is necessary to ensure lighter patients are not over-dosed and 
heavier patients are not under-dosed.  However, the lack of impact of either eGFR 
or ethnicity on the PK suggests that dosage adjustment for these variables is not 
necessary to achieve comparable drug exposure across patient populations. 
The model-simulated median AUC of 10.17 mg.h/L following a regimen of 
0.7 mg/kg q24h is consistent with AUCs estimated using non-compartmental 
techniques.  For example, Bekersky et al calculated an AUC0-24 of 13.9 +/- 2 mg.h/L 
after 0.6 mg/kg IV in healthy volunteers.327  However, the simulations following 
1mg/kg resulted in a median AUC of 14.52 mg.h/L, which is considerably lower 
than that derived from a non-compartmental analysis (NCA) conducted by 
Ayestarán et al for the same dose administered to neutropenic patients (28.98 +/- 
15.46 mg.h/L).328 The reason for this is not immediately clear but may relate to 
physiological differences between these two critically unwell patient cohorts.329 
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Our meta-analysis of clinical outcomes from studies of DAmB 
monotherapy is limited by the fact that the included studies recorded CSF sterility 
at diverse time points ranging from 2 weeks77 to 10 weeks.63  Nevertheless, the 
meta-analysis suggests that the dosage of DAmB has a significant impact on the 
proportion of patients with sterile CSF and that achieving CSF sterility is dose-
dependent up to 1mg/kg q24h.  However, DAmB does not have a dose-dependent 
relationship with mortality at either 2 or 10 weeks.   
The potential reasons that DAmB dosage has a positive impact on CSF 
sterilisation, but not mortality are as follows: first, AmB toxicity may contribute to 
mortality.53,321  Nephrotoxicity is dose-dependent and likely multifactorial.  It is 
associated with 4.5 times increase in the odds of mortality from cryptococcal 
meningoencephalitis at 10 weeks.53  Free drug interacts with the distal tubules of 
the nephron causing increased monovalent ion delivery, with consequent afferent 
arteriolar constriction.54  Direct tubular toxicity results in hypokalaemia and 
hypomagnesaemia leading to cardiotoxicity.54,55  Conversely, rapid infusion of 
AmB can result in extracellular shift of potassium, causing hyperkalaemia and 
cardiac dysrhythmias.56  Anaemia occurs in up to 75% of patients treated with 
DAmB as a result of direct suppression of erythropoiesis.54  Severe anaemia more 
than doubles the odds of 10-week mortality from cryptococcal 
meningoencephalitis.53  Secondly, mortality may be driven by factors not directly 
resulting from either disease or treatment.  For example, nosocomial bacteraemia 
may occur in up to 15-18% of patients hospitalised for cryptococcal 
meningoencephalitis.330  Third, fungal burden – and therefore conceivably, time 
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to CSF sterility - is just one of multiple clinical variables associated with mortality 
in cryptococcal meningoencephalitis.  Older age, altered mental status, low body 
weight, high peripheral white blood cell count and anaemia are independently 
associated with mortality at either 2 or 10 weeks.286  Immune reconstitution 
inflammatory syndrome (IRIS) remains a significant cause of mortality, occurring 
in 3 - 49% of cryptococcal meningoencephalitis patients surviving to initiation of 
antiretroviral treatment and carrying a mortality rate of up to 36%.262,331  Raised 
intracranial pressure is an additional factor associated with mortality and at least 
1 therapeutic lumbar puncture imparts a relative survival advantage of 69% in the 
first 10 days of treatment.332  Finally, the trial cohorts included in the meta-analysis 
were from diverse sites in Africa, Asia, Europe and the USA.  Factors such as health 
seeking behaviour and nutritional status may have influenced mortality outcomes.  
Our meta-analysis did not include any baseline factors besides DAmB dosage and 
we are therefore unable to identify whether they account for the heterogeneity 
in mortality that is not explained by DAmB dosage.  
The discordance between the influence that drug dosage has on CSF 
sterilisation and mortality is reflective of a growing consensus that CSF sterility is 
just one of many determinants of mortality in cryptococcal meningoencephalitis.  
A systematic review of 27 clinical trials determined that there was no correlation 
between CSF sterility at 2 weeks and all-cause mortality at either 2 or 10 weeks.296  
The most biologically plausible explanation for this is that fungal burden in the CSF 
may not reflect the extensive encephalitis that is characteristic of cryptococcal 
meningitis (which is more accurately termed meningoencephalitis).  
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Histopathological defects are more marked in patients co-infected with HIV; fungi 
accumulate in perivascular spaces, are deposited [predominantly extracellularly] 
in brain parenchyma, and form granulomatous cryptococcomas in brain 
tissue.104,106  It is conceivable that brain parenchymal damage is a dominant 
determinant of mortality and that clearance of fungi in CSF is not mirrored by 
clearance in the cerebrum and other CNS sub-compartments.  CSF sterility is an 
imperfect surrogate for the extent to which drug has penetrated to and sterilised 
the central nervous system. 
The meta-analysis suggests a strong dose-exposure-response relationship.  
Higher dosages are likely to be required to achieve efficacious drug exposure at 
the site of infection.  DAmB has a large molecular weight (924 g/mol) and complex 
binding properties.89  It is greater than 95% protein bound in plasma (Table 1) and 
does not readily penetrate the intact blood-brain barrier.  Its concentration in 
meninges and cryptococcomas has been technically difficult to quantify in any 
finer detail than brain homogenates in preclinical models.84,333  We were therefore 
required to extrapolate the CNS PK-PD relationships of DAmB based solely on 
plasma PK data, without certainty about how this relates to CNS PK.  Furthermore, 
there is a lack of clarity regarding the DAmB concentration required for 
therapeutic efficacy at the site of infection. Animal studies estimate that the 
cerebral concentration of DAmB at which the suppression of growth is half-
maximal is 0.02 mg/litre in mice and 0.154 mg/litre in rabbits.84  AmB exposure 
above the level required to optimise antifungal activity appears only to contribute 
to toxicity.83,84  Our simulations suggest that the optimal plasma AUC value in 
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humans lies somewhere between 10-15 mg.h/L, though the information required 
to extrapolate this to cerebral DAmB concentrations is not currently available.  The 
application of non-invasive, high-resolution technologies including Matrix-
Assisted Lazer Desorption and Ionisation- Mass Spectroscopy Imaging (MALDI-
MSI) is now possible, and offers the exciting potential to elucidate the PK/PD index 
associated with efficacy at the site of infection by enabling quantification of drug 
in specific cerebral sites, as has been demonstrated in murine models with 
gatifloxacin,334 doxycycline,335 pretomanid336 and rifampicin.337 
It may be the case that the maximal antifungal effect of DAmB is achieved 
with a dose of approximately 0.7 mg/kg, or slightly higher, and that gains made 
above this dose in terms of CSF sterility are offset by losses in terms of excessive 
toxicity.  This may explain why significant increases in the proportion of patients 
achieving CSF sterility are not mirrored by reductions in mortality.  The present 
analysis is not sufficient to more precisely define the optimal dosage of DAmB.  
This is partly due to the lack of consensus regarding DAmB exposure targets.  We 
are unable to propose exposure targets based on our dataset, which does not 
include site-specific PK or detailed toxicodynamic data.  In addition, the 
pharmacodynamic and clinical outcome data presented herein are derived from 
patient cohorts that are distinct from the patients that provided samples for the 
PK analysis.  DAmB monotherapy at dosages of 0.7 mg/kg q24h and 1.0 mg/kg 
q24h has not been directly compared in a randomised controlled trial.  However, 
comparison of these dosages in combination with 5FC has been performed.  
Bicanic et al demonstrated increased early fungicidal activity with 1mg/kg q24h 
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DAmB versus 0.7mg/kg q24h DAmB, both in combination with 5FC 100mg/kg/day 
in four divided dosages, but this was not reflected in reductions in mortality. A 
higher percentage of deaths was seen in the higher dose DAmB arm at both 2 
weeks (9% versus 3%) and 10 weeks (26% versus 21%) but this was not statistically 
significant (p= 0.62 and 0.77 at 2 and 10 weeks, respectively).75   
In summary, these analyses suggest that the optimal dosage of DAmB for 
the treatment of cryptococcal meningoencephalitis lies between 0.7-1.0 mg/kg 
q24h.  The precise drug exposure target that optimises clinical outcomes without 
producing significant toxicity remains to be defined.  The extent of inter-individual 
PK variability in DAmB is modest and unlikely to account for the consistently poor 
clinical outcomes from cryptococcal meningoencephalitis. 
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4 Population pharmacokinetics of liposomal amphotericin B 




 Over recent years, considerable interest has arisen in the use of 
abbreviated amphotericin B-based induction regimens for cryptococcal 
meningoencephalitis.  Shortening the duration of amphotericin B therapy offers 
the potential benefits of reduced hospital admission times, lower requirement for 
laboratory monitoring for toxicity, less burden on nursing staff to set up and 
administer intravenous infusions and lower financial costs associated with each of 
these factors.  The Antifungal Combinations for Treatment of Cryptococcal 
Meningitis in Africa (ACTA) trial drove huge progress in this regard, demonstrating 
that 7 days of DAmB (1 mg/kg/day) plus flucytosine (100 mg/kg/day) followed by 
7 days of fluconazole (1200 mg/day) is non-inferior to regimens based on two 
weeks of DAmB, in terms of mortality at ten weeks14 and one year.57 
Liposomal amphotericin B (LAmB) is a formulation of amphotericin B that 
delivers drug in unilamellar liposomes consisting of a spherical phospholipid 
bilayer into which amphotericin B compound is incorporated.  Each liposome is 
less than 100 nm in diameter and has a particle size of 0.05-0.08 µm (table 1.2).  
LAmB is particularly suited to abbreviated therapy for cryptococcal 
meningoencephalitis because it has a relatively good safety profile that permits 
higher dosages,338 a long terminal elimination phase in tissues83,339 and it achieves 
4- to 10-fold greater concentrations in brain tissue than other polyene 
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formulations at equivalent dosages.333  Despite over 25 years of clinical experience 
with LAmB for treatment of a range of IFIs in adults and children, there are limited 
data describing the pharmacological properties of the drug and in particular its 
population pharmacokinetics.26,340-342  There are no population PK models 
describing LAmB at high doses in abbreviated regimens in adult patients.    
In rabbits and mice, abbreviated LAmB regimens produce sustained 
antifungal activity.83  The AMBIsome Therapy Induction OptimisatioN (AMBITION) 
trial seeks to determine whether the same is true in humans.343  The current PK 
study was conducted as a substudy of phase III of the AMBITION trial.  By 
describing the population PK of LAmB administered at a high dose and in an 
abbreviated regimen to trial participants, we provide a basis for understanding the 
action of this drug in a clinically relevant population.  An improved understanding 
of the PK of LAmB is essential to optimise abbreviated dosing of this drug.   
 
4.2 Materials and methods 
4.2.1 Clinical study 
In phase III of AMBITION, patients with HIV-associated cryptococcal 
meningoencephalitis were randomised to either a single high dose of LAmB (10 
mg/kg/day) followed by 14 days of flucytosine (100 mg/kg/day) plus fluconazole 
(1200 mg/day) – the intervention arm - or 7 days of DAmB (1 mg/kg/day) plus 
flucytosine (100 mg/kg/day), followed by 7 days of fluconazole (1200 mg/day) – 
the control arm.343  The primary endpoint was all-cause mortality.343  The present 
PK study recruited patients allocated to the intervention arm.  Due to the 
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combination regimen received by participants in the AMBITION trial and the fact 
that the oral component of induction therapy differed between study arms, we 
were unable to assess the PD of LAmB using data from this cohort. 
The PK substudy was conducted at Queen Elizabeth Central Hospital in 
Blantyre, Malawi.  Ethical approval was granted by the Malawi National Health 
Sciences Research Committee as well as the Research Ethics Committee of the 
London School of Hygiene and Tropical Medicine.  All patients who had capacity 
to do so provided written, informed consent for participation in the trial and then 
separately for inclusion in the PK substudy.  Where patients were incapacitated, 
consent was obtained from a next of kin with legal responsibility and then re-
attempted with the patient if it became possible according to their clinical status. 
 
4.2.2 Pharmacokinetic sampling 
LAmB was administered over a 2-hour period following pre-hydration with 
1 litre of 0.9% sodium chloride containing 20 mmol potassium chloride.  Blood 
samples were collected on day 1 at 0, 2, 4, 7, 12 and 23 hours after the LAmB 
infusion was started, and then on day 7 at 2, 4, 7, 12 and 23 hours.  A volume of 2 
mL of blood was collected into heparinised collection tubes and placed on ice at 
the bedside.  Within 30 minutes of collection, samples were centrifuged at 1500g 




4.2.3 Bioanalysis of pharmacokinetic samples 
Amphotericin B concentrations in plasma were quantified by reverse phase 
ultra-performance liquid chromatography (UPLC) interfaced with a triple 
quadrupole mass spectrometer using the ACQUITY UPLC system (Waters, 
Manchester, UK).  Amphotericin B was extracted by protein precipitation, using 
natamycin as internal standard in methanol (2.5 µg/mL) and with 200 µL 
natamycin/ methanol solution to 50 µL patient sample.  Positive pressure was 
applied to filter out the protein precipitate and collect the supernatant.  A volume 
of 200 µL was added to each well containing supernatant before samples were 
analysed by UPLC – tandem mass spectrometry.  A 5 µL aliquot was injected onto 
the reverse phase ACQUITY UPLC HSS T3 column (Waters, Manchester, UK) to 
separate compounds based on their hydrophobicity.  Gradient starting conditions 
were 95% A : 5% B, with 0.1% formic acid in water as mobile phase A and 0.1% 
formic acid in acetonitrile as mobile phase B.  Mobile phase B was increased to 
99% over 2 minutes and then reduced to starting conditions for 1 minute of 
equilibration.  Flow rate was 0.4 mL/minute.  
The calibration line for amphotericin B encompassed the concentration 
range 0.25- 50.0 mg/L and was constructed using blank matrix.  The lower limit of 
quantitation was 0.25 mg/L.  The coefficient of variation was <9.0% over the 




4.2.4 Minimum inhibitory concentration testing 
 MICs to amphotericin B were determined in triplicate by Etest according 
to the manufacturer’s instructions (Biomerieux, France).  Briefly, cryptococcal 
colonies grown from CSF on days 1, 7 and 14 of treatment were inoculated into 
distilled water and the solution adjusted to 1.0 McFarland standard.  The solution 
was streaked three times, with 60-degree rotation between each application, onto 
RPMI agar (with L glutamine, without sodium bicarbonate).   This streaking 
procedure was performed twice per plate.  Once the agar was dry, sterile forceps 
were used to apply the Etest strip to the surface.  Results were read after 48 hours 
incubation at 30°C and 100% growth inhibition.  Candida albicans ATCC 90028 was 
the quality control strain.  Etests were performed in real time during the clinical 
study, rather than on stored isolates. 
 
4.2.5 Population pharmacokinetic modelling 
 The PK data were analysed using the non-parametric adaptive grid (NPAG) 
algorithm of the program Pmetrics version 1.5.2 for R version 3.6.1.273  Both two- 
and three-compartment structural models were explored to fit patient data, with 
zero-order input into the central compartment and options of both first order and 
non-linear (Michaelis Menten) elimination kinetics from the central compartment.  
Both mean and median parameter values were examined.  The fit of the various 
models to the data was assessed and compared on the basis of observed-versus-
predicted values before and after the Bayesian step, the coefficient of 
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determination of the linear regression of these data, the Akaike Information 
criterion (AIC), the log-likelihood value, the mean weighted error (a measure of 
bias) and the bias-adjusted, mean weighted squared error (a measure of 
precision).  The chosen base model took the following form: 
1. 𝑑𝑑𝑑𝑑(1)
𝑑𝑑𝑑𝑑
= 𝑅𝑅(1) − �𝑆𝑆𝑆𝑆𝑆𝑆
𝑉𝑉
+ 𝐾𝐾12� ∗ 𝑋𝑋(1) + 𝐾𝐾21 ∗ 𝑋𝑋(2) 
2. 𝑑𝑑𝑑𝑑(2)
𝑑𝑑𝑑𝑑
= 𝐾𝐾12 ∗ 𝑋𝑋(1) − 𝐾𝐾21 ∗ 𝑋𝑋(2) 
3. 𝑌𝑌(1) = 𝑑𝑑(1)
𝑉𝑉
 
Equations 1 and 2 describe the rate of change of the amount of drug (mg) 
in the central compartment and the peripheral compartment, respectively.  R(1) 
is the intravenous infusion of LAmB into the central compartment.  SCL is the first-
order clearance of drug from the central compartment in L/h.  The volume of the 
central compartment is represented by V.  K12 and K21 are the first order 
intercompartmental rate constants.  The model output (concentration of 
amphotericin B in the central compartment) is described by equation 3.  The three-
compartment model that was tested included an additional equation to describe 
movement of drug from the general peripheral compartment (2) to a separate 
compartment (3), designed to represent the CNS; equation 4. 
4. 𝑑𝑑𝑑𝑑(3)
𝑑𝑑𝑑𝑑
= 𝐾𝐾23 ∗ 𝑋𝑋(2) −  𝐾𝐾32 ∗ 𝑋𝑋(3) 
To determine whether non-linear clearance kinetics better described the 
movement of amphotericin B out of the central compartment than first order 
clearance kinetics, models that replaced equation 1 with equation 5 were run: 
5. 𝑑𝑑𝑑𝑑(1)
𝑑𝑑𝑑𝑑
= 𝑅𝑅(1) − � 𝑉𝑉𝑉𝑉𝑉𝑉𝑉𝑉
𝐾𝐾𝑉𝑉∗𝑉𝑉+𝑑𝑑(1)
+ 𝐾𝐾12� ∗ 𝑋𝑋(1) + 𝐾𝐾21 ∗ 𝑋𝑋(2) 
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In equation 5, Vmax represents the maximal rate of enzymatic metabolism 
of amphotericin B in mg/hr and Km represents the concentration of amphotericin 
B in the central compartment when enzyme activity is half maximal.   
Bidirectional stepwise multivariate linear regression was employed to 
identify any significant associations between clinical covariates and LAmB PK.  
Patient age, weight, CD4+ cell count, baseline serum creatinine and baseline 
creatinine clearance (derived from Cockroft-Gault equation) were investigated as 
independent predictors of the Bayesian posterior estimates of PK parameters 
from the baseline model.  No such associations were found to be statistically 




 Potential relationships between drug exposure and toxicity were explored.  
Exposure was measured in the first 24 hours and over the first week of therapy by 
calculating AUC0-24 and AUC0-168 through trapezoidal approximation in Pmetrics 
using the Bayesian posterior PK predictions from the population model.273  Toxicity 
was defined as changes from baseline values prior to commencement of therapy, 
with the following parameters:  a drop in haemoglobin of ≥ 2 g/dl or to ≤ 8 g/dl; a 
rise in creatinine of 35 µmol/L or ≥ double baseline value; a fall in potassium to 
<3.0 mmol/L or a rise in alanine transferase to ≥ 3 times baseline value.  Toxic 
levels were recorded at any time during the first week of treatment. 
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4.2.7 Monte Carlo simulations 
 The Pmetrics-integrated Monte Carlo engine was used to simulate 9999 
patients administered single doses of LAmB ranging from 1 mg/kg to 15 mg/kg.  To 
mimic the clinical trial, all LAmB doses administered to simulated patients were 
delivered by IV infusion over 2 hours.  The simulations served dual purposes.  
Firstly, simulation of the 10 mg/kg single dose regimen was used for internal 
model validation by means of a visual predictive check (VPC).  This was performed 
to verify the accuracy with which the model predicted observed amphotericin B 
concentrations.  The VPC was constructed by plotting simulated concentration-
time profiles (5th, 50th and 95th percentile) over observed concentrations.  The 
proportion of observed concentrations that fell within the 5th and 95th percentiles 
was measured.  Secondly, simulations of AUC resulting from a range of single 
LAmB doses provided insight into the expected parameters of drug exposure and 
the extent of PK variability resulting from those regimens. 
 
4.2.8 Bridging studies 
Since patients in phase III of AMBITION received flucytosine (100 
mg/kg/day) and fluconazole (1200 mg/day) alongside LAmB, it was not possible to 
relate clinical PD outputs from the trial to LAmB PK specifically.  A PD model 
defined in a preclinical murine model of cryptococcal meningoencephalitis83 was 
therefore used, with the AUC determined by trapezoidal approximation for each 
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simulated human patient substituted into the inhibitory Emax model generated 
from murine data:  




where  Cdens is the cerebral density of cryptococcus at baseline, Emax is the 
maximum antifungal effect produced by LAmB, EC50 the exposure of LAmB that 
produces 50% of the maximal antifungal effect, and AUC the area under the 
concentration-time curve for each simulated patient.  This Emax model was 
previously used to predict residual fungal burden at 10 days.83  A linear regression 
was performed to predict the intercept and slope for each simulated patient’s 
fungal burden over time, and from the linear regression values a predicted day 10 
residual fungal burden was calculated. 
 
4.3 Results 
4.3.1 Patient cohort 
 In total, 32 patients allocated to the intervention arm of AMBITION phase 
III were recruited to the PK study between November 2018 and October 2019.  




Table 4.1: Baseline patient data  
Demographic or clinical 
characteristic 
   
Sex (Male:Female) 21:11   
 Mean Median Range 
Age (years) 36.7 35.5 20 - 67 
Weight (kg) 51.9 50.0 40.0 – 83.0 
Haemoglobin (g/dL) 10.9 11.0 7.0 – 17.0 
Creatinine (mmol/L) 69.1 64.5 21.0 – 155.0 
Creatinine clearance 
(mL/minute) 106.5 105.2 36.5 – 369.0 
Urea (mmol/L) 4.4 4.0 2.0 - 369.0 
Potassium (mmol/L) 3.8 3.8 2.5 - 5.5 
Alanine transferase (IU/L) 26.8 19.0 3.0 – 95.0 
CD4+ T-cell count (cells/mm3) 11.1 11.5 0.0 – 24.0 
HIV viral load (Log10 copies/mL) 5.54 4.84 0 – 6.22 
 
 
4.3.2 Pharmacokinetic data 
The PK dataset contained 282 plasma observations from 32 patients, a mean of 
8.8 samples per patient.  Figure 4.1 displays the plasma concentrations of 




Figure 4.1: Amphotericin B concentrations in plasma in 32 patients  
 
  
4.3.3 Minimum inhibitory concentrations 
A total of 57 clinical strains isolated from CSF were available for MIC 
testing.  The modal MIC was 0.19 mcg/mL (19 strains), with median MIC 0.19 mg/L 
and range 0.01 – 0.64 mg/L (figure 4.2). 
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Figure 4.2:  Distribution of MICs from 57 clinical CSF samples in the study population  
 
 
4.3.4 Population pharmacokinetic model 
 Compared with the two-compartment model, the three-compartment 
model did not result in improved AIC, log likelihood or measures of imprecision or 
bias.  Similarly, no substantial improvement in these measures of fit was achieved 
when the first-order clearance model was replaced with a non-linear clearance 
mechanism.  Using the two-compartment model as reference, there was no 
significant difference in the fit of the three-compartment model or the non-linear 
clearance model (p-value for the comparison of the joint distribution of population 
parameter values between each model > 0.05, table 4.2).  The third compartment 
and the non-linear clearance model were both therefore discarded. 
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compartments 2470 2480 -0.347 2.588 -0.088 0.861 NA 
Three 




2488 2503 -0.203 3.065 -0.017 0.928 0.572 
AIC: Akaike Information Criterion 
  
Multivariate linear regression of clinical covariates did not reveal any 
significant associations between the Bayesian posterior estimates of clearance 
and volume versus age, sex, weight, renal function (baseline creatinine and 
creatinine clearance), or CD4+ cell count.  The baseline two-compartment PK 
model was therefore not modified.  The final chosen model was the simplest 
option, comprising two compartments, linear clearance and no scaling by clinical 
variables.  The observed-versus-predicted values for amphotericin B after a single 
dose of 10 mg/kg are shown in figure 4.3.  Population PK parameter estimates 
from the final model are displayed in table 4.3. 
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Figure 4.3: Scatter plots of observed versus predicted values for the chosen 
population pharmacokinetic model after the Bayesian step 
 
(A) Fit of the final model to the plasma data from the population.  Predicted concentration = 6.08 
+ (1.02 * observed concentration); r2 = 0.39.  
(B)  Fit of the Bayesian posterior PK estimates for individual patients from the final model to the 
observed data. Predicted concentration = 1.75 + (1.0 * observed concentration); r2 = 0.81.  
 
Table 4.3: Population parameter estimates from the final 4-compartment 
pharmacokinetic model 
Parameter Mean Median Standard deviation 
Clearance (L/h) 0.72 0.56 0.43 
Volume (L) 5.67 6.34 2.88 
K12 12.39 8.34 10.18 
K21 22.52 22.30 5.73 
 
4.3.5 Internal model validation 
 Taking the median weight in the cohort of 50 kg, a VPC was performed by 
simulating 9999 patients who were administered a single dose of LAmB (10 mg/kg) 
and using the final PK model.  In total, 90.1% of observations from the original 
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datafile fell within the 5th and 95th simulated percentiles, indicating adequate 
model fit (figure 4.4). 
 
Figure 4.4: Visual predictive check of the final model 
 
Black circles indicate observed amphotericin B concentrations.  The continuous lines represent the 
5th, 50th and 95th percentiles of DAmB concentrations in 1000 simulated patients.  In total, 90.1% 
of observed amphotericin B concentrations fall within the 5th and 95th percentiles estimated by the 
final model. 
 
4.3.6 Pharmacodynamic relationship 
A relationship between exposure and response was apparent from the 
murine data, which revealed a fungistatic effect with adequate exposure to 
LAmB.83  In the inhibitory Emax model derived from the murine data, Cdens, Emax and 
EC50 were 7.503 log10 CFU/g, 3.894 and 19.15 mg/L, respectively.  According to this 
model, maximum antifungal effect in mice is attained with an AUC0-24 of 
approximately 580 mg.h/L, which followed a single dose of 20 mg/kg LAmB.  
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Beyond this, progressively increasing AUC0-24 values achieve negligible gains in PD 
effect (figure 4.5). 
 




4.3.7 Monte Carlo simulation and bridging studies 
Monte Carlo simulations were performed in Pmetrics using the final two-
compartmental model.273  Dosages of LAmB from 1 mg/kg to 15 mg/kg were 
simulated.  In each simulated regimen, LAmB was infused over 2 hours as a single 
dose on day 1.  The predicted values for AUC0-24 and associated antifungal effect 
according to the Emax model derived from murine data are displayed in figure 4.6. 
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Figure 4.6: Simulated area under the concentration-time curve and residual fungal 




Histograms on the left display simulated AUC0-24 following a single dose of LAmB on day 1.  Line 
plots on the right show predicted fungal burden in cerebral tissue on day 10.  With greater doses 
of LAmB, the variability in residual fungal burden at 10 days declines.  The benefit in terms of 




4.3.8 Measures of toxicity 
Anaemia was common in the clinical cohort, with baseline haemoglobin ≤ 
8 g/dL in 16% of patients (n=5).  Anaemia developed on treatment in 56% of 
patients (n=18).  Renal injury with a rise in creatinine was evident in 47% of 
patients during the course of treatment (n=15).  Before treatment, hypokalaemia 
(potassium ≤ 3.0 mmol/L) was present in 6% of patients (n=2), however 25% of 
patients became hypokalaemic during the course of treatment (n=8).  Finally, 22% 
of patients (n=7) developed a rise in ALT by ≥ 3 times baseline value.  There were 
no significant correlations between LAmB exposure (in terms of either AUC0-24 or 
AUC0-168) and any of these measures of toxicity. 
 
4.4 Discussion 
This study is the first to assess and model the population PK of LAmB 
administered as a single high dose to adult patients with cryptococcal 
meningoencephalitis.  A simple 2-compartment model with first order clearance 
of drug from the central compartment fit the data well and enabled the extent of 
inter-individual variability in PK to be quantified at the population level.  PK models 
describing concentration-dependent clearance mechanisms did not provide any 
improvement in model fit over models describing first order clearance of 
amphotericin B.  This finding contrasts with other reports, which suggest that 
nonlinear clearance mechanisms may be activated with high doses of LAmB (7.5 – 
15 mg/kg/day).344  However, both the present analysis and another341 that 
modelled data derived from adult patients administered a dose of 10 mg/kg found 
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no evidence of nonlinear PK at this dose and it may be that these alternative 
clearance mechanisms are only activated at doses higher than 10 mg/kg.  In 
addition, since patients in the present study received a uniform weight-based 
dosage of LAmB and there was modest variation in bodyweight among the cohort, 
we had limited ability to detect PK nonlinearity. 
Simulated AUCs produced from high dose LAmB regimens exhibited 
considerable variability.  Exploration of clinical covariates (i.e. age, sex, measures 
of renal function and CD4+ cell count) did not reveal the source of this variability.  
It is possible that the complex logistical nature of this study, which was conducted 
in a relatively chaotic clinical setting of limited resources, accounted for some 
variation in drug administration and PK sampling times, though all reasonable 
efforts were made to mitigate this.  A degree of variability may be accounted for 
by process noise inherent to the laboratory drug assay.  However, a substantial 
portion of the PK variability observed in this study likely represents true PK 
variability that is characteristic of LAmB itself, as has been reported by others.26,341  
Indeed, we are not the first to report the absence of a relationship between weight 
and LAmB PK342 and it has been suggested that any such signal may be obscured 
by the inherent PK variability of the drug.341 
We found no relationship between LAmB exposure and the frequency of 
adverse events.  The fact that LAmB was well tolerated in our cohort is 
unsurprising, since 10 mg/kg of LAmB is routinely administered for visceral 
leishmaniasis and dosages as high as 15 mg/kg/day are well tolerated in adult 
patients.344,345  The low propensity of LAmB to cause nephrotoxicity, compared 
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with DAmB, may be related to the lipoprotein binding affinities of each 
formulation; LAmB preferentially binds high density lipoproteins (HDL), which are 
taken up by the reticuloendothelial system (RES).346,347  Levels of amphotericin B 
in the kidney are therefore lower than those in the RES after LAmB 
administration.347  In contrast, DAmB has an affinity for low density lipoproteins 
(LDL), receptors for which are highly expressed on glomerular endothelium.348,349  
Furthermore, the liposome vehicle of amphotericin B in LAmB may enhance the 
drug’s selectivity for fungal cell membranes over mammalian cell membranes, 
through the interaction of the liposome with fungal phospholipases.344,350,351  
Resistance to amphotericin B is rare, likely due to the extreme fitness costs 
to yeasts imposed by the evolution of such resistance.70,352  Clinical strains isolated 
from our cohort exhibited universally low MICs.  The biological relevance of this is 
difficult to interpret, however, since the factors that determine amphotericin B 
susceptibility at the site of infection in the CNS (for example, drug penetration, 
local pathophysiology and immune response) are not replicated in the laboratory 
conditions under which MICs are measured, and in any case vary between mice 
and humans.  We therefore quantified drug exposure in terms of PK in isolation 
(AUC0-24), rather than qualifying it with a PD measure such as AUC/MIC.   
Since the clinical PD data were confounded by the coadministration of 
additional antifungal agents in our cohort, we used a previously published PD 
model from murine data83 and bridged those findings to hypothetical human 
patients using the posterior predictions from our PK model and Monte Carlo 
simulations.  The population PK variability captured in our PK model and explored 
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further in the simulations enabled predictions of PD variability.  The central 
assumption to performing a bridge in this manner is that drug partitioning from 
plasma to the site of infection is comparable in mice and humans, and that the PD 
relationship is consistent between these species.279  These assumptions permit the 
characterisation of drug exposure in terms of the pathogen itself, rather than the 
host, so that this exposure can be translated between different hosts.  In mice, the 
concentration of LAmB in the cerebrum scales in proportion to plasma 
concentrations and there appears to be minimal delay in drug partitioning 
between the central and CNS compartments;83 plasma levels are therefore likely 
to provide a reasonable surrogate for CNS levels.  Of note, we were unable to 
verify the relationship between plasma and CNS LAmB PK in the present study, 
since we had access to plasma PK data only.  LAmB is greater than 95% bound to 
plasma proteins (Table 1) and is consistently detectible at only negligible levels in 
CSF.119  We were therefore obliged to extrapolate PK-PD relationships between 
plasma PK and CNS PD, without certainty regarding LAmB penetration into the 
CNS.  Nevertheless, our simulations predict a dose-response relationship between 
single dose LAmB and reduction in CNS fungal burden.  The magnitude of this 
dose-response relationship declined with doses in excess of approximately 7 to 10 
mg/kg, above which reductions in fungal burden were less pronounced with each 
dose escalation.  The benefit of increasing dosage above 10 mg/kg is to reduce the 
population variability around achieving maximal antifungal response, rather than 
increasing the magnitude of that response.  This adds support to the choice of 10 
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mg/kg as the dosage for single dose LAmB regimens for cryptococcal 
meningoencephalitis.   
While the murine model that we reference has provided a relevant basis 
for this bridging study, preclinical PD data from short-course LAmB regimens are 
scarce and it would be preferable to have additional corroborative information to 
support our findings.  In particular, data from rabbits rather than mice may provide 
additional insights into the PK of LAmB in abbreviated regimens.  The rabbit model 
of cryptococcal meningoencephalitis has several advantages over the murine 
model in terms of its applicability to clinical infection and PD.  Firstly, infection in 
rabbits can be traced with serial aspiration of CSF to quantify fungal burden, 
mimicking investigations of clinical infection.250  Secondly, immunocompetent 
rabbits (like humans but unlike mice) are naturally resistant to disseminated 
cryptococcal infection and require immunosuppression prior to inoculation of 
yeast.250,353  Third, a chronic basilar meningitis develops in rabbits and humans 
that is associated with mononuclear cell infiltration in the CSF.165,250 Fourth, many 
adverse prognostic features for cryptococcal meningoencephalitis are shared 
between rabbits and humans, including high cryptococcal antigen titres in CSF, 
high baseline fungal burden in CSF, paucity of CSF leukocytes and systemic 
dissemination of infection.250,286,303,354  Finally, LAmB clearance in rabbits is 
reportedly non-linear and so this model may offer a more clinically relevant PK-PD 
model for human doses of LAmB that are greater than 10 mg/kg/day, where non-
linear clearance is reported.344,348  Lestner et al found that while maximal anti-
cryptococcal activity was achieved in mice with an AUC0-24 of 580 ± 30 mg.h/L after 
 148 
a single dose, experiments in rabbits demonstrated that a sustained CNS response 
required three consecutive daily doses of 5 mg/kg, a cumulative AUC0-72 of 2,499 
mg.h/L.83  To achieve this AUC in humans would require huge dosages with 
unacceptable risks of toxicity.  Moreover, the relevance of an AUC measured over 
72 hours to human cryptococcal PD is unclear.  Is it necessary to achieve 
therapeutic concentrations over a prolonged period of 72 hours rather than 24 
hours?  Single-dose data from humans would suggest that a higher AUC of shorter 
duration is sufficient for sustained antifungal effect, and this maximises the 
practical benefits of the abbreviated IV regimen - particularly in resource-
constrained settings.  This highlights an important limitation of measuring drug 
exposure using AUC - measures of concentration and time are amalgamated such 
that there is some loss of precision in terms of the target shape of that AUC.  
Detailed PK/PD studies in rabbits that test single ascending dosages as well as 
various short-course daily regimens may provide valuable insight into this 
dilemma. 
The pharmacological mechanisms that explain why LAmB should be 
effective in single-dose or abbreviated regimens remain somewhat elusive.  
Despite the simplicity with which our population model was able to capture the 
plasma PK of LAmB, the drug exhibits complex molecular pharmacology which is 
not fully understood.  It is clear from our model that plasma concentrations fall to 
negligible levels 48 – 72 hours after a single dose of 10 mg/kg of LAmB.  From 
preclinical models and from the phase II trial of AMBITION, we know that despite 
the fall in plasma levels the drug appears to exert ongoing anti-cryptococcal 
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activity that is noninferior to prolonged regimens of DAmB.83,343,355  This would 
imply that there is ongoing drug exposure at the site of infection – that is, in the 
meninges and/or cerebral tissue.  Certainly LAmB has a long terminal half-life in 
both plasma and cerebrum – approximately 152 hours in one study327 -  however 
one would nevertheless expect that if concentration-time profiles in the CNS and 
in plasma were synchronised, drug exposure in the CNS would fall to 
subtherapeutic levels over too short a time for antifungal effect to be adequate.  
It has been suggested that there is an exhaustive number of CNS binding sites for 
amphotericin B, from which the drug does not readily disengage.  Once saturated, 
these sites form a reservoir of drug that has ongoing antifungal activity.83  This 
theory is supported by our PD simulations, which predict that while single dosages 
of LAmB above 10 mg/kg result in progressively increased AUC0-24, they impart 
limited additional PD effect beyond reducing the variability around achieving 
maximal antifungal activity.  Similarly, studies comparing daily administration of 
different dosages of LAmB for cryptococcal meningoencephalitis338 and other 
disease states356-358 found no additional antifungal activity at higher dosages.  
Alternatively, or perhaps in addition to persistence of drug in the CNS, it is possible 
that concentrations of amphotericin B achieved in meninges and/or cerebral 
tissue are considerably higher than those in plasma, though murine data does not 
support this possibility.83 
 There are a number of limitations of this study, many of which apply to PK-
PD bridging studies in general.78  We used a murine PK-PD model of single dose 
LAmB to simulate PD response in humans.  Several differences between the 
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experimental murine model and our own clinical population PK study have the 
potential to limit the reliability of the bridge.  The murine experiment used a 
laboratory strain of C. neoformans, which may have altered virulence compared 
to the clinical strains causing cryptococcal meningoencephalitis in the clinical 
cohort.  The impact of this possibility on our bridging study would have been 
minimised by our AUC rather than AUC/MIC-based analysis.  Experimental models 
of cryptococcal meningoencephalitis study an acute infection, the pathology of 
which may be markedly different from the chronic, indolent pathology that 
characterises clinical cryptococcal meningoencephalitis.  Pathophysiological 
differences potentially impact drug partitioning into CNS sub-compartments, as 
we have reviewed elsewhere.100  In all bridging studies of this nature, there is an 
inherent assumption that the PD endpoint of interest in animals is predictive of 
clinical outcome in humans.  In the largest simulated PD response following a 
single dose of 15 mg/kg, the median fungal burden remaining in cerebrum was 
3.70 log10 CFU/g.  Whether this is sufficient antifungal activity in 
immunocompromised humans is debateable.  Indeed, the differences in immune 
status between experimental mice, which are inherently susceptible to 
disseminated cryptococcal infection without requiring iatrogenic 
immunocompromise and humans who are overwhelmingly profoundly 
immunocompromised when they develop cryptococcal meningoencephalitis, 
render comparisons between the groups fraught with uncertainty.  In addition, 
the murine PD model assumed a mono-exponential decline in PD, which may not 
reflect the heterogeneity in PD response among fungal subpopulations that 
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appear to be present in clinical disease.67,262  The assumption of mono-exponential 
fungal decline risks the prediction of CNS sterility when residual infection may 
exist, with implications for the risk of ongoing disease or relapse.  The only way to 
validate the targets derived from animal data as clinically applicable PD endpoints 
is to corroborate those targets with extensive clinical outcome data, which at 
present do not exist for the treatment of cryptococcal meningoencephalitis with 
LAmB.  
 In summary, this study provides the first population PK model of high single 
dose LAmB in patients with HIV-associated cryptococcal meningoencephalitis.  
The bridging study represents an initial attempt to contextualise the drug 
exposure produced by this regimen in terms of its predicted PD impact, and was a 
necessary strategy to adopt in the absence of non-confounded PD data from 
humans.  The bridging approach was also mindful of the fact that opportunities to 
conduct a PK-PD study in humans with HIV-associated cryptococcal 
meningoencephalitis administered a single dose of LAmB in monotherapy are 
unlikely to be forthcoming in the foreseeable future, since regimens with a 
backbone of fluconazole and flucytosine have been shown to be safe and relatively 
efficacious.40  As stated, more detailed studies of LAmB monotherapy at high 
doses in rabbits may help to elucidate the PK-PD relationships of single dose 
regimens.  Finally, this study underscores the importance of thorough and detailed 
PK-PD analysis in the development of novel antifungals, by demonstrating the 
challenges associated with post-hoc PK-PD analysis. 
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5 Population Pharmacodynamics of Itraconazole for 
Disseminated Infection Caused by Talaromyces marneffei 
 
5.1 Abstract 
First-line treatment of talaromycosis with amphotericin B deoxycholate 
(DAmB) is labour intensive and toxic.  Itraconazole is an appealing alternative 
antifungal agent.  Pharmacokinetic (PK) and pharmacodynamic (PD) analyses of 
itraconazole in talaromycosis are lacking.  Pharmacokinetic data were obtained 
from 76 patients and serial CFU counts in blood were available for 66 of these.  
Both itraconazole and its active metabolite, hydroxyitraconazole, were measured 
and modelled alongside the PD data in a population model.  Itraconazole PK 
variability was considerable, with area under the concentration-time curve over 
24 hours (AUC24) mean ± standard deviation 3.34 ± 4.31 mg*h/liter.  
Hydroxyitraconazole pharmacokinetics were similarly variable: AUC24 3.57 ± 4.46 
mg*h/liter.  Levels of both analytes were overwhelmingly low; itraconazole 
minimum concentration (Cmin) 0.11 ± 0.16 mg/liter; hydroxyitraconazole Cmin 
0.13 ± 0.17 mg/liter.  The mean maximal rates of drug-induced killing for 
itraconazole and hydroxyitraconazole were 0.206 and 0.208 log10 CFU/mL/h, 
respectively.  The concentrations of itraconazole and hydroxyitraconazole that 
induced half-maximal rates of kill were 13.449 and 8.640 mg/liter, respectively.  
Forty-eight percent of patients who were fungaemic at presentation remained 
fungaemic after 14 days of itraconazole therapy.  There was no relationship 
between itraconazole Cmin:MIC and time to sterilisation of the bloodstream (HR 
1.01, 95% CI 0.99 to 1.03, p=0.43), time to death (HR 0.99, 95% CI 0.96 to 1.02, 
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p=0.77) or early fungicidal activity (EFA) (predicted log10 EFA/ml/day = -0.64 - 0.004 
* (Cmin:MIC), p = 0.18).  Similarly, there was no relationship between AUC:MIC 
and time to sterilisation of the bloodstream (HR 1.00, 95% CI 0.99 to 1.00, p=0.50), 
time to death (HR 1.00, 95% CI 0.99 to 1.00, p=0.91) or EFA (predicted log10 
EFA/ml/day = -0.64 - 0.0001 * (AUC:MIC), p = 0.19).  This study illustrates why, 
despite encouraging preclinical data, itraconazole failed to satisfy non-inferiority 
criteria against DAmB for talaromycosis.  This was a PK failure and the case for 
itraconazole in talaromycosis remains open.  
 
5.2 Introduction 
Talaromyces marneffei is a thermally dimorphic fungus with endemicity 
limited to Southeast Asia (northern Thailand, Vietnam and Myanmar), South Asia 
(northeastern India) and East Asia (southern China, Hong Kong and Taiwan)359.  In 
these regions, talaromycosis is the third most common opportunistic infection 
after tuberculosis and cryptococcal meningoencephalitis and a leading cause of 
morbidity and mortality among people living with HIV/AIDS.44,360  Mortality rates 
are as high as 30% at 6 months, despite modern antifungal chemotherapy and 
supportive care.44,361,362  Talaromycosis is also increasingly reported in patients 
with underlying immunosuppressive conditions other than HIV.363  Disseminated 
infection manifests as fever, bone marrow involvement (anemia, leukopenia, 
thrombocytopenia), skin lesions, weight loss, lymphadenopathy, 
hepatosplenomegaly, respiratory failure and circulatory collapse.44,364   
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 Itraconazole is an orally bioavailable broad-spectrum antifungal agent with 
a relatively favorable safety profile in comparison to other systemic antifungal 
agents.50  It is used for the prevention and treatment of a wide range of fungal 
diseases including aspergillosis, candidiasis and those caused by dimorphic fungi 
such as histoplasmosis, blastomycosis and talaromycosis.365-369  Itraconazole is 
lipophilic, poorly soluble at physiological pH and highly protein bound.100  It 
partitions into lipid-rich tissues and drug exposure increases at the effect site in 
the setting of tissue infection and inflammation.365,370  Higher exposures are 
associated with greater clinical response but also increased likelihood of 
toxicity.371-378  Itraconazole has recently been shown in a randomized clinical trial 
to be inferior to amphotericin B deoxycholate (DAmB) for the induction phase of 
treatment for talaromycosis, with risk of death at week 24 11.3% in the DAmB 
group and 21.0% in the itraconazole group (p < 0.001).50 
This study describes the population pharmacokinetics (PK) and 
pharmacodynamics (PD) of itraconazole for patients with talaromycosis.  The PK-
PD study was performed as a substudy of the aforementioned clinical trial that 
compared itraconazole to DAmB for the initial 14 day induction phase of 
treatment of talaromycosis.50  The pharmacodynamics of itraconazole were 
estimated using serial quantification of fungal density in the bloodstream of 
patients that were fungaemic. 
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5.3 Materials and methods 
5.3.1 Clinical study 
The PK and PD data were collected during a substudy of a multicentre 
prospective randomised clinical trial (Itraconazole versus Amphotericin B for 
Talaromycosis (IVAP) trial, ISRCTN5914416750), which compared clinical response 
and mortality following treatment with itraconazole (300mg q12h for 3 days 
followed by 200mg q12h for 11 days) to DAmB (0.7 mg/kg/day) for induction 
therapy for HIV-associated talaromycosis.50  Patients were recruited between 
October 2012 and December 2015 from the Hospital for Tropical Diseases in Ho 
Chi Minh City, Vietnam.  Patients in the itraconazole arm were encouraged to take 
a small meal or to drink cola prior to drug administration, which was directly 
observed during the 14-day induction period of treatment.  Patients over 18 years 
of age with culture-confirmed talaromycosis and HIV infection were eligible for 
the trial.  Exclusion criteria included infection of the central nervous system, 
pregnancy, liver transaminase level > 400 U/litre, absolute neutrophil count < 500 
cells/mm3, creatinine clearance < 30 ml/min, or existing prescription of any 
antifungal therapy for more than 48 hours.  IVAP trial participants at the Hospital 
for Tropical Diseases in Ho Chi Minh City were invited to participate in the PK-PD 
substudy.  Ethical approval was granted by the Hospital for Tropical Diseases, the 
Oxford University Tropical Research Ethics Committee, and the Vietnam Ministry 
of Health.   
 
 156 
5.3.2 Pharmacokinetic and pharmacodynamic sampling 
A total of 76 patients randomised to receive itraconazole agreed to 
participate in the PK-PD substudy.  For the PK, 2 mL of blood was collected in 
heparinised collection tubes and placed immediately on ice.  Within 30 minutes of 
collection, samples were centrifuged at 2000 rpm for 15 minutes and the plasma 
stored at -80 °C until analysis.  Itraconazole and hydroxyitraconazole were 
extracted on site in Ho Chi Minh City (extraction procedure described below).  
Samples containing acetonitrile as internal standard were plated onto Sabouraud 
dextrose agar in three independent experiments to confirm sterility.  Samples 
containing extracted drug were stored at -80°C until shipment to the University of 
Liverpool for analysis. 
 For the PD analysis, blood was collected for daily quantitative culture for 
the first 4 days of treatment and then on alternate days for the remainder of the 
first 14 days of treatment, until there was no microbial growth.  Quantitative 
culture was performed by serially diluting 100 µL of blood 10-fold and plating onto 
Sabouraud dextrose agar.  Plates were incubated at 37°C for quantification of 
fungal burden. 
 
5.3.3 Bioanalysis of pharmacokinetic samples 
Itraconazole and hydroxyitraconazole concentrations in plasma were 
measured using LC-MS/MS methodology (1260 Agilent UPLC coupled to an Agilent 
6420 Triple Quad mass spectrometer, Agilent Technologies UK Ltd, Cheshire, UK).  
Itraconazole was extracted in Vietnam by protein precipitation.  In total, 300 µL of 
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acetonitrile containing 6,7-Dimethyl-2,3-Di-(2-Pyridyl)-Quinoxaline 10 ng/mL was 
added to 100 µL of matrix.  Samples were vortexed thoroughly and then 
centrifuged at 13600 rpm for 3 minutes.  Three hundred µl of supernatant was 
removed and placed in a 500 µL Eppendorf tube for storage at -80 degrees Celsius 
prior to shipping to the University of Liverpool.  Samples were thawed and 
vortexed before 150 µL supernatant was transferred to a 96-well autosampler 
plate.  Thirty µL was injected on an Agilent ZORBAX C18 RRHD (2.1 X 50mm, 1.8 
µm) (Agilent Technologies UK Ltd, Cheshire, UK). 
Chromatographic separation was achieved using a gradient consisting of 60% 
A:40% B (0.1% aqueous Trifluoroacetic Acid (TFA) as mobile phase A and 0.1% TFA 
in acetonitrile as mobile phase B).  The mass spectrometer was operated in 
positive ion mode and a multiple reaction monitoring (MRM) method used for 
optimum sensitivity and selectivity.  The limit of quantitation of both itraconazole 
and hydroxyitraconazole was 0.005 µg/mL.  The intra-day coefficient of variation 
(CV) for itraconazole was < 13.5% and the inter-day CV < 10.5%, over the 
concentration range 0.005 – 8.0 µg/mL.  For hydroxyitraconazole, the intra-day CV 
was < 9.0 % and the inter-day CV was < 8.7% over the same concentration range. 
 
5.3.4 Minimum inhibitory concentration testing 
The MICs of itraconazole against Talaromyces marneffei were determined 




5.3.5 Population pharmacokinetic modelling 
Concentration-time data for itraconazole in plasma were modelled using 
the population PK program Pmetrics (version 1.5.0).273  The population PK of 
itraconazole were solved as a first step, before constructing and fitting a 
population PD model.   
 The base PK model was itself constructed in a 2-step process, since 
itraconazole has an active metabolite, hydroxyitraconazole.  Firstly, a model was 
developed to describe the PK of the parent drug.  Three clearance models were 
tested: linear clearance only, Michaelis-Menten clearance (concentration-
dependent, saturable clearance) and a combination of both of these mechanisms.  
The final base model for the PK of the parent drug took the form: 
1. 𝑑𝑑𝑑𝑑(1)
𝑑𝑑𝑑𝑑
=  −𝐾𝐾𝐾𝐾 ∗ 𝑋𝑋(1) 
2. 𝑑𝑑𝑑𝑑(2)
𝑑𝑑𝑑𝑑
= 𝐾𝐾𝐾𝐾 ∗ 𝑋𝑋(1) − �𝐾𝐾23 + 𝑉𝑉𝑉𝑉𝑉𝑉𝑉𝑉
𝐾𝐾𝑉𝑉∗𝑉𝑉𝑉𝑉+𝑑𝑑(2)
� ∗ 𝑋𝑋(2) + 𝐾𝐾23 ∗ 𝑋𝑋(3) 
3. 𝑑𝑑𝑑𝑑(3)
𝑑𝑑𝑑𝑑
= 𝐾𝐾23 ∗ 𝑋𝑋(2) − 𝐾𝐾32 ∗ 𝑋𝑋(3) 
Where equations 1, 2 and 3 describe the rate of change in amount of itraconazole 
in milligrams in the gut, central and peripheral compartments, respectively.  Ka is 
the absorption rate constant from the gut to the central compartment.  X(1), X(2) 
and X(3) are the amounts of itraconazole in the gut, central and peripheral 
compartments respectively, in milligrams.  K23 and K32 represent first-order 
transfer constants connecting the central and peripheral compartments.  Vmax is 
the maximal rate of enzymatic metabolism of itraconazole (mg/hr) and Km (mg/L) 
is the concentration of itraconazole in the central compartment at which enzyme 
activity is half maximal.  Vp is the volume of the central compartment in litres.   
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 The same variations of clearance mechanism were investigated to 
incorporate the hydroxyitraconazole (metabolite) data in the PK model.  In this 
case, solely linear clearance, without a saturable clearance component, provided 




=  � 𝑉𝑉𝑉𝑉𝑉𝑉𝑉𝑉
𝐾𝐾𝑉𝑉∗𝑉𝑉𝑉𝑉+𝑑𝑑(2)






=  𝐾𝐾45 ∗ 𝑋𝑋(4) − 𝐾𝐾54 ∗ 𝑋𝑋(5) 
Where equations 4 and 5 describe the rate of change in amount of 
hydroxyitraconazole in milligrams in the central and peripheral compartments, 
respectively.  Accordingly, X(4) and X(5) are the amounts of hydroxyitraconazole 
in those compartments in milligrams, with K45 and K54 the first-order 
intercompartmental rate constants.  SclM is the first-order clearance of 
hydroxyitraconazole from the central compartment (litres/hour), and Vm the 
volume of the central compartment of hydroxyitraconazole in litres.  Vm was fixed 
as a ratio of Vp, taken from the median ratio of parent to metabolite 
concentrations at each time point in the data.   
 Multivariate bidirectional linear regression of each subject’s covariates 
against the posterior parameter values was performed to determine whether any 
clinical variables impacted PK parameters.  The fit of the model to the data was 
assessed using a visual inspection and linear regression of the observed-predicted 
scatter plots both before and after the Bayesian step.  Measures of precision and 
bias were assessed.  Models were compared by assessing 2 x difference in log-
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likelihood values evaluated against a chi-square distribution with the appropriate 
number of degrees of freedom (difference in number of parameters between 
candidate models).  Information loss was estimated using the Akaike information 
criterion.  Predictive performance was evaluated in terms of bias and precision 
through calculation of the mean weighted error and the mean weighted squared 
error, respectively.   
 Since the data were collected in a real-world clinical environment, precise 
drug administration and blood sampling times varied between individuals.  
Estimates of drug exposure in uniform time intervals across different individuals 
were therefore not possible.  The Cmin for each patient was calculated as the 
mean of the lowest model-estimated PK output per day, over the time frame for 
which there were data (and therefore model estimates) for that patient.  The AUC 
was calculated as the total average AUC for the treatment course divided by the 
number of 24-hour intervals for which data were available per patient.  This was 
done in Pmetrics from each patient’s posterior mean parameter estimates using 
the trapezoidal rule.  
 
5.3.6 Pharmacodynamic modelling 
 The population PK model described above was used to obtain the mean 
Bayesian estimates for each patient’s PK parameters.  These were fixed for each 
patient and input to ADAPT 5381 in order to estimate the weighting functions for 
the PD.  The weighting functions were estimated using the variance model: 
variance = [intercept + slope*fb]^2, where fb is the fungal burden measured from 
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the quantitative cultures.  Each patient’s PD data were fitted to the PD model one 
individual at a time, employing the following structural model: 
6. 𝑑𝑑𝑑𝑑
𝑑𝑑𝑑𝑑












�)� ∗ 𝑁𝑁 
In this model, N is the number of CFUs in the bloodstream, t is time and dN/dt is 
the rate of change of fungal burden in the bloodstream.  Kkillmax, EC50 and H are 
the maximal rate of fungal kill, the concentration of drug that induces half maximal 
rate of killing, and the Hill (slope) function, respectively.  The model enabled 
itraconazole and hydroxyitraconazole to affect the PD simultaneously and 
independently: parameters suffixed with ‘p’ refer to the parent drug, itraconazole; 
those suffixed with ‘m’ to the metabolite, hydroxyitraconazole.  As previously, X(2) 
and X(4) are the amounts of itraconazole and hydroxyitraconazole in the central 
compartment respectively, in milligrams.  The initial condition, IC, represents an 
estimate of the pre-treatment fungal density in the bloodstream.  These PD 
parameters were estimated for each patient alongside the weighting functions 
(intercept and slope) from the variance model.  These weighting functions were 
then transcribed into the PD datafile for Pmetrics and the model was run in 
Pmetrics to arrive at a solution for the population PD.  Population PD model fit was 
determined according to the same criteria as were used for the population PK 
model.  Bayesian posterior estimates of the population PD parameters were then 
obtained from the final PD model.   
 In building the PD model, several methods for handling data below the 
lower limit of quantification (LLQ) were investigated.  This was necessary because 
the quantitative cultures were performed by serially diluting 100 µL of blood and 
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the lowest fungal count recorded was 0.699 log10 CFU/mL; that is, 5 CFU/mL.  It is 
possible that there were samples with CFU counts below 5 CFU/mL but that these 
colonies were not picked up in the 100µl of blood plated and were therefore 
recorded as zero.  Thus, there is a degree of uncertainty inherent in measurements 
towards the lower values of the measurement, as is true for many laboratory 
assays.  The PD model was run with these ‘zero’ CFU counts supplied to Pmetrics 
as 1 (i.e. unchanged; 0 log10 CFU/mL), as LLQ/2 (0.350 log10 CFU/mL), and by 
discarding these datapoints altogether, to determine which of these 3 methods 
provided the best model fit.  Early fungicidal activity (EFA) was calculated by 
performing a linear regression on Log10 CFU/mL versus day of CSF culture, taking 
the slope of the regression line as the EFA for each patient. 
 
5.3.7 Statistical modelling  
For patients who had both PK and PD data available, Cox proportional hazard 
models were fitted to examine the effect of AUC/MIC and Cmin/MIC for 
itraconazole on the time to sterilization of fungal cultures and the time to death.  
The Cox models took the form:  h(t) = h0(t)exp (β1*PDI + β2*BFB) where t is time 
to event, h(t) is the hazard function and h0(t) is the baseline hazard.  β1 and β2 are 
the coefficients for regression.  The hazard ratio is estimated by exp(βi).  PDI and 
BFB are the pharmacodynamic index (either AUC/MIC or Cmin/MIC) and the 
baseline fungal burden, respectively.  The relationship between each 
pharmacodynamic index and EFA was assessed using a linear regression model, 
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which took the form: EFA = β0 + β1*PDI + β2*BFB + ε, where β0 is the intercept, β1 
and β2 are the coefficients for the regression and ε is the model error term.   
 
5.4 Results 
5.4.1 Study participants 
Pharmacokinetic data were available from 76 patients and 
pharmacodynamic data were available for 65 of these.  All 76 patients had culture-
positive disseminated talaromycosis, with T. marneffei isolated from blood, skin 
lesions, lymph nodes and/or serous fluid.  The 66 patients included in the 
pharmacodynamic study were all fungaemic. 
Forty-three percent of patients were female.  The median age was 33 years 
(interquartile range, 29 – 36), weight 45 kg (IQR 45 – 50), body mass index 17.1 
kg/m2 (IQR, 15.6 – 19.0) and estimated glomerular filtration rate (eGFR) using the 
abbreviated Modification of Diet in Renal Disease Study (MDRS) calculation 113.9 
ml/min/1.73m2 (IQR, 86.7 – 139.1).  All patients had advanced HIV disease, with 
median CD4 cell count 9 cells per microlitre (IQR, 4 to 20).   
 
5.4.2 Pharmacokinetic data 
The dataset included 1316 itraconazole observations and 1314 
hydroxyitraconazole (OH-itraconazole) observations, 17.32 and 17.29 
observations of itraconazole and OH-itraconazole, respectively per patient.  The 
median ratio of OH-itraconazole concentration/itraconazole concentration per 
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Figure 5.1: Itraconazole and hydroxyitraconazole concentrations in 76 patients 
  
Black diamonds represent itraconazole concentrations.  White triangles represent 
hydroxyitraconazole concentrations.  The median concentration of hydroxyitraconazole to 
itraconazole per time point is 0.905. 
 
 
5.4.3 Population pharmacokinetic analysis 
The PK model was built in two stages.  First, the parent drug (itraconazole) 
was modelled in isolation with a saturable term for drug clearance.  The second 
stage of model building involved adding metabolite (i.e. OH-itraconazole) data 
into the model.  The saturable clearance mechanism of the parent drug fed into 
the central compartment of the metabolite.  An acceptable fit of the base model 
to the data was achieved with first-order clearance of the metabolite from the 
central compartment.   
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 The potential impact of covariates on the PK was assessed.  Multivariate 
linear regression of covariates did not reveal any significant relationships between 
the Bayesian posterior PK estimates (i.e. clearance, volume) versus age, sex, 
weight, BMI, renal function (creatinine level and eGFR) or CD4 cell count.  Hence, 
further model building was not performed.  The final PK model comprised five 
compartments, representing the gastrointestinal tract, the parent drug in the 
central compartment (circulation), the metabolite in the central compartment, 
the parent drug in the peripheral compartment and the metabolite in the 





Figure 5.2: Structure of the pharmacokinetic-pharmacodynamic model for 
itraconazole in talaromycosis 
 
After ingestion, itraconazole is absorbed from the gastrointestinal tract into the bloodstream 
according to the absorption rate constant, Ka.  Saturable hepatic metabolism of itraconazole 
results in the presence of hydroxyitraconazole in the bloodstream.  Both itraconazole and 
hydroxyitraconazole undergo bidirectional transfer between the central and peripheral 
compartments.  Hydroxyitraconazole is partially removed from the central compartment through 
first-order clearance.  The PD effect on the burden of talaromycosis in the bloodstream is produced 
by the additive effect of itraconazole and hydroxyitraconazole in the bloodstream.  Black dashed 
arrows indicate clearance mechanisms.  Grey dashed arrows indicate the PK compartments that 
produce PD effects.  Solid black arrows indicate rate constants. 
 
* Saturable clearance of parent drug by hepatic metabolism.  ** First order clearance of 
metabolite.  GI: gastrointestinal.  PD: pharmacodynamic.  X(1): amount of itraconazole in the gut.  
X(2): amount of itraconazole in the bloodstream.  X(3): amount of itraconazole in the peripheral 
compartment.  X(4): amount of hydroxyitraconazole in the bloodstream.  X(5): amount of 
hydroxyitraconazole in the peripheral compartment.  K23, K32, K45, K54: first-order transfer 
constants between central and peripheral compartments.  N: number of colony-forming units in 
the bloodstream.  
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The observed-versus-predicted values for the plasma concentrations of 
itraconazole and hydroxyitraconazole are shown in figure 5.3.  Parameter values 
for the final model are summarised in table 5.1.  Mean predicted parameter values 
described the observed values better than medians and were used in subsequent 
modelling and analyses.   
 
Figure 5.3:  Scatter plots of observed versus predicted values for the chosen 
population pharmacokinetic model after the Bayesian step  
 
 
Left panel: itraconazole concentrations.  r2 0.88; intercept -0.005 (95% confidence interval -0.01 to 
0.004); regression slope 1.10 (95% CI 1.07 to 1.13).  Right panel: hydroxyitraconazole 
concentrations.  r2 0.93; intercept -0.001 (95% CI -0.01 to 0.005); regression slope 1.02 (95% CI 
0.996 to 1.04). 
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Table 5.1: Parameter estimates for the final pharmacokinetic model 
Parameter (Units) Mean Median Standard deviation 
Ka (h-1) 1.781 0.238 4.275 
Vp (liters) 783.762 668.104 287.724 
K23 (h-1) 16.200 20.831 12.804 
K32 (h-1) 6.449 1.152 9.554 
Vmax (mg/hour) 55.836 37.767 36.512 
Km (mg/liter) 0.426 0.223 0.473 
K45 (h-1) 1.562 0.005 5.501 
K54 (h-1) 25.713 29.986 9.191 
SclM (liters/hour) 133.351 135.899 70.765 
Vm (liters) 866.057* 738.255* 287.724 
 
Ka, absorption rate constant from the gut to the central compartment; Vp, volume of the central 
compartment for itraconazole; K23, first-order transfer constant of itraconazole from the central 
to the peripheral compartment; K32, first-order transfer constant of itraconazole from the 
peripheral to the central compartment; Vmax, maximal rate of enzymatic metabolism of 
itraconazole; Km, concentration of itraconazole in the central compartment at which clearance is 
half maximal; K45, first-order transfer constant of hydroxyitraconazole from the central to the 
peripheral compartment; K54, first-order transfer constant of hydroxyitraconazole from the 
peripheral to the central compartment; SclM; first-order clearance of hydroxyitraconazole from 
the central compartment; Vm, volume of the central compartment for hydroxyitraconazole.  *fixed 
as 1.105*Vp      
 
The distribution of mean values for the area under the concentration-time curve 
per 24-hour period (AUC24) and minimum concentration per dosing interval (Cmin) 
are shown in Figure 5.4.  The mean AUC24 of itraconazole was 3.34 mg*h/liter 
(standard deviation 4.31 mg*h/liter; coefficient of variation 129%), median AUC24 
1.91 mg*h/liter.  For hydroxyitraconazole, the mean AUC24 was 3.57 mg*h/litre 
(standard deviation 4.46 mg*h/litre; CV 125%), median AUC24 2.27 mg*h/litre.  
The mean Cmin of itraconazole was 0.11 mg/litre (standard deviation 0.16 
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mg/litre, CV 147%), median Cmin 0.06 mg/litre.  For hydroxyitraconazole, the 
mean Cmin was 0.13 mg/litre (standard deviation 0.17 mg/litre, CV 132%), median 
Cmin 0.08 mg/litre. 
 
5.4.4 In vitro susceptibility tests 
Minimum inhibitory concentrations (MICs) against itraconazole were 
determined by broth microdilution using CLSI methodology (M38)382 for isolates 
from 69 patients.  Of these, 70% had an MIC of 0.008 mg/litre, 27% 0.016 mg/litre 
and 3% 0.03 mg/litre.   
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Figure 5.4: Histograms of the distribution of average AUC values (A) and mean Cmin values (B) for the 76 patients in the pharmacokinetic study 
 
  
Average AUC values were calculated as the AUC over the entire duration of treatment for each patient, divided by the number of days of treatment.  Cmin values were 
calculated as the mean of each daily Cmin per patient.  The mean AUC24 of itraconazole was 3.34 mg*h/liter (standard deviation 4.31 mg*h/liter; coefficient of variation 
129%), median AUC24 1.91 mg*h/liter.  For hydroxyitraconazole, the mean AUC24 was 3.57 mg*h/litre (standard deviation 4.46 mg*h/litre; CV 125%), median AUC24 2.27 
mg*h/litre.  The mean Cmin of itraconazole was 0.11 mg/litre (standard deviation 0.16 mg/litre, CV 147%), median Cmin 0.06 mg/litre.  For hydroxyitraconazole, the mean 
Cmin was 0.13 mg/litre (standard deviation 0.17 mg/litre, CV 132%), median Cmin 0.08 mg/litre. 
A B 
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5.4.5 Population pharmacodynamic modelling 
Pharmacodynamic data were available from 65 patients who received 
itraconazole.  In total, 342 quantitative cultures were obtained with a mean of 
5.26 observations per patient.  There was a large degree of variation in the time-
to-sterilisation of blood cultures with a mean 330 hours and a range of 13 – 3306 
hours.  The median EFA was -0.3 Log10 CFU/mL/day, with range -1.6 to 0.1.  
 The PD model was fitted to the data in two steps.  First, the PK was solved 
as described above.  The mean Bayesian estimates for each individual’s PK were 
fixed and taken forwards for the pharmacodynamic modelling.  The 
pharmacodynamics were then solved by supplying each patient’s PK as a covariate 
alongside the dosing history and individual pharmacodynamic data.  The problem 
of clean plates was assessed in a number of different ways as described, but 
ultimately ‘zero’ values supplied as LLQ/2 provided the best model fit to the data, 
with acceptable levels of bias and imprecision (Figure 5.5).  The parameter 
estimates for the population PD model are summarised in table 5.2.  Mean 
parameter values predicted the observed values better than medians.  After 
completion of the 14-day induction phase of treatment, 25 of the 52 patients in 
the itraconazole arm who were fungaemic at baseline remained fungaemic (48%; 
Figure 5.6(a)).  The time-course of the reduction in fungal burden over the first 14 
days of itraconazole treatment in all 65 patients for whom PD data were available 
is displayed in Figure 5.6(b). 
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Figure 5.5: Scatter plots of observed versus predicted values for the chosen 
population pharmacodynamic model after the Bayesian step 
 
For the linear regression, r2 0.68; intercept -0.07 (95% confidence interval -0.09 to 0.22); slope 0.99 











Table 5.2: Parameter estimates for the final pharmacodynamic model 
 
Kkillmax, maximum rate of drug-induced killing of T. marneffei; H, Hill/ slope function; EC50, plasma 
concentration of drug that induces half-maximal kill rate; IC, estimated fungal density just prior to 
initiation of itraconazole.  Parameters suffixed with ‘p’ describe the parent drug, itraconazole.  
Parameters suffixed with ‘m’ refer to the metabolite, hydroxyitraconazole.
Parameter Mean Median 
Standard 
deviation 
Kkillmaxp (log10CFU/mL/h) 0.206 0.010 0.436 
Hp 2.194 2.999 1.176 
EC50p (mg/liter) 13.449 14.976 3.222 
Kkillmaxm (log10CFU/mL/h) 0.208 0.055 0.422 
Hm 1.325 0.671 0.957 
EC50m (mg/liter) 8.640 6.697 3.515 
IC (CFU/mL) 1442.141 5.909 4412.916 
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(a) Kaplan-Meier plot of the time to sterilisation (limited to the 14-day induction phase of 
treatment).   
(b) Time course of reduction in fungal burden for the 65 patients who provided PD data.  
Open triangles are observed data points from individual patients; solid lines are model 






We explored both AUC/MIC and Cmin/MIC as measures of drug exposure.  
Potential relationships were sought between drug exposure and various 
pharmacodynamic endpoints that included time-to-sterilisation, time-to-death 
and EFA in the first 14 days.  Higher initial fungal burden was significantly 
associated with a longer time-to-sterilisation (HR 0.25; 95% confidence interval 
0.17 to 0.37; p<0.001).  There was a trend towards an association between 
baseline fungal burden and time-to-death (HR 1.47, 95% CI 0.97 to 2.19, p < 0.1).  
All subsequent analyses were adjusted for baseline fungal burden.   
Cox proportional hazard models revealed that there was no relationship 
between Cmin:MIC and time-to-sterilization (HR 1.01, 95% CI 0.99 to 1.03, p=0.43) 
or time-to-death (HR 0.99, 95% CI 0.96 to 1.02, p=0.77).  Similarly, there was no 
relationship between AUC:MIC and time to sterilisation of the bloodstream (HR 
1.00, 95% CI 0.99 to 1.00, p=0.50) or time to death (HR 1.00, 95% CI 0.99 to 1.00, 
p=0.91) (figure 5.7).  Linear regression following adjustment for baseline fungal 
burden revealed that Cmin:MIC had no significant impact on EFA (EFA (log10 
CFU/ml/day) = -0.64 - 0.004 * (Cmin:MIC), p = 0.18).  There was also no significant 
relationship between AUC:MIC and EFA (EFA (log10 CFU/ml/day) = -0.64 – 0.0001* 
(AUC:MIC), p = 0.19).  These relationships are displayed in Figure 5.8.  In case these 
negative findings were a function of the fact that a small number of patients 
achieved rapid sterilisation of the bloodstream, data from individual patients with 
the greatest EFA values and fastest time to sterilization were examined closely for 
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higher AUC and Cmin values, and for higher AUC:MIC and Cmin:MIC values.  No 
such correlation was found. 
 
Figure 5.7: Cox model predictions of hazard ratios depending on PD index 
 
 
All models are adjusted for the median baseline fungal burden of 2.2 log10 CFU/ml.  A: The hazard 
ratio for time to sterility with increasing Cmin:MIC is 1.01 (95% confidence interval 0.99 to 1.03), 
p=0.43.  B: The hazard ratio for time to sterility with increasing AUC:MIC is 1.00 (95% confidence 
interval 0.99 to 1.00), p=0.50.  C: The hazard ratio for time to death with increasing Cmin:MIC is 
0.99 (95% confidence interval 0.96 to 1.02), p=0.77.  D: The hazard ratio for time to death with 







Figure 5.8: Relationship between pharmacodynamic indices and early fungicidal 
activity   
 
(A) Predicted log10 EFA = -0.64 - 0.004 * (Cmin:MIC), p = 0.18.  A one-unit increase in Cmin:MIC 
decreases the log10 EFA by -0.004 CFU/mL/day (95% confidence interval -0.010 to 0.002.  (B) 
Predicted log10 EFA = -0.64 - 0.0001 * (AUC:MIC), p = 0.19.  A one-unit increase in AUC:MIC 
decreases the log10 EFA by -0.0001 CFU/mL/day (95% confidence interval -0.0003 to 0.0001).  Both 
linear regression models were adjusted for a median baseline fungal burgen of 2.2 log10 CFU/ml.   
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5.5 Discussion 
Itraconazole is attractive as a potential agent for the treatment for 
talaromycosis because of its potent in vitro activity against T. marneffei,383,384 its 
improved tolerability profile compared with DAmB and its oral bioavailability.  
Multiple large case series have demonstrated outcomes from talaromycosis 
treated with itraconazole that are comparable to those after treatment with 
DAmB.44,385,386  However, itraconazole induction therapy was shown in the IVAP 
trial to be associated with excessive mortality from talaromycosis at 6 months and 
significantly reduced fungicidal activity when compared with DAmB.50  Our study 
suggests that the poor PD clinical outcomes from itraconazole are related to 
concentration-dependent therapeutic failure. 
Our PK parameter estimates for itraconazole are in keeping with those 
described in previous population PK models.269  Itraconazole is extensively 
metabolised in the liver with negligible renal clearance.  Renal function did not 
account for any portion of PK variability in the present analysis.  In addition, there 
was very modest variability in weight among study participants who all had 
advanced HIV disease, which was insufficient to fully explore the potential impact 
of weight on PK.  The rates of kill induced by itraconazole and hydroxyitraconazole 
were similar.  This finding is consistent with in vitro potencies of itraconazole and 
hydroxyitraconazole, which are comparable against a large range of fungal 
pathogens.387  There are scarce data available on the relative potencies of 
itraconazole and hydroxyitraconazole against T. marneffei in particular, hence our 
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approach of enabling distinct PD influence of each of the parent drug and its 
metabolite in the structural PKPD model. 
Drug exposure targets for itraconazole have been established for 
oropharyngeal candidiasis, invasive aspergillosis, cryptococcosis and 
histoplasmosis based on observations that patients tend to have better clinical 
outcomes with trough concentrations of at least 0.5-1 mg/litre.367,369,375,388,389  The 
appropriate PK-PD target for patients with talaromycosis is not known.  Our study 
did not provide further insight into this issue because a relationship between drug 
exposure and microbiological and/or clinical response was not evident, despite 
exploration of multiple different PK and PD measures and indices.  There were too 
few patients with drug exposures high enough to elicit maximal antifungal activity 
and thereby separate the population into groups with a high and low probability 
of therapeutic success.  We were also unable to explore models of multi-
exponential decline in fungal burden, despite this rich dataset, because there were 
so few patients with an appreciable PD response.  At the end of the 14-day 
induction period, approximately 50% of patients were still fungaemic.  There was 
extensive variability in the PK, such that one would expect a relationship between 
the PK and the PD to be apparent if it exists.  MICs were low and cannot be 
implicated in the poor PD response observed.  What is remarkable about our data 
is the almost universally low levels of itraconazole detected in the plasma of the 
patient population.  Only 3 of 76 patients (4%) achieved a Cmin of 0.5 mg/litre.  
Therefore, almost all patients were at the lower end of the exposure-response 
curve as defined for other fungal pathogens, and simply did not mount sufficient 
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drug exposure to generate a PD response.  Our data is subject to a potential 
limitation - due to biosafety regulations, drug was extracted from samples in 
Vietnam prior to shipment to the UK.  Extraction of calibration curves and quality 
control assays were then performed at the University of Liverpool.  The potential 
for data discrepancies induced by these methodologies was limited by freezing the 
calibration curve and quality control samples following extraction, so that they 
were subject to the same conditions as patient samples.  it is nevertheless 
reassuring that our estimates for the population PK are consistent with those 
described elsewhere.269 
The concept of concentration-dependent therapeutic failure is well 
understood for the triazoles and results from a number of issues common to this 
class of antifungals.  Firstly, oral bioavailability is frequently suboptimal.  In the 
case of itraconazole, dissolution and absorption depend on an acidic environment 
(pKa value 3.7).  In healthy volunteers, itraconazole absorption from capsule 
formulations has been improved by 80% by co-administration of cola (pH 2.5)390 
and Cmax increased by approximately 70% after a meal.124  Patients in the IVAP 
trial were encouraged to eat a meal or drink cola prior to drug administration.  
However, since the basis for these recommendations were data collected from 
studies of healthy volunteers, it is possible that these are insufficient or ineffective 
approaches to gastric acidification in the presence of HIV-associated achlorhydria 
or gastrointestinal disease.391  The second contributor to concentration-
dependent therapeutic failure in triazoles is significant PK variability, principally 
related to variation in oxidative metabolism.392  Itraconazole is extensively 
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metabolised by cytochrome (CY)P450 3A4 isoenzymes, the phenotype of which 
varies significantly between individuals.  In our model, estimates of AUC0-24 were 
highly variable, with coefficient of variation (CV%) values of 129% and 125% for 
the parent drug and the metabolite, respectively.  Similarly, CV values for 
estimates of Cmin were 147% and 132% for the parent and the metabolite, 
respectively.  Thirdly, drug-drug interactions are common among the triazoles and 
we were unable to account for these in this analysis.  First-line antiretroviral 
treatment in Vietnam at the time of the trial consisted of tenofovir, lamivudine 
and efavirenz, the latter replaced with nevirapine when clinically indicated.  
Efavirenz in an inducer of numerous hepatic enzymes, including CYP3A4.  
Coadministration of itraconazole (200 mg bid) and efavirenz (600 mg od) 
decreases itraconazole Cmax, AUC and Cmin by 37%, 39% and 44%, respectively 
and decreases hydroxyitraconazole Cmax, AUC and Cmin by 37%, 35% and 43%, 
respectively.393  Nevirapine induces both CYP3A4 and CYP2B6, and has been 
proposed as an inducer of P-glycoprotein.394  Nevirapine reduces itraconazole 
Cmax, AUC and Cmin by 62%, 39% and 13% respectively.395    Finally, the 
formulation of itraconazole is known to have significant impact on serum drug 
concentrations, the oral bioavailability of capsule formulations being 
approximately 30% that of oral solutions.124,374  Patients in the described cohort 
were administered a capsule formulation of itraconazole from Stada (now 
Stellapharm), Vietnam.  To the best of our knowledge, there are no published data 
on the bioequivalence of this formulation versus other formulations of 
itraconazole. 
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Whether the low EFA observed in this study differs significantly from 
placebo is not known and ethically impossible to establish.  Ultimately, however, 
the reduced fungicidal activity may have directly resulted in adverse clinical 
outcomes including increased mortality.  Evidence for this would require further 
study including a dataset with enough variability in PD effect to establish whether 
a link between EFA and mortality exists.  More generally, this PK-PD sub-study 
illustrates that in clinical trial settings, as in practice, it is imperative that 
antimicrobial dosing is specifically tailored to the target population rather than 
inferred from healthy volunteers, or populations that are in other ways potentially 
distinct in a physiological sense.  This is not straightforward in the case of 
itraconazole, which was developed in an era before the quantitative 
pharmacometric approaches adopted during modern drug development were 
commonplace.  Neither is it straightforward in a population of patients with 
advanced HIV, whose physiology may be markedly heterogeneous.  Faced with 
these challenges, a number of measures may be appropriate to de-risk clinical 
trials by strengthening the PK-PD studies associated with those trials (box 5.1). 
The large PK variability of itraconazole, and capacity for drug interactions, 
mean that TDM is widely advocated in clinical practice to achieve therapeutic 
levels.  This study represents an opportunity to define target levels for TDM, yet it 
is unable to do so due to the universally low levels of drug exposure achieved and 
consequent lack of PD effect produced in the study population.  Moreover, 
treatment guidelines for talaromycosis were recently updated as a result of the 
IVAP trial, to state that all patients with talaromycosis should receive amphotericin 
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B induction therapy regardless of disease severity.396  The evidence for this has 
been graded as the highest possible (AI), since data demonstrating the inferiority 
of itraconazole were obtained from a large randomised controlled trial.  This could 
deprioritise the future question of the role of itraconazole in talaromycosis.  
A different formulation, dosage and/or or mode of administration may 
have provided higher systemic drug exposure and led to better mycological and 
clinical outcomes.  This PK-PD substudy illustrates the importance of antimicrobial 
dosing and administration that is specifically tailored to the target population 
rather than inferred from healthy volunteers, as well as the pivotal role of PK-PD 
analyses in clinical trials of therapeutics.  Without exposure-response information, 
it is impossible to optimise dose selection or interpret the significance of altered 
drug exposure.  As a consequence, patients may receive medication that offers 







1. Establish a target for drug exposure  
Identify a PK target that controls the biomarker (for example, fungal burden).  If 
necessary, an approximation of this can be determined through the translation of 
data obtained from animal models or in vitro work such as a hollow fibre model.   
 
2. Model PK in special populations and in response to administration conditions 
Can clinically relevant alterations in drug exposure be predicted in response to age, 
weight, renal impairment or hepatic impairment?  Does food affect bioavailability?  
Does the timing of drug administration have a significant impact on safety and/or 
efficacy?  
 
3. Assess bioequivalence 
Careful assessment of generic drug formulations to ascertain bioequivalence with 
reference formulations is essential for reliability and generalisability of trial findings.   
 
4. Perform an interim PK analysis 
After 10 or 20 patients have been recruited, an interim analysis could assess 
whether drug exposure is in line with putative PK targets.  This could serve as an 
early checkpoint to mitigate against significant under- or over-dosing.  The ideal 
scenario would be TDM for trial participants as part of study procedures, though this 
of course requires a validated PK target. 
 
5. Consider drug-drug interactions 
Data on co-administered medications must be collected, including dosage and 
frequency of administration, to explore sources of PK variability in trial drug and 
inform decisions around dosage adjustment. 
Box 5-1: Strategies to strengthen PK aspects of clinical trials of antimicrobial 
therapy 
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6 Immune signatures in CSF and functional analysis of 
phagocytes in whole blood from patients with HIV-




 Pharmacodynamic and clinical outcomes from cryptococcal 
meningoencephalitis are not influenced by the attainment of PK targets alone.  
The host response is central to the pathogenesis of cryptococcal infection, 
determining whether infection is contained within pulmonary granulomas or is 
able to disseminate throughout the body and to the central nervous system.104,126  
The ability of cryptococcal cells to survive and replicate within host macrophages 
not only promotes persistence and spread of infection, but is thought to enable 
cryptococcal evasion of immune surveillance, interfering with inflammatory 
signalling that forms part of an effective host response.134-136,397   Defects in both 
humoral and cellular immune pathways have been identified that are associated 
with severity of infection and response to treatment.  For example, in murine 
cryptococcal infection, survival is decreased in the setting of decreased 
concentrations of proinflammatory Th1-type cytokines such as interleukin (IL)-12, 
IL-18 and interferon-gamma (IFN-γ).170-172  Similarly, in human cerebrospinal fluid 
(CSF), low concentrations of IFN-γ, IL-6 and granulocyte colony stimulating factor 
(G-CSF) are associated with high fungal burden, slower clearance of infection and 
increased mortality.152,154  Conversely, a robust early proinflammatory response 
and classical (M1) macrophage activation increases early fungicidal activity (EFA) 
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and imparts a mortality benefit.90-93  In addition, a Th17-type response with 
increased circulating IL-17A, IL-21, IL-6 and transforming growth factor (TGF)-β 
contributes to anti-cryptococcal responses.398-400 
In terms of cellular immunity, murine experiments have demonstrated that 
depletion of host macrophages and dendritic cells results in dramatically reduced 
survival from cryptococcal infection.146,401  The burden of cryptococcal 
meningoencephalitis in HIV-infected persons is testament to the importance of 
CD4+ T cells in control of infection and there is a negative correlation between CSF 
CD4+ T cell count and CSF fungal burden in clinical cryptococcal 
meningoencephalitis.154  CD4+ T cells produce IFN-γ, contributing to beneficial 
inflammation with classical macrophage activation.149  However, there is evidence 
from HIV-seronegative patients with cryptococcal meningoencephalitis that even 
in the setting of a relatively strong cellular immune response with ample 
proinflammatory Th1-type cytokines, monocyte/macrophages may undergo 
alternative (M2) activation and display signs of defective phagocytic activity.402  
Moreover, while Th2-type responses and alternative macrophage activation have 
detrimental effects on outcome in murine models of cryptococcal 
meningoencephalitis,150,170,176 this has not been observed in human 
infection.152,154 
The relationship between T-cell responses, macrophage activation 
pathways and clinical manifestations and outcomes from cryptococcal infection 
are therefore not straightforward or dichotomous.  In this study we aimed to 
provide further insight into the host response to cryptococcal infection in the CNS 
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by examining both soluble biomarkers in CSF and phagocyte functional activity in 
peripheral whole blood.  Phagocyte function was quantified through 
measurement of phagocytosis and phagosomal superoxide burst, which - 
alongside nitric oxide synthase pathways – is essential for phagocyte microbicidal 
activity.  Superoxide burst occurs when nicotinamide adenine dinucleotide 
phosphate (NADPH) oxidase on the phagolysosome membrane pumps electrons 
into the phagolysosome, triggering the production of superoxide (O2-) radicals, 
known as reactive oxygen species (ROS).403  ROS interact with numerous essential 
microbial cellular targets and inflict direct damage on microbial DNA.403,404   We 
employed a flow cytometry-based assay that measures the phagocytic activity and 
superoxide burst of both neutrophils and monocytes, with the aim of assessing 
the degree to which these specific phagocyte lineages contribute to fungicidal 
activity during clinical cryptococcal meningoencephalitis.  This functional 
phagocyte assay was performed on samples of whole blood in real time rather 
than on isolated or cultured cells, so that the activity of the phagocytes under 
study was examined in the context of potentially important chemokines, cytokines 
and antibodies – thereby maintaining some of the physiological conditions that 
exist in vivo.405 
This study was performed as a substudy of the AMBITION trial, recruiting 
patients with HIV-associated cryptococcal meningoencephalitis (HIV/CM) from 
both study arms.343   In this chapter, we initially quantify concentrations of 
biomarkers measured in samples of CSF collected at three serial time points over 
the first 14 days of therapy.  We examine the interrelatedness of these cytokines 
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and chemokines, and their association with indicators of disease severity and 
clinical outcome.  We next report on the functional activity of neutrophils and 
monocytes at serial time points over the first 14 days of therapy, in patients with 
HIV/CM and in both HIV-positive and HIV-negative control patients, and the 
association of that activity with clinical outcomes.  Finally, associations between 




6.2 Materials and methods 
6.2.1 Study participants and clinical procedures 
Participants were recruited from Queen Elizabeth Central Hospital in 
Blantyre, Malawi.  HIV-positive patients with a confirmed first episode of 
cryptococcal meningoencephalitis (diagnosed by positive CSF cryptococcal antigen 
test or India Ink stain) were recruited from the phase III AMBITION trial.343  Ethical 
approval for AMBITION was obtained from the Malawi National Health Sciences 
Research Committee as well as the Research Ethics Committee of the London 
School of Hygiene and Tropical Medicine.  All patients who had capacity to do so 
provided written, informed consent for participation in the trial.  Where patients 
were incapacitated, consent was obtained from a next of kin with legal 
responsibility and then re-attempted with the patient if it became possible 
according to their clinical status.  Patients were enrolled within 48 hours of 
presentation.  The maximum antifungal therapy received by any patient prior to 
recruitment as part of routine clinical care was 2 consecutive daily doses of 
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fluconazole (1200 mg).  No patient received amphotericin B or flucytosine prior to 
recruitment.  CSF was obtained by lumbar puncture (LP) prior to initiation of study 
drugs (day 1) and then on day 7 and 14 per study protocol, with opening pressure 
recorded at each time point.  Additional LPs were performed as required for 
management of raised intracranial pressure throughout the patient’s hospital 
admission.  Blood samples were collected into sodium-heparin tubes for the 
phagocyte functional assay on day 1 (prior to initiation of study drugs), day 7 and 
day 14.  Patients in the AMBITION trial were randomised 1:1 to receive 
cryptococcal meningoencephalitis induction therapy with either a single high dose 
of LAmB (10 mg/kg/day) followed by 14 days of flucytosine (100 mg/kg/day) plus 
fluconazole (1200 mg/day) – the intervention arm - or 7 days of DAmB (1 
mg/kg/day) plus flucytosine (100 mg/kg/day), followed by 7 days of fluconazole 
(1200 mg/day) – the control arm.  As part of the AMBITION trial, quantitative 
cryptococcal culture (QCC) was performed on days 1, 7 and 14 using serial 
dilutions of 100 µl CSF with colony counting after 48 hours growth at 30°C.  In 
addition, CSF cell count, white cell differential, protein and glucose were 
performed as part of routine clinical care.  For this sub-study, patients were 
followed up for 10 weeks with respect to mortality outcomes. 
For the phagocyte functional assay, blood samples were obtained from 
control participants at a single time point.  HIV-positive control participants (no 
clinical evidence of cryptococcal meningoencephalitis) were recruited from the 
‘Evaluating the reactivation of herpesviruses and inflammation as cardiovascular 
and cerebrovascular risk factors in antiretroviral therapy initiators in an African 
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HIV-infected population’ (RHICCA) study, described elsewhere.406  HIV-negative 
controls were recruited from either the RHICCA study, and from the 
‘Characterisation of the breakdown in immune competence of the lung that 
favours development of tuberculosis in HIV-infected adults’ (CLIC) study. Both 
RHICCA and CLIC studies received ethical approval from the research ethics 
committees of the University of Malawi, College of Medicine and the Liverpool 
School of Tropical Medicine. All control participants provided written informed 
consent. 
 
6.2.2 Measurement of soluble biomarkers in CSF 
 
 All CSF samples were processed within 1 hour of collection.  Samples were 
centrifuged at 3000 rpm (1500 g) for 10 minutes at 4°C prior to freezing at -80°C 
until analysis on site in Malawi (Malawi Liverpool Wellcome Trust Clinical Research 
Programme).  We used the Luminex multianalyte platform (Luminex, Merck 
Millipore, Herts UK) to measure CSF concentrations of IFN-γ, tumour necrosis 
factor-alpha (TNF-α), granulocyte-macrophage colony-stimulating factor (GM-
CSF), granulocyte colony-stimulating factor (G-CSF), IL-2, IL-4, IL-5, IL-6, IL-7, IL-8 
(CXCL8), IL-10, IL-17A, IL-12p70, IL-1 receptor antagonist (IL-1ra), IL-12p40, IL-15, 
IFN-γ inducible protein 10 (IP-10/ CXCL10), vascular endothelial growth factor 
(VEGF)-A, monocyte chemoattractant protein 1/ chemokine (C-C motif) ligand 2 
(MCP-1/ CCL2), macrophage inflammatory protein (MIP)-1a/ CCL3, MIP-1b/CCL4 




6.2.3 Phagocyte functional activity in whole blood 
 
 Zymosan reporter particles were prepared as described previously.405  
Briefly, 6 mg zymosan (Sigma-Aldrich) was washed three times in 1x phosphate-
buffered saline (PBS) by centrifugation at 10,000 rpm for 1 minute.  Washed 
zymosan particles were doubly coupled to a calibration fluorochrome (Alexa Fluor 
405-SE, Invitrogen) and a fluorescent reporter (OxyBURST Green H2DCFDA-SE, 
Invitrogen) that is sensitive to oxidation.  To achieve zymosan coupling, washed 
particles were suspended in 950 µl coupling buffer (0.1 M boric acid adjusted to 
pH 8.0 with NaOH) containing 10 µl of 25 mg/ml OxyBURST/ DMSO solution and 5 
µl of 5 mg/ml Alexa Fluor 405-SE/DMSO solution.  After mixing, this zymosan/ 
coupling buffer suspension was incubated in the dark at room temperature for 1 
hour, before being washed in 1 ml coupling buffer.  Zymosan particles were 
resuspended in coupling buffer and incubated in the dark at room temperature 
twice more, with a coupling buffer wash between each incubation.  After a total 
of three 1-hour incubation periods in coupling buffer, zymosan particles were 
washed 3 times in PBS before storage in PBS containing 0.01% sodium azide in the 
dark at 4°C.  The final stock concentration of zymosan reporter particles was 
approximately 5 x 106 particles/ml. 
 To assess whole blood phagocyte function, 50 µl zymosan stock particle 
suspension was washed three times in 1 ml of RPMI-1640 to remove sodium azide.  
Particles were resuspended in 250 µl RPMI-1640 to a final dilution of 1:6, with an 
approximate concentration of 8 x 106 zymosan particles/ml.  Within 2 hours of 
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blood draw, whole blood was diluted 1:1 with warmed RPMI-1640 and incubated 
with 20 µl washed zymosan particle suspension at 37°C with rocking.  In parallel, 
1:1 diluted blood in RPMI-1640 was processed as a control.   
 Phagocytosis and superoxide burst were measured at 10, 30, 60 and 90 
minutes after the addition of reporter particles.  At each time point, 100 µl diluted 
blood was removed from the incubating solution and stained with anti-CD45 
PerCP, anti-CD66b APC and anti-CD14 PE-Cy7 antibodies at concentrations of 1:33, 
1:50 and 1:100, respectively.  After 10 minutes of staining, 3 ml of BD FACS lysing 
solution (containing formaldehyde and diethylene glycol; BD Biosciences) was 
added to the zymosan-containing tube and the control tube to arrest biological 
activity, fix leukocytes and lyse red blood cells.  Each tube was incubated at room 
temperature for 10 minutes after addition of the lysing solution, before cells were 
washed in 1x PBS by centrifugation at 500 g for 10 minutes.  Cells were 
resuspended in 500 µl PBS and counting beads (Countbright, Life Technologies) 
were added per manufacturer’s instruction.  Cells were analysed on a BD LSR 
Fortessa flow cytometer (Becton Dickinson, USA) with forward scatter threshold 
(FSC) set at 5000.  Total antibody compensation beads (AbCTM, Invitrogen, BD 
Biosciences) were used and data analysed using FlowJo software version 10.0 
(Tree Star, San Carlos, CA). 
 
6.2.4 Flow cytometry analysis of whole blood phagocytes 
 The gating strategy used to identify monocytes and neutrophils is outlined 
in Figure 6.1A.  Absolute cell numbers were counted using counting beads.  The 
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proportion of cells that had phagocytosed zymosan reporter particles was 
calculated by quantifying the expression of the calibration fluorochrome.  The 
median fluorescence intensity (MFI) of zymosan positive and zymosan negative 




Figure 6.1: Gating strategy for identification of neutrophils and monocytes in whole 




Figure 6.1 A) Gating strategy: neutrophils and monocytes were identified using forward scatter 
height (FSC-H) and FSC-area (FSC-A) to exclude singlets, aggregates, cryptococcal cells and cellular 
debris.  The CD45 versus side scatter area (SCC-A) plot identified phagocytes of interest and these 
were subclassified based on staining for CD14 versus CD66.  Control (no cryptococcal 
meningoencephalitis) samples were examined without addition of zymosan reporter particles to 
define the gate for identification of phagocytes undergoing superoxide burst.  B) Phagosomal 
superoxide burst activity in neutrophils and monocytes over time.  Zymosan-induced superoxide 
burst is detected by the oxidation-sensitive reporter fluorochrome and increases over time and 





6.2.5 Data analysis 
 
 Statistical analysis was performed in R version 1.1.383 ( 2009 – 2017 
RStudio, Inc.).  The final data set for this study, including soluble biomarker 
concentrations, phagocyte functional activity, CSF cell counts and differential, CSF 
biochemistry and clinical variables comprised 38 variables.  Two statistical 
techniques were employed to reduce the dimensionality of the large set of soluble 
biomarkers: principal component analysis (PCA) and network analysis.  PCA 
reduces the number of dimensions in a dataset by describing linear functions 
(principal components, PCs) that capture the variance in a dataset and which are 
unrelated to one another, thereby increasing the interpretability of the data while 
minimising information loss.407  Multiple comparisons are avoided because the 
dataset is then examined in terms of a series of PCs that account for a decreasing 
proportion of the overall variance of the dataset, rather than in terms of individual 
variables.  Network analysis, in contrast, is a technique with its basis in network 
theory, which enables the visualisation of relationships between variables by 
mapping them according to the symmetry or otherwise of their proximity to one 
another.  A threshold of acceptable correlation values is chosen and used to 
construct an adjacency matrix.  The adjacency matrix is used to create a network 
of ‘nodes’ (the variables) and ‘edges’ (the connection between each variable).  
Network analysis places significance on the associations between variables, 
creating a web of variables and highlighting clusters of variables that are more 
closely related to one another than to other variables.  The cytokine network 
analyses presented here were performed after filtering associations to include 
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only those that showed strong correlations (Pearson’s correlation coefficient, r, ≥ 
0.70; p-value < 0.05).   
Prior to PCA and network analysis, analyte concentrations were log 
transformed and normalised to the mean.  A ‘slope’ value was calculated for each 
biomarker for each patient as a linear regression of the concentration of that 
biomarker over time (between study days 1 and 14).  PCA and network analyses 
were performed on both the log-transformed, normalised biomarker values from 
day 1 of the study, and on the slope of the change in value of each biomarker over 
the duration of the study.  To assess phagocyte function, an Activity Index (AI) of 
phagosomal superoxide burst was calculated for both neutrophils and monocytes 
at each time point (10, 30, 60 and 90 minutes), on each sampling day (1, 7 and 14), 
by subtracting the MFI of the zymosan-negative cells from the MFI of the zymosan-
positive cells and dividing this by twice the robust standard deviation of the 
zymosan-negative cells.  This standardised the data with respect to inter-individual 
variability in cellular auto fluorescence.  AI results were summarised for further 
analyses (described below) as a peak AI value for both neutrophils and monocytes 
for each study day, and a slope value for each cell type per patient, calculated as 
a linear regression of peak AI value per day versus time.  The clinical study and 




Figure 6.2: Clinical study and initial analytical strategy  
 
 
Figure 6.2.  Samples of CSF and blood were collected on days 1, 7 and 14 for the laboratory 
assays indicated.  Data were summarised for further analysis as described in the box on the right 
of the diagram.  QCC: quantitative cryptococcal culture.  
 
 
 A number of clinical outcome variables were examined with respect to the 
measured soluble biomarkers and measures of phagocyte function: fungal burden 
(log10 colony-forming units (CFU)/ml CSF) on day 1 prior to study drug 
administration, day 7 and day 14; opening intracranial pressure (cm H2O) at 
baseline; early fungicidal activity (EFA) - calculated for each patient as a linear 
regression of log10 CFU/mL of CSF versus time - and date of death (followed up to 
10 weeks).  Opening pressure was explored as both a continuous and a categorical 
variable, the latter defined as low opening pressure if it was recorded as ≤ 30 cm 
H2O, high if ≥ 30 cm H2O.  Early fungicidal activity (EFA) was also explored as both 
a continuous and a categorical variable, defined as low EFA if the rate was ≤ 0.2 
log10CFU/mL/day and high EFA if > 0.2 Log10CFU/mL/day.  This EFA cut-off value 
was chosen because EFA > 0.2 Log10CFU/mL/day is associated with survival.263,264  
Associations between the PCs, the described measures of phagocyte AI, CSF cell 
counts and biochemistry and clinical outcome variables, were examined using 
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Pearson’s correlation coefficient.  Linear regression was used to examine the 
relationship between PCs and continuous clinical outcome variables and logistic 
regression for categorical outcome variables.  The relationship between PCs and 
time to death was described using Cox proportional hazards models.  Models that 
examined associations with mortality were adjusted for baseline fungal burden, 
since this is consistently associated with mortality from HIV/CM.286  Associations 
with opening pressure were adjusted for baseline fungal burden in CSF, since 
these variables are correlated.408  Associations with EFA were adjusted for baseline 
fungal burden and study arm.  Data were non-normally distributed; as such, 
unpaired groups were compared using the Mann-Whitney U test.  Paired groups 
were compared using the Wilcoxon test.  Statistical significance was defined as a 




 CSF was available from 65 patients with confirmed HIV-associated 
cryptococcal meningoencephalitis.  In total, whole blood was collected from 19 
patients with HIV/CM, 15 HIV-positive control patients and 15 HIV-negative 
controls.  The number of HIV/CM patients for whom both CSF was analysed for 
soluble immune mediators, and blood for phagocytic function, was 11 (8 HIV/CM 
patients provided samples for the phagocytosis assay only).  The median age was 
37 years (interquartile range (IQR) 34 – 42), median weight 50 kg (IQR 47 – 56) and 
median CD4+ T cell count 37 cells/mm3 (IQR 15 – 94).  Of 65 patients for whom 
 199 
CSF data were available, 24 (37%) were female.  The cumulative case fatality rate 
was 9% at 2 weeks (6/65) and 28% at 10 weeks (18/65).   
 
6.3.2 CSF soluble biomarkers: study day 1 
 Baseline CSF biomarker concentrations are shown in Figure 6.3.  Values for 
IL-4 were below the limit of detection in 61 of 65 cases, so IL-4 measurements 
were excluded from further analysis.  The distribution of biomarker concentration 
values was consistent for the majority of cytokines/ chemokines across different 
study days, with modest variation in log-transformed, normalised concentrations 
(Figure 6.4).   
 
Figure 6.3: Baseline CSF soluble biomarker concentrations in 65 patients with HIV-
associated cryptococcal meningoencephalitis 
 
Figure 6.3.  Boxes indicate interquartile range, with median marked inside box.  Whiskers represent 
10th and 90th percentiles. 
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Figure 6.4: Density plots showing log-transformed concentrations of soluble 




PCA was used to search for soluble biomarkers contributing to PCs that 
accounted for a substantial proportion of the variance in the dataset.  From the 
PCA of day 1 biomarker concentrations, PC1 and PC2 accounted for 61.5% and 
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10.5% of the variance respectively (Figure 6.5A).  The PC loadings for each cytokine 
demonstrated a that a large group of biomarkers of Th1-, Th2- and Th17-type 
responses drove the variance in PC1 and that the contribution of each of those 
biomarkers to PC1 was approximately equal (Figures 6.5B and 6.5C).  Thus, PC1 
scores were moderately positive across almost all biomarkers, with a large number 
of predominantly pro-inflammatory and adaptive cytokines and chemokines that 
are involved in monocyte/ macrophage chemoattraction or stimulation.  The 
variance in PC2, in contrast, was primarily accounted for by positive loading scores 
in a group of just three biomarkers: TNF-α (associated with inflammatory, Th-1 
type immune responses), G-CSF and IL-7 (associated with stimulation and 
development of granulocytes and T-lymphocytes, respectively), with neutral or 
negative loadings in all other markers besides IL-15, which contributed a low-
positive loading score to PC2.  The chemokines RANTES and IP-10, and the anti-
inflammatory cytokines IL-10 and IL-1RA, were inversely correlated with PC2 
scores (Figures 6.5 B and 6.5 C). 
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Figure 6.5:  Principal component analysis of soluble biomarker concentrations on 






A) PC1 and PC2 accounted for 61.5% and 10.5% of the variance respectively.  B) The majority of 
soluble biomarkers in the dataset form a group to account for the variance in PC1.  PC2 is 
overwhelmingly characterised by positive loadings in TNF-α, G-CSF and IL-7.  C)  The loading scores 
for PC1 are homogeneous and modestly positive across 17 of 21 contributing biomarkers.  PC2 is 
overwhelmingly characterised by positive loadings in TNF-α, G-CSF and IL-7, with neutral or 
negative loadings in all other markers besides IL-15. 
 
6.3.3 Relationships between CSF soluble biomarkers on study day 1 and clinical 
outcomes 
Having defined correlated variables that contribute to PC1 and PC2, which 
cumulatively explain 72% of the variance in the dataset of cytokines measured on 
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day 1, associations between those PCs and immunological and clinical variables 
were sought.  PC1 and PC2 were applied as independent variables in models to 
assess their relationship with peripheral CD4+ T cell count, CSF leucocyte count, 
CSF lymphocyte percentage, baseline fungal burden in CSF, EFA in CSF, lumbar 
puncture opening pressure and mortality at 10 weeks (Table 6.1 and Table 6.2, 
Figure 6.6).  For a unit increase in PC1, CSF white cell count was predicted to 
increase by 0.26 cells per mm3 and opening pressure by 0.31 cm H2O.  In addition, 
there was a trend towards increased risk of death in patients with higher PC1 
scores (Cox proportional hazard ratio 1.11 for PC1, adjusted for baseline fungal 
burden; p value 0.09).  Logistic regression corroborated the association between 
PC1 and opening pressure, predicting that for a unit increase in PC1, the odds of 
having high opening pressure (defined as ≥ 30 cm H2O) increase by a factor of 1.35.  
PC2 was not significantly associated with mortality in the Cox proportional hazards 
model (Table 6.1).  There was no significant association between PC1 or PC2 and 
either EFA or mortality when these clinical outcomes were examined as 




Table 6.1:  Correlations between PC scores and laboratory and clinical variables  
 PC1 PC2 
Variable Pearson’s r p value Pearson’s r p value 
Peripheral CD4+ cell count (per mm3) -0.12 0.64 0.11 0.67 
CSF WCC (per mm3) 0.26 0.04 -0.04 0.75 
CSF lymphocytes (% of CSF WCC) 0.10 0.73 -0.62 0.56 
Opening pressure (cm H2O)* 0.31 0.01 -0.08 0.49 
Baseline fungal burden (log10 CFU/ml) -0.11 0.38 -0.01 0.92 
EFA (log10 CFU/ml/day) -0.03 0.8 0.01 0.94 
Mortality at 10 weeks Cox PH estimate 0.09 Cox PH estimate 0.29 
1.11 0.78 
 
*Association between PC1 and opening pressure remained significant after adjusting for baseline 
fungal burden; p-value 0.01.  CSF WCC: cerebrospinal fluid white cell count; CFU: colony-forming 
units.  PH: proportional hazards.  Significant associations highlighted in red. 
 
 
Table 6.2:  Odds ratios for categorical outcomes given increases in PC scores 
 PC1 PC2 
Variable Odds ratio (CI) p value Odds ratio (CI) p value 
Early fungicidal activity (high) 1.02 (0.86 – 1.25) 0.77 0.91 (0.61 – 1.43) 0.66 
Opening pressure (high) 1.35 (1.14 – 1.65) 0.001 0.74 (0.38 – 1.20) 0.28 
Mortality at 10 weeks (death) 1.15 (0.97 – 1.37) 0.11 0.78 (0.43 – 1.25) 0.35 
 
CI: Confidence interval from 2.5% - 97.5%.  Models evaluating odds ratios for opening pressure and 





Figure 6.6: Associations between PCs 1 and 2 and clinical outcome variables 
 
 
Figure 6.6 A) Linear regression predicted that for a unit increase in PC1, opening pressure was 
predicted to increase by 0.31 cm H2O.  In a logistic regression model, the odds of having high 
opening pressure increase by a factor of 1.35 for each unit increase in PC1.  B – D) There was no 
significant association between PC scores and early fungicidal activity, baseline fungal burden or 
mortality at 10 weeks. 
 
 
6.3.4 Network analysis: study day 1 
 Relationships between day 1 concentrations of soluble biomarkers were 
further analysed using network analysis.  Applying network analysis to variables 
from study day 1, a recurring pattern emerged whereby the same biomarkers that 
contributed strongly to PC2 (TNF-α, G-CSF and IL-7) correlated more closely with 
one another than they did with any other soluble biomarkers in patients with 
favourable clinical outcomes of low opening pressure and survival at 10 weeks 
(figure 6.7A - D).  The pattern was less clear when patients were categorised 










Figure 6.7: Network plots of the associations among 21 soluble biomarkers in CSF 












Figure 6.7: Network plots of the associations among 21 soluble biomarkers in CSF for A) patients 
with opening pressure ≤ 30 cm H2O, B) patients with opening pressure > 30 cm H2O, C) patients 
who survived to 10 weeks, D) patients who were dead by 10 weeks, E) patients with high EFA and 
F) patients with low EFA.  
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6.3.5 CSF soluble biomarkers: change in concentration over time 
 Concentrations of soluble biomarkers in CSF were available from 61 
patients on day 1, 55 patients on day 7 and 53 patients on day 14.  A linear 
regression of the log-transformed, normalised concentration of each biomarker 
for each patient over time on treatment provided a ‘slope’ value for each cytokine 
per patient.  There was modest inter-cytokine variation in the mean slope value 
over the study period, though the variability in slope values for each cytokine was 
more heterogeneous (figure 6.8). 
 
Figure 6.8:  Change in CSF biomarker concentrations over time in patients with HIV-
associated cryptococcal meningoencephalitis 
 
 
Figure 6.8: Boxes indicate interquartile range, with median marked inside box.  Whiskers represent 





 PCA of the slope values for each biomarker in each patient revealed that 
the first two PCs of correlated cytokines and chemokines accounted for the 
majority of variance in the dataset.  PC1 accounted for 52.3% of the variance, and 
PC2 10.0% (Figure 6.9A).  As with the PCA of day 1 results, a large group of co-
correlated variables drove the variance in PC1 and the contribution of the majority 
of those variables to PC1 was proximately equal (figures 6.9B and 6.9C).  The 
variance in PC2, in contrast, was primarily accounted for by negative loading 
scores in the slopes of the same biomarkers that provided positive contributions 
to PC2 in the PCA of day 1 results: TNF-α, G-CSF and IL-7 (figures 6.9B and 6.9C).  
There was no statistically significant difference in PC1 or PC2 values between study 




Figure 6.9:  Principal component analysis of the slope of soluble biomarker 






Figure 6.9: A) PC1 and PC2 accounted for 52.3% and 10.0% of the variance respectively.  B) The 
majority of slope values form a group to account for the variance in PC1.  PC2 is characterised by 
negative loadings in G-CSF, IL-7 and TNF-α, and to a lesser degree IL-5.  C)  As with the PCA for day 
1 values, the loading scores for PC1 in the PCA of slope values are relatively homogeneous and 
modestly positive across 15 of 21 contributing biomarkers, with the slope values of MIP-1A and 
MIP-1B contributing slightly more positive loading scores.  PC2 is overwhelmingly characterised by 





6.3.6 Relationships between change in soluble biomarker concentrations over 
time and clinical outcomes 
PC1 and PC2 of the slopes of each soluble biomarker were applied as 
independent variables to assess their relationship with mortality and EFA (Figure 
6.10).  There was no association between EFA and PC1, either in univariate 
regression analysis or when adjusting for baseline fungal burden and study arm (p 
value 0.57 unadjusted; 0.53 adjusted).  PC2 was significantly associated with EFA 
when adjusted for baseline fungal burden and study arm, however the predicted 
unit change was negligible - for every unit increase in PC2, EFA increased by 0.03 
log10 CFU/ml/day (p value 0.01).  Logistic regression revealed that there was no 
significant association between the PCA of the slope of cytokine concentrations 
over time and mortality at 10 weeks when adjusted for baseline fungal burden (p 
value for association between PC1 and mortality at 10 weeks, 0.77; between PC2 
and mortality at 10 weeks, 0.18).  A Cox proportional hazard model revealed no 
association between PC1 or PC2 of slope values and time to death.  Similarly, there 
was no association between PC1 or PC2 and EFA when the latter was expressed as 
a categorical variable, either unadjusted or adjusted for baseline fungal burden 
and study arm (p value for association between PC1 and EFA category, 0.49; 




Figure 6.10: Associations between PCs 1 and 2 and clinical outcome variables 
 
Figure 6.10: There was no significant association between PCs 1 and 2 from the PCA of slope values, 
and either A) mortality at 10 weeks, or B) early fungicidal activity. 
 
 
6.3.7 Network analysis: change in soluble biomarker concentrations over time 
 
 Network analysis was applied to the slope values for each soluble 
biomarker over time.  The slopes of the same three biomarkers that contributed 
strongly positive loading scores to PC2 in the PCA of day 1 concentrations, and 
negative loading scores to the PCA of the slope values for biomarkers (TNF-α, G-
CSF and IL-7), were seen to correlate more closely with one another than they did 
with any other soluble biomarkers in patients with favourable clinical outcomes of 
high EFA and survival at 10 weeks (Figure 6.11A to D).   
Taking both day 1 PCA results and slope value PCA results together, there 
is a suggestion that a coordinated immune response in TNF-α, G-CSF and IL-7 may 
be beneficial, with higher values prior to treatment initiation and stable or 
decreasing values during treatment.  With the exception of the relationship 
between TNF-α and opening pressure, these cytokines were not themselves 




significant association with cytokines that are characteristic of Th1- and Th17-type 
immune responses (Figure 6.13) implies that they form an integral part of pro-
inflammatory pathways that promote classical macrophage activation. 
 
Figure 6.11:  Network plots of the associations among 21 soluble biomarkers in CSF 









Figure 6.11: Network plots of the associations among the slopes of 21 soluble biomarkers in CSF 
for A) patients with EFA ≤ 0.2 log10 CFU/ml/day, B) patients with EFA > 0.2 log10 CFU/ml/day, C) 






Figure 6.12: Associations between TNF-, G-CSF and IL-7 and clinical outcomes or markers of disease severity 
 
 
Figure 6.12: Associations between TNF-α (top row), G-CSF (middle row) and IL-7 (bottom row) and clinical outcomes of opening pressure (column 1), early fungicidal 
activity (column 2), 10-week mortality (column 3) and baseline fungal burden (column 4).  Fast EFA defined as > 0.2 log10 CFU/ml/day, slow EFA ≤ 0.2 log10 CFU/ml/day.  
Box plots show median and inter-quartile range, with whiskers indicating range.  Categorical variables compared using Mann-Whitney test.  Dot plots show best-fit 
regression line and 95% confidence intervals, with Pearson’s regression coefficient (‘R’). 
 
Opening pressure (cm H2O) EFA (log10 CFU/ml/day) Mortality at 10 weeks 
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Figure 6.13:  Associations between TNF-α, G-CSF and IL-7 and clinical outcomes or 
markers of disease severity 
 
 
Figure 6.13: Correlations between TNF-α (top row), G-CSF (middle row) and IL-7 (bottom row) and 
biomarkers that are characteristic of Th1-type responses (IFN-γ, column 1), regulatory responses 
(IL-10, column 2) and Th17-type immune responses (IL-17, column 3).  Dot plots showing best-fit 




6.3.8 Phagocyte functional activity 
Phagosomal superoxide burst activity in neutrophils and monocytes was 
measured at 10, 30, 60 and 90 minutes.  The fluorescence of cells that had 
internalised zymosan reporter particles was compared with the cells that had not 
internalised zymosan reporter particles.  Both the proportion of zymosan positive 
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cells and the intensity of superoxide reporter fluorescence increased over the 
course of the assay in both neutrophils and monocytes (Figure 6.14A and 6.14B).  
Oxidation of both neutrophils and monocytes occurred rapidly and within 60 
minutes for both cell types across HIV-negative controls, HIV-positive controls and 
in HIV/CM patients (Figure 6.14A and 6.14B).  In HIV/CM patients, but not control 
patients, AI generally reached a plateau after 60 minutes.  At all assay time points, 
neutrophil and monocyte AI was reduced in patients with HIV/CM compared with 
both HIV-positive and HIV-negative controls.  Neutrophil AI was reduced in HIV-
positive controls compared with HIV-negative controls (Figure 6.14 A and C).  In 
HIV/CM patients, oxidative activity in neutrophils was unchanged between study 
days 1, 7 and 14 (Figure 6.14A), whereas in monocytes there was a trend towards 
recovery of oxidative activity throughout the study period to day 14 (Figure 6.14B 
and 6.14D).  There was no significant difference in phagocytic activity between 
AMBITION study arms in either neutrophils or monocytes (p value < 0.05 for 





Figure 6.14: Activity index of superoxide burst over time in control subjects and 






Figure 6.14: Activity index in A) neutrophils and B) monocytes over the duration of the assay.  AI 
was significantly different between both HIV positive (HIV +) and HIV negative (HIV -) controls and 
HIV/CM patients on all study days, in both C) neutrophils and D) monocytes. All p values for 
comparisons < 0.001 (t test for pairwise comparisons). 
 
 
6.3.9 Relationships between phagocyte function and clinical outcomes 
 The slope of AI values over the study period was calculated through a linear 
regression of peak AI values per patient per day and was assessed to give an 
indication of phagocyte recovery during antifungal therapy.  Both the peak AI 
value per patient on study day 1 and the slope of peak AI values over the duration 
of the study (from days 1 to 14) were examined as independent variables for their 
impact on baseline fungal burden, opening pressure and EFA (Table 6.3).  Peak 
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neutrophil AI was negatively associated with opening pressure (Pearson’s r -0.33, 
p 0.04) and baseline fungal burden (r -0.50, p 0.001), and positively associated with 
EFA (r 0.33, p 0.04).  The slope of neutrophil AI was positively associated with CSF 
white cell count (r 0.41, p 0.01).  Peak and slope AI in monocytes was positively 
associated with opening pressure (r 0.36, p 0.02 and r 0.45, p 0.004 for peak and 
slope monocyte AI values, respectively).  There was insufficient data to examine 
the relationships between measures of AI and mortality at 10 weeks. 
 
Table 6.3:  Relationship between phagocyte function and laboratory and clinical 
variables 
 Peak AI - 
neutrophils 
AI slope - 
neutrophils 
Peak AI - 
monocytes 
AI slope - 
monocytes 




p value Pearson’s 
r 




CSF WCC (per 









-0.50 0.001 -0.03 0.86 0.17 0.28 0.11 0.53 
EFA (Log10 
CFU/ml/day) 0.33 0.04 0.03 0.88 -0.27 0.11 -0.18 0.27 
 
*Association between peak AI in neutrophils, peak AI in monocytes and AI slope in monocytes and 
opening pressure remained significant after adjusting for baseline fungal burden (p<0.05 for each 
correlation).  Significant associations highlighted in red. 
 
 
Since there was a suggestion that some measures of phagosome function 
were significantly associated with clinical outcomes, we constructed a correlation 
plot to explore the relationships between these AI measures and the PCs derived 
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from the PCA of soluble biomarkers on day 1 (Figure 6.15).  There were positive 
correlations between the AI slope value in monocytes and both PC1 (Pearson’s r 
0.58, p value 0.0001) and PC2 (r 0.71, p value < 0.0001), however it is notable that 
the subset of patients for whom there were data for both biomarker quantification 
and functional phagocytosis was just n=11. 
 
Figure 155:  Correlation plot to explore relationships between measures of 
phagocytic activity index and soluble biomarker PCs 
 
 
Figure 6.15: Larger circles indicate stronger correlations.  Deeper blue shades indicate more 
positive correlations; deeper red shades more negative correlations.   Blank regions indicate that 













 In this study we present a comprehensive analysis of the phenotype of the 
immune response at the site of clinical HIV-associated cryptococcal 
meningoencephalitis.  This includes serial measurements of soluble biomarkers 
over time as well as examining whole blood functional phagocyte activity – to our 
knowledge the first time these measures have been applied in conjunction to 
HIV/CM patients.  Our analysis of CSF soluble biomarkers on study day 1 suggests 
that a coordinated proinflammatory response is associated with favourable 
clinical outcomes – in particular, the coordination of TNF-α, G-CSF and IL-7 
concentrations was associated with lower intracranial pressure and survival at 10 
weeks.  The analysis of the trend, or slope, in CSF cytokine concentrations over 
time revealed additional associations with EFA and corroborated the finding that 
a coordinated profile among these three cytokines has a positive impact on 
survival.   
 TNF-α is released from cells of monocyte/ macrophage lineage and 
functions as a core inflammatory mediator, involved in protection against a wide 
range of pathogens including Listeria monocytogenes, Salmonella typhimurium, 
Mycobacterium tuberculosis and Candida albicans.409-412  TNF-α activates 
macrophages and polymorphonuclear leukocytes (PMNs), including neutrophils, 
triggering superoxide burst and nitric oxide-dependent cell killing.413  In addition, 
TNF-α stimulates IFN-γ production, the beneficial role of which is well 
documented in patients with HIV/CM.174,180  There is some evidence that 
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cryptococcal cells themselves inhibit the production of TNF-α,173 which may partly 
explain its inverse correlation with fungal burden and EFA.   
G-CSF promotes the differentiation of stem cells into neutrophils and 
monocytes, increasing their numbers as well as their phagocytic and microbicidal 
activity.414,415  In vitro experiments have suggested that G-CSF may also have direct 
immunomodulatory properties, since the addition of G-CSF to neutrophils, 
monocytes or monocyte-derived macrophages led to enhanced cryptococcal 
killing both in the presence and absence of azole antifungal treatment.416  There 
are reports from HIV-negative patients with cryptococcal meningoencephalitis of 
the identification of autoantibodies to another colony-stimulating factor, GM-CSF, 
suggesting the importance of colony-stimulating factors in immunity to 
cryptococcal meningoencephalitis.417   
IL-7 is an essential cytokine for lymphopoiesis, evidenced by the absence 
of B- and T-cells in animals deficient in IL-7418-420 and of T-cells in humans lacking 
IL-7.421  IL-7 appears to play a key role in T-cell homeostasis – its release from 
stromal cells is thought to be triggered by low levels of circulating CD4+ T-cells, 
resulting in expansion of both CD4+ and CD8+ T-cells, regardless of baseline levels 
of CD8+ T-cells.422,423  This is in keeping with the observation that the CD4+ T-cell 
predominance observed in blood and CSF in healthy persons is replaced by CD8+ 
T-cells in PLHIV.154,165  
These cytokines do not operate in isolation and our finding that their 
concentrations are closely correlated with biomarkers characteristically 
associated with Th1-type immune responses (IFN-γ), regulatory cytokines (IL-10) 
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and Th17-type responses (IL-17) support the conclusion that they form part of a 
larger proinflammatory network that promotes beneficial clinical responses to 
HIV/CM.  This is in keeping with other clinical studies of the host response to 
cryptococcal meningoencephalitis in CSF, which demonstrate that reduced 
concentrations of Th1-type biomarkers in CSF such as IL-6, G-CSF and IFN-γ are 
associated with higher fungal burden, slower clearance of infection and early 
mortality.152,154,155,174  The use of dexamethasone as an adjunct to antifungal 
therapy for HIV/CM is associated with rapid early declines in TNF-α in CSF, slower 
fungal clearance and a trend towards excess mortality.183,184  Conversely, 
increased concentrations of the Th1-type cytokines IL-6, IL-8, IL-17, IFN-γ and TNF-
α in CSF are associated with survival benefit.152,155,175   
 The phagocyte functional assay suggested that phagocytosis and 
phagosomal superoxide burst were significantly reduced in HIV/CM patients 
compared with control participants in both neutrophils and monocytes, and in 
HIV-positive controls compared with HIV-negative controls in neutrophils.  Peak AI 
in neutrophils on day 1 was associated with markers of clinical benefit – reduced 
opening pressure and fungal burden, and increased EFA.  However, the same was 
not true of monocytes, in which increased AI was associated with increased 
opening pressure.  This is consistent with phagocyte biology – neutrophils do not 
proliferate and have a short half-life in vivo of approximately 6-12 hours.424  
Following phagocytosis and the production of ROS, neutrophils undergo apoptosis 
– a process that is essential to limit the release of inflammatory mediators and 
constrain tissue damage.425,426  This may explain why despite the significant 
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associations between peak AI in neutrophils and clinical outcomes, the slope in 
neutrophil AI over time was not significantly associated with these indices.  Once 
neutrophils have phagocytosed invading cryptococci in the acute setting, their 
populations diminish, and other immune factors take over antifungal action.  
Monocyte populations, in contrast, have an in vivo half-life of approximately 22 
hours and monocyte apoptosis can be blocked by proinflammatory cytokines 
including TNF-a and G-CSF.427,428  The significant association between monocyte AI 
slope and opening pressure, that was not seen between neutrophil AI slope and 
opening pressure, may therefore reflect ongoing monocyte activity over the study 
period, enabled by inhibition of monocyte apoptosis by the presence of 
inflammatory cytokines (themselves also associated with opening pressure, as 
demonstrated in the PCA and network analyses).   
Notably, peak neutrophil AI was negatively correlated with opening 
pressure, whereas peak and slope monocyte AI values were positively correlated 
with opening pressure.  An explanation for this may be that the short half-life of 
neutrophils results in their predominant action being that of phagocytosis prior to 
apoptosis, whereas the ongoing action of monocytes - which includes not only 
phagocytosis but also antigen presentation and production of proinflammatory 
cytokines429 - contributes to more widespread inflammation in the CNS, which is 
overall beneficial but amplifies the risk of increased intracranial pressure.  The 
hypothesis that the overriding feature of monocyte activity in this setting is the 
contribution to generalised inflammatory activity rather than reduction in fungal 
burden through phagocytosis is supported by the positive correlation of monocyte 
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AI slope with PC1 and PC2 from the PCA of day 1 soluble biomarker 
concentrations.   
Despite its prospective nature and the fact that it presents a detailed 
overview of immune biomarkers and phagocyte function from serial samples 
collected over time, this study is subject to a number of limitations.  Firstly, our 
cohort was relatively small and heterogeneous.  In particular, samples for the 
phagocyte functional assay were collected from a limited number of patients and 
a substantial proportion of these were distinct from the patients who provided 
CSF samples for multiplex biomarker analysis.  It would have been preferable to 
have data from all assays from all patients and we recommend that correlations 
between biomarker concentrations and phagocytic activity index are sought in 
larger cohorts.  Secondly, we do not have samples of CSF from control patients 
without cryptococcal meningoencephalitis, due to ethical considerations that 
restrict the collection of CSF without clinical indication.   Thirdly, prospective 
clinical findings (EFA and mortality) were likely influenced by the PK of the drugs 
received by patients.  While we controlled for study arm in the analysis of 
prospective clinical findings, we did not have access to individual PK parameters 
for all study drugs, which may have exhibited significant inter-individual variability.  
Finally, the principal clinical indicator for which we found consistent findings 
throughout or data and which tied our results together was opening pressure.  It 
is likely that non-immune factors played a role in increasing intracranial pressure, 
for which we were unable to account in this study.  For example, while we adjusted 
our analyses for fungal burden, we did not measure Cryptococcus cell or capsule 
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size, both of which are associated with increased intracranial pressure via 
obstruction of CSF drainage.154,430  
 In summary, we have added to an emerging body of literature that 
suggests the importance of proinflammatory Th1-type activity in the host 
response to cryptococcal meningoencephalitis.  The association of phagocyte 
function with soluble immune biomarker signatures provides further insight into 
the mechanism of host anticryptococcal activity.  In keeping with previous clinical 
studies, we have not seen a dichotomous Th1/Th2 response in CSF.152  Instead, a 
complex network of closely correlated biomarkers that may be categorised as Th1, 
Th2 and/or Th17 appears to result in generalised inflammation that is associated 




7.1 Principal finding: the neglect of PK-PD analyses stalls progress in 
antifungal therapeutics and is potentially harmful to patients. 
Pharmacokinetic and pharmacodynamic analyses have been underutilised 
in the field of therapeutics for invasive fungal infections (IFIs), where they present 
an opportunity for improved understanding of treatment outcomes.  In turn, PK-
PD analyses have the potential to enhance the accuracy and efficiency of efforts 
to optimise the treatment of these deadly diseases.  This is the central conclusion 
of this thesis, drawing on evidence from each of chapters 2 – 6. 
 Several clinical observations formed the basis of the investigations 
presented in this thesis.  Decades of experience with treating HIV-associated 
cryptococcal meningoencephalitis have concluded that fluconazole monotherapy, 
even at high doses, fails to achieve satisfactory clinical outcomes at a population 
level, while treatment with amphotericin B deoxycholate (DAmB) produces 
greater rates of treatment success as well as greater rates of toxicity.  A novel 
liposomal amphotericin B (LAmB)-based regimen offers hope for a less toxic and 
logistically more straightforward strategy.  Despite promising pharmacological 
attributes, itraconazole was inferior to DAmB for the treatment of disseminated 
talaromycosis in a recent clinical trial.  Until now, however, the PK-PD rationale for 
these observations has remained elusive or has been inferred from preclinical 
observations.  This thesis examines the PK-PD principles underlying these 
observations based on clinical data derived from relevant patient populations. 
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In chapter 2, the inferiority of fluconazole monotherapy compared with 
polyene-based therapy is explained in PK-PD terms.  Despite proven 
anticryptococcal activity and excellent CNS partitioning, fluconazole fails to attain 
PD targets even in wild type strains of C. neoformans.  Extensive variability in 
systemic fluconazole PK and its CNS penetration increases the risk of suboptimal 
exposure.  Similarly, chapter 3 demonstrates the PK-PD basis for the clinical 
outcomes observed following DAmB administration for cryptococcal 
meningoencephalitis.  This drug sterilises CSF in a dose-dependent manner, but at 
doses approaching 1.0 mg/kg the benefit of CSF sterilisation is offset by increased 
mortality, which may be related to excessive toxicity or pathophysiological 
changes that we were unable to account for.  The PK model and bridging study 
presented in chapter 4 suggests that the novel high dose LAmB-based regimen 
currently being trialled for cryptococcal meningoencephalitis is dosed optimally in 
terms of achieving maximal PD effect.  These analyses, therefore, have provided 
at least part of the pharmacological explanation for clinical observations in these 
drug-disease combinations.  The fact that all PK samples were taken from patients 
currently undergoing treatment for HIV-associated cryptococcal 
meningoencephalitis rather than from healthy volunteers increases the 
confidence with which these findings can be applied to relevant patient 
populations. 
PK-PD studies are essential components of some larger scientific 
endeavours, though their inclusion in those endeavours is frequently neglected.  
Chapters 4 and 5 highlight the importance of PK-PD studies in drug development 
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and clinical trial design, respectively.  In chapter 4, it was not possible to link the 
population model built to describe LAmB PK to clinical PD data, since 
incomparable combination treatment regimens were administered in the two trial 
arms of AMBITION.  That is to say that the non-polyene component of each trial 
arm differed, so the PD effect of the polyene could not be isolated.  A murine 
bridging study was performed to generate data to simulate the PD effect of high 
dose LAmB, with associated limitations as described in chapter 4.  Had thorough 
clinical PK-PD studies been incorporated into the development of LAmB, this 
approximation of PD effect through the murine bridging study would not have 
been necessary.  Chapter 5 describes a missed opportunity within the clinical trial 
investigating the non-inferiority of itraconazole versus DAmB for talaromycosis to 
generate data to explain the trial outcome pharmacologically, or to set a target for 
therapeutic drug monitoring of itraconazole in this disease, since very few of the 
patients mounted sufficient drug exposure to generate PD effect.  This limitation 
may have been avoided had PK-PD studies been incorporated into trial design at 
an earlier stage. 
PK-PD factors are not the sole determinants of clinical outcome from IFIs.  
This is demonstrated in chapters 3 and 6.  The analysis presented in chapter 3 
indicates the dosage at which PD benefits begin to be outweighed by mortality 
that may be unrelated to CSF fungal burden.  Chapter 6 presents a detailed 
examination of the host response to cryptococcal meningoencephalitis and 
suggests that immunological factors are important in determining clinical 
outcome.  In addition, this chapter provides novel insights into the role of 
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phagosomal activity as part of a coordinated inflammatory response against 
disseminated cryptococcal infection.  This adds to a growing body of literature that 
indicates that there is a potential role for immunomodulatory therapy in 
cryptococcal meningoencephalitis, which may be in addition to traditional 
antifungal therapy. 
The analyses presented in this thesis are subject to a number of general 
limitations.  In chapter 2, our conclusions regarding the probability of PD target 
attainment are based on the assumed relevance of a PK-PD target derived from 
murine data.  Similarly in chapter 4, LAmB PD is modelled based on an inhibitory 
Emax model generated from murine data.  In chapter 3, the DAmB PD data from 
patients in the PK study population were confounded by the co-administration of 
fluconazole, so PD outcomes were modelled based on a meta-analysis of clinical 
studies in comparable, but necessarily different, patient populations.  In all of 
these analyses, then, PD data originated from patients or subjects that were 
unmatched to the patients that the PK data originated from.  Nevertheless, the PD 
data used were the most applicable data available, and overall findings were 
biologically and clinically plausible in each case. 
For PK datapoints where the level was below the bioanalytical limit of 
quantitation (LLQ), we investigated various methods for handling these values: 
datapoints below the LLQ were set either to half the LLQ, to zero, or were treated 
as missing values.  There are limitations to each of these approaches since they 
have the effect of artifactually prolonging the half-life of the drug, curtailing the 
half-life or withholding information, respectively.  In each of the PK models, we 
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selected the option that enabled the best fit.  In chapters 2, 3 and 4, the impact of 
these approaches on simulated PD outcomes would be minimal, since PD was 
linked to AUC, which is mainly determined by measurable drug levels.  In chapter 
5, itraconazole exposure was so low in the population that the consequences of 
each approach would again have been minimal.  However, the uncertainty 
surrounding these datapoints undoubtedly reduces the degree to which the PK 
models can reflect reality. 
 
7.2 Future directions 
In IFIs, as in other infectious diseases, there exists large heterogeneity in 
PD outcomes.  Despite receiving the same dose and regimen of the same drug or 
combination of drugs, treatment response varies markedly from patient to 
patient.74,322  PK analyses such as those presented here can quantify variability in 
drug exposure, including that at the site of infection, and suggest the degree to 
which this is responsible for variability in PD and clinical response.  However, as 
illustrated in chapter 6, non-pharmacological aspects of infection can also impact 
upon clinical outcomes.  The reliance on PD trends such as EFA as surrogate 
indicators of mortality in clinical studies263,264 raises the importance of an 
appreciation of the broad determinants of those trends.  A clear next step for this 
research is to investigate non-pharmacological determinants of PD response in 
more detail.  In the example of cryptococcal meningoencephalitis, a search for 
immune signatures in CSF in a larger patient population with matched control 
samples would be valuable, particularly focussing on pre-treatment levels of 
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soluble biomarkers since these were the most informative in our analysis.  A 
similar analysis in peripheral blood samples may offer additional insight.  
Verification of the signal emerging from our functional phagocytosis assay, that 
suggests that phagosomal activity forms part of a widespread beneficial pro-
inflammatory response to cryptococcal meningoencephalitis, should similarly be 
sought in greater patient numbers. 
An additional source of heterogeneity in PD response may arise from the 
microbiological characteristics of the infecting organism itself.  Again, to take the 
example of cryptococcal meningoencephalitis, there is evidence that isolates of 
particular genomic lineages of Cryptococcus spp. exhibit distinctive phenotypes 
and are associated with higher rates of mortality than other lineages.192  There are 
further clinical associations with genomic strain characteristics at the sub-lineage 
level.189-191,193  Moreover, there is increasing evidence of strain heterogeneity 
within an individual patient’s infection, and the expansion of heterogeneity in 
terms of drug tolerance or resistance during suboptimal drug treatment.67,194,431-
433  Phenotypic virulence attributes may conceivably also vary within an individual 
patient’s infection.  The impact of genotypic and phenotypic attributes on markers 
of PD response, such as EFA, has not been clarified. 
An especially valuable future line of research would be to acquire matched 
individual-level data on the PK parameters, immunological networks and 
microbiological characteristics of clinical infection with Cryptococcus spp. – or 
other invasive fungal pathogens.  In this scenario, the relative contribution of each 
of those features to PD response and ultimately to clinical outcome could be 
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calculated.  For example, if a host has a weak inflammatory response to 
cryptococcal infection in the CNS, and/ or is infected with a particularly virulent 
strain of Cryptococcus spp., can adequate drug exposure compensate for that and 
produce a favourable PD outcome?  And secondarily, would such an outcome 
guarantee a favourable clinical outcome or are there nuances to this relationship 
that could be established clinically? 
 
7.3 Conclusion 
 Pharmacometric analysis has historically been a neglected area of research 
in the antimicrobial arena and particularly in mycology.  Each chapter in this thesis 
illuminates to some degree the scientific explanation for a clinical observation and 
thereby highlights the utility of clinical PK-PD research in relevant patient 
populations.  More generally, this work demonstrates that PK-PD tools can de-risk 
efforts to optimise antifungal treatment regimens, enhance the efficiency of those 
efforts and contribute to the preservation of the precious antifungal 
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ABSTRACT In 2019, the WHO tuberculosis (TB) treatment guidelines were updated
to recommend only limited use of streptomycin, in favor of newer agents or amika-
cin as the preferred aminoglycoside for drug-resistant Mycobacterium tuberculosis.
However, the emergence of resistance to newer drugs, such as bedaquiline, has
prompted a reanalysis of antitubercular drugs in search of untapped potential. Using
211 clinical isolates of M. tuberculosis from South Africa, we performed phenotypic
drug susceptibility testing (DST) to aminoglycosides by both critical concentration
and MIC determination in parallel with whole-genome sequencing to identify known
genotypic resistance elements. Isolates with low-level streptomycin resistance medi-
ated by gidB were frequently misclassified with respect to streptomycin resistance
when using the WHO-recommended critical concentration of 2 g/ml. We identified
29 M. tuberculosis isolates from South Africa with low-level streptomycin resistance
concomitant with high-level amikacin resistance, conferred by gidB and rrs 1400, re-
spectively. Using a large global data set of M. tuberculosis genomes, we observed 95
examples of this corresponding resistance genotype (gidB-rrs 1400), including identi-
fication in 81/257 (31.5%) of extensively drug resistant (XDR) isolates. In a phyloge-
netic analysis, we observed repeated evolution of low-level streptomycin and high-
level amikacin resistance in multiple countries. Our findings suggest that current
critical concentration methods and the design of molecular diagnostics need to be
revisited to provide more accurate assessments of streptomycin resistance for gidB-
containing isolates. For patients harboring isolates of M. tuberculosis with high-level
amikacin resistance conferred by rrs 1400, and for whom newer agents are not avail-
able, treatment with streptomycin may still prove useful, even in the face of low-
level resistance conferred by gidB.
KEYWORDS Mycobacterium tuberculosis, aminoglycosides, drug resistance
mechanisms, multidrug resistance, tuberculosis, whole-genome sequencing
Despite recent advances, tuberculosis (TB) remains the number one infectious killerworldwide (1). The ongoing global epidemic of drug-resistant TB and limited
effective treatment regimens for drug-resistant Mycobacterium tuberculosis have re-
sulted in significant morbidity and mortality (1). Recognition of the inadequacy of the
current antitubercular drug development pipeline, and the emergence of resistance to
new drugs—including bedaquiline (2–9), delaminid (3, 4), clofazimine (5, 7), and
linezolid (6)— has prompted a reanalysis of the existing arsenal of antitubercular drugs
in search of untapped potential. Streptomycin may be one such underutilized drug.
Discovered in 1944, streptomycin, an injectable streptidine aminoglycoside antibi-
otic, was the first antimicrobial agent with proven activity against M. tuberculosis. In
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conjunction with isoniazid and para-aminosalicylic acid (PAS), streptomycin formed
part of the first multidrug combination chemotherapy for TB, introduced in 1952. Its
initial widespread use led to the early emergence of streptomycin resistance, which
subsequently limited its clinical utility. Streptomycin remained an integral component
of first-line TB therapy until the 1980s, and its empirical use in retreatment TB regimens
was recommended until recently (10).
While the majority of the molecular determinants of aminoglycoside resistance are
known, commercial diagnostic tests that assay for genotypic streptomycin resistance
are lacking. Resistance to streptomycin does not contribute to the definition of exten-
sively drug resistant (XDR) TB, which is defined as multidrug-resistant (MDR) isolates
with additional resistance to quinolones and other injectable agents (amikacin, kana-
mycin) (11). Streptomycin is currently classified as a group C second-line agent for use
in longer MDR-TB regimens (10), which are recommended in limited circumstances
only. While XDR isolates are frequently cross-resistant to second-line injectable agents,
there may be untapped potential for continued use of streptomycin for low-level
resistance.
In our large collection of M. tuberculosis isolates from South Africa, we characterized
aminoglycoside-resistance phenotypes in conjunction with whole-genome sequencing
to identify patterns of aminoglycoside resistance. Subsequently, we used a global data
set of over 5,000 M. tuberculosis genomes to assess the occurrence of genotypic
low-level streptomycin resistance concomitant with high-level amikacin resistance
worldwide.
RESULTS
Using 211 sequenced clinical isolates of M. tuberculosis from South Africa (Table S2
in the supplemental material), we performed critical concentration testing for strepto-
mycin and kanamycin, and observed incomplete cross-resistance between these two
aminoglycosides (Table S3). Amikacin critical concentration was not performed due to
anticipated near complete cross-resistance with kanamycin (12), which was confirmed
by our MIC testing (Fig. S1). Using genomic sequences for these 211 isolates, we sought
known drug resistance markers for these aminoglycoside drugs. A total of 140 isolates
were found to have genotypic markers of streptomycin resistance, with mutations in
rpsL, rrs (non-1400), and gidB, whereas 50 isolates had mutations in rrs 1400, which
confers high-level resistance to both amikacin and kanamycin (Table 1). Two isolates
TABLE 1 Distribution of resistance-associated mutations in a South African data seta
Drug Gene Polymorphismb Number of isolates
Streptomycin rpsL K43R 31
K88R 8
rrs (non-1400) 513 7
516 6
907 1
gidB nt 62, del 1 bp 1
nt 103, del 1 bp 1
nt 108, del 1 bp 3
nt 116, del 1 bp 3
nt 282, del 130 bp 78




Kanamycin/amikacin rrs 1400 50
Kanamycin eis promoter 14 2
aOf the 211 South African isolates, 140 were found to have genotypic streptomycin resistance with
mutations in rpsL, rrs (non-1400), and gidB, as detailed in the table. Fifty strains were found to have
genotypic amikacin/kanamycin resistance with mutations in rrs 1400, and two isolates had kanamycin
resistance with an eis promoter mutation.
bnt, nucleotide; del, deletion; bp, base pairs.
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contained mutations in the promoter region of eis, which confers resistance to kana-
mycin, but not to streptomycin or amikacin. Co-occurrence of streptomycin and
amikacin/kanamycin resistance genotypes was determined (Table 2), including identi-
fication of seven isolates with more than one streptomycin-resistance-determining
mutation (Table S4).
In comparing MIC data from Sensititre testing with known aminoglycoside resis-
tance genotypes, we evaluated the relationship between genotypic and phenotypic
resistance to streptomycin (Fig. 1A), amikacin (Fig. 1B), and kanamycin (Fig. S1). There
was a bell-shaped distribution (Fig. 1A) of isolates containing gidB mutations with
low-level streptomycin resistance (median MIC 4 g/ml; interquartile range [IQR], 2 to
4 g/ml) (Table 3). By critical concentration testing per the WHO-recommended guide-
lines, the majority of isolates with gidB mutations (76%, 70/92) were classified as
resistant to streptomycin. In contrast, high-level streptomycin resistance was observed
in isolates with either rrs (non-1400) or rpsL mutations, with median MIC 32 g/ml (IQR,
16 to 32 g/ml) and 32 g/ml (IQR, 16 to 32 g/ml), respectively. Three isolates with no
identifiable streptomycin mutations were noted to have high MICs to streptomycin
(MIC 16 to 32 g/ml), suggesting that additional streptomycin resistance mutations
remain to be discovered, but this could also be due to errors in phenotyping. Nearly
every isolate with high-level amikacin and kanamycin resistance contained an rrs 1400
mutation (Fig. 1B, Fig. S2).
When comparing the MIC of each isolate to streptomycin and amikacin, numerous
isolates had mismatched phenotypes, indicating that resistance to amikacin did not
confer resistance to streptomycin, and vice versa (Fig. 2). In particular, 29 isolates from
South Africa exhibited low-level streptomycin resistance (MIC 4 g/ml or 8 g/ml) and
concomitant high-level amikacin resistance (MIC 16 g/ml) (circled area, Fig. 2). These
findings suggest that use of streptomycin instead of amikacin would be the preferred
aminoglycoside for treatment of these isolates. The vast majority of isolates with this
phenotype (93%, 27/29) contained a gidB resistance genotype, and 100% (29/29)
contained an rrs 1400 mutation.
From the genomic data, we constructed a phylogeny to determine the interrelat-
edness of isolates with (i) low-level streptomycin resistance and (ii) concomitant
low-level streptomycin and high-level amikacin resistance in phenotypic testing (Fig. 3).
The 57 isolates with low-level streptomycin resistance were distributed throughout the
phylogeny. The majority (25/29, 86%) of South African isolates with low-level strepto-
mycin and high-level amikacin resistance belonged to the Tugela Ferry XDR clone,
which was responsible for epidemic XDR in the region in the early 2000s (13). However,
there were four isolates outside this cluster, indicating that this phenomenon was not
unique to this clone.
To determine whether the phenomenon of low-level streptomycin and high-level
amikacin resistance occurred outside South Africa, we analyzed our large data set of
5,310 M. tuberculosis isolates from 43 countries (14). Within this data set, 257 isolates
contained mutations for resistance to all four drugs that define XDR (rifampin, isoniazid,
TABLE 2 Distribution of co-occurring genotypic resistances to streptomycin and amikacin/
kanamycin in a South African data seta
Streptomycin genotype
Amikacin/kanamycin genotype
WT rrs 1400 eis promoter Total
WT 67 2 2 71
rpsL 33 2 0 35
rrs (non-1400) 8 5 0 13
gidB 44 41b 0 85
Total 152 50 2 204
aOf note, 7 isolates were identified to contain more than one streptomycin resistance mutation, as described
in Table S4 in the supplemental material.
bThe boldface type indicates the number of isolates with co-occurrence of gidB and rrs 1400 mutations that
confer low-level streptomycin and high-level amikacin resistance.
Optimizing Aminoglycoside Choice in TB Antimicrobial Agents and Chemotherapy
September 2020 Volume 64 Issue 9 e00860-20 aac.asm.org 3







ofloxacin, and amikacin). As phenotypic data were not available for this data set, we
used co-occurrence of a gidB resistance mutation and rrs 1400 mutation as a genotypic
predictor of this combination of low-level streptomycin resistance and high-level
amikacin resistance (Fig. 4). We identified 378 unique isolates with gidB mutations,
including 95 isolates with co-occurrence of gidB mutations and rrs 1400 mutation (Table
S5). All 95 isolates contained resistance-conferring mutations to both isoniazid and
rifampin (MDR genotype) in addition to resistance to either ofloxacin or kanamycin
(pre-XDR), and 81/95 of these isolates were XDR. Of the 257 XDR isolates in the
5,310-isolate data set, 81 (31.5%) of the XDR isolates contained this gidB-rrs 1400
FIG 1 Clinical strains of M. tuberculosis were observed to have a range of susceptibility to aminoglyco-
sides, mediated by resistance genotype. A total of 211 isolates of M. tuberculosis from South Africa
underwent MIC determination and aminoglycoside resistance genotyping to identify mutations that
confer resistance to streptomycin or amikacin, respectively. (A) Streptomycin MIC testing revealed a
bell-shaped curve distribution of gidB strains with low-level streptomycin resistance, whereas strains
containing rrs (non-1400) or rpsL mutations had higher resistance. Of note, three isolates containing
resistance elements in both gidB and rpsL were included among the rpsL isolates. (B) Amikacin MIC
testing revealed high-level resistance among strains containing the rrs 1400 mutation. Kanamycin MIC
results mirrored that of amikacin (Fig. S1 in the supplemental material).
TABLE 3 gidB mutations confer low-level streptomycin resistance, whereas rrs and rpsL
mutations confer high-level resistance
Streptomycin genotype Median MIC to streptomycin in g/ml (IQR)a
WT 1 (0.5–2)
gidB 4 (2–4)
rrs (non-1400) 32 (16–32)
rpsL 32 (32–32)
aFor each streptomycin resistance genotype, median MIC to streptomycin and interquartile range (IQR) is
listed.
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combination, indicating frequent occurrence in global XDR-TB. The majority of isolates
with the gidB-rrs 1400 pattern were LAM4 and likely members of the Tugela Ferry XDR
clade. However, there were nine other spoligotypes with isolates containing this
pattern, indicating multiple independent evolutionary events. Beyond South Africa,
isolates with this resistance pattern were also identified in Belarus, China, Iran, Portugal,
Romania, South Korea, and Sweden, indicating that this phenomenon of streptomycin-
low and amikacin-high resistance is of global importance for management of drug-
resistant TB.
DISCUSSION
In both a South African and a global data set, significant numbers of M. tuberculosis
isolates contained mutations associated with concomitant low-level streptomycin re-
sistance and high-level amikacin resistance. Current guidelines that recommend only
limited use of streptomycin (10) may be unwittingly withholding a potentially lifesav-
ing, inexpensive, and available drug from certain patients with drug-resistant TB.
Similarly, current WHO-endorsed laboratory procedures for performing phenotypic DST
to streptomycin by critical concentration may obscure the potential utility of strepto-
mycin by not distinguishing between high and low-level resistance.
Given additional newer agents with excellent activity against drug-resistant TB, such
as bedaquiline, the updated 2019 WHO guidelines limit use of aminoglycosides (10).
Kanamycin is no longer recommended in the treatment of drug-resistant TB patients on
longer regimens. Amikacin is now the preferred aminoglycoside, and its use is limited
to adults on longer regimens in situations in which DST results confirm susceptibility
and for whom high-quality audiometry testing for hearing loss can be performed.
Streptomycin use is recommended only when amikacin is not available, and again in
situations when DST results confirm susceptibility and in whom safety monitoring can
be ensured.
While treatment-related ototoxicity and nephrotoxicity are well established, strep-
tomycin could still hold therapeutic potential for individuals with drug-resistant TB
harboring isolates with low-level streptomycin resistance. If an aminoglycoside is being
considered for inclusion in a drug-resistant TB regimen, if the rrs 1400 mutation is
present, which confers high-level resistance to amikacin, than we recommend selection
of streptomycin, even in the face of low-level resistance, such as that conferred by gidB.
To our knowledge, clinical outcomes for individuals harboring isolates with low-level
streptomycin resistance mediated by gidB and treated with a streptomycin-containing
regimen have not been assessed. An expanded role for streptomycin in drug-resistant
FIG 2 Significant numbers of M. tuberculosis isolates exhibit concomitant low-level streptomycin resis-
tance and high-level amikacin resistance. Isolates are represented by streptomycin genotype (see key)
and plotted as a function of the relative phenotypic resistance to both amikacin and streptomycin. The
red dotted circle indicates the 29 isolates with concomitant low-level streptomycin resistance and
high-level amikacin resistance.
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TB may also increase risk of adverse events related to drug toxicity. Ensuring safety of
a streptomycin-based regimen would necessitate implementation of monitoring pro-
cedures, including audiometry and measurements of renal function, which constitute
an additional burden— especially for resource-limited settings.
In South Africa, due to a clonal outbreak of XDR-TB in Tugela Ferry, a large fraction
of circulating XDR-TB isolates contain an 130-bp deletion in gidB that confers low-level
streptomycin resistance and an rrs 1400 mutation that confers high-level cross-
resistance to amikacin, kanamycin, and capreomycin (15, 16). In a recent long-term
cohort study of XDR-TB treatment outcomes in South Africa, only 1% of patients were
treated with streptomycin, whereas 98% received capreomycin (17). As treatment
FIG 3 Concomitant low-level streptomycin and high-level amikacin phenotypic resistance in South African M.
tuberculosis isolates across the phylogeny. Midpoint rooted maximum-likelihood phylogeny of 211 M. tuberculosis
isolates, containing representatives of four of the seven known M. tuberculosis lineages. Phenotypic MDR and XDR
are indicated by black and white boxes at the tip of each leaf node. The levels of phenotypic resistance to
streptomycin (low, MIC 4 to 8 g/ml; high, MIC 16 g/ml) and amikacin (low, MIC 4 to 8 g/ml; high, MIC 16 g/
ml) are indicated by box color, per the key. Strains with concomitant low-level streptomycin resistance and
high-level amikacin resistance are indicated in red. While the majority of isolates with low-level streptomycin
resistance and high-level amikacin resistance pertained to the Tugela Ferry XDR outbreak clone, four examples
were observed outside the outbreak clone, indicating that this was not an isolated evolutionary event.
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outcomes for XDR-TB in South Africa were notoriously abysmal (17), including strep-
tomycin may prove useful for patients in whom new drugs are not available because
of resistance or contraindications.
Current WHO-endorsed laboratory procedures for performing phenotypic DST to
streptomycin by critical concentration fail to provide key information relevant to
streptomycin inclusion in a regimen for drug-resistant TB. The MIC distribution for
isolates containing gidB mutations straddles the WHO-recommended critical concen-
tration of 2 g/ml (Fig. 1A). This modest increase in MIC among isolates containing gidB
mutations in comparison to wild-type isolates likely contributes to inconsistencies in
testing. Isolates containing gidB mutations are frequently misclassified in terms of their
susceptibility to streptomycin on critical concentration testing (as occurred in 24% of
FIG 4 Concomitant low-level streptomycin and high-level amikacin genotypic resistance evolved repeatedly in a
global data set of M. tuberculosis. Midpoint rooted maximum-likelihood phylogeny of 5,310 M. tuberculosis strains
from a global data set containing representatives of all seven known M. tuberculosis lineages. The presence and
levels of genotypic resistance to streptomycin (low, gidB; high, rrs [non-1400] and rpsL) and amikacin (high, rrs 1400)
are indicated by box color near the leaf nodes. Ninety-five isolates with genotypic mutations predicted to confer
both low-level streptomycin resistance and high-level amikacin resistance (gidB-rrs 1400) are indicated in red.
Concomitant low-level streptomycin resistance and high-level amikacin resistance occurred across the phylogeny,
indicating that this phenomenon is of global relevance for TB control.
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isolates in this study). As critical concentration testing is typically performed only at a
single concentration, isolates with low-level streptomycin resistance—which may po-
tentially be treated successfully with streptomycin— cannot be distinguished from
those with high-level resistance. Similarly, wild-type strains that do not contain geno-
types predicted to confer resistance to streptomycin can exhibit low-level streptomycin
resistance that is above the critical concentration threshold (as seen in four South
African isolates in this study), which may result in withholding a potentially useful drug.
The WHO-recommended critical concentration for streptomycin in M. tuberculosis is
based on weak scientific evidence (12). The upper limit of wild-type MIC distribution,
termed the epidemiological cutoff value (ECOFF), for streptomycin is 2 g/ml (18). That
this is the same value as the critical concentration in DST reflects the lack of clinical and
pharmacokinetic/pharmacodynamic data to inform a more practical selection of a
critical concentration. Potential strategies to address this issue include: (i) raising the
streptomycin critical concentration; (ii) adding a second streptomycin drug concentra-
tion to traditional critical concentration testing (e.g., test at both 2 g/ml and 8 g/ml
to disambiguate between low-level and high-level streptomycin resistance); (iii) per-
forming additional reflex testing when an isolate is identified by traditional critical
concentration DST to be resistant to both streptomycin and kanamycin (e.g., more
detailed phenotypic analysis or streptomycin resistance genotype determination); or
(iv) forgoing critical concentration testing in all forms and instead expanding genotypic
aminoglycoside resistance testing.
Recent efforts to expand the complement of drug resistance mutation panels
included on rapid molecular TB diagnostics have not included streptomycin (19).
Whole-genome sequencing (WGS) studies of clinical isolates of M. tuberculosis have
demonstrated that the majority (92% to 95%) of streptomycin-resistant isolates can be
explained by known mutations (20, 21). Thus, omitting streptomycin resistance deter-
minants from rapid drug resistance panels is a missed opportunity to both identify and
grade streptomycin resistance relative to amikacin resistance. One potential reason for
this exclusion is mutations in gidB can occur anywhere in the gene, where they cause
frameshift, nonsense, or deletion mutations. Thus, they are difficult to identify with
current SNP-based diagnostics and instead require whole-gene-based strategies, such
as high-resolution melt analysis (22) or rapid WGS.
It is important to address several limitations of this study. MIC determination was
performed with Sensititre, which is not the gold standard for M. tuberculosis DST.
However, prior investigation comparing Sensititre with traditional methods have shown
excellent concordance for aminoglycoside testing (23, 24). In addition, phenotyped
isolates derived only from South Africa, and the population structure contained clonal
XDR isolates from the Tugela Ferry epidemic. However, the phenomenon of genotypic
resistance conferring low-level streptomycin and high-level amikacin resistance was
also seen outside this clone. Thus, this observation carries implications for M. tubercu-
losis treatment in other settings.
Our findings suggest that current critical concentration methods for streptomycin
resistance determination and the design of molecular diagnostics for resistance may
need to be revisited for improved categorization of isolates harboring gidB mutations,
which confer low-level streptomycin resistance. In the context of limited therapeutic
options for drug-resistant M. tuberculosis, our results show the potential utility of
streptomycin, even for isolates observed to have low-level resistance from gidB muta-
tions.
MATERIALS AND METHODS
Clinical isolates. We selected for inclusion a random subset of 211 clinical isolates of susceptible and
drug-resistant M. tuberculosis from South Africa from our larger sequenced strain set (15).
Drug susceptibility testing by critical concentration. As previously described (15), DST was
performed prospectively by critical concentration on Middlebrook 7H11 using the WHO-recommended
drug concentrations for streptomycin (2.0 g/ml) and kanamycin (6.0 g/ml). Amikacin critical concen-
tration was not performed, as isolates with acquired resistance to amikacin essentially always have
resistance to kanamycin (12).
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MIC determination. MIC determination for three aminoglycosides (amikacin, kanamycin, and strep-
tomycin) was performed using MycoTB Sensititre plates (TREK Diagnostic Systems), per the manufac-
turer’s instructions. The lowest concentration of drug that did not show visible growth was recorded as
the MIC to the respective drug.
Whole-genome sequencing and analysis. Whole-genome sequencing (WGS) and analysis were
performed as previously described (15). Genotypic resistance to streptomycin, amikacin, and kanamycin
was defined as identification of polymorphisms that are known to be associated with drug resistance, per
the refined genotypic resistance definition in Desjardins and Cohen et al. (20) (Table S1). Isolates
belonging to the Tugela Ferry XDR clone were identified by phylogenetic clustering with the reference
isolates KZN605, collected during the epidemic, as well as the presence of canonical drug-resistance
mutations (15). SNP calls from Cohen et al. were used (15). RAxML version 7.3.0 (25) was used to construct
a phylogenetic tree from concatenated SNPs, with 1,000 bootstrap replicates.
Data availability. All sequencing data can be found in the Sequence Read Archive NCBI umbrella
project identifier PRJNA183624.
SUPPLEMENTAL MATERIAL
Supplemental material is available online only.
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Abstract
Background: Cryptococcal meningitis (CM) is a major cause of mortality in HIV programmes in Africa despite
increasing access to antiretroviral therapy (ART). Mortality is driven in part by limited availability of amphotericin-based
treatment, drug-induced toxicities of amphotericin B deoxycholate and prolonged hospital admissions. A single, high-
dose of liposomal amphotericin (L-AmB, Ambisome) on a fluconazole backbone has been reported as non-inferior to
14 days of standard dose L-AmB in reducing fungal burden. This trial examines whether single, high-dose L-AmB given
with high-dose fluconazole and flucytosine is non-inferior to a seven-day course of amphotericin B deoxycholate plus
flucytosine (the current World Health Organization [WHO] recommended treatment regimen).
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Methods: An open-label phase III randomised controlled non-inferiority trial conducted in five countries in sub-Saharan
Africa: Botswana, Malawi, South Africa, Uganda and Zimbabwe. The trial will compare CM induction therapy with (1) a
single dose (10 mg/kg) of L-AmB given with 14 days of fluconazole (1200 mg/day) and flucytosine (100 mg/kg/day) to
(2) seven days amphotericin B deoxycholate (1 mg/kg/day) given alongside seven days of flucytosine (100 mg/kg/day)
followed by seven days of fluconazole (1200 mg/day). The primary endpoint is all-cause mortality at ten weeks with a
non-inferiority margin of 10% and 90% power. Secondary endpoints are early fungicidal activity, proportion of grade III/IV
adverse events, pharmacokinetic parameters and pharmacokinetic/pharmacodynamic associations, health service costs,
all-cause mortality within the first two and four weeks, all-cause mortality within the first ten weeks (superiority analysis)
and rates of CM relapse, immune reconstitution inflammatory syndrome and disability at ten weeks. A total of 850
patients aged ≥ 18 years with a first episode of HIV-associated CM will be enrolled (425 randomised to each arm). All
patients will be followed for 16 weeks. All patients will receive consolidation therapy with fluconazole 800 mg/day to
complete ten weeks of treatment, followed by fluconazole maintenance and ART as per local guidance.
Discussion: A safe, sustainable and easy to administer regimen of L-AmB that is non-inferior to seven days of daily
amphotericin B deoxycholate therapy may reduce the number of adverse events seen in patients treated with
amphotericin B deoxycholate and shorten hospital admissions, providing a highly favourable and implementable
alternative to the current WHO recommended first-line treatment.
Trial registration: ISRCTN, ISRCTN72509687. Registered on 13 July 2017.
Keywords: Cryptococcal meningitis, HIV, AmBisome, Amphotericin B, Fluconazole, Flucytosine, Clinical trial
Background
Early mortality among people initiating HIV treatment in
Africa is considerably higher than in high-income
countries [1–4]. Despite antiretroviral therapy (ART)
roll-out, approximately half of HIV-infected individuals in
sub-Saharan Africa are not on ART and about one-third
still present for care with very low CD4 counts. The inci-
dence of opportunistic co-infections such as CM in this
group is high [5] and CM remains the most common
cause of adult meningitis in much of Africa [6]. As a
result, cryptococcal meningitis (CM) is a major cause of
mortality in HIV-infected patients in Africa and is associ-
ated with 10–20% of all HIV-related deaths [7]. Further-
more, the number of CM cases remains high despite
increased ART access; they now include both ART-naïve
and ART-experienced patients, with half of patients diag-
nosed with CM having had prior exposure to ART but
with persisting low CD4 counts due to non-adherence
and/or ART failure [8–10]. The poor outcomes reported
using currently available antifungal therapy in African
centres are a critical driver of this high mortality. Mortal-
ity using amphotericin B deoxycholate-based therapy in
Africa, even in clinical trial settings, remains in the region
of 35–45% [10–13]. Amphotericin B deoxycholate therapy
requires hospitalisation for at least seven days and its tox-
icity profile requires costly laboratory monitoring. The
average hospitalisation cost for CM treated with ampho-
tericin B deoxycholate is USD 800–1000 in Zimbabwe
where the annual per capita gross domestic product is <
USD 1000. Many clinical centres in sub-Saharan Africa
lack access to reliable laboratory monitoring and have lim-
ited nursing capacity making safe administration of
conventional amphotericin B deoxycholate difficult or
impossible. Consequently, amphotericin B deoxycholate
therapy is often not available in Africa. Fluconazole, the
oral alternative widely used in Africa, is much less rapidly
fungicidal than amphotericin-B, even at a dosage of up to
1200 mg/day, and mortality at ten weeks is 50–60% [14,
15]. Given the HIV prevalence and incidence in Southern
and East Africa, inadequate ART coverage, suboptimal
monitoring of individuals on ART leading to treatment
failure and limited access to screening and pre-emptive
treatment for CM, CM will remain a major cause of
morbidity and mortality in the region for the foreseeable
future. New treatment strategies are urgently needed.
Until recently, World Health Organization (WHO)
treatment guidelines recommended a 14-day course of
amphotericin B deoxycholate-based treatment for CM
induction therapy. The recently completed phase III
ACTA trial showed that patients receiving a short,
seven-day course of amphotericin B deoxycholate plus
flucytosine had lower mortality at ten weeks (24%, 95%
confidence interval [CI]: 16–32) compared to patients
receiving 14-day course of amphotericin B plus flucyto-
sine (38%, 95% CI: 29–47, unadjusted hazard ratio [HR]
0.56, 95% CI: 0.35–0.91) [10]. The trial also confirmed
that flucytosine (5FC) is a significantly superior partner
drug for amphotericin B-based treatments compared
with fluconazole, leading to a substantial mortality
reduction of 38% (95% CI: 16–55, p = 0.002). As a
consequence, the WHO guidelines were revised and
now recommend first-line treatment with seven days of
amphotericin B deoxycholate and flucytosine 100 mg/
kg/day followed by seven days of fluconazole 1200 mg/
Lawrence et al. Trials          (2018) 19:649 Page 2 of 13
day. In settings where flucytosine is unavailable, which
reflects most settings in Africa, the guidelines continue
to recommend 14 days of amphotericin B deoxycholate
with fluconazole [16].
A newer lipid-based formulation of amphotericin B
deoxycholate (L-AmB or AmBisome©) is particularly
suited for use in short-course yet highly effective induction
treatment for HIV-associated CM, due to: (1) the potential
for high dosing made possible by the lower rates of
drug-induced toxicity; and (2) the long tissue half-life. In
the context of HIV-associated CM, 14-day courses of con-
ventional amphotericin B deoxycholate are associated with
an average drop in haemoglobin of 2.3 g/dL and a mean
increase in creatinine of 73% [17]. Even at high doses,
L-AmB is associated with significantly less nephrotoxicity
and anaemia as well as lower rates of infusion reactions
than conventional amphotericin B deoxycholate [18]. The
long tissue half-life of L-AmB following high-dose adminis-
tration in patients is well-established [19–22], as is its
effective penetration into brain tissue [23]. The concept of
single or intermittent dosing with very high doses is also
established in both prophylaxis in haematology patients
and treatment of visceral leishmaniasis in lower- and
middle-income countries [24]. Single doses of up to
15 mg/kg have been safely given; doses of 10 mg/kg are
routinely given with demonstration of efficacy for treat-
ment of visceral leishmaniasis and invasive fungal infec-
tions [24, 25]. Pharmacokinetic data from animal models
[20] and humans [19] suggest that increasing L-AmB dos-
ing from the currently recommended 3–4 mg/kg may lead
to improved outcomes and, as with standard amphotericin
B, that intermittent dosing regimens may be as effective as
daily therapy [20]. Although L-AmB is recommended as
treatment for HIV-associated CM in several national
guidelines, optimal dosing is unknown and the strategy of
short-course high dosing of L-AmB has not yet been tested
in a phase III clinical trial [18].
A randomised controlled trial comparing L-AmB
3 mg/kg/day, L-AmB 6 mg/kg/day and amphotericin B
deoxycholate 0.7 mg/kg/day, all given for 14 days,
showed no difference in mortality outcome between
any of these regimens [18]; 3 mg/kg/day is widely used
as the standard dose. However, murine models suggest
dosing of 3 mg/kg/day may be sub-optimal [20]. Fur-
ther evidence to support this comes from the recently
completed phase II AMBITION trial which was per-
formed with the primary objective of determining the
rate of cryptococcal clearance from cerebrospinal fluid
(CSF), presented as Early Fungicidal Activity (EFA), of
three alternative schedules of intermittent high-dose
L-AmB in comparison with 14 days of standard daily
L-AmB for induction therapy for HIV-associated CM
[26]. Eighty participants were recruited at sites in
Botswana and Tanzania and randomised to one of four
treatment arms: (1) L-AmB 10 mg/kg day 1 (single
dose); (2) L-AmB 10 mg/kg day 1, L-AmB 5 mg/kg day
3 (two doses); (3) L-AmB 10 mg/kg day 1, L-AmB
5 mg/kg days 3 and 7 (three doses); or (4) the control
arm, being standard 14-day L-AmB (3 mg/kg/day). All
treatment arms received high-dose fluconazole
(1200 mg/day) for 14 days. This phase II trial was
stopped by the Data Monitoring Committee (DMC) at
the pre-planned interim analysis stage of 80 patients as
the primary endpoint had been reached with the rec-
ommendation that the trial proceed onto the current
clinical endpoint phase III trial using single dose
L-AmB. The primary analysis showed that the EFA in
all three short-course high-dose arms was comparable
to, or greater than, the control arm, with statistical
non-inferiority between all short-course arms and con-
trol at the pre-defined non-inferiority (NI) of 0.2 log10
colony forming units (CFU)/mL/day difference (Fig. 1).
There was no evidence for any dose response effect
with additional L-AmB doses, suggesting maximal fun-
gicidal activity was achieved with a single 10 mg/kg
dose. All three high-dose short-course L-AmB regimens
were well tolerated, with only one Division of AIDS
(DAIDS) grade IV laboratory toxicity event occurring
during induction therapy, and a total of seven grade III
and no grade IV clinical adverse events (AEs) associated
with high-dose L-AmB. This toxicity profile compared
to 33% of patients reporting grade III or IV anaemia in
a combined cohort of 368 patients treated in Africa
with conventional amphotericin B for 14 days [27].
There were no safety concerns with short-course treat-
ment and no patients receiving short-course L-AmB re-
quired additional ‘rescue’ L-AmB therapy. Overall
mortality in the trial was 29% at ten weeks, comparing
very favourably with recent trials of amphotericin B
deoxycholate-based treatments, with no significant dif-
ference between arms [17].
However, although EFA is an extremely valuable
tool to rapidly screen novel antifungal treatment regi-
mens and is associated with mortality [28], it has not
been validated as a true ‘surrogate’ marker of out-
come. Large phase III trials with a mortality endpoint
are critical to define the optimal treatment regimens




The AMBITION trial is an open label, phase III, rando-
mised controlled non-inferiority, multi-centre trial to
compare single, high-dose L-AmB treatment to
seven-day amphotericin B deoxycholate-based treatment
for HIV-associated CM (Additional files 1 and 2).
Lawrence et al. Trials          (2018) 19:649 Page 3 of 13
Hypothesis
Short-course, high-dose L-AmB given with 14 days of
high-dose fluconazole and flucytosine will be non-inferior
to seven days of daily-dosed amphotericin B deoxycholate
given with seven days of flucytosine, followed by seven
days of high-dose fluconazole, for the treatment of
HIV-associated CM with all-cause mortality as the
primary efficacy endpoint.
Objectives
The primary objective is to determine whether single,
high-dose L-AmB given with 14 days of high-dose
fluconazole and flucytosine is non-inferior to seven days
of daily-dosed amphotericin B deoxycholate given with
seven days of flucytosine, followed by seven days of
high-dose fluconazole in terms of all-cause mortality in
HIV-associated CM patients.
Setting
The trial will be conducted in six large referral hospitals
across five countries in sub-Saharan Africa. The sites
include: Princess Marina Hospital, Gaborone, Botswana;
Mitchells Plain District Hospital, Cape Town, South Africa;
Parirenyatwa Central Hospital, Harare, Zimbabwe; Queen
Elizabeth Central Hospital, Blantyre, Malawi; Kamuzu
Central Hospital, Lilongwe, Malawi; and the Infectious
Diseases Institute, Kampala and Mbarara, Uganda.
Outcome measures
The primary outcome measure is all-cause mortality
within the first ten weeks after randomisation (non-inferi-
ority). Secondary outcome measures include: EFA derived
from serial lumbar punctures (LPs) on days 1, 7 and 14;
proportions of patients in each arm developing clinical
and DAIDS laboratory-defined grade III/IV AEs; median
% change from baseline in laboratory defined parameters;
PK parameters and PK/PD associations of single high-
dose L-AmB; health service costs; all-cause mortality
within the first two and four weeks; all-cause mortality
within the first ten weeks (superiority analysis); rates of
cryptococcal relapse / IRIS within the first ten weeks; and
disability at ten weeks.
Sample size
The WHO now recommends seven days amphotericin B
deoxycholate-based regimens for the treatment of CM if
flucytosine is available as an adjunctive antifungal. A
non-inferiority design has been chosen as the primary aim
of this trial is to identify an alternative safe and easy to
administer short-course L-AmB treatment regimen that
can be implemented in settings where giving amphotericin
B deoxycholate-based treatment is difficult or impossible.
An efficacious single dose L-AmB treatment would also
markedly facilitate CM therapy in settings currently using
amphotericin B deoxycholate-based treatment, reducing
the duration of hospitalisation and the associated risks (e.g.
nosocomial sepsis) and costs. Ten-week mortality in our
previous trials using amphotericin B deoxycholate-based
regimens at the study sites has been in the range of 28–
41% [13, 29]; it was 30% with short-course high-dose
L-AmB treatments in the recent phase II study. Assuming
35% ten-week mortality in both the control and test groups
and using a 10% non-inferiority margin (i.e. the upper mar-
gin of the one-sided 95% CI of the difference in ten-week
Fig. 1 Primary and key secondary outcomes of the AMBITION Step I phase-II randomised controlled trial. The figure shows: (a) all three short-
course treatment arms were non-inferior to control; (b) EFA and the individual patient slopes over the initial 14 days of treatment; and (c) all
three short-course treatment arms remained non-inferior to control when controlling for baseline fungal burden (QCC), baseline CD4 count,
baseline mental status, QCC and CD4 count, QCC count, CD4 count, mental status and QCC, CD4 count, mental status, sex, age and ART
status [26]
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mortality between the two arms does not exceed 10%) and
one-sided 5% type one error, 390 participants would be
required per arm to achieve 90% power. This sample size
will also have 83.25% power at a one-sided α = 0.025 or
two-sided α = 0.05. The 10% non-inferiority margin has
been chosen to ensure that only clinically unimportant
differences are deemed non-inferior and is in keeping with
conventional practice. If the ten-week mortality is
increased to 40% the equivalent sample size is 412 per arm.
Making a conservative allowance for withdrawals and
losses to follow-up of up to 8% (losses are in the range of
2–4% in similar trials [10]), or a higher than anticipated
mortality rate, we plan to enrol 425 participants per arm.
Thus, we will randomise a total of 850 participants. This
will be the largest CM treatment trial conducted in Africa.
Inclusion and exclusion criteria
Consecutive patients aged ≥ 18 years with a first episode of
CM (confirmed by either India ink or cryptococcal antigen
[CrAg] test in the CSF) will be enrolled. Participants must
be HIV-infected or willing to undertake an HIV test if their
status is unknown. Participants must provide written
informed consent or, if unable to consent, have a next of
kin who agrees to the patient participating in the study,
providing written consent. Pregnant (confirmed by urinary
or serum pregnancy test) or lactating women, patients with
a previous serious reaction to study drugs, or patients on
antifungal treatment at CM treatment doses (amphotericin
B deoxycholate ≥ 0.7 mg/kg or fluconazole ≥ 800 mg/day)
for > 48 h or concomitant medication that is contraindi-
cated with the study drugs at the time of assessment will
be excluded.
Consent
Written informed consent to enter the trial and be rando-
mised will be obtained from participants or, in the case of
those lacking capacity to consent, from next of kin with
legal responsibility (if appropriate and in keeping with na-
tional guidance and regulations). Consent will be obtained
after explanation of the aims, methods, benefits and poten-
tial hazards of the trial, and before any trial-specific proce-
dures are performed or any blood is taken for the trial.
Once the patient’s mental status improves and they regain
the capacity to consent, persons enrolled via surrogate
consent will be re-consented, with care taken to ensure
they understand that they are: (1) free to withdraw from
the research study; and (2) if they do withdraw, this will
not jeopardise their future care. Patients who withdraw will
revert to the standard of care at the treatment site (usually
amphotericin B deoxycholate and fluconazole daily for two
weeks or fluconazole monotherapy for two weeks). It will
be made unambiguously clear that the participant (or
guardian) is free to refuse to participate in all or any aspect
of the research trial, at any time and for any reason,
without incurring any penalty or affecting their access to
the standard treatment available at the recruiting site (or
that of their relative). Separate consent forms will be com-
pleted for the storage and/or genetic analysis of samples as
determined by local guidelines. Original signed consent
forms will be kept by the investigator and documented in
the electronic case report form (eCRF), a copy given to the
participant or family and a copy placed in the participant’s
medical notes.
Allocation
Patients will be randomised individually using a
computer-generated programme. Randomisation codes will
be generated via a permuted-block randomisation method
and stratified by site. Block sizes will vary at four and six.
Randomisation lists will be created for each site by an inde-
pendent statistician and each list will be housed on the
electronic data capture system (EDC) for that particular
site. The full lists will be inaccessible to trial staff. Rando-
mised allocation for each trial participant will be provided
to trial staff from the randomisation list for that site. In-
ternally, the EDC selects against the electronic randomisa-
tion and guarantees to make the selection in the natural
order of the list. Once a selection is made, the randomisa-
tion record is tagged with the participant study allocated
identifier, date and time of randomisation, and other EDC
system audit values (username, machine name, etc).
Interventions
Participants will be randomised to receive either intraven-
ous L-AmB 10 mg/kg on day 1 given with 14 days of oral
fluconazole 1200 mg/day and oral flucytosine 100 mg/kg/
day (intervention) or intravenous amphotericin B deoxy-
cholate 1 mg/kg/d for seven days given with seven days of
oral flucytosine 100 mg/kg/day followed by seven days of
oral fluconazole 1200 mg/day (control) (Fig. 2). After the
two-week induction phase, all participants will then
receive oral fluconazole 800 mg/day to complete ten
weeks therapy and 200 mg/day thereafter. ART will be
commenced four to six weeks after initiation of antifungal
therapy, in line with national guidelines. Given the com-
bination of oral and intravenous therapies, the differing
duration in days of intravenous therapy and the known
drug-induced toxicities that require monitoring and man-
aging, blinding of treatment allocation was deemed to be
impractical. To counter this, an objective endpoint of
all-cause mortality has been chosen. In addition, all staff
performing quantitative cell cultures are blind to treat-
ment, as are coordinating investigators, including the Trial
Management Group (TMG) members.
Rescue medication
Although the results from our phase II trial demonstrate
that it is unlikely that CSF fungal burden will increase
Lawrence et al. Trials          (2018) 19:649 Page 5 of 13
after initiation of treatment, if the day 7 LP identifies an
increase in CFU from baseline this will be reported as a
serious adverse event (SAE) and experienced, senior cli-
nicians at the coordinating centre will be responsible for
managing this situation on a case-by-case basis to ensure
all participants receive effective induction therapy.
Schedule
All participants will be admitted to hospital for a minimum
of one week. As the induction phase occurs over two
weeks if participants are well enough to be discharged after
day 7 and before day 14, treatment will be given under
close outpatient supervision during the second week, en-
suring compliance to the trial intervention and facilitating
close clinical and laboratory monitoring. After the intensive
phase, participants will be seen in clinic at four, six, eight
and ten weeks and a single telephone follow-up to ascer-
tain vital status and level of disability will be made at week
16. Every effort will be made (e.g. with mobile telephone
calls, home visits and financial help with travelling ex-
penses) to obtain accurate and complete follow-up data for
ten weeks after the start of treatment. Particular attention
will be paid to the possibility, in ART-naïve participants, of
developing IRIS after starting ART [30].
Participants will have a full history and examination at
baseline (Table 1). Blood will be drawn for full blood
count (FBC), urea, creatinine, electrolytes and alanine
transaminase (ALT). If unknown, HIV serology will be
Fig. 2 Trial schema. Trial entry, randomisation and treatment. ART antiretroviral therapy, EFA early fungicidal activity, PD pharmacodynamics, PK
pharmacokinetics, SAE serious adverse event
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performed in addition to CD4 and viral load samples, as
clinically indicated. Women of reproductive age will
have a pregnancy test (urine or serum). All participants
will have an LP for opening pressure, total and differen-
tial white cell count, protein, glucose, India ink, CrAg,
routine culture, quantitative fungal culture and immune
parameters. Further blood samples will be collected on
days 3, 5, 7, 10, 12, 14 and 28 for urea and creatinine.
FBC and ALT will be repeated on days 7, 14 and 28.
Additional samples will be taken alongside monitoring
blood tests for sub-studies, including PK/PD studies. LPs
will be repeated on days 7 and 14 for opening pressure,
quantitative fungal culture, CSF drug levels and immune
parameters. Raised intracranial pressure will be managed
with LPs as per a standard operating procedure. Crypto-
coccal clearance rates will be calculated using summary
statistics for each patient: the rate of decrease in log10
CFU per mL CSF per day derived from the slope of the
linear regression of log10 CFU against time for each pa-
tient. A linear regression model will be used to compare
mean rates of decline EFA for each arm, giving summary
differences with 95% CI and significance levels [31, 32].
We will adjust analyses for potential confounding fac-
tors, including baseline fungal burden. Disability at ten
weeks will be assessed using two simple questions and a
modified Rankin scale.
Statistical methods
The primary endpoint (all-cause mortality at ten weeks)
will be analysed using a generalised linear model (GLM).
The model will have treatment group as the sole predictor,
a binomial distribution and an identity-link function, from
which the (unadjusted) risk difference between the treat-
ment groups and its one-sided 95% CI will be estimated. If
the upper limit of the one-sided 95% CI falls below the
non-inferiority margin of 10%, non-inferiority will be de-
clared. Sensitivity analyses of the primary endpoint mak-
ing different assumptions for the losses to follow-up will
be conducted. Covariate-adjusted analyses for the primary
endpoint will be conducted by adding pre-specified covar-
iates into the GLM model to derive the adjusted risk
difference and the upper limit of one-sided 95% CI. Im-
putation for baseline missing covariates will be made for
the covariate-adjusted analysis. Subgroup analysis of the
primary endpoint will also be performed on prespecified
covariates.
The analyses of the secondary endpoints will be based
on superiority test using a 5% two-sided significance
level. Analyses of survival data will be conducted using
unadjusted Cox regression analysis to calculate the HR
and 95% CI between the treatment groups. Kaplan–
Meier survival curves by treatment group will be calcu-
lated and displayed. A log-rank test will be conducted to
compare the survival curves between the treatment
groups. Analyses of binary secondary outcomes will be
performed in a similar way as the primary endpoint
analysis using GLMs with treatment group as the sole pre-
dictor. The point estimate of the treatment effect with
two-sided 95% CI will be derived. The safety analysis will
be descriptive and the frequency and proportions of par-
ticipants suffering clinical and laboratory-defined side ef-
fects will be generated by treatment arms. Other statistical
analyses may be performed if deemed necessary.
Data will be analysed using SAS 9.4 and Stata 13.
Findings will be reported according to the Consolidated
Standards of Reporting Trials (CONSORT) guidelines
for randomised controlled trials. Primary analyses will be
based on the intention-to-treat population and second-
ary analyses will be based on the per-protocol popula-
tion. All analyses will be described in detail in the
finalised and signed statistical analysis plan before data
are locked and unblinding occurs.
Dissemination of results
The results of the trial will be analysed, presented and
published as soon as possible. The TMG will form the
basis of the Writing Committee and will advise on the
nature of the publication. The names of all investigators
will be included in the authorship of any publication. An
authorship policy will be agreed by all investigators be-
fore the commencement of the trial. The independent
members of the Trial Steering Committee (TSC) and
DMC will be listed with their affiliations in the acknowl-
edgements or appendix sections of the main publication.
The funders will have no role in the decision to publish
or the content of the publication.
Ethical approval
The Research Ethics Committee of the London School of
Hygiene and Tropical Medicine have approved the protocol
v2.1 07.11.17 (ref. 14,355). Approval has also been granted
by the following: University of Botswana Office of Research
and Development (UBR/RES/IRB/BIO/042); Botswana
Ministry of Health and Wellness Health Research and
Development Division (HPDME:13/18/1); Princess Marina
Hospital Research and Ethics Committee (PMH 5/
79(407-1-2017); University of Cape Town Human Research
Ethics Committee (642/2017); Malawi National Health
Sciences Research Committee (1907); Mulago Hospital
Research and Ethics Committee (MHREC 1297); and the
Medical Research Council of Zimbabwe (MRCZ/A/2263).
Any amendments will be submitted and approved by each
ethics committee.
Timeline
In total, 850 participants will be recruited over a
three-year period with a planned trial completion date of
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31 December 2020. This is feasible based upon previous
experience and rates of CM at the hospital sites.
Ancillary studies
PK/PD
The PK/PD of L-AmB, fluconazole and flucytosine and
the impact of PK variability on outcome will be
described. Plasma samples will be collected at the end of
the L-AmB infusion and then at 2, 4, 8, 12 and 24 h in a
sub-study of participants at the Blantyre study site. A
portion (0.5 mL) of the CSF sample obtained for quanti-
tative counts will be reserved to measure fluconazole
and flucytosine concentrations and thereby estimate the
extent of penetration of these drugs into the CSF.
Amphotericin levels will not be measured in CSF since
they are known to be negligible. A PK-PD model will be
constructed to explore the persistence of amphotericin B
within the central nervous system and the resultant anti-
fungal effect. Amphotericin penetration into the CNS
will be estimated using compartmental modelling
techniques. Monte Carlo simulation will enable further
insights into the regimen(s) that may be associated with
maximal antifungal activity.
Economic analysis
An economic analysis will be conducted to provide evi-
dence for the cost-effectiveness of short-course L-AmB
treatment. The objective of the economic analysis is to es-
timate the cost consequences and the cost-effectiveness of
short-course L-AmB treatment compared to current care.
Both societal and healthcare perspectives are chosen and
health service patient costs including household costs,
treatment cost and hospitalisations in both arms will be
compared over the trial period in a probabilistic approach,
using Monte Carlo bootstrapping methods in STATA,
@Risk software and TreeAge. In the country-specific
cost-consequence analyses, the societal and health service
costs will be compared and used along with the trial-wide
primary endpoint data to perform cost-effectiveness mod-
elling using a decision-tree model for each country with
historical data as comparison.
Semi-quantitative CrAg testing and diagnostic quantitative
polymerase chain reaction (PCR)
A newly developed point of care, lateral flow, semi-quanti-
tative CrAg test is now available from Institut Pasteur and
Biosynex. We will use this semi-quantitative test in real
time to determine antigen titre at baseline, in blood and
CSF, and compare results to the currently established point
of care test. Secondary trial analyses will include the associ-
ation of baseline titre with outcome and exploration of the
possibility of a differential treatment response between
arms according to baseline titre. If such a differential re-
sponse was observed, this sub-study could provide the
rationale for and demonstrate the means for individualised
treatment, based on a rapid assessment of antigen load. A
novel diagnostic quantitative PCR (DNA and RNA) tool
will be also be used in each treatment arm and correlated
with quantitative culture counts. We aim to estimate the
fungal load and fungal viability in blood and CSF at base-
line using the PCR in addition to fungal load kinetics on
treatment. The objective will be to develop a practical
alternative to time-consuming quantitative cultures in
order to improve detection of fungaemia and measurement
of fungal burden and develop a novel biomarker for asses-
sing the best fungicidal treatments in this and subsequent
research studies.
Quality control and assurance
Trial oversight will be provided by the TMG, TSC and
Independent DMC. The study sponsor is the London
School of Hygiene and Tropical Medicine. The sites will
be monitored at regular intervals with visits by the trial
manager/monitor in order to monitor the conduct of
the trial and ensure that the principles of International
Conference of Harmonisation (ICH) Good Clinical Prac-
tice (GCP) are being adhered to. Sites will be visited by
an internal monitor for initiation visits before starting
recruitment, after the first 10–15 participants, at 40%
and 70% of recruitment targets and at trial closure, with
additional visits made if required. Visits will ensure that
all training has been completed, that drug supply and
equipment are in place and that all staff are up to date
on the protocol and procedures. A monitor from the
Sponsor will visit at least three of the six sites. Central
monitoring will be performed in addition to the on-site
monitoring procedures. Bimonthly reports on the pro-
gress of the trial as well as the frequency of DAIDS
laboratory-defined grade III/IV AEs/SAEs/suspected un-
expected serious adverse events (SUSARs) will be com-
piled by the trial manager/statistician and reviewed by
the Sponsor. All Grade IV AEs, all SAEs and all SUSARs
will be reported to the TMG within 24 h [27].
Data collection and data management
eCRF data collected and validated using the EDC will be
stored in an electronic database that is protected using a
scheme of authentication and encryption. Paper docu-
ments, such as clinical notes and administrative documen-
tation, will be kept in a secure location and held for at
least five years after the end of the trial. During this period,
all data should be accessible to the competent or equiva-
lent authorities, the sponsor and other relevant parties
with suitable notice. Security of electronic records and
data is a significant concern. All components of the
distributed data systems will use authentication and
encryption to render subject identity and personal health
information unusable, unreadable or indecipherable to
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unauthorised individuals. Full drive encryption will be im-
plemented at the hardware layer of all devices storing pro-
tected health information. A three-factor scheme will be
used to authenticate users through the hardware layer to
the application layer where personal health information is
available. The applications will have user profiles to con-
trol access to certain data and reports. The application and
database layers will use a combination of hashing and en-
cryption for sensitive and personal data. Mobile devices
and the staff operating them will not be equipped with the
encryption keys to decrypt selected sensitive data fields.
Confidentiality
We will follow the principles of the UK Data Protection
Act (DPA) regardless of the countries where the trial is
being conducted. Consent forms will be stored under
the supervision of each local primary investigator (PI) in
a secured office and accessible to trial staff only. Partici-
pants’ personal details are stored in an encrypted, separ-
ate server to the main database and participants are
identified by their study number throughout the trial.
Termination of the study
The trial will be considered closed when the last patient
has completed ten weeks of active follow-up in the
study, the 16-week telephonic follow-up call, and all
follow-up and laboratory reports, including repeat
plasma HIV viral load testing in ART failure cases, have
been received. Early termination could occur if the
DMC decides there is an unacceptable level of AEs in
either test arm or if the intervention arm is shown to be
inferior with stringent p value testing.
Indemnity
The sponsor of the trial is the London School of
Hygiene and Tropical Medicine and as such provides in-
demnity for the trial. All personnel involved in the trial
will be expected to be indemnified by their employing
authority. Local insurance will be taken out where local
regulations require this.
Discussion
The potential impact of a safe, sustainable regimen of
high-dose L-AmB with non-inferior efficacy when com-
pared to one week of daily-dosed amphotericin B deoxy-
cholate would be to reduce the number of AEs seen in
patients treated with amphotericin and shorten the
length of hospital admissions. It is hoped that our eco-
nomic analysis will demonstrate the cost-effectiveness of
this intervention across all our sites in southern Africa
and provide a highly favourable alternative to the
current WHO-recommended first-line treatment.
Trial status
The study is jointly funded through the European and De-
veloping Countries Clinical Trials Partnership (EDCTP),
Swedish International Development Cooperation Agency
(SIDA) and Wellcome Trust / Medical Research Council
(UK) / UKAID Joint Global Health Trials. Recruitment
commenced in Botswana in January 2018 and in South
Africa in July 2018; recruitment will commence at the
other sites pending the requisite ethical and regulatory
approvals.
Additional files
Additional file 1: AMBITION Study Protocol v2.1 date: 7th November
2017. (PDF 1954 kb)
Additional file 2: AMBITION Study SPIRIT Checklist. (DOC 121 kb)
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Objectives: The objectives of this study were to explore inter-study heterogeneity in the pharmacokinetics (PK)
of orally administered rifampicin, to derive summary estimates of rifampicin PK parameters at standard dosages
and to compare these with summary estimates for higher dosages.
Methods: A systematic search was performed for studies of rifampicin PK published in the English language up
to May 2017. Data describing the Cmax and AUC were extracted. Meta-analysis provided summary estimates
for PK parameter estimates at standard rifampicin dosages. Heterogeneity was assessed by estimation of the
I2 statistic and visual inspection of forest plots. Summary AUC estimates at standard and higher dosages were
compared graphically and contextualized using preclinical pharmacodynamic (PD) data.
Results: Substantial heterogeneity in PK parameters was evident and upheld in meta-regression. Treatment
duration had a significant impact on the summary estimates for rifampicin PK parameters, with Cmax 8.98 mg/L
(SEM 2.19) after a single dose and 5.79 mg/L (SEM 2.14) at steady-state dosing, and AUC 72.56 mgh/L
(SEM 2.60) and 38.73 mgh/L (SEM 4.33) after single and steady-state dosing, respectively. Rifampicin dosages of
at least 25 mg/kg are required to achieve plasma PK/PD targets defined in preclinical studies.
Conclusions: Vast inter-study heterogeneity exists in rifampicin PK parameter estimates. This is not explained by
the available modifying variables. The recommended dosage of rifampicin should be increased to improve effi-
cacy. This study provides an important point of reference for understanding rifampicin PK at standard dosages
as efforts to explore higher dosing strategies continue in this field.
Introduction
When it was introduced as part of combination therapy for TB in the
1960s, rifampicin revolutionized treatment and shortened the dur-
ation of therapy from 18 to 9 months. This would subsequently be
shortened further to 6 months with the addition of pyrazinamide.1
Despite experience gained over the past five decades, the optimal
dosage of rifampicin has not been established definitively. The cur-
rent recommendation of 10 mg/kg in guidelines from the WHO has
not changed since the introduction of rifampicin, at which time it
was based on toxicological and financial concerns, with limited
pharmacokinetic (PK) data available.2,3
For therapeutic drug monitoring (TDM) of rifampicin in TB treat-
ment, a Cmax of 8–24 mg/L (free plus bound drug) was suggested
in the 1990s. This recommendation was based on a review of
observed PK parameters and on expert opinion. Data from patients
infected with HIV were not included.4,5 There was no pharmacody-
namic (PD) component to the target, as MIC data were lacking in
VC The Author(s) 2018. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/
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patient samples at that time. In the ensuing 20 year period, this
original reference range was accepted as the target for rifampicin
Cmax in numerous studies addressing the utility of TDM for rifampi-
cin.6–11 Treatment response is slow if rifampicin concentrations fall
below this range.12,13
More sophisticated PK/PD analyses have since been performed
on data from murine and human studies and there is a growing
consensus that current dosages of rifampicin are inadequate; drug
exposure appears scarcely to reach the upstroke of the dose–
response curve.14 Accordingly, the target range of Cmax for rifampi-
cin TDM has been revised to emphasize the need to exceed 8 mg/L,
rather than focus on an upper limit.15 At steady-state, drug expos-
ure is thought to increase more than proportionally in response to
modest dose increases.16 Increased dosages of rifampicin correl-
ate with day 2 early bactericidal activity in a near-linear fashion in
TB patients.17 There is an accumulating body of evidence demon-
strating the safety and efficacy of higher-than-standard rifampicin
doses in in vitro, animal and human studies and the adoption of
this approach holds great appeal as a strategy to shorten TB treat-
ment.18–23
Dose fractionation experiments have demonstrated that the
PK/PD index most closely linked to rifampicin microbial kill is AUC/
MIC, a finding corroborated by hollow-fibre models, which have
additionally shown that Cmax/MIC is more closely linked to the sup-
pression of resistance and the post-antibiotic effect.20,21 In TB
patients, the 0–24 h AUC has a greater value than Cmax or clinical
features in predicting long-term clinical outcome.24
Scientific comparison of the findings of clinical trials investigat-
ing high rifampicin dosages requires an understanding of the PK
parameters achieved with currently used dosages, so that the im-
pact of dose escalation can be appreciated. For this reason, we
conducted a systematic review and meta-analysis of published
data describing rifampicin PK. As Cmax/MIC and AUC/MIC are the
PK/PD indices best characterized, we focused on these PK parame-
ters. The objectives of this study were: (i) to explore the inter-study
heterogeneity in rifampicin PK; (ii) to derive summary estimates of
rifampicin PK parameters at standard dosages; (iii) to compare
these with summary estimates for higher-than-standard rifampi-
cin dosages; and (iv) to contextualize these PK estimates using the
available PD data.
Methods
Search strategy and selection criteria
Studies were identified in accordance with the Preferred Reporting Items
for Systematic Reviews and Meta-Analyses (PRISMA) guidelines.25 PubMed,
Scopus and MEDLINE electronic databases were searched. In PubMed and
Scopus, titles and abstracts were searched using the terms ‘rifampicin’ OR
‘rifampin’ OR ‘antituberculous’ OR ‘antimycobacterial’ AND ‘pharmacokinet-
ics’, to identify studies reported in the English language up to May 2017. The
MEDLINE database was searched using the keywords ‘pharmacokinetic*’
OR ‘bioequivalence’ AND title words ‘rifampicin’ OR tubercul*’. Two
reviewers (K. E. S. and G. D.) screened titles and abstracts for relevance and
appraised full texts for inclusion in the meta-analysis using pre-specified se-
lection criteria. Key articles were identified by consensus between K. E. S.
and G. D. Prospective clinical studies were included if they collected PK data
from adult patients with Mycobacterium tuberculosis infection and/or
healthy adult volunteers receiving orally administered rifampicin.
Patients who received rifampicin for indications other than TB were
excluded, because physiological fluctuations associated with different
disease states are known to interfere with PK.26 Studies that collected data
relating to paediatric populations were excluded, as were non-human stud-
ies, abstracts, reviews and correspondence. Papers reporting PK parameters
derived from modelling analyses were excluded for several reasons: vari-
ability in modelling methods has the potential to introduce additional het-
erogeneity; over-parameterization of models can lead to statistical
shrinkage and loss of data variability; and datasets are often reported in
both modelling and non-compartmental analyses (NCAs), which would risk
reporting some data in duplicate. Finally, studies assessing the impact of ri-
fampicin on the PK of another drug, rather than reporting the PK of rifampi-
cin itself, were excluded.
Assessment of quality of studies
No validated tool exists to assess methodological rigour in PK studies. The
priority is that samples are collected from subjects representative of target
populations receiving dosage regimens of interest and relevance, rather
than subjects who are randomized to one or other intervention. We consid-
ered this in our selection of studies, as well as ensuring that authors clearly
described the pharmaceutical product, bioanalytical methods and statistic-
al tools used.
Data extraction
A data extraction form was designed and one reviewer (K. E. S.) extracted
data from the included studies on the following items in addition to rifampi-
cin PK parameters: study design; study population; sex; age; body weight;
HIV status; treatment regimen; duration of treatment; rifampicin dose;
whether rifampicin was administered as a separate drug or in a fixed-dose
combination; whether dosing was daily or intermittent; PK sampling times;
assay method; and data analysis method. These variables were selected
a priori as it was felt that they were the factors most likely to impact rifam-
picin PK. Rifampicin was considered to be at steady-state if it had been
administered for 7 days to allow for saturation of first-pass metabolism
and the establishment of metabolic autoinduction.
Data synthesis
In many of the studies, more than one group of participants was compared,
e.g. HIV-positive and HIV-negative participants.27 In others, more than one
treatment was compared, e.g. in a crossover trial comparing separate
drug formulations with fixed-dose combinations.28 These groups were
analysed in the same way that data were presented in the papers; that
is, separate study arms were analysed separately rather than mean val-
ues being calculated for each study. This meant that some studies
contributed two or more sets of PK parameters to the meta-analysis.
To enable comparison of PK parameters across all studies, data were
collected as means and standard deviations. Where summary statistics
were not published in this format, authors were contacted to request
that they share either raw data or results of an NCA of their data. If data
were summarized as median and range or IQR and raw data or NCA
results were unobtainable from the authors, we estimated the mean
and standard deviation from the summary statistics provided using pre-
viously described methods.29
As the Cmax of rifampicin occurs around 2 h after ingestion and half-life
is of the order of 2.5–4 h,30 concentrations remaining in plasma after 24 h
from ingestion will be negligible. This was supported by the lack of a statis-
tically significant difference between the estimates of AUC produced from
the 0–24 h time interval and the 0–48 h time interval and those calculated
from the 0–infinity (1) interval. The AUC0–24, AUC0–48 and AUC0–1 results
were therefore combined into a single measure of AUC and only these esti-
mates were included in the final analysis to minimize design-related
heterogeneity. Hereafter, any reference to AUC refers to the combined
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protein bound and the active portion is believed to be unbound drug, stud-
ies reported total drug PK parameters; this analysis used the same.15,30
Summary measures
Data were analysed in Microsoft Excel version 15.28 (Microsoft 2016) and
using the metafor package in R version 3.3.1.31 The main objective of the
analysis was to collate and summarize available data on the PK parameters
of rifampicin derived from subjects taking WHO-recommended dosages.
The focus of the meta-analysis was therefore on the 8–12 mg/kg dosing
bracket. A linear model was used to incorporate the following variables: HIV
status (positive or negative); TB status (positive or negative); combination
therapy [limited to patients taking rifampicin monotherapy versus those
taking combination therapy with isoniazid, pyrazinamide and ethambutol
(RHZE)]; intermittent dosing; diabetes status; and treatment duration.
A restricted maximum likelihood mixed-effects model was used to perform
a meta-analysis of Cmax and AUC estimates, with application of the
DerSimonian–Laird estimator of residual heterogeneity. This approach fits a
random-effects model. Standard errors of the study-specific estimates are
adjusted to incorporate a measure of the heterogeneity among the effects
of independent variables observed in different studies.32 The degree to
which demographic and clinical variables accounted for inter-study
heterogeneity was assessed using meta-regression. Heterogeneity of PK
estimates overall and within subgroups was assessed by estimation of the
I2 statistic and visual inspection of forest plots.
A second objective was to explore the effect of higher-than-
recommended doses of rifampicin on drug exposure. The .12 mg/kg group
of studies was split into more specific dosing subgroups and the mean and
standard error derived from meta-analysis in standard weight-based dos-
ing categories was compared with the summary statistics extracted from
studies of higher rifampicin dosages. As the number of studies at higher
dosages was small, we were unable to incorporate dose escalation as a
variable in the meta-regression, so graphical comparison of summary sta-
tistics from studies at standard and higher dosages was performed instead.
Results
The search retrieved 3075 titles, of which 70 studies were deemed
eligible, containing 179 distinct study arms (Figure S1, available as
Supplementary data at JAC Online). The characteristics of the stud-
ies are summarized in Table S1. The cohorts contained a total
of 3477 study participants. HPLC was used to measure rifampicin
levels in 66 of the 70 studies. The remaining studies used
spectrophotometry33–35 or a plate diffusion assay.36 These three
studies were retained in the meta-analysis because their exclusion
did not significantly impact overall PK parameter estimates.
By far the most common weight-based dosing category in the
included studies was 8–12 mg/kg (118 of 163 study arms for which
dosing information was extracted, 72%), in line with WHO rifampi-
cin dosing guidelines. Unless explicitly stated, results presented
hereafter pertain to those studies in which patients received this
recommended dose.
Cmax data were highly heterogeneous and influenced by
treatment duration
Cmax was highly heterogeneous between studies, with an I
2 statis-
tic of 95.36% (95% CI 95.13%–97.15%). Meta-regression of Cmax
estimates with a multivariate model including all variables found
two modifiers to have a statistically significant impact on Cmax:
duration of treatment and TB status. The effect on inter-study vari-
ability was minor, however: I2"91.36% (95% CI 90.50%–94.77%)
after meta-regression. The population summary estimates for
Cmax after univariate analysis were 11.51 mg/L (SEM 0.38) after sin-
gle dosing and 7.04 mg/L (SEM 0.58) after steady-state dosing
(P"0.001) (Figure S2). In multivariate analysis, the difference in
Cmax estimate according to dosing duration was upheld. Single
dosing (n"1139 in 66 study arms) resulted in an adjusted mean
Cmax of 8.98 mg/L (SEM 1.34) and steady-state dosing (n"904 in
42 study arms) resulted in an adjusted Cmax of 5.79 mg/L (SEM
0.90) (P"0.001). The adjusted summary estimate of Cmax for
healthy volunteers (n"946 in 60 study arms) as compared with
TB patients (n"1075 in 46 study arms) was 8.98 mg/L (SEM 1.34)
in healthy volunteers and 6.39 mg/L (SEM 0.85) in TB patients
(P"0.01). Notably, the majority of healthy volunteer cohorts were
studied after a single dose of rifampicin (109/120 healthy volun-
teer cohorts, 91%) and most TB patients were studied after
steady-state dosing (53/63 TB patient cohorts, 84%). When multi-
variate analysis was limited to subjects dosed at steady-state, TB
status had a negligible and non-significant modifying effect on
Cmax: healthy volunteers 7.08 mg/L (SEM 1.21); TB patients
7.04 mg/L (SEM 1.28) (P"0.98). No other modifying variables had
a significant impact on the adjusted Cmax estimate (Table S2).
Only treatment duration had a consistently significant
impact on AUC in univariate analysis
In keeping with the findings in relation to the Cmax estimate, inter-
study variability in the AUC estimate was extreme, with an I2 stat-
istic of 99.53% (95% CI 99.28%–99.60%) in the meta-analysis
before inclusion of modifying variables. In univariate analysis, the
effect of steady-state dosing was to approximately halve the
mean AUC estimate, from 72.56 (SEM 2.60) to 38.73 mgh/L (SEM
4.33) (P , 0.0001) (Table 1 and Figure 1). Univariate analysis indi-
cated significant associations between the AUC estimate and
three additional covariates: HIV status, TB status and whether ri-
fampicin was dosed in monotherapy or in combination (Table 1).
However, steady-state dosing was disproportionately represented
compared with single dosing in both HIV-positive patients and TB
patients (100% and 82% of HIV-positive and TB patients, respect-
ively, were studied at steady-state). Once these analyses were
repeated with data limited to steady-state dosing, neither HIV sta-
tus nor TB status had a significant impact on the AUC estimate
(Figure 2a and b). Similarly, when the analysis was limited to those
who underwent steady-state dosing, combination therapy made
no significant difference to the AUC estimate: AUC 39.54 (SEM
3.83) versus 36.73 mgh/L (SEM 4.88) for rifampicin monotherapy
versus RHZE combination therapy (P"0.57).
Significance of effect of treatment duration on AUC was
upheld in meta-regression, but vast heterogeneity
remained
When all modifying variables were incorporated into a mixed-
effects meta-regression model, the impact on inter-study hetero-
geneity was negligible (I2"98.69%, 95% CI 98.38%–99.14%).
Only treatment duration had a significant impact on AUC: adjusted
AUC 56.26 mgh/L (SEM 13.90) after a single dose and 20.94 mgh/L
(SEM 6.49) after steady-state dosing (Table 2). After multivariate
meta-regression analysis, combination therapy with RHZE no
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had a negligible, although statistically significant, modifying ef-
fect on the AUC estimate (Table 2).
Current rifampicin dosages for TB are unlikely to be
sufficient for PK/PD target attainment
There appeared to be a slightly greater than proportional increase
in AUC with increasing dosage (Table 3 and Figure 3a), although
additional data from ongoing trials will help to clarify this. In seek-
ing to relate these reported drug exposures to measures of clinical
outcome, we used published PK/PD indices associated with effi-
cacy in murine studies21 and MIC data from human clinical WT
M. tuberculosis isolates.37 These murine studies report that an
AUC/MIC of 271 is required for a 1 log cfu reduction in vivo.21 The ri-
fampicin WT MIC distribution ranges from 0.03 to 0.5 mg/L, with a
median of 0.25 mg/L and proposed epidemiological cut-off value
(ECOFF) of 0.5 mg/L.37 Taking the median WT MIC of 0.25 mg/L,
doses of 13 mg/kg appear sufficient to achieve the AUC/MIC target
of 271. Taking the ECOFF MIC of 0.5 mg/L, however, available data
indicate that a rifampicin dose of 25 mg/kg is required to attain
this PK/PD target associated with a 1 log cfu reduction (Figure 3b).
Discussion
This meta-analysis, to our knowledge the most comprehensive to
have been conducted on rifampicin PK, has demonstrated vast
inter-study heterogeneity in PK parameter estimates. Having col-
lated data collected globally, spanning 35 years and with the inclu-
sion of HIV status, TB status, combination therapy, intermittent
dosing, diabetes status and treatment duration as modifying vari-
ables, we have been unable to explain this heterogeneity. The vast
heterogeneity within and between studies has made it impossible
to assess the degree to which physiological differences between
individual patients impacts upon rifampicin PK or PK variability, as
has been reported with other antimicrobials.38,39
The summary estimates of Cmax and AUC will serve as useful
reference points for clinicians and academics concerned with the
dosing of rifampicin for TB. At standard, WHO-recommended
doses, mean rifampicin Cmax and AUC are both significantly
reduced in patients dosed at steady-state: Cmax 8.98 versus
5.79 mg/L and AUC 72.56 versus 38.73 mgh/L after a single dose
and steady-state dosing, respectively. These decreases in PK
parameters are expected due to extensive, saturable first-pass
metabolism and well-characterized autoinduction of metabolism,
resulting in enhanced clearance after repeated doses.30,40,41
Whilst there was a trend towards HIV positivity being associated
with lower rifampicin AUC, this did not hold up in meta-regression
analysis, which may explain the conflicting results of previous
investigations into the effect of HIV positivity on rifampicin
exposure.5,27,42–44 The case of AUC in TB patients versus healthy
volunteers was similar in that the significance of the association
was lost in meta-regression analysis.
With increasing dose, there is a greater than proportional in-
crease in AUC. This is encouraging for the community that is seek-
ing to increase rifampicin exposure. Taking 38.73 mgh/L as the
mean rifampicin AUC at steady-state dosing of 8–12 mg/kg and
the ECOFF MIC of 0.5 mg/L37 gives an AUC/MIC ratio of 77, far
Table 1. Univariate analysis of variables influencing estimated rifampicin AUC
Variable and category Number of study arms Number of patients AUC estimate (mgh/L) 95% CI SEM P
Duration of therapy
single dose 58 1053 72.56 66.39–78.74 2.60 ,0.0001
steady-state dosing (.1 week) 34 846 38.73 33.82–42.67 4.33
HIV status
HIV negative 14 236 56.66 47.37–65.96 4.08
HIV positive 9 126 37.16 27.08–47.23 6.56 0.003a
mixed HIV population 14 569 41.36 34.82–47.90 5.77 0.005a
TB status
TB patients 36 947 46.14 39.39–52.89 5.29 ,0.0001
healthy volunteers 56 952 69.41 62.17–76.66 3.31
Drug combination
rifampicin monotherapy 11 122 63.21 54.53–71.89 4.43 0.0478
RHZE 39 842 51.70 40.29–63.11 5.82
Diabetes status
no diabetes 12 227 84.56 73.70–95.42 5.54 0.44
diabetes 2 42 73.17 44.46–101.88 14.65
Dosing frequency
daily dosing 87 1617 61.52 55.62–67.42 3.01 0.35
intermittent dosing 3 189 46.01 13.69–78.33 16.49
Univariate analysis indicated significant differences in estimated AUC depending on treatment duration, HIV status, TB status and combination
therapy.
Steady-state refers to dosing for7 days to allow for saturation of first-pass metabolism and the establishment of metabolic autoinduction.
P values indicate significance of difference between pooled AUC estimates within each study variable.
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below the optimal PK/PD index suggested by Jayaram et al.21 from
murine data (prior to reference). Taking the MIC value from the
very lower end of the WT range (0.03 mg/L) gives a ratio of 1291.
The discrepancy between these ratios may explain in part why
some patients develop rifampicin resistance on currently recom-
mended doses while others are successfully treated with the
same dose. The PK variability demonstrated herein is likely also to
contribute to this phenomenon. Of note, this PK/PD index indicates
the potency of a single drug used in isolation and does not reflect
the efficacy of rifampicin used in clinical settings and in combin-
ation with other agents. There are also likely to be microbiological
and host immune factors that influence treatment success. Our
calculations nevertheless highlight the inadequacy of current ri-
fampicin doses and the need for these to increase.
This analysis is limited by the fact that many studies summar-
ized their results as median and range or IQR and, as stated, where
raw data could not be obtained from authors of those studies
means and standard errors were estimated using a previously
described method.29 This may have introduced inaccuracies. Our
categorization of studies according to weight-based dosing was
necessarily crude and in some cases based on the average weight
of the study population in question. In addition, we were not able
to consider the impact of covariates that were not consistently
measured on heterogeneity in PK estimates. These included
co-medications and associated drug–drug interactions, specific
formulations of rifampicin that have been demonstrated to exhibit
altered PK,33,45,46 and patient ethnicity.
We acknowledge that the heterogeneity amongst the included
studies, likely caused in part by these and other design and report-
ing factors, is extreme. Nevertheless, we believe that our largely
descriptive analysis has value in highlighting the importance of
these factors, in addition to the widely recognized role
of inter-individual variability, in terms of their impact on the PK of
rifampicin.47,48 The extreme residual inter-study variability not
accounted for by our meta-regression analysis may thus represent
significant true biological variability between study populations,
which should be further explored. In addition, the degree of PK
variability that is attributable to protein-bound versus unbound ri-
fampicin is not known. Future studies that directly assess these
factors would be valuable, as would studies that employ mathem-
atical PK models to quantify rifampicin PK variability. Monte Carlo
simulation of rifampicin exposure based upon the AUC distribu-
tions presented in this meta-analysis would enable exploration of
various dosing regimens. If these simulations could incorporate
predictions of toxicity and drug resistance, they would support risk
reduction of novel regimens before they enter clinical use.
This meta-analysis has collated and quantitatively summarized
the existing literature on the PK of rifampicin, which is believed to
be the key driver of PD and ultimately treatment outcome. It pro-
vides an important point of reference for understanding rifampicin
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Figure 1. Forest plot displaying estimated rifampicin AUC after univariate analysis according to dosing duration. In univariate analysis, the effect of
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Author and year (arm number) AUC, mg·h/L [95% CI]
38.03 [31.92, 44.14]Summary estimate for mixed HIV population
39.26 [27.56, 50.95]Summary estimate for HIV positive
42.04 [34.78, 49.30]Summary estimate for HIV negative










































































Author and year (arm number) AUC (mg·h/L) [95% CI]
39.81 [35.32, 44.30]Summary estimate for TB patients
30.39 [16.72, 44.05]Summary estimate for healthy volunteers
(a)
(b)
Figure 2. (a) Forest plot displaying estimated rifampicin AUC after univariate analysis according to HIV status; data are limited to steady-state dos-
ing. Once data were limited to steady-state dosing, HIV status no longer had a significant impact on rifampicin AUC estimate. P values for comparison
were .0.05. (b) Forest plot displaying estimated rifampicin AUC after univariate analysis according to TB status; data are limited to steady-state dos-
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efficacy at current dosages as exploration of higher dosages
continues.
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(mgh/L) 95% CI SEM P
Duration of therapy
single dose 56.26 29.01–83.50 13.90 ,0.0001
steady-state dosing
(.1 week)
20.94 8.28–33.60 6.49 ,0.0001
HIV status
HIV negative 53.16 41.63–64.68 5.85 0.60
HIV positive 48.13 33.26–63.61 7.74 0.31
mixed HIV population 54.53 37.08–71.98 8.90 0.85
TB status
TB patients 56.26 43.22–69.29 6.65 0.10
healthy volunteers 67.09 54.11–80.07 6.62 0.10
Drug combination
rifampicin monotherapy 87.71 59.48–113.93 13.89 0.72
RHZE 72.19 50.91–101.47 12.90 0.67
Diabetes status
no diabetes 109.97 61.03–158.91 24.97 0.03
diabetes 113.30 59.03–167.55 27.68 0.04
Dosing frequency
daily dosing 54.94 24.42–85.46 15.57 0.93
intermittent dosing 39.02 17.01–60.95 11.18 0.12
Meta-regression of all available variables found that treatment duration
alone had a substantial and significant impact on estimated rifampicin AUC.
Steady-state refers to dosing for 7 days to allow for saturation of first-
pass metabolism and the establishment of metabolic autoinduction.
P values indicate significance of difference between pooled AUC esti-
mates and overall population estimate.
Table 3. Rifampicin AUC at steady-state: meta-analysed standard dose







8–12 846 38.2 4.3 a
13 23 79.7 5.4 16
15 55 46.4 3.4 49
17 11 100.1 11.0 50
20 113 95.2 3.8 23,49–51
25 15 140.5 11.2 23
30 15 204.8 22.6 23
35 35 194.6 12.3 23,51
With increasing dose, there is a greater than proportional increase in
AUC. Data are displayed in Figure 3(a).
Steady-state refers to dosing for 7 days to allow for saturation of first-
pass metabolism and the establishment of metabolic autoinduction.
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Figure 3. (a) Impact of increasing dose on rifampicin AUC. With increas-
ing dose, there appears to be a greater than proportional increase in
AUC. Error bars show SEM. Data are displayed in Table 3. (b) Impact of
increasing dose on rifampicin AUC/MIC. Taking the ECOFF MIC of 0.5 mg/L,
available data indicate that a rifampicin dose of 25 mg/kg is required to
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ABSTRACT
Introduction: Mortality from invasive fungal disease involving the central nervous system (CNS) is
excessive. Achieving therapeutic drug concentrations at the site of infection within the CNS is always
difficult and its evaluation is complex due to anatomical barriers and variable pathophysiological
lesions.
Areas covered: This review provides an updated summary of the CNS PK of antifungal therapies. It
considers factors that influence the success of antifungal regimens for CNS infection as well as
preclinical and clinical data that quantify antifungal pharmacokinetics (PK) in the CNS. Furthermore, it
presents state-of-the-art technologies to enhance the clinical use of existing antifungal drugs, and
introduces novel antifungal drugs in development.
Expert opinion: The antifungal drugs currently available are either suboptimal, or are being used
suboptimally, for CNS disease. Therapeutic drug monitoring is mandatory to enhance their effective-
ness. Novel drugs in development may offer more efficacious options. In all cases, contemporary
technologies to assess CNS PK offer the opportunity to enhance our understanding and use of
antifungal drugs for CNS fungal disease.
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Mortality from invasive fungal diseases involving the central
nervous system (CNS) frequently exceeds 50% [1]. There are
unique challenges for drug penetration within the CNS. The
blood–brain barrier (BBB) and blood–cerebrospinal fluid bar-
rier (BCSFB) create an obstacle for free diffusion of compounds
into the CNS. Hence, plasma drug concentrations are not
reliable surrogates for concentrations within diseased areas
of the brain [2]. Complex pathophysiology and nonspecific
clinical presentations often lead to a late diagnosis of CNS
mycoses and this further compromises pharmacological treat-
ment. This review provides a summary of current knowledge
of the CNS pharmacokinetics (PK) of antifungal therapies.
2. CNS PK of antifungal drugs
The CNS is comprised of multiple sub-compartments that
include the cerebrospinal fluid (CSF), cerebral parenchyma,
ventricles, and meninges [3]. These areas are pharmacologi-
cally distinct. A number of issues are pertinent for a complete
understanding of the potential utility of an antifungal agent
for the treatment of CNS mycoses: first, pathological changes
within the CNS resulting from fungal invasion; second, physi-
cochemical drug properties that influence the extent of parti-
tioning into the CNS and areas of diseased tissue; and finally,
PK variability.
2.1. Pathophysiology of CNS fungal infections
Fungi vary considerably in the extent to which they are neu-
rotropic. For some pathogens, such as Cryptococcus neofor-
mans and Cladophiolophra, involvement of the CNS is so
characteristic that it must be actively excluded if a diagnosis
is established from a non-CNS site. For others, such as
Aspergillus spp., CNS involvement is well characterized but is
not invariably present. In addition, involvement of the CNS
may depend on the host. For example, hematogenous
Candida meningoencephalitis (HCME) is a disease that is char-
acteristic of premature neonates, but highly unusual in adults.
Table 1 summarizes the considerable pathophysiological dif-
ferences between CNS mycoses.
The nature and extent of underlying immunological deficits
also has an important impact on patterns of infection and the
cadence of clinical disease. For example, profoundly immuno-
suppressed patients with invasive CNS aspergillosis often pre-
sent with a stroke-like illness resulting from cerebral infarction.
This results from invasion and thrombosis of cerebral arteries
by Aspergillus spp. In contrast, patients with chronic sinus
aspergillosis may develop CNS disease via direct hyphal inva-
sion through the lamina papyracea. These patients often only
have mild immunological deficits (e.g. diabetes, low-dose cor-
ticosteroid treatment) with clinical signs and symptoms that
develop over many months. The histopathology of these two
diseases is distinct. Cerebrovascular aspergillosis is associated
with a paucity of inflammation, infarction and cerebral
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hemorrhage. In contrast, chronic Aspergillus sinusitis is asso-
ciated with florid pyogranulomatous inflammation.
Systemic physiological changes associated with CNS
mycoses may also have an impact on the PK of antifungal
drugs. Systemic infection alters cerebral blood flow, blood and
tissue pH and intra- and extra-cellular fluid volumes, all of
which exert profound influence on systemic PK and drug
penetration into the CNS [52–54]. Meningeal inflammation
may increase the concentration of antimicrobial agents in
the CSF by over 10-fold [55]. In some cases, the BBB is com-
pletely disrupted, allowing unfettered access of the drug to
the pathogen.
2.2. Physicochemical properties of the drug
The CNS is protected from many circulating xenobiotics by the
presence of blood tissue barriers that limit diffusion from the
endovascular compartment into the CSF and brain parench-
yma. A summary of antifungal drug characteristics that
influence the degree to which drugs partition across the BBB
and the BCSFB is presented in Table 2. Tight cellular connec-
tions in the BBB and BCSFB (approximately 2 nm) prevent the
passive diffusion of large compounds into the CNS [3]. Efficient
diffusion is possible only to an upper molecular weight limit of
300–400 g/mol [56].
The lipophilicity of compounds influences the extent of CNS
partitioning [52,67]. Drug lipophilicity is quantified as the partition
coefficient (LogP) between aqueous and lipophilic phases (usually
determined with water and octanol). A more physiologically rele-
vant expression of lipophilicity is LogD, which accounts for the fact
that many drugs are ionized at physiological pH. Compounds that
are not ionized at physiological pH have the greatest lipophilicity
and better penetrate the BBB and BCSFB [52,68]. LogP and LogD
values of approximately 2–4 are associated with optimal BBB
penetration [68,69]. Protein binding also influences the degree of
partitioning into the CNS. Passive diffusion of molecules into the
CNSdepends on a concentrationgradient betweenunbounddrug
in the plasma and that in the brain [70]. Protein binding is often
inversely correlated with LogP.
Finally, efflux pumps in the BBB and BCSFB may remove
compounds from the CNS via an energy-dependent process
[3,52]. P-glycoprotein is a membrane-bound efflux pump with
an affinity for lipophilic molecules. Some triazole agents (itra-
conazole, posaconazole and isavuconazole [71]) are substrates
for P-glycoprotein, while other triazoles (fluconazole and vor-
iconazole) are not. There is conflicting evidence regarding the
role of P-glycoprotein in the efflux of amphotericin B from the
CNS [72,73].
2.3. PK variability
Several antifungal drugs exhibit nonlinear and/or highly vari-
able PK. The PK of itraconazole, voriconazole, posaconazole,
and flucytosine are sufficiently variable to warrant routine ther-
apeutic drugmonitoring (TDM) in the context of invasive fungal
disease, regardless of whether there is CNS involvement [74].
This variability is inevitably more extreme when penetration
into the CNS is considered, since it is amplified by barriers
such as the BBB and BCSFB as well as pathological changes
within the CNS itself. Thus, while plasma drug concentrations
are highly variable, CNS drug concentrationslikely more so, and
the former are an unreliable surrogate for the latter.
The prediction and evaluation of the CNS PK of antifungals is
thereby complex. Inter- and intra-individual variability in each
contributing factor extends this complexity [52,74]. Ideally, the
information required to establish robust pharmacokinetic–phar-
macodynamic (PK–PD) targets at the site of infection in the CNS
includes all of thepoints listed inBox1. Using this information, data
can be modeled using a variety of approaches to predict human
CNS PK. These approaches can broadly be categorized into classi-
cal population PK modeling (the ‘top–down’ approach) and phy-
siologically based PK (PBPK)modeling (the ‘bottom–up’ approach)
[75]. For example, population PK models have been constructed
from preclinical investigations of micafungin [76] and anidulafun-
gin [77], with Monte Carlo simulation used to bridge the results to
neonatal populations at risk of Candida meningoencephalitis.
While PBPKmodels describing theCNSPKof antifungals are scarce,
Article highlights
● The pathophysiology of fungal infections of the CNS is varied and
impacts the pharmacokinetic-pharmacodynamic targets of antifungal
drugs for these infections.
● Physicochemical properties of drugs influence their propensity to
reach therapeutic CNS concentrations.
● Antifungal pharmacokinetic variability is significant, and heightened
in the context of CNS penetration.
● Several new antifungal agents are in development and may be of
clinical utility for CNS infections.
● Advancing technologies enhance our ability to quantify and evaluate
CNS pharmacokinetics.
This box summarizes key points contained in the article
Box 1. Desirable information for the accurate setting of PK–PD targets
for fungal CNS infection
1. Principal PK parameter of interest, depending on whether drug
activity is determined bymaximum concentration (Cmax), area under
the curve (AUC), or time above a given therapeutic threshold.
2. Drug susceptibility/ MIC of the infecting fungus.
3. Magnitude of the PK–PD index required in terms of the unbound
concentration of drug that issufficient to exert PD effect on the target
organism.
4. Histopathological site(s) of disease within the CNS.
5. Rate constant describing the movement of drug into the CNS from the
circulation.
6. Rate constant(s) describing the movement of drug within CNS
compartments of interest.
7. Rate constant(s) describing the clearance of drug from the target site.
8. Rate constant(s) describing the clearance of drug from the body.
9. Time-dependent differences in plasma and tissue drug concentrations
(hysteresis).
10. PK parameters associated with toxicity in measurable physiological
compartments (usually thesystemic circulation).
11. Clinical and physiological covariates that influence the PK of the drug
in question.
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Table 1. Overview of CNS mycoses
Fungal species Clinical setting
Predilection for CNS
involvement in









































HIV infection, steroid therapy,
travel to southwest USA,
Central and South America













































































































~ 18 Amphotericin B





























EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY 3
examples of the application of PK modeling to the prediction of
CNS PK exist in the general pharmacology literature. A multi-
compartmental PBPK model has been shown to adequately
describe the PK profiles of nine structurally diverse drugs in the
plasma, brain extracellular fluid andCSF of rats [78]. Themodelwas
additionally able to predict human concentration-time profiles in
brain compartments [78,79]. PBPK models can also predict the
influence of genetic polymorphisms on CNS PK and PD [80].
3. Evaluation of data relating to the CNS PK of
antifungal drugs
Studies of the CNS penetration of antifungal drugs in humans
are often limited. Firstly, drug concentrations in CSF, which is
the only readily available biological matrix in clinical studies,
may not be representative of concentrations in other CNS sub-
compartments. Secondly, studies tend to report point esti-
mates of CNS drug partitioning rather than integral measures-
drug concentrations over time (i.e. area under the
concentration-time curve; AUC) in the plasma and the CNS.
For ethical and technical reasons, quantification of drug in the
CNS using conventional methods such as collecting samples of
tissue for liquid chromatography–mass spectrometry (LC–MS) or
bioassay in clinical studies is challenging (see e.g. [81,82]).
Information of this type is usually derived from preclinical mod-
els. Using more contemporary technologies, clinically relevant
estimation of CNS drug partitioning is becoming easier.
Examples of these technologies are intracerebral microdialysis
[70] and non-invasive imaging techniques such as positron emis-
sion tomography (PET) [83] and magnetic resonance (MR) ima-
ging [84]. Key findings that preclinical and clinical studies have
provided are presented in the following section of this review,
alongside a review of their clinical application.
4. The triazoles
4.1. Fluconazole
Fluconazole has physicochemical properties that enable it to
traverse the BBB and BCSFB (Table 2). The equilibration of
fluconazole between plasma and cerebral extracellular fluid
occurs rapidly and is independent of dose [85]. Relatively
high concentrations are found in the CSF. PK studies in rabbits
and adult Rhesus monkeys demonstrated mean CSF:plasma
AUC ratios of 0.84 and 0.86, respectively, with a long half-life
in the CSF of approximately 27 h [86,87].
Early human CNS PK studies using bioassay or LC–MS reported
a range of partition ratios from0.52 to 0.89 [81,88]. Subsequently, a
combined approach using PET scanning and plasma PK sampling
demonstrated an approximately uniform distribution of flucona-
zole in the healthy human brain, with a brain:plasma penetration
ratio of 1.31 [83]. This was corroborated by an analysis of four
patients undergoing brain tumor excision in whom healthy brain
parenchyma was also removed. In these patients, HPLC demon-
strated a mean healthy brain:plasma fluconazole ratio of 1.33 [82].
A fluconazole regimen of 1200 mg/day for the 2-week induc-
tion phase of treatment for cryptococcal meningoencephalitis is
often used in settings where polyenes are unavailable. This
dosage is more rapidly fungicidal than 800 mg/day [89]. The
addition of flucytosine to fluconazole is recommended because
it reduces mortality [90]. These oral regimens for cryptococcal
meningitis are pragmatic recommendations given the unavail-
ability of polyenes in many regions with a high burden of cryp-
tococcal meningitis, despite broad agreement that amphotericin
B deoxycholate is currently the agent of choice [91,92].
Fluconazole is also used at dosages of 400–1200 mg/day to
treat CNS infection with Coccidioides [93,94].
4.2. Itraconazole
Itraconazole concentrations in CSF are negligible, with CSF:plasma
concentration ratios of < 0.002 to 0.12 in preclinical models [2,95–
97]. Even in the setting of infection and inflammation, itraconazole
is undetectable in rabbit CSF [97]. Low CSF concentrations have
been attributed to rapid binding to red blood cells and circulating
plasma proteins, inhibiting BCSFB penetration [98]. However, mur-
ine experiments have demonstrated rapid, dose-dependent pene-
tration and linear accumulation of itraconazole in brain tissue up to
8 min post-dose, implying that it does cross the BBB [99]. In a
murine model of CNS histoplasmosis, itraconazole levels were
almost universally undetectable in brain tissue 3 h post-dose
[100]. Itraconazole has a strong affinity for P-glycoprotein, which
Table 1. (Continued).
Fungal species Clinical setting
Predilection for CNS
involvement in








































§ Key: ++++, very common, through +/–, very rare.
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results in rapid efflux from the CNS such that half-life in cerebral
tissue may be considerably shorter than that in plasma (0.4 h
versus 5 h, respectively) [99,101].
The efficacy of itraconazole for the treatment of cryptococcal
meningoencephalitis [97], CNS aspergillosis [102], and Coccidioides
meningitis [95] is well established in laboratory animalmodels. The
apparent discrepancy between CNS drug concentrations and ther-
apeutic efficacy of itraconazole in CNS fungal infections may be
due to a combination of higher drug concentrations in the brain
tissue than in CSF, and the relatively low minimum inhibitory
concentration (MIC) of itraconazole against target fungi such as
Candida [103] and Histoplasma [100]. In addition, the pharmacolo-
gically activemetabolite of itraconazole, hydroxyl-itraconazole, has
been detected in brain parenchyma with greater consistency than
has the parent drug [100]. In humans, itraconazole is effective for
primary prophylaxis of cryptococcal meningitis, with a relative risk
of incident cryptococcal meningitis of 0.12 (95% confidence inter-
val, 0.03, 0.51) versus placebo [104]. Inconsistent success rates have
been reported for the treatment of cryptococcal meningitis with
itraconazole. The treatment of six patients with 200 mg/day
resulted in therapeutic failure (deterioration or death) in three
patients (50%) [105]. Of 20 evaluable patients with culture- or
antigen-diagnosed cryptococcal meningitis treated with itracona-
zole 400 mg/day, 13 (65%) achieved clinical and microbiological
cure [106]. Cryptococcal meningitis progressed in two patients
receiving itraconazole 600mg/day [107]. After recovery from cryp-
tococcal meningitis, maintenance therapy with itraconazole is
associated with significantly more relapses of cryptococcal menin-
gitis compared with fluconazole [108].
Itraconazole is not included in current cryptococcal menin-
gitis treatment guidelines from the World Health Organization
[109], though it may be used as prophylaxis against cryptococ-
cal meningitis, particularly in patients with CD4 counts < 100
cells/µL [110]. Despite the availability of newer antifungal
agents, the oral bioavailability and broad spectrum of antifun-
gal activity of itraconazole mean that it remains a useful drug
for the management of invasive mycoses worldwide [111]. It is
recommended as second-line therapy for CNS infection with
Candida, Aspergillus, Histoplasma, and Coccidioides spp [93].
4.3. Voriconazole
Voriconazole has a relatively lowmolecular weight (349 g/mol), is
moderately lipophilic and is a weak substrate for P-gp (Table 1). It
exhibits good CNS penetration. In guinea pigs, 10-mg/kg vorico-
nazole penetrates the BBB into brain parenchyma rapidly, reach-
ing peak concentrations of 6.8 µg/g and 2.7 µg/g 15 min and 1 h
post dose, respectively [112]. The CSF:plasma ratio in healthy
animals is 0.68 [112].
Studies in humans have demonstrated that voriconazole
penetrates the BBB and BCSFB, including into brain parench-
yma [113] and cerebral abscesses [114]. A wide range of con-
centrations in human CSF range have been reported, from
0.08 to 3.93 µg/mL in the initial 10 h post voriconazole admin-
istration. CSF:plasma ratios are 0.22–1.0 [112]. This wide range
is likely due to the extensive PK variability of voriconazole
[74,115–119]. In contrast to CSF, concentrations in the brain
are ≥ 2-fold plasma levels [84]. A study that used fluorine-19
MR spectroscopy reported steady-state brain:plasma voricona-
zole concentration ratios of 3.0 (90% CI 1.9–4.7) pre-dose and
1.9 (90% CI 1.2–3.0) post-dose in healthy adult men [84].
Voriconazole exhibits potent activity against Aspergillus spp.
(Table 2) and is a standard-of-care for CNS aspergillosis [120]. It is
also indicated for CNS infection with Scedosporium apiospermum
complex and fluconazole-resistant Candida spp. (Table 2), the
latter being primarily confined to the neonatal setting.
4.4. Posaconazole
Posaconazole is structurally similar to itraconazole, but less lipo-
philic [2]. It is both a substrate and an inhibitor of P-gp in vitro
[121], although polymorphisms of P-gp do not affect posacona-
zole AUC in vivo [122]. The oral suspension of posaconazole
exhibits variable bioavailability and inconsistent PK [123,124].
Alternative tablet, capsule and intravenous formulations have
been partly successful in addressing these issues [125–129].
Based on the physicochemical properties of posaconazole, poor
CNS penetration is expected (Table 2). In murine models of
infection with C. gattii and Fonseca monophora, mean posacona-
zole brain:serum concentration ratios are < 0.54 with dosages of



















Correlation of measurable CNS
concentration with biological
activity References
Fluconazole 309 2.17 0.5 10 No Good [57–59]
Itraconazole 705 6.99 4.9 98 Yes Poor [58,59]
Voriconazole 349 2.56 2.1 58 No Good/variable [59]
Posaconazole 700 6.1 4.4 99 Yes Poor [59]
Isavuconazole 718 −3.33 3.6 99 No Good [60,61]
DAmB 924 < 0.4 0.95 −2.8 > 95 No Poor [62,63]
LAmB 924 0.05–
0.08
0.95 −2.8 > 95 Contentious Poor [63,72,73]
ABLC 924 1.6–11 0.95 −2.8 > 95 No Poor [3,63]
ABCD 924 0.12–
0.14
0.95 −2.8 > 95 No Poor [3,63]
5FC 120 −0.89 −2.34 5 No Good [3,58]
Caspofungin 1093 −2.8 −3.88 98 No Good [64,65]
Micafungin 1140 −3.8 −1.62 98 No Good [64,65]
Anidulafungin 1291 0.21 −3.32 98 No Good [65,175]
a From Ref. [3].
b From Refs. [2,66].
c From Refs. [3,59]
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10–20 mg/kg. These increase to 0.69–0.84 following dosages of
40 mg/kg [130,131].
Human CNS PK data for posaconazole are sparse and lim-
ited to case reports. The CSF:plasma concentration ratios
range from 0 (single CSF sample analyzed in each case)
[132,133] to < 0.009 (in six serial CSF samples) [134] in patients
without significant meningeal inflammation. In patients with
bacterial meningitis and cerebral fungal infection, CSF:plasma
posaconazole concentration ratios as high as 0.44 and 2.37 are
reported, suggesting that meningeal inflammation may
improve CNS penetration [133]. Posaconazole penetrates into
fungal brain abscesses [133].
Posaconazole is not recommended as a first-line agent for
any fungal infection of the CNS. Posaconazole is indicated as
second line therapy for coccidioidomycosis [135], and mucor-
mycosis [136] and as salvage therapy for invasive aspergillosis
[137,138] and histoplasmosis [139] (Table 2 [93],).
4.5. Isavuconazole
Isavuconazole is structurally similar to fluconazole and vorico-
nazole, although it has a higher molecular weight and LogD
value (Table 2). Studies in healthy rats suggest that the mean
brain:plasma isavuconazole concentration ratio is 1.8 [140].
Following administration of 14C-labeled isavuconazonium sul-
fate, radioactivity in brain tissue increases in proportion with
radioactivity in blood, and reaches a maximum at 2h post-
dose before declining to undetectable levels 24 h post-dose
[140]. Similar CNS penetration is evident in a murine model of
cryptococcal meningitis with brain:plasma AUC ratios of
approximately 1.35 [141].
Data describing the PK of isavuconazole in the human CNS
are scant. However, isavuconazole is non-inferior to voricona-
zole for the treatment of suspected invasive aspergillosis [142]
and has been used effectively for the treatment of invasive
mucormycosis with brain involvement [143].
5. Polyenes
There are several formulations of amphotericin B (AmB) avail-
able for clinical use: amphotericin B deoxycholate (DAmB),
liposomal amphotericin B (LAmB), amphotericin B lipid com-
plex (ABLC) and amphotericin B colloidal dispersion (ABCD)
[93,144]. ABCD is no longer marketed in many countries. All
approved formulations are administered intravenously. The
large molecular weight of AmB is likely to be the primary
reason for its relatively poor CNS penetration [145,146]
(Table 2). An in vitro model of the BBB demonstrated that
permeability to both LAmB and DAmB was significantly
increased in response to enlargement of endothelial cell junc-
tions via exposure to either tumor necrosis factor alpha or
lipopolysaccharide [147]. In addition, AmB may be a substrate
for efflux pumps at the BBB [72,73].
In a rabbit model of CNS C. albicans infection, CSF:plasma
ratios ≤ 0.02 and brain:plasma ratios ≤ 0.27 were reported for
all four AmB formulations [145]. The CNS penetration ratios of
all formulations are higher in the setting of CNS infection
compared with healthy brain tissue (maximum AmB CSF:
plasma ratio 0.03 with ABCD and ABLC; maximum brain:
plasma ratio 0.11 with ABCD) [145].
LAmB has the lowest CNS penetration ratio of all formula-
tions despite its smaller particle size (Table 2). However, the PK
of LAmB is characterized by serum concentrations 30-fold
greater than other AmB formulations. Thus, the absolute con-
centration of AmB in brain tissue following LAmB administra-
tion is ultimately several times higher than following
administration of the other formulations [3,145]. An immuno-
histochemistry study of LAmB in brain sections of mice with
cryptococcal meningitis revealed that amphotericin B was
present in both intravascular and perivascular spaces [148].
The proportion of liposome-associated AmB versus free drug
in brain tissue after administration of LAmB is unknown.
After as few as three dosages of DAmB, there is prolonged
mean residence time of AmB in rabbit brain tissue despite
negligible concentrations in CSF [149]. In human studies of
LAmB PK, CSF:plasma concentration ratios of 0.001 have been
reported [150]. Autopsy studies have found concentrations of
AmB in human cerebral cortex to be lower than those in liver,
spleen, kidney and lung, with no significant difference
between the concentrations detected after administration of
LAmB and ABCD [151].
Despite consistent reports of low or undetectable CNS con-
centrations of AmB, its efficacy against many CNS mycoses in
humans, including cryptococcal meningitis, is well established
[152–155]. A likely explanation for this is that amphotericin B
concentrations are high in the meninges where the yeast pre-
dominantly resides.
The clinical utility of polyenes in regions of the world with
high burden of fungal CNS infection, in particular cryptococcal
meningitis but also CNS histoplasmosis, murcomycosis, sporo-
trichosis and trichosporonosis, is limited by the requirement
for intravenous administration, prolonged inpatient admission
and close monitoring for toxicity.
6. Flucytosine
Flucytosine has several attributes that are conducive to high
CNS penetration including low molecular weight, low-protein
binding and polarity (Table 2). High-dose-proportional con-
centrations are consistently recorded in both brain parench-
yma [156] and CSF, with CSF:plasma ratios 0.74–0.84 in
humans from 1–2 h after dosing [157,158]. The activity of
flucytosine appears to be time- rather than concentration-
dependent [157,159,160].
Flucytosine is active against Cryptococcus spp., most Candida
species and has some activity against Aspergillus species [74,109].
Its use in monotherapy is widely thought to be precluded by the
development of resistance, which has been consistently docu-
mented in vitro [161–163]. While reports on the clinical use of
flucytosine monotherapy are sparse, a case series of 23 patients
with cryptococcal meningitis treated with flucytosine monother-
apy reported that of 12 patients who failed therapy, the devel-
opment of resistance was implicated in 50% [164].
In practice, flucytosine is used in combination therapy. In this
setting, flucytosine is vital to secure optimal outcomes in crypto-
coccal meningitis: Trials comparing DAmB alone with DAmB in
combination with either flucytosine or fluconazole have
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demonstrated superior outcomes in the flucytosine combination
arms, in terms of CSF sterilization [165,166] and mortality [165]. Its
addition to AmB facilitates reduced treatment durations for cryp-
tococcalmeningitis [167]. 5FCmay also have a role inHCME,where
its addition to AmB is at least additive and may be synergistic in
preclinical models [168,169]. A retrospective study of humans with
Candida meningitis reported survival in 15 of 17 patients treated
with the combination of flucytosine and AmB [170]. This combina-
tion is recommended for Candida meningitis in children [171]
though caution is advised because of the risk of toxicity, particu-
larly in premature neonates [172].
7. Echinocandins
Caspofungin, micafungin, and anidulafungin do not exten-
sively partition into the CNS due to their large molecular
weight and high level of protein binding (Table 2 [173],).
Micafungin achieves brain:plasma concentration ratios < 0.01
at doses of 0.5–2 mg/kg in healthy rabbits [174]. In rabbits
with HCME, micafungin penetrates all CNS compartments
(cerebrum, cerebellum, spinal cord, meninges and CSF) in a
dose-dependent fashion, but only with dosages > 2 mg/kg
[76]. The presence of CNS infection and inflammation does not
increase the CNS penetration of micafungin [76]. Brain tissue
concentrations of anidulafungin also increase in a dose-depen-
dent manner, achieving brain:plasma ratios of 0.10–0.12 at
doses of 0.5–10 mg/kg in neutropenic rabbits with dissemi-
nated C. albicans infection [175]. Studies of radiolabelled cas-
pofungin at dosages of 1–2 mg/kg demonstrate brain:plasma
penetration ratios of < 0.09 in rodents [176]. For all three
echinocandins, penetration into each of lung, liver, spleen
and kidney exceeds that into brain tissue [174–176].
Human CNS PK data for echinocandins is limited to case
reports. A patient with a cerebral mass treated with micafungin
at a dosage of 100mg q24h achieved a brain:plasma concentra-
tion ratio of 0.18, 23 h after dosing [177]. A patient dosed with
micafungin 300 mg/day for CNS aspergillosis achieved a CSF:
plasma ratio of 0.0005 [178]. A case report of a patient treated for
Candida endocarditis describes the development of new cerebral
abscesses during caspofungin treatment [179].
There is experimental evidence fromwell characterized rabbit
models of HCME that anidulafungin and micafungin are poten-
tially effective agents [76,77]. The weight-based dosages pre-
dicted for efficacy from PK–PD bridging studies are in excess of
those recommended in adults for invasive candidiasis. This find-
ing promoted further clinical studies of micafungin that included
dosages up to 15 mg/kg. The European Society of Clinical
Microbiology and Infectious Diseases recommends that a dosage
of 10mg/kg is considered for neonatal HCME [76]. Echinocandins
may also be considered as an adjunct to other first-line antifun-
gal agents for the treatment of CNS infection caused by
Aspergillus spp., S. apiospermum complex, and Lemontospora
prolificans (Table 1).
8. Expert opinion
The antifungal drugs currently available are either suboptimal or
are being used suboptimally, for CNS disease. However, the tech-
nological and scientific capacity to improve this situation exists.
Reformulation of drugs may improve their distribution
through the BBB and BCSFB. In particular, nanoparticulate
drug formulations offer promise in terms of CNS distribution.
These submicrometer units may improve drug transport
across the BBB by transiently increasing BBB permeability or
by internalizing into brain capillary endothelial cells and thus
traversing the intact BBB transvascularly [180,181]. These con-
cepts and a description of specific carriers are presented else-
where [182,183]. A number of examples of the exploration of
nanostructured antifungal drug preparations exist. A nanosus-
pension formulation of amphotericin B increased AmB con-
centrations in mouse brains by a factor of 2.5–4.25 relative to
LAmB [184]. Amphotericin B-containing micelles, modified
using a ligand of low-density lipoprotein receptor-related pro-
tein present on the BBB, have shown better BBB penetration
than unmodified micelles or amphotericin B deoxycholate
both in vitro and in vivo [185]. Nanostructured liposomes can
increase itraconazole concentrations by 2-fold in mouse brains
[186]. These chemical modifications represent potential ave-
nues to maximize the utility of currently available antifungal
drugs for CNS infections.
TDM is a standard of care for the triazoles and 5FC regardless
of the site of infection [187,188]. For CNS mycoses, antifungal
TDM is even more critical to ensure adequate concentration at
the effect site. Targets for TDM for efficacy are generally based on
non-CNS disease. Hence, clinicians must use their judgment as to
which target to aim for in TDM. From a pragmatic perspective,
aiming for higher concentrations within the therapeutic range is
a reasonable strategy (rather than being reassured by concentra-
tions that are just within the therapeutic range).
8.1. Novel antifungal drugs with potential for use as CNS
agents
Several promising new antifungal compounds are under investi-
gation and may hold promise as treatments for CNS disease.
Viamet Pharmaceuticals (Durham, NC, USA) have developed VT-
1129, a quaternary azole that is efficacious in murine models of
cryptococcal meningitis [189] and systemic candidiasis [190].
Cidara Therapeutics (San Diego, CA, USA) is developing a novel
semisynthetic echinocandin, CD101. CD101 is active against
Candida and Aspergillus spp [191]., but in preclinical models dis-
plays tissue distribution patterns in keeping with currently avail-
able echinocandins, penetrating poorly into brain
parenchyma [192].
F901318 (F2G limited, Eccles, UK) is the leading compound
in a novel class of antifungals, the orotomides, which block
fungal pyrimidine synthesis [193]. F901318 is active against
Aspergillus spp., including resistant strains [194], as well as
Penicillium spp., Coccidiodes immitis, H. capsulatum,
Blastomyces dermatitidis, Fusarium spp., and Scedosporium
spp [193]. F901318 is detectable in brain tissue after adminis-
tration to mice [193]. Amplyx Pharmaceuticals (San Diego, CA,
USA) have developed a novel antifungal agent, APX001, which
inhibits a glycosylphosphatidylinositol-anchored fungal wall
transfer protein [195]. APX001 exhibits highly selective in
vitro antifungal activity against Candida spp., including strains
resistant to fluconazole, Aspergillus fumigatus, A. niger, A. fla-
vus, A. terreus, Fusarium, Pseudallescheria boydii, and S.
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prolificans [196,197]. In a murine model of disseminated C.
auris infection, APX001 improves survival by up to 2-fold
relative to anidulafungin, with demonstrable PD effect in
brain tissue [195]. APX001 was granted orphan drug status
by the US Food and Drug Administration in 2016 [198].
Another novel first-in-class antifungal agent is SCY-078
(SCYNEXIS, Jersey City, NJ, USA). SCY-078 is a semisynthetic
derivative of enfumafungin and the only compound in the
triterpene class of antifungals [199]. It is a potent inhibitor of
β-[1,3]-D-glucan synthesis in fungal cell walls and demon-
strates broad spectrum activity against Candida spp [200].,
including C. auris [201] and Aspergillus spp [202] in vitro.
Preclinical in vivo models using SCY-078 for treatment of dis-
seminated candidiasis have demonstrated promising potency
and PK [199].
8.2. New technologies for the assessment of CNS PK of
antifungals
Historically, studies assessing the CNS PK of antifungals in vivo
have taken brain tissue homogenates and measured drug
using LC–MS, as demonstrated in this review. Modern techni-
ques enable more refined CNS PK models including informa-
tion about the spatial distribution of drug within tissues. We
have seen that PK differences in various brain compartments
can be assessed using microdialysis. This technique measures
drug penetration into fluid compartments of the CNS using a
dialysis probe to detect free drug in the cerebral interstitial
fluid. The use of microdialysis in humans is limited to intrao-
perative settings and the technique may be unsuitable for the
quantification of highly protein-bound or lipophilic drugs
[203]. PET scanning and MR spectroscopy are non-invasive
techniques that can estimate drug distribution into the
human brain by detecting radiolabelled molecules. PET can
provide longitudinal trends in drug distribution but its use is
limited by cost, the inability to distinguish parent compounds
from metabolites, and the requirement for radioactive labeling
[75,204,205].
Matrix-Assisted Laser Desorption and Ionization – Mass
Spectroscopy Imaging (MALDI-MSI) does not require radiola-
belling and can provide rapid, highly resolved spatial drug
distribution data. In murine brains, MALDI-MSI has been
employed to quantify a number of antibiotics including gati-
floxacin [206], doxycycline [207], pretomanid [208], and rifam-
picin [209] to the subcompartmental level. Serial tissue
sections taken over time can yield longitudinal data. The
technique has not yet been applied to assess the CNS distri-
bution of antifungal drugs. To do so could elucidate informa-
tion regarding mechanisms of drug action, distribution, and
inter-subject variability in CNS drug penetration. This would
enable precision spatial PK modeling with vastly enhanced
translational utility from laboratory animals to humans and
from plasma drug levels to those in the CNS.
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ABSTRACT Robust population pharmacokinetic (PK) data for fluconazole are
scarce. The variability of fluconazole penetration into the central nervous system
(CNS) is not known. A fluconazole PK study was conducted in 43 patients receiv-
ing oral fluconazole (usually 800 mg every 24 h [q24h]) in combination with am-
photericin B deoxycholate (1 mg/kg q24h) for cryptococcal meningitis (CM). A
four-compartment PK model was developed, and Monte Carlo simulations were
performed for a range of fluconazole dosages. A meta-analysis of trials reporting
outcomes of CM patients treated with fluconazole monotherapy was performed.
Adjusted for bioavailability, the PK parameter means (standard deviation) were
the following: clearance, 0.72 (0.24) liters/h; volume of the central compartment,
18.07 (6.31) liters; volume of the CNS compartment, 32.07 (17.60) liters; first-
order rate constant from the central to peripheral compartment, 12.20 (11.17)
h1, from the peripheral to central compartment, 18.10 (8.25) h1, from the cen-
tral to CNS compartment, 35.43 (13.74) h1, and from the CNS to central the
compartment, 28.63 (10.03) h1. Simulations of the area under concentration-
time curve resulted in median (interquartile range) values of 1,143.2 (range,
988.4 to 1,378.0) mg · h/liter in plasma (AUCplasma) and 982.9 (range, 781.0 to
1,185.9) mg · h/liter in cerebrospinal fluid (AUCCSF) after a dosage of 1,200 mg
q24h. The mean simulated ratio of AUCCSF/AUCplasma was 0.89 (standard devia-
tion [SD], 0.44). The recommended dosage of fluconazole for CM induction ther-
apy fails to attain the pharmacodynamic (PD) target in respect to the wild-type
MIC distribution for C. neoformans. The meta-analysis suggested modest im-
provements in both CSF sterility and mortality outcomes with escalating dosage.
This study provides the pharmacodynamic rationale for the long-recognized fact
that fluconazole monotherapy is an inadequate induction regimen for CM.
KEYWORDS cryptococcal meningitis, pharmacokinetics, pharmacodynamics,
fluconazole, central nervous system pharmacokinetics, central nervous system
infections, meta-analysis
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Mortality from cryptococcal meningitis remains unacceptably high. More than 90%of the estimated 223,100 annual incident cases of cryptococcal meningitis occur
in Sub-Saharan Africa and Asia-Pacific regions (1). The most effective regimen for
induction is amphotericin B deoxycholate and flucytosine (2, 3). However, access to
these drugs is limited in many regions where the burden of cryptococcal meningitis is
greatest (4, 5). In these settings, high-dose fluconazole is used for induction mono-
therapy, despite consistent evidence of reduced survival in comparison to that with
other agents and combinations (6–8).
Fluconazole was discovered by Pfizer, Inc. (Sandwich, United Kingdom) in 1978 (9).
The objective was to discover an orally bioavailable agent for the treatment of invasive
mycoses with a lower propensity to develop resistance than flucytosine (9). Fluconazole
inhibits cytochrome P450-dependent demethylation of lanosterol in the ergosterol
biosynthetic pathway (10). The ratio of the area under the concentration-time curve
(AUC) to the MIC is the pharmacodynamic (PD) index that best links drug exposure of
fluconazole with the observed antifungal effect (11, 12).
Successful antimicrobial therapy within the central nervous system depends on the
achievement of effective drug concentrations within relevant subcompartments that in-
clude the cerebrum, meninges, and cerebrospinal fluid (CSF) (13). Fluconazole has a low
molecular weight (approximately 300 g/mol), is weakly protein bound, and is not known to
be a substrate for central nervous system (CNS) efflux pumps (14, 15). Its ability to partition
from the endovascular compartment into the CNS has been established in laboratory
animal models (16, 17) and clinical studies (18, 19). Brain/plasma penetration ratios of up to
1.33 have been reported in humans (19). However, there is a surprising paucity of popu-
lation pharmacokinetic (PK) data for fluconazole in all clinical contexts. Furthermore, the
extent and variability of penetration into the CNS are not known.
The primary aim of this study was to quantify the extent and variability of CNS
penetration of fluconazole in adults with cryptococcal meningitis. We developed a
population PK model that quantified the interindividual variability in drug exposure in
plasma and cerebrospinal fluid (CSF). We investigated the impact of a range of clinically
relevant covariates on fluconazole PK. Monte Carlo simulation was used to assess the
implications of PK variability in terms of achieving fluconazole PD targets. Finally, we
conducted a meta-analysis of clinical trials of fluconazole monotherapy to estimate the
contribution of dosage to clinical outcome.
RESULTS
Patients. A total of 43 patients (23 from Vietnam and 20 from Uganda) were
recruited over an 11-month period between January and November 2016. Twenty-two
patients (52%) were female. Patient characteristics (overall median [range]) were the
following: age, 33 years (20 to 73 years); weight, 48 kg (32 to 68 kg); body mass index
(BMI), 18 kg/m2 (12 to 25 kg/m2); creatinine at enrollment, 70 mol/liter (37 to 167
mol/liter); and estimated glomerular filtration rate (eGFR) using the Cockcroft-Gault
equation, 84.8 ml/min/1.73 m2 (35.4 to 146.7 ml/min/1.73 m2). The baseline creatinine
concentration was significantly lower in Vietnamese patients than in Ugandan patients
(median, 56 versus 79 mol/liter; P value, 0.02). However, this did not manifest as a
significant difference in eGFR due to different age, sex, and weight profiles between the
two patient populations. There were no statistically significant differences between
ethnic groups for other demographic variables. The demographic data are shown by
ethnicity and for the study population as a whole in Table 1.
Pharmacokinetic data. The final data set included 312 plasma observations and 52
CSF observations from the Vietnamese cohort. From the Ugandan cohort, the data set
included 196 plasma observations and 115 CSF observations. A single CSF observation
from one Ugandan patient was excluded because no fluconazole was detectable in an
isolated sample after 13 days of therapy. This was inconsistent with results from other
patients and could not be verified. The mean numbers of plasma samples and CSF
samples per patient were 11.8 and 3.9, respectively. Figure 1 shows the raw plasma and
CSF concentration-time profiles from study participants.
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Population pharmacokinetic analysis. The final mathematical model was a linear
model comprised of an absorption compartment, central compartment, peripheral
compartment, and CSF compartment. The fit of the final model to the clinical data was
acceptable. The mean parameter estimates better fitted the data than medians and
were used to calculate Bayesian estimates of drug exposure for each individual patient.
A linear regression of the observed-versus-predicted fluconazole concentrations in
plasma after the Bayesian step was given by the following calculation: observed
fluconazole concentration  1.03  predicted fluconazole concentration  0.27 (r2 
0.80). For the observed-versus-predicted fluconazole concentrations in CSF, the linear
regression was given by the following: observed fluconazole concentration  1.03 
predicted fluconazole concentration  0.07 (r2  0.81) (Fig. 2 and Table 2). The mean
weighted population bias values for fluconazole concentrations in plasma and CSF
were 0.20 and 0.30, respectively. The bias-adjusted population imprecision values in
plasma and CSF were 2.21 and 1.55, respectively. The population PK parameter esti-
mates for the final model are shown in Table 3.
Covariate investigation. Multivariate linear regression of each subject’s covariates
versus the Bayesian posterior parameter values revealed a weak relationship between
patient weight and estimated volume of distribution (slope, 0.22; 95% confidence
interval (CI) for the slope, 0.06 to 0.51; P value, 0.05). Incorporation of weight into the
PK model was therefore explored. However, values for log likelihood, Akaike informa-
tion criterion (AIC), and population bias and imprecision were comparable between the
two models. The simple base model was therefore used to describe the data and for the
TABLE 1 Patient demographics
Demographic or clinical characteristica
Value for the group
P valuegVietnam Uganda Combined
Sexb
No. of males 13 8 23
No. of females 10 12 20
Age (yr)c 0.75
Mean 38 33 35
Median 33 33 33
Range 20–73 24–50 20–73
Weight (kg)d 0.23
Mean 46 49 48
Median 45 49 48
Range 32–68 35–60 32–68
BMI (kg/m2)e 0.73
Mean 18 18 18
Median 18 18 18
Range 12–25 15–22 12–25
Creatinine (mol/liter)b 0.02
Mean 67 81 74
Median 56 79 70
Range 37–167 43–145 37–167
eGFR (ml/min/1.73 m2)f 0.10
Mean 88.3 80.7 84.7
Median 84.8 81.4 84.8
Range 35.4–136.1 49.8–146.7 35.4–146.7






gP value for difference between Vietnam and Uganda groups by Mann-Whitney test of significance.
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subsequent simulations. The model comparisons and the fit to data are summarized in
Table 2.
There was no relationship between the Bayesian estimates of clearance and volume
and the covariate of either ethnicity or sex in the base model. The mean (95% CI)
clearance was 0.74 liters/h (0.64 to 0.83 liters/h) and 0.71 liters/h (0.59 to 0.82 liters/h)
for Vietnamese and Ugandan patients, respectively (P  0.51). The mean (95% CI)
volume was 16.88 liters (14.33 to 19.44 liters) and 19.44 liters (16.88 to 22.0 liters) for
Vietnamese and Ugandan patients, respectively (P  0.16). In males, the mean (95% CI)
clearance was 0.79 liters/h (0.67 to 0.90 liters/h). In females, clearance was 0.66 liters/h
(0.57 to 0.75 liters/h) (P  0.09). In males, the mean (95% CI) volume was 18.07 liters
(15.47 to 20.67 liters). In females, the mean volume was 18.07 liters (15.41 to 20.73 liters)
(P  0.97).
Fluconazole penetration into the CSF. There was large variability in the AUCs
generated from each patient’s posterior estimates. The 38 patients who received 800
mg of fluconazole q24h had a median (interquartile range [IQR]) AUC from 144 to 168
h after treatment initiation (AUC144 –168) of 945.4 (799.2 to 1,139.8) mg · h/liter in plasma
(AUCplasma) and 784.2 mg · h/liter (615.9 to 879.4) in CSF (AUCCSF). From these posterior
estimates, the mean ratio of AUCCSF/AUCplasma was 0.82 (standard deviation, 0.22).
Monte Carlo simulation was used to estimate the distribution of drug exposure for
dosages of 400 mg, 800 mg, 1,200 mg, and 2,000 mg q24h of fluconazole (Fig. 3). PK
variability was marked, both in plasma and CSF. After administration of a dosage of
1,200 mg of fluconazole q24h, the median (IQR) simulated plasma AUC144 –168 was
1,143.2 (988.4 to 1,378.0) mg · h/liter and the CSF AUC144 –168 was 982.9 (781.0 to
1,185.9) mg · h/liter. The mean simulated ratio of AUCCSF/AUCplasma was 0.89 (SD, 0.44).
Probability of target attainment analysis. Monte Carlo simulation was used to
predict the probability of achieving a total drug AUC/MIC ratio of 389.3 in plasma.
This PD target was shown in a murine model of cryptococcal meningitis to be
associated with a stasis endpoint (i.e., no net change in fungal density at the end of the
experiment compared with that at treatment initiation) (11). Only 61% of simulated
FIG 1 Fluconazole concentrations in 43 patients. Black diamonds represent plasma concentrations. White triangles represent CSF
concentrations.
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patients receiving 1,200 mg of fluconazole q24h achieved this PD target when the MIC
for the infecting strain was 2.0 mg/liter. For MICs of 4.0 mg/liter, 1% of simulated
patients administered 1,200 mg q24h achieved the PD target (Fig. 4).
Meta-analysis of clinical outcome data. A systematic review identified 163 rele-
vant manuscripts, of which 11 were duplicates. After reviewing titles and abstracts, 28
studies were deemed potentially relevant for inclusion in the meta-analysis. Detailed
examination of these studies resulted in the ultimate inclusion of 12 papers describing
clinical outcomes from cryptococcal meningitis treated with fluconazole monotherapy.
In total, 28 patients in 1 study received 200 mg of fluconazole q24h (20), 19 patients in
2 studies received 400 mg of fluconazole q24h (7, 21), 97 patients in 3 studies received
800 mg q24h (22–24), 113 patients in 4 studies received 1,200 mg q24h (8, 23–25), and
1 study described outcomes of 16 patients on 1,600 mg (24) and 8 patients on 2 g of
fluconazole q24h (24). All included patients were HIV positive. Baseline characteristics
and reported clinical outcomes are presented in Table 4.
The final model suggests that the combination of dose and baseline fungal burden
explains the total heterogeneity in the estimated proportion of patients with sterile CSF
after 10 weeks of treatment (P value for residual heterogeneity, 0.64). However, there
FIG 2 Scatter plots showing observed-versus-predicted values for the chosen population pharmacokinetic model after the Bayesian step. (A) Population predicted
concentration of fluconazole in plasma. R2  0.49; intercept, 2.89 (95% CI, 0.51 to 5.27); slope, 0.89 (95% CI, 0.82 to 0.97). (B) Individual posterior predicted concentration
of fluconazole in plasma. R2  0.80; intercept, 0.27 (95% CI, 1.08 to 1.62); slope, 1.03 (95% CI, 0.98 to 1.07). (C) Population predicted concentration of fluconazole
in CSF. R2  0.46; intercept, 3.39 (95% CI, 0.09 to 6.87); slope, 1.03 (95% CI, 0.87 to 1.2). (D) Individual posterior predicted concentration of fluconazole in CSF. R2 
0.81; intercept, 0.07 (95% CI, 1.97 to 1.84); slope, 1.03 (95% CI, 0.95 to 1.10). Circles, dashed lines, and solid lines represent individual observed-predicted data points,
line of identity, and the linear regression of observed-predicted values, respectively. FLC, fluconazole; CI, confidence interval.
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was not a significant relationship between dose and CSF sterility at 8 to 10 weeks (P
value, 0.45). After adjustment for dose, the test for residual heterogeneity in both 2- and
10-week mortality was not significant (P values, 0.70 and 0.22, respectively), indicating
that dose alone adequately explained total heterogeneity in mortality outcomes at
both time points. For both 2- and 10-week mortality outcomes, there was a nonsig-
nificant trend toward reduced mortality with escalating dosage (Fig. 5).
DISCUSSION
Fluconazole is the only drug available for induction therapy for cryptococcal men-
ingitis in many regions of the world where the incidence of disease is highest. An
accumulating body of evidence suggests that fluconazole is a suboptimal agent for this
indication (26). While this has long been recognized, an explanation for the relatively
poor efficacy of fluconazole is absent. This study presents a uniquely comprehensive
clinical data set describing the PK of fluconazole. It provides robust estimates of CNS
penetration and the variability of those estimates. A high degree of CNS partitioning
has been observed in previous clinical studies with fluconazole (19, 27). Distribution
into the CNS is facilitated by low molecular weight, low protein binding, and moderate
lipophilicity (15, 28). Fluconazole has proven activity against Cryptococcus neoformans
(29, 30). This study provides a further understanding as to why, despite these attributes,
fluconazole is inferior to amphotericin B deoxycholate as an agent for induction
monotherapy for cryptococcal meningitis (6–8).
In contrast to previous studies of fluconazole PK (31–33), our data do not suggest a
TABLE 2 Evaluation of the predictive performance of the considered and final models
Model and measured






P valuedR2c Intercept Slope
Model 1
Plasma 2,451 4,928 0.20 2.21 0.80 0.27 1.03 0.56
CSF 0.30 1.55 0.81 0.07 1.03
Model 2
Plasma 2,413 4,854 0.36 2.38 0.80 0.01 1.03
CSF 0.41 1.81 0.80 0.89 1.01
aModel 1 did not include any covariates. Model 2 incorporated a function to scale the volume of distribution in central compartment to patient weight.
bAIC, Akaike information criterion.
cRelative to the regression line fitted for the observed-versus-predicted values after the Bayesian step.
dComparison of the joint distribution of population parameter values for each model.
TABLE 3 Population parameter estimates from the final 4-compartment pharmacokinetic
model
Parametera Mean Median SD
Ka (h1) 8.78 1.73 11.98
SCL/F (liters/h) 0.72 0.65 0.24
Vc/F (liters) 18.07 17.41 6.31
Kcp (h1) 12.20 8.36 11.17
Kpc (h1) 18.10 18.34 8.25
ICgut (mg) 34.67 49.99 22.74
ICcentral (mg) 35.86 49.98 19.67
ICCNS (mg) 31.06 49.96 23.47
ICperipheral (mg) 34.29 49.96 13.21
Kcs (h1) 35.43 42.55 13.74
Ksc (h1) 28.63 29.04 10.03
Vcns/F (liters) 32.07 30.49 17.60
aSCL, clearance; Vc, volume of distribution in central compartment; F, bioavailability; Kcp, first-order rate
constant from the central to peripheral compartment; Kpc, first-order rate constant from the peripheral to
central compartment; IC, initial condition in the respective compartment; Kcs, first-order rate constant from
the central to CNS compartment; Ksc, first-order rate constant from CNS to central compartment; Vcns,
volume of distribution in CNS compartment.
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significant relationship between fluconazole clearance and creatinine clearance nor
between patient weight and volume of distribution. The reason for this is not imme-
diately clear but may relate to the relatively narrow range of creatinine clearance in our
population and the fact that the vast majority of patients in our cohort had low body
weight, with the range of this covariate also being relatively narrow.
The PK model suggests that current regimens of fluconazole are inadequate for
induction therapy for cryptococcal meningitis. This has routinely been ascribed to the
FIG 3 AUC distributions in 5,000 simulated patients at escalating fluconazole dosages. Light gray bars indicate simulated plasma AUC144 –168. Dark
gray bars indicate simulated CSF AUC144 –168.
FIG 4 Probability of pharmacodynamic target attainment in plasma as a function of isolate MIC and
fluconazole dosage. Each line represents the proportion of 5,000 simulated patients that achieve the PD
target at the respective dosage (in milligrams) of fluconazole. The PD target was a plasma AUC/MIC ratio
of 389.3. Bars show the proportion of WT strains of C. neoformans at the indicated MIC.
Plasma and CSF Pharmacokinetics of Fluconazole Antimicrobial Agents and Chemotherapy
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overly simplistic notion that fluconazole is a fungistatic agent. Our analyses provide
further insight into the limitations of this drug. Previous estimates of fluconazole
CNS/plasma partition ratios have ranged from 0.52 to 1.33 (18, 19, 27, 34). We have
extended these estimates by rigorously quantifying the marked variability in the CSF
PK. This variability has consequences at both microbiological and clinical levels. Sub-
optimal exposure of fluconazole promotes the expansion of intrinsically resistant
cryptococcal subpopulations present at the initiation of therapy (35). In addition, the
evolution of C. neoformans during therapy to become increasingly triazole resistant has
FIG 5 Meta-analysis of clinical trials of fluconazole monotherapy showing dose-adjusted effects on
2-week mortality (A) and 10-week mortality (B). Right-hand columns provide observed and estimated
proportions of patients dead at the indicated time.
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been demonstrated in clinical studies (36, 37). To be clinically effective, adequate
concentrations of drug must be present at the site of infection for long enough to exert
an antimicrobial effect on both susceptible and resistant subpopulations. The present
analysis demonstrates the challenges in achieving that aim.
At the recommended fluconazole dosage of 1,200 mg q24h, the probability of PD
target attainment (PTA) bisects the MIC distribution for wild-type (WT) C. neoformans
isolates. This is consistent with the findings of Sudan et al. (11). Approximately half of
patients will fail therapy because they are not able to generate the drug exposure
required to prevent progressive fungal growth. Since clinical PK-PD targets are not
available for fluconazole in cryptococcal meningitis, we have used a target derived from
a murine study (11). This assumes that CNS partitioning is the same in mice and
humans. The cerebrum/plasma AUC ratio in the murine study was 46.9% (11). It is
conceivable that this is in keeping with our CSF/plasma AUC ratio of 82% though clearly
it would be preferable to have clinical PK-PD targets defined. Nevertheless, our PTA
analysis is supported by the 53% 10-week mortality outcomes for patients receiving
1,200 mg of fluconazole q24h, estimated in the meta-analysis. Importantly, such PTA
analyses are based on an AUC/MIC of 389.3, which is more than an order of magnitude
greater than the AUC/MIC ratio required for Candida albicans (12).
Progressive escalation of the dosage of fluconazole is not likely to be an effective
strategy for improving cryptococcal meningitis induction therapy. The drug expo-
sure required to reliably treat isolates with MICs of 4.0 mg/liter is difficult to
achieve and potentially toxic. Our meta-analysis suggests that escalating dosages of
fluconazole do not increase the proportion of patients with sterile CSF at 10 weeks.
Dosages of 2,000 mg q24h do not appear to significantly improve 10-week mortality
outcomes in comparison to a dose of 1,200 mg q24h. The AIDS Clinical Trials Group
(ACTG) study (https://clinicaltrials.gov/show/NCT00885703) is investigating the use of
higher dosages of fluconazole (1,600 mg and 2,000 mg q24h) for the treatment of
cryptococcal meningitis in HIV-infected individuals, and results are pending. The addition of
flucytosine to high-dose fluconazole (1,200 mg q24h) for cryptococcal meningitis in-
creases antifungal activity and improves mortality outcomes (8, 24), suggesting that com-
bination therapy is required to optimize antifungal activity in fluconazole-containing reg-
imens.
In summary, this study provides part of the pharmacodynamic rationale for the
long-recognized fact that fluconazole monotherapy is an ineffective induction
regimen for cryptococcal meningitis. We have developed a fluconazole population
PK model that suggests that approximately half of patients with cryptococcal
meningitis caused by WT strains of C. neoformans will be undertreated by currently
recommended dosages of fluconazole for induction therapy. In doing so, we have
addressed a knowledge gap regarding the reason for the inferiority of this drug for
cryptococcal meningitis. There is a pressing need for improved provision of afford-
able combination treatments and development of more effective drugs.
MATERIALS AND METHODS
Clinical pharmacokinetic studies. Patients from whom plasma and CSF samples were obtained for
this PK study have been described previously (38). Briefly, adult patients (n  3) were initially recruited
from a multicenter randomized controlled trial of adjuvant dexamethasone in HIV-associated cryptococ-
cal meningitis. The trial is reported elsewhere (International Standard Registered Clinical Number
59144167) (38). Following the early cessation of this trial, patients were recruited from a prospective
descriptive study at the same sites (n  40). Study sites were The Hospital for Tropical Diseases in Ho Chi
Minh City, Vietnam, and Masaka General Hospital, Uganda. The study protocols were approved by the
relevant institutional review boards and regulatory authorities at each trial site and by the Oxford
University Tropical Research Ethics Committee.
Fluconazole was administered orally. In cases where the conscious level of the patient did not enable
oral administration, fluconazole was administered via nasogastric tube. The majority of patients received
800 mg of fluconazole q24h. Two patients received one-off doses of 400 mg q24h. Two received one-off
doses of 600 mg q24h. One patient’s regimen of 800 mg of fluconazole q24h was escalated to 1,200 mg
q24h for 6 days from day 8 of treatment. All patients received combination therapy with amphotericin
B deoxycholate at 1 mg per kg infused over 5 to 6 h.
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Measurement of fluconazole concentrations. Fluconazole concentrations were measured using a
validated liquid chromatography-tandem mass spectrometry (LC-MS/MS) methodology (1260 Agilent
UPLC [ultra-performance liquid chromatograph] coupled to an Agilent 6420 Triple Quad mass spectrom-
eter; Agilent Technologies UK, Ltd., Cheshire, United Kingdom). Briefly, fluconazole was extracted by
protein precipitation; 300 l of cold methanol containing the internal standard fluconazole-D4 at 0.625
mg/liter (TRC, Canada) was added to 10 l of sample (plasma or CSF). The solution was vortex mixed for
5 s and filtered through a Sirocco precipitation plate (Waters, Ltd., Cheshire, United Kingdom). Super-
natant (150 l) was transferred to a 96-well auto sampler plate, and 3 l was injected on an Agilent
Zorbax C18 Rapid Resolution High Definition (RRHD) column (2.1 by 50 mm; particle size, 1.8 m) (Agilent
Technologies UK, Ltd., Cheshire, United Kingdom).
Chromatographic separation was achieved using a gradient consisting of 70% A/30% B (0.1% formic
acid in water as mobile phase A and 0.1% formic acid in methanol as mobile phase B). The organic phase
was increased to 100% over 90 s, with an additional 90 s of equilibration.
The mass spectrometer was operated in multiple-reaction-monitoring scan mode in positive polarity.
The precursor ions were 307.11 m/z and 311.1 m/z for fluconazole and the internal standard, respectively.
The product ions for fluconazole were 220.1 m/z and 238.1 m/z; for the internal standard the product ions
were 223.2 m/z and 242.1 m/z. The source parameters were set as follows: capillary voltage, 4,000 V; gas
temperature, 300°C; and nebulizer gas, 15 lb/in2.
The standard curve for fluconazole encompassed the concentration range of 1 to 120 mg/liter and
was constructed using blank matrix. The limit of quantitation was 1 mg/liter. In plasma, the intraday
coefficient of variation (CV) was 3.4%, and the interday CV was 6.7% over the concentration range of
1 to 90 mg/liter. In CSF, the intraday CV was 5.2%, and the interday CV was 5.3% over the same
concentration range.
Population pharmacokinetic modeling. The concentration-time data for fluconazole in plasma and
CSF were analyzed using the nonparametric adaptive grid (NPAG) algorithm of the program Pmetrics
(39), version 1.5.0, for the R statistical package, version 3.1.1. The initial PK mathematical model fitted to
the data contained four compartments and took the following form:
dX(1)
dt
 Ka  X(1) (1)
dX(2)
dt
 Ka  X(1)  Kcp  Kcs  SCLV   X(2)  Ksc  X(3)  Kpc  X(4) (2)
dX(3)
dt
 Kcs  X(2)  Ksc  X(3) (3)
dX(4)
dt
 Kcp  X(2)  Kpc  X(4) (4)
Y(1)  X(2) ⁄ V (5)
Y(2)  X(3) ⁄ Vcns (6)
where equations 1, 2, 3, and 4 describe the rate of change in amount of drug in milligrams in the gut,
central, CSF, and peripheral compartments, respectively. Ka is the absorption rate constant from the gut
to the central compartment. X(1), X(2), X(3), and X(4) are the amounts of fluconazole (in milligrams) in the
gut, central (c), CSF (s) and peripheral compartments (p), respectively. Kcp, Kpc, Kcs, and Ksc represent
first-order transfer constants connecting the various compartments. SCL is the first-order clearance of
drug (liters/hour) from the central compartment. V is the volume of the central compartment. The CSF
compartment [X(3)] has an apparent CSF volume (Vcns), given in liters. Equations 5 and 6 are the output
equations describing fluconazole levels in the central and CSF compartments, respectively. The output
in each compartment is denoted Y.
Model error was attributed separately to process noise (including errors in sampling times or dosing)
and assay variance. Process noise was modeled using lambda, an additive error term. The data were
weighted by the inverse of the estimated assay variance.
The data for some patients indicated that they had taken fluconazole at an undocumented time prior
to study enrollment since there was detectable drug in the first PK sample. To accommodate this,
nonzero initial conditions of all four compartments were estimated in the structural model. A switch was
coded whereby the parameterized estimate of each initial condition was multiplied by a binary covariate
equal to 1 when fluconazole was detected in the first PK sample or by 0 when no fluconazole was
detected in the first PK sample.
Population pharmacokinetic covariate screening. The impacts of patient weight, BMI, sex, eth-
nicity, and baseline eGFR on the PK of fluconazole were investigated. Bidirectional stepwise multivariate
linear regression was employed to assess the relationship between each covariate and the Bayesian
estimates for volume of distribution and clearance from the central compartment from the standard
population PK model. Covariates that were retained with significant multivariate P values (0.05) in the
regression model were explored individually. The relationship between retained continuous covariates
and Bayesian estimates of PK parameters was explored using univariate linear regression. The difference
between Bayesian estimates of volume and clearance according to categorical covariates (sex and
ethnicity) was compared using a Mann-Whitney test.
Population pharmacokinetic model diagnostics. The fit of the model to the data was assessed by
visual inspection of diagnostic scatterplots displaying observed-versus-predicted values before and after
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the Bayesian step. Linear regression was performed, and the coefficient of determination, intercept, and
regression slope were noted for each model. In addition, the log-likelihood value, Akaike information
criterion (AIC), mean weighted error (a measure of bias), and bias-adjusted, mean weighted squared error
(a measure of precision) were calculated and compared for each model.
Monte Carlo simulation and calculation of probability of target attainment. Monte Carlo
simulation (n  5,000) was performed in Pmetrics (39). The support points from the final joint density
were used. For the simulations, the initial conditions of all compartments were defaulted to zero.
Fluconazole was administered at a range of dosages: 400 mg q24h, 800 mg q24h, 1,200 mg q24h, and
2,000 mg q24h. The plasma and CSF AUC values for fluconazole were calculated using trapezoidal
approximation after the sixth dose, from 144 to 168 h after treatment initiation.
Wild-type fluconazole MIC data were obtained from a previously published collection of 5,733 C.
neoformans isolates estimated using Clinical and Laboratory Standards Institute (CLSI) methodology (40).
The modal MIC was 4 mg/liter (1,629 of 5,733 strains; 28%). Almost half of strains had MICs of 4 mg/liter
(2,834 of 5,733 strains; 49%). The epidemiological cutoff value for C. neoformans versus fluconazole was
8 mg/liter. This collection of strains included molecular types VNI to VNIV, and the patterns of MIC
distribution were comparable across all molecular types (40). The proportion of simulated patients that
would achieve a previously published plasma AUC/MIC target of 389.3 was determined. This target was
defined as the magnitude of drug exposure required for fungal stasis (defined as prevention of
progressive fungal growth) in a murine study that employed CLSI methodology (11). To our knowledge,
no CSF PK/PD target has been defined in preclinical or clinical studies of fluconazole for cryptococcal
meningitis. In the present study, the probability of attaining this plasma PK/PD target was examined at
each simulated fluconazole dose.
Meta-analysis of clinical outcome data. The AUC/MIC target used in the probability of target
attainment analysis was derived from murine studies. To enhance clinical relevance, we sought PD data
from humans. The PD data from patients in the present PK study are confounded by the coadministration
of amphotericin B deoxycholate. For this reason, a search for clinical trials of fluconazole monotherapy
for cryptococcal meningitis was performed. The electronic databases Pubmed and Medline were
searched on 31 January 2018 using the terms “fluconazole” and “cryptococcal meningitis.” Preclinical
studies and case reports were excluded. To reduce potential heterogeneity, only studies of HIV-positive
participants were included in the meta-analysis. Baseline variables were chosen a priori for extraction
from the studies if they had previously been determined to have a significant impact on clinical outcome.
These were mental status, CSF fungal burden, and patient age (6, 41). Where it was not reported, baseline
CSF fungal burden was extrapolated from CSF cryptococcal antigen titer according to a correlation
published by Jarvis et al. (6).
For consistency with the literature, we collected data on clinical outcomes commonly presented in
cryptococcal meningitis trials: CSF sterility at 8 to 10 weeks, 2-week mortality, and 10-week mortality.
Mixed-effects meta-analysis adjusted for fluconazole dosage was performed. Fungal burden in CSF, CD4
count, and proportion of patients with reduced Glasgow coma score (GCS) at baseline were explored to
assess the degree to which these modifiers accounted for interstudy heterogeneity in clinical outcome.
The mixed-effects model took the form: 	i  
0  
1Zi1  . . .  
1Zij  ui, where 	i is the corresponding
(unknown) true effect of the ith study, Zij is the value of the jth moderator variable for the ith study with
corresponding model coefficients 
, and ui are study-specific random effects such that ui  N(0,2). Here,
N indicates that the random effects are normally distributed, 0 is the mean of the random effects, and
2 denotes the amount of residual heterogeneity, estimated using the DerSimonian-Laird estimator (42).
Additional model parameters were estimated via weighted least squares with weights relative to the
estimated 2. The null hypothesis H0:2  0 was tested using Cochran’s Q-test, and model parameters were
tested with the Wald-type test statistic.
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ABSTRACT There is a limited understanding of the population pharmacokinetics
(PK) and pharmacodynamics (PD) of amphotericin B deoxycholate (DAmB) for cryp-
tococcal meningitis. A PK study was conducted in n  42 patients receiving DAmB
(1 mg/kg of body weight every 24 h [q24h]). A 2-compartment PK model was devel-
oped. Patient weight influenced clearance and volume in the final structural model.
Monte Carlo simulations estimated drug exposure associated with various DAmB
dosages. A search was conducted for trials reporting outcomes of treatment of cryp-
tococcal meningitis patients with DAmB monotherapy, and a meta-analysis was per-
formed. The PK parameter means (standard deviations) were as follows: clearance,
0.03 (0.01)  weight  0.67 (0.01) liters/h; volume, 0.82 (0.80)  weight  1.76
(1.29) liters; first-order rate constant from central compartment to peripheral com-
partment, 5.36 (6.67) h1; first-order rate constant from peripheral compartment to
central compartment, 9.92 (12.27) h1. The meta-analysis suggested that the DAmB
dosage explained most of the heterogeneity in cerebrospinal fluid (CSF) sterility out-
comes but not in mortality outcomes. Simulations of values corresponding to the
area under concentration-time curve from h 144 to h 168 (AUC144 –168) resulted in
median (interquartile range) values of 5.83 mg · h/liter (4.66 to 8.55), 10.16 mg · h/li-
ter (8.07 to 14.55), and 14.51 mg · h/liter (11.48 to 20.42) with dosages of 0.4, 0.7,
and 1.0 mg/kg q24h, respectively. DAmB PK is described adequately by a linear
model that incorporates weight with clearance and volume. Interpatient PK variabil-
ity is modest and unlikely to be responsible for variability in clinical outcomes. There
is discordance between the impact that drug exposure has on CSF sterility and its
impact on mortality outcomes, which may be due to cerebral pathology not re-
flected in CSF fungal burden, in addition to clinical variables.
KEYWORDS cryptococcal meningitis, pharmacokinetics, pharmacodynamics,
amphotericin B deoxycholate, meta-analysis, population pharmacokinetics
Cryptococcal meningitis is a leading infectious cause of morbidity and mortalityworldwide, with approximately 223,100 incident cases and 181,100 deaths annually
(1). The 10-week mortality rate for patients receiving the current standard of care is 24%
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to 31% (2–5). There have been no new antifungal agents developed for use in
low-to-middle-income countries in the last 3 decades. Given the paucity of new agents,
one important strategy for improving clinical outcomes is a better understanding and
use of currently available compounds.
Amphotericin B (AmB) is a polyene antifungal agent with broad-spectrum activity
against yeasts and molds, as well as against some parasites. AmB was initially isolated
from a streptomycete and was originally described in 1955 (6). AmB was the first
therapeutic option for treatment of lethal invasive fungal diseases such as cryptococcal
meningitis (7, 8). Amphotericin B deoxycholate (DAmB) is the most potent formulation
of AmB on a milligram-to-milligram basis (9, 10) and is a mainstay for the treatment of
cryptococcal meningitis.
Clinical studies have progressively examined escalating dosages of 0.4 mg/kg of
body weight every 24 h (q24h) (11, 12), 0.7 mg/kg q24h (13–15), and 1.0 mg/kg q24h
(5) of DAmB for cryptococcal meningitis. The primary motivation of these studies was
identification of the dosage that induces maximal antifungal activity. A regimen of 1.0
mg/kg q24h in combination with 5FC (flucytosine) for 1 week is currently recom-
mended for induction therapy (16). High DAmB dosages are associated with increased
rates of cerebrospinal fluid (CSF) sterilization (2) and improved mortality (4, 5, 17).
However, the broad clinical utility of DAmB is compromised by dose-limiting toxicities
that include infusional reactions, phlebitis, nephrotoxicity, and anemia (18, 19). A
detailed understanding of the therapeutic index for each DAmB dosage level is lacking.
Here, we describe the development of a population pharmacokinetic model of
DAmB. In addition, a meta-analysis of clinical trials of DAmB monotherapy was
performed to estimate the contribution of various DAmB dosages to the observed
heterogeneity in study outcomes. Finally, Monte Carlo simulations were performed
to estimate the mean, median, and dispersion values corresponding to drug
exposures that are associated with microbiological and clinical outcomes of DAmB
monotherapy.
RESULTS
Demographics. A total of 42 patients (22 from Vietnam and 20 from Uganda) were
recruited over an 11-month period between January and November 2016. A total of 22
(52%) of the patients were female. The overall median (range) age was 33 years (20 to
73 years), the overall median weight was 48 kg (32 to 68 kg), the overall median body
mass index was 18 kg/m2 (12 to 25 kg/m2), the overall median level of creatinine at
enrollment was 69 mol/liter (37 to 167 mol/liter), and the overall median estimated
glomerular filtration rate (determined using the Cockcroft-Gault equation) was 76.7
ml/min/1.73 m2 (35.4 to 146.7 ml/min/1.73 m2). The demographic data are shown by
ethnicity and overall in Table 1. There were no statistically significant differences
between ethnic groups in any demographic variable.
Pharmacokinetic data. The final data set included 282 of 312 total observations
from the Vietnamese cohort and 197 of 241 total observations from the Ugandan
cohort (mean, 11.4 samples per patient; range, 6 to 18). In total, 74 plasma samples
were excluded because of absent information regarding the time that the pharmaco-
kinetic (PK) samples were drawn. Figure 1 shows the raw plasma concentration-time
profiles from study participants.
Population pharmacokinetic models. Initial exploration of structural models re-
vealed that a two-compartment model fitted the data better than a three-compartment
model. Specifically, the three-compartment structural model resulted in a more nega-
tive log likelihood value (55.5 versus 42.8) and a higher Akaike information criterion
(AIC) value (127.3 versus 101.9). Accordingly, subsequent model development was
based on a two-compartment base model.
Model 1 was a standard two-compartment model without inclusion of covariates.
Linear regressions of the Bayesian estimates of clearance and volume (derived from the
mean population PK parameter values from model 1) with weight and estimated
glomerular filtration rate (eGFR) as covariates are presented in Fig. 2a and b, respec-
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tively. A relationship was apparent between patient weight and both estimated clear-
ance (slope, 0.05; 95% confidence interval [CI] for estimate of slope, 0.02 to 0.08; P 
0.002) and estimated volume of the central compartment (slope, 1.08; 95% CI, 0.05 to
2.11; P  0.001). Similarly, linear regression data showed a positive relationship




P value for difference
between Vietnam
and Uganda dataVietnam Uganda Combined
Sexb (no. of males:no. of females) 12:10 8:12 20:22
Age (yrs)c
Mean 38 33 36 0.75g
Median 33 33 33
Range 20–73 24–50 20–73
Weight (kg)d
Mean 47 49 48 0.21g
Median 46 49 48
Range 32–68 35–60 32–68
BMI (kg/m2)e
Mean 18 18 18 0.73h
Median 18 19 18
Range 12–25 15–22 12–25
Creatinine (mol/liter)b
Mean 71 81 75 0.06g
Median 62 79 69
Range 37–167 43–145 37–167
eGFR (ml/min/1.73 m2)f
Mean 90.6 79.3 84.7 0.19g
Median 89.8 73.5 76.7
Range 35.4–136.1 49.8–146.7 35.4–146.7






gMann-Whitney test of significance.
hUnpaired t test of significance.
FIG 1 Amphotericin B serum concentrations in 42 patients. Patients received 1.0 mg/kg of amphotericin
B deoxycholate (DAmB), infused over 5 to 6 h.
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between eGFR and estimated clearance (slope of linear regression, 0.01; 95% CI for the
slope, 0 to 0.02; P  0.05) and volume (slope, 0.67; 95% CI, 0.36 to 0.98; P  0.001).
These covariates were incorporated into the structural model as follows: model 2
incorporated weight as a covariate with a linear term for clearance; model 3 incorpo-
rated weight as a covariate with a nonlinear term for clearance; and model 4 incorpo-
rated both weight and baseline renal function as covariates in the structural model,
with linear clearance. Population PK parameter estimates for all 4 models are shown in
Table 2. There were no statistically significant differences in the estimated clearance
and volume data from the standard model (model 1) according to ethnicity. The mean
(95% CI) values for clearance were 2.03 liters/h (1.69 to 2.38) and 2.24 liters/h (1.91 to
2.56) for Vietnamese and Ugandan patients, respectively (P value, 0.37). The mean (95%
CI) volumes were 33.55 liters (17.96 to 49.13) and 63.93 liters (40.98 to 86.88) for
Vietnamese and Ugandan patients, respectively (P value, 0.09).
The fit of the model to the data was acceptable for all 4 two-compartment models.
The model diagnostics are presented in Table 3. The values corresponding to the
coefficient of determination of a linear regression of observed-versus-predicted plots
after the Bayesian step were 0.72, 0.74, 0.69, and 0.73 for models 1, 2, 3, and 4,
respectively. The values for intercept and slope approximated 0 and 1, respectively, for
each regression (Table 3). The mean parameter values predicted the observed values
better than the medians. The measures of population bias and imprecision were
comparable between the models, with bias values of 0.85, 0.34, 0.23, and 0.43
and imprecision values of 3.13, 2.97, 2.16, and 3.29 for models 1, 2, 3, and 4, respec-
tively. The more positive log likelihood value and lower Akaike information criterion
(AIC) value for model 2 suggested that the inclusion of weight as a covariate explained
a portion of the observed variance.
The model that incorporated an exponential term for clearance (model 3) decreased
the log likelihood value and increased the AIC value (Table 3). The inclusion of eGFR in
FIG 2 Linear regression of the relationship between (a) patient weight and (b) estimated glomerular filtration rate and Bayesian
posterior estimates for clearance and volume of distribution. Circles are Bayesian estimates from each patient. Solid line: linear
regression. (a) (Left panel) R2  0.32. Clearance  0.05 · weight  0.2. (Right panel) R2  0.12. Volume  1.08 · weight  24.8. (b)
(Left panel) R2  0.17. Clearance  0.01 · eGFR  1.03. (Right panel) R2  0.36. Volume  0.67 · eGFR  31.13.
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model 4 failed to increase the log likelihood value or reduce the AIC value further. In
addition, there was no statistically significant difference between model 1 and either
model 3 or model 4; the latter models were therefore rejected. Model 2 was chosen as
the final model. Observed-versus-predicted plots for the population and Bayesian
posterior values in the final model are shown in Fig. 3. Figure 4 shows a visual predictive
check (VPC) of the final model.
Meta-analysis of clinical outcome data. Five clinical trials that included a DAmB
monotherapy arm were identified. There was one trial in which 63 patients received 0.4
mg/kg of body weight q24h (11), 3 trials in which a combined total of 208 patients
received 0.7 mg/kg q24h (13–15), and 1 trial in which 99 patients received 1.0 mg/kg






SCL (liters/h) 2.19 2.46 0.77
Vc (liters) 27.77 13.88 28.06
K12 (h1) 3.84 2.16 6.57
K21 (h1) 1.14 0.32 3.06
Model 2
SCLslope (liters/h/kg) 0.03 0.03 0.01
SCLintercept (liters/h) 0.67 0.57 0.01
Vcslope (liters/kg) 0.82 0.36 0.80
Vcintercept (liters) 1.76 1.99 1.29
K12 (h1) 5.36 3.83 6.76
K21 (h1) 9.92 0.46 12.27
Model 3
SCL (liters/h/kg) 0.12 0.12 0.04
Vc (liters/kg) 1.40 0.51 1.75
K12 (h1) 1.69 0.50 4.09
K21 (h1) 8.31 0.27 12.32
Model 4
SCLslope (liters/h/kg) 0.01 0.01 0.01
SCLintercept (liters/h) 1.50 1.31 0.74
Vcslope (liters/kg) 1.26 0.52 1.39
Vcintercept (liters) 1.64 0.01 2.96
K12 (h1) 3.86 0.73 7.74
K21 (h1) 11.24 0.40 13.44
aSCL, first-order clearance of drug (in liters per hour) from the central compartment; Vc, volume of
distribution in the central compartment; K12, first-order rate constant from the central compartment to the
peripheral compartment; K21, first-order rate constant from the peripheral compartment to the central
compartment.















Model 1 56.3 1,137 124.8 0.85 3.13 0.72 0.08 0.97
Model 2 42.8 1,251 101.9 0.34 2.97 0.74 0.01 1.01
Model 3 102.7 577 221.7 0.23 2.16 0.69 0.00 1.04
Model 4 43.1 1,704 102.7 0.43 3.29 0.73 0.01 1.02
aModel 2 included a linear function to scale DAmB clearance to patient weight. Model 3 included a
nonlinear function to scale DAmB clearance to patient weight. Model 4 included a function to scale DAmB
clearance to patient weight and eGFR.
bR2 values are expressed relative to the regression line fitted for the observed versus predicted values after
the Bayesian step.
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q24h (5). An additional study that reported clinical outcomes in untreated cryptococcal
meningitis patients was also included. The baseline variables and clinical outcomes of
these study arms are summarized in Table 4. Due to the small number of studies, we
were unable to adjust for baseline variables that may have had an impact on outcome
FIG 3 Scatter plots showing observed versus predicted values for the chosen population pharmacokinetic model after the Bayesian step
(model 2). (Left panel) R2  0.17. Intercept  0.18 (95% CI, 0.03 to 0.32). Slope  0.89 (95% CI, 0.70 to 1.09). (Right panel) R2 0.74. Inter-
cept  0.01 (95% CI, 0.04 to 0.07). Slope  1.01 (95% CI, 0.95 to 1.07). Circles, dashed lines, and solid lines represent individual
observed-predicted data points, the line of identity, and the linear regression of observed and predicted values, respectively. All observed
and predicted amphotericin B concentrations (conc) are indicated in milligrams per liter. AmB, amphotericin B; CI, confidence interval.
FIG 4 Visual predictive check of the final model. The black circles indicate observed DAmB concentrations. The continuous lines represent
the 5th, 50th, and 95th percentiles of DAmB concentrations for 1,000 simulated patients. In total, 83.4% of observed DAmB concentrations
fall within the 5th and 95th percentiles estimated by the final model, indicating adequate model fit.
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measures (e.g., age, CD4 cell count, baseline level of consciousness, baseline fungal
burden, and baseline cryptococcal antigenemia). The forest plots of the dose-adjusted
random-effects model are shown in Fig. 5. The model suggests that dose adjustment
accounted for 77% of the heterogeneity in CSF sterility (P  0.007) but that it did not
have a significant impact on the heterogeneity in either the 2-week mortality outcomes
(33%, P  0.14) or the 10-week mortality outcomes (45%, P  0.07).
Monte Carlo simulations. Monte Carlo simulations (n  5,000) were performed
using the final population PK model. This enabled exploration of the consequences
of the population PK variability, quantified in the final model, on plasma DAmB
concentrations in a simulated population receiving the dosage regimens for which
clinical trial outcome data were available. The median (interquartile range) area
under the concentration-time curve from h 144 to h 168 (AUC144 –168) was 5.83
mg/liter · h (4.66 to 8.55 mg/liter · h) for patients receiving DAmB 0.4 mg/kg q24h,
10.16 mg/liter · h (8.07 to 14.55 mg/liter · h) for 0.7 mg/kg q24h, and 14.51 mg/liter · h (11.48
to 20.42 mg/liter · h) for 1.0 mg/kg q24h. The AUC144–168 distributions from the simulations
are shown in Fig. 6.
DISCUSSION
We conducted a PK study in HIV-positive adults with cryptococcal meningitis in
regions of high disease burden and developed a population PK model that enabled the
extent of interpatient variability to be quantified. We described the PK of DAmB using
a 2-compartment PK model with intravenous (i.v.) infusion and first-order clearance of
drug from the central compartment. Simulated AUC values revealed relatively modest
PK variability, suggesting that the frequently poor clinical outcomes are not the result
of significant PK variability. The relationship between weight and drug clearance
suggests that weight accounts for a portion of the observed variance. Dosage adjust-
ment on the basis of weight is necessary to ensure that lighter patients are not
overdosed and heavier patients are not underdosed. However, the lack of impact of
either eGFR or ethnicity on the PK data suggests that dosage adjustment for these
variables is not necessary to achieve comparable levels of drug exposure across patient
populations.
The model-simulated median AUC value of 10.17 mg · h/liter following a regimen of
0.7 mg/kg of body weight q24h is consistent with AUC values estimated using
FIG 5 Meta-analysis of clinical trials of DAmB monotherapy, showing dose-adjusted effects on CSF sterility (left panel), mortality at 2 weeks (middle panel), and
mortality at 10 weeks (right panel). (Left panel) Tau value for unadjusted model: 4.22. Tau value for dose-adjusted model: 0.98. Dose adjustment accounts for (4.22 
0.98)/4.22  77% of the heterogeneity in clinical outcomes. P value for dose adjustment, 0.007. (Middle panel) Tau value for unadjusted model: 1.90. Tau value for
dose-adjusted model: 1.28. Dose adjustment accounts for (1.90  1.28)/1.90  33% of the heterogeneity in clinical outcomes. P value for dose adjustment, 0.14. (Right
panel) Tau value for unadjusted model: 9.0. Tau value for dose-adjusted model: 4.93. Dose adjustment accounts for (9.00  4.93)/9.00  45% of heterogeneity in clinical
outcomes. P value for dose adjustment, 0.07. RE, random effects. Day et al., reference 5; Saag et al., reference 11; Leenders et al., reference 13; van der Horst et al.,
reference 14; Brouwer et al., reference 15; Mwaba et al., reference 20.
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noncompartmental techniques. For example, Bekersky et al. calculated an AUC0 –24
value of 13.9 	 2 mg · h/liter after administration of 0.6 mg/kg i.v. in healthy volunteers
(21). However, the simulations performed following administration of 1 mg/kg resulted
in a median AUC value of 14.51 mg · h/liter, which is considerably lower than that
derived from a noncompartmental analysis (NCA) conducted by Ayestarán et al. for the
same dose administered to neutropenic patients (28.98 	 15.46 mg · h/liter) (22). The
reason for this is not immediately clear but may relate to physiological differences
between these two critically unwell patient cohorts (23).
Our meta-analysis of clinical outcomes of studies of DAmB monotherapy is limited
by the fact that the included studies recorded CSF sterility at diverse time points
ranging from 2 weeks (14) to 10 weeks (11). Nevertheless, the meta-analysis suggests
that the dosage of DAmB has a significant impact on the proportion of patients with
sterile CSF and that achieving CSF sterility is dose dependent up to 1 mg/kg q24h.
However, the DAmB data did not have a dose-dependent relationship with mortality
rates at either 2 or 10 weeks.
The potential reasons that DAmB dosage had a positive impact on CSF sterilization
but not on mortality are as follows. First, AmB toxicity may contribute to mortality (18,
19). Nephrotoxicity is dose dependent and likely multifactorial. It is associated with a
4.5 increase in the odds of mortality from cryptococcal meningitis at 10 weeks (18).
Free drug interacts with the distal tubules of the nephron causing increased monova-
lent ion delivery, with consequent afferent arteriolar constriction (24). Direct tubular
toxicity results in hypokalemia and hypomagnesemia, leading to cardiotoxicity (24, 25).
Conversely, rapid infusion of AmB can result in an extracellular shift of potassium,
causing hyperkalemia and cardiac dysrhythmias (26). Anemia occurs in up to 75% of
patients treated with DAmB as a result of direct suppression of erythropoiesis (24).
Severe anemia more than doubles the odds of 10-week mortality from cryptococcal
meningitis (18). Second, mortality may be driven by factors not directly resulting from
either disease or treatment. For example, nosocomial bacteremia may occur in up to
15% to 18% of patients hospitalized for cryptococcal meningitis (27). Third, fungal
burden—and therefore, conceivably, time to CSF sterility—is just one of multiple
clinical variables associated with mortality in cryptococcal meningitis. Older age, altered
mental status, low body weight, high peripheral white blood cell count, and anemia are
independently associated with mortality at either 2 or 10 weeks (4). Immune reconsti-
tution inflammatory syndrome (IRIS) remains a significant cause of mortality, occurring
in 3% to 49% of cryptococcal meningitis patients who survive to initiation of antiret-
roviral treatment and carrying a mortality rate of up to 36% (17, 28). Raised intracranial
FIG 6 AUC distributions based on Monte Carlo simulations. Simulated dosing regimens are 0.4, 0.7, and 1.0 mg/kg q24h. Medians, 25th percentiles (P25), and
75th percentiles (P75) are displayed on each histogram.
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pressure is an additional factor associated with mortality, and treatment incorporating
at least 1 therapeutic lumbar puncture imparts a relative survival advantage of 69% in
the first 10 days of treatment (29). Finally, the trial cohorts included in the meta-analysis
were from diverse sites in Africa, Asia, Europe, and the United States. Factors such as
health-seeking behavior and nutritional status may have influenced the mortality
outcomes. Our meta-analysis did not include any baseline factors other than DAmB
dosage, and we are therefore unable to determine whether they account for the
heterogeneity in mortality that is not explained by DAmB dosage.
The discordance between the influence that drug dosage has on CSF sterilization
and mortality is reflective of a growing consensus that CSF sterility is just one of many
determinants of mortality in cryptococcal meningitis. A systematic review of 27 clinical
trials determined that there was no correlation between CSF sterility at 2 weeks and
all-cause mortality at either 2 or 10 weeks (30). The most biologically plausible expla-
nation for this is that fungal burden in the CSF may not reflect the extensive enceph-
alitis that is characteristic of cryptococcal meningitis (which is more accurately termed
“meningoencephalitis”). Histopathological defects are more marked in patients coin-
fected with HIV; fungi accumulate in perivascular spaces, are deposited [predominantly
extracellularly] in brain parenchyma, and form granulomatous cryptococcomas in brain
tissue (31, 32). It is conceivable that brain parenchymal damage is a dominant deter-
minant of mortality and that clearance of fungi in CSF is not mirrored by clearance in
the cerebrum and other CNS subcompartments. CSF sterility is an imperfect surrogate
for the extent to which drug has penetrated into and sterilized the central nervous
system.
The meta-analysis suggests a strong dose exposure-response relationship. Higher
dosages are likely to be required to achieve efficacious drug exposure at the site of
infection. DAmB has high molecular mass (924 g/mol) and complex binding properties
(33). It does not readily penetrate the intact blood-brain barrier. Its concentration in
meninges and cryptococcomas has been technically difficult to quantify in any finer
detail than in brain homogenates in preclinical models (34, 35). This challenge is
compounded by a lack of clarity regarding the DAmB concentration required for
therapeutic efficacy at the site of infection. Animal studies have produced estimates
indicating that the cerebral concentrations of DAmB at which the suppression of
growth is half-maximal are 0.02 mg/liter in mice and 0.154 mg/liter in rabbits (34).
AmB exposure above the level required to optimize antifungal activity appears to
contribute only to toxicity (34, 36). Our simulations suggested that the optimal
plasma AUC value in humans lies somewhere between 10 and 15 mg · h/liter,
though the information required to extrapolate this to cerebral DAmB concentra-
tions is not currently available. The application of noninvasive, high-resolution
technologies, including matrix-assisted laser desorption ionization–mass spectros-
copy imaging (MALDI-MSI), is now possible and offers the exciting potential to
elucidate the pharmacokinetic/pharmacodynamic (PK/PD) index associated with
efficacy at the site of infection by enabling quantification of drug in specific cerebral
sites, as has been demonstrated in murine models that used gatifloxacin (37),
doxycycline (38), pretomanid (39), and rifampin (40).
It may be the case that the maximal antifungal effect of DAmB is achieved with a
dose of approximately 0.7 mg/kg, or slightly higher, and that gains made above this
dose in terms of CSF sterility are offset by losses in terms of excessive toxicity. This may
explain why significant increases in the proportions of patients achieving CSF sterility
are not mirrored by reductions in mortality. The present analysis is not sufficient to
more precisely define the optimal dosage of DAmB. This is partly due to the lack of
consensus regarding DAmB exposure targets. We are unable to propose exposure
targets based on our data set, which does not include site-specific PK or detailed
toxicodynamic data. In addition, the pharmacodynamic and clinical outcome data
presented here were derived from patient cohorts that were distinct from the
patients that provided samples for the PK analysis. Outcomes from DAmB mono-
therapy at dosages of 0.7 mg/kg q24h and 1.0 mg/kg q24h have not been directly
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compared in a randomized controlled trial. However, comparison of these dosages
in combination with 5FC has been performed. Bicanic et al. demonstrated increased
early fungicidal activity with DAmB at 1 mg/kg q24h versus 0.7 mg/kg q24h, both
in combination with 5FC at 100 mg/kg/day in four divided dosages, but this was not
reflected in reductions in mortality. A higher percentage of deaths was seen in the
higher-dose DAmB arm at both 2 weeks (9% versus 3%) and 10 weeks (26% versus
21%), but the data were not statistically significant (P  0.62 and 0.77 at 2 and 10
weeks, respectively) (2).
In summary, these analyses suggest that the optimal dosage of DAmB for the
treatment of cryptococcal meningitis lies between 0.7 and 1.0 mg/kg q24h. The precise
drug exposure target that optimizes clinical outcomes without producing significant
toxicity remains to be defined. The extent of interindividual PK variability in DAmB is
modest and unlikely to account for the consistently poor clinical outcomes from
treatment of cryptococcal meningitis.
MATERIALS AND METHODS
Clinical pharmacokinetic studies. Plasma samples were obtained from adults with HIV-associated
cryptococcal meningitis. Patients were initially recruited from a multicenter randomized controlled
trial of adjuvant treatment with dexamethasone in HIV-associated cryptococcal meningitis, reported
elsewhere (n  3; International Standard Registered Clinical Number 59144167) (17). Following the
early cessation of that trial, they were recruited from a prospective descriptive study at the same
sites (n  39). Patients were recruited at 2 sites: The Hospital for Tropical Diseases in Ho Chi Minh
City, Vietnam, and Masaka General Hospital, Uganda. The study protocols were approved by the
relevant institutional review boards and regulatory authorities at each trial site and by the Oxford
University Tropical Research Ethics Committee.
The protocol for the randomized controlled trial has been described previously (41). Briefly, patients had
HIV infection, a syndrome consistent with cryptococcal meningitis, and laboratory evidence of cryptococcal
infection. Patients who were pregnant, had renal failure, had gastrointestinal bleeding, had received more
than 7 days of anticryptococcal antifungal therapy, were already taking corticosteroids, or required cortico-
steroid therapy for coexisting conditions were excluded. The inclusion and exclusion criteria for the prospec-
tive descriptive study were identical to those of the clinical trial. Patients received DAmB at 1 mg/kg of body
weight once daily by intravenous infusion over 5 to 6 h, as well as 800 mg fluconazole per day. Two patients
recruited during the clinical trial received dexamethasone according to the following regimen: 0.3 mg/kg/day
intravenously (i.v.) for week 1 and 0.2 mg/kg/day i.v. for week 2 and then orally at 0.1 mg/kg/day for week 3,
3 mg/day for week 4, 2 mg/day for week 5, and 1 mg/day for week 6, followed by cessation of treatment. For
the first five patients enrolled, blood samples were obtained immediately prior to intravenous DAmB infusion
and then at h 1, 2, 4, 8, 12, 16, 20, and 24. The results for these patients informed a subsequent sampling
strategy defined using optimal design theory such that patients were sampled predose and then at 1, 2, 4,
8, 12, and 24 h after initiation of the infusion. PK sampling occurred on treatment days 1 or 2 and 7. Whenever
patients had lumbar punctures performed for other clinical indications such as raised intracranial pressure,
paired plasma samples were collected for subsequent PK analysis. Therefore, additional sparse samples were
taken for up to 17 days after initial dosing. Quantitative fungal counts were determined for each lumbar
puncture, as described previously (15).
Measurement of amphotericin B concentrations. Amphotericin B concentrations in plasma were
measured using high-performance liquid chromatography (HPLC) with a Shimadzu Prominence HPLC
system (Shimadzu, Milton Keynes, United Kingdom). Amphotericin B was extracted by protein precipi-
tation. A total of 300 l of methanol that contained piroxicam (Sigma-Aldrich, Dorset, United Kingdom)
at 2 mg/liter was added as an internal standard to 100 l of matrix. Samples were vortex mixed for 5 s
and then centrifuged at 13,000  g for 3 min.
A 150-l volume of supernatant was removed and placed in a 96-well plate, to which 50 l of water
was added. A 50-l aliquot was injected into a Kinetex 5 XB-C18 liquid chromatography column
(Phenomenex, Macclesfield, United Kingdom). Chromatographic separation was achieved using a gra-
dient under starting conditions of 75% mobile phase A/25% mobile phase B (with 0.1% formic
acid–water as mobile phase A and 0.1% formic acid–acetonitrile as mobile phase B). Mobile phase B was
increased to 80% over 5 min and then reduced to the starting conditions for 2 min of equilibration.
Amphotericin B and the internal standard were detected using UV detection at wavelengths of 406 nm
and 385 nm; they eluted after 4.1 and 4.6 min, respectively.
The standard curve for amphotericin B encompassed the concentration range of 0.05 to 8.0 mg/liter
and was constructed using blank matrix. The limit of quantitation was 0.05 mg/liter. The coefficient of
variation was 9.3% over the concentration range of 0.05 to 8 mg/liter. The intraday variation and
interday variation were 7.9%.
Population pharmacokinetic modeling. A PK model was fitted to the data using the nonparametric
adaptive grid (NPAG) algorithm of the program Pmetrics (42) version 1.5.0 for R statistical package 3.1.1.
The data were weighted using the inverse of the estimated assay variance. Both two- and three-
compartment models were tested, with zero-order intravenous input and first-order elimination from the
central compartment. The two-compartment model took the following form:
Pharmacokinetics of Amphotericin B Deoxycholate Antimicrobial Agents and Chemotherapy
July 2018 Volume 62 Issue 7 e02526-17 aac.asm.org 11









 R(1)  SCL
V
 K12 X(1)  K21  X(2) (a)
dX(2)
dt





where equations a and b describe the rates of change of the amount of drug (in milligrams) in the central
and peripheral compartments, respectively. X(1) and X(2) represent the amounts of amphotericin B (in
milligrams) in the central (c) and peripheral (p) compartments, respectively. R(1) represents the intrave-
nous infusion of DAmB into the central compartment. SCL represents the first-order clearance of drug (in
liters per hour) from the central compartment. V represents the volume of the central compartment. K12
and K21 represent the first-order intercompartmental rate constants. Equation c represents the model
output. The three-compartment model contained the following additional equation to connect the third
compartment to the second compartment in series:
dX(3)
dt
 K23  X(2)  K32  X(3) (d)
An initial condition was estimated to accommodate detectable drug in the first PK sample from those
patients who had received a dose of DAmB at an undocumented time before study enrollment. The
nonzero initial condition was estimated by assigning the respective parameters in the structural model
(not shown in the equations above). A switch was coded whereby a parameterized estimate of the initial
condition was multiplied by a binary covariate equal to 1 (where the first PK sample was drawn after a
dose of DAmB) or 0 (where this represented a predose sample).
Once the standard model (model 1) was fitted, the effects of patient weight, baseline eGFR, and
patient ethnicity on the PK of DAmB were investigated. Bidirectional stepwise multivariate linear
regression of each subject’s covariates versus the Bayesian posterior parameter values revealed a
significant (P  0.05) relationship between both weight and eGFR and estimated PK parameters.
Univariate linear regression was employed first to assess the relationship between patient weight and the
Bayesian estimates for both clearance and volume. Since a positive relationship was observed between
weight and both PK parameters, the population PK model was refitted to the data (model 2) with
incorporation of the following equations to describe clearance (SCL) (equation e) and volume (V)
(equation f) as functions of patient weight (Wt):
SCL  Int _c  (Wt  Sl_c) (e)
V  Int _v  (Wt  Sl_v) (f)
where Int is the intercept and Sl the slope of the linear regression describing the relationship between
weight and clearance or volume; the intercept and slope for each of these PK parameters are parame-
terized separately. Thus, equation a of the structural model was replaced with the following equation:
dX(1)
dt
 R(1)   Intc  (Wt  Slc)
Intv  (Wt  Slv)
 K12 X(1)  K21  X(2) (a.2)
In addition, a power function was explored to describe the relationship between weight and
clearance. In this model (model 3), clearance was parameterized and scaled with weight to the exponent
0.75. This exponent has previously been demonstrated to usefully scale for size (43, 44). A linear
relationship was maintained between volume and weight. Thus, in model 3, equation a was replaced
with the following equation:
dX(1)
dt
 R(1)  SCL  Wt0.75
V  Wt
 K12 X(1)  K21  X(2) (a.3)
Univariate linear regression was similarly employed to assess the relationship between eGFR and the
Bayesian estimates for clearance and volume from model 1. A weaker but nevertheless positive
association was demonstrated. Consequently, a further structural model (model 4) was fitted to the data,
with the following equation (equation g) employed to describe clearance (SCL):
SCL  Int_c  (Wt  Sl_c)   eGFRmedeGFR (g)
where eGFR represents the estimated glomerular filtration rate calculated for each patient by the use of
the Cockcroft-Gault equation and med_eGFR represents the population median estimated glomerular
filtration rate. In model 4, equation a was replaced with the following equation:
dX(1)
dt




Intv  (Wt  Slv)
 K12 X(1)  K21  X(2) (a.4)
To explore whether there were significant differences between the model-predicted PK parameters
in Vietnamese and Ugandan patients, Bayesian estimates of volume of distribution and clearance from
the central compartment were compared using a Mann-Whitney test and Student’s t test, respectively.
Since no significant relationship between ethnicity and DAmB PK was apparent, this variable was not
incorporated in the final model.
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The fit of the model to the data was assessed using a linear regression of observed-versus-predicted
values before and after the Bayesian step. The coefficient of determination of the linear regression was
noted in combination with the intercept and slope of the regression for each model. Model comparison
was achieved through calculation of the log likelihood value, the Akaike information criterion (AIC), the
mean weighted error (a measure of bias), and the bias-adjusted, mean weighted squared error (a
measure of precision). To verify the ability of the final model to predict observed concentrations with
acceptable accuracy, a visual predictive check (VPC) of the data was performed. For the VPC, the
covariance matrix in Pmetrics was utilized to simulate 1,000 patients administered DAmB on a milligram-
per-kilogram basis. Simulated weight values were limited to the range observed in our clinical cohort.
Meta-analysis of clinical outcome data. The pharmacodynamic data from patients enrolled in the
present clinical study are confounded by the coadministration of fluconazole (17). Therefore, a search
was performed for clinical trials of treatment for cryptococcal meningitis with at least one arm comprised
of adult patients receiving DAmB monotherapy. For consistency, the included trials were limited to those
that recruited HIV-positive patients. Baseline clinical variables with a demonstrated ability to predict
patient mortality—namely, altered mental status, patient age, and baseline CSF fungal burden—were
selected a priori and extracted from the studies (4, 30). To aid meaningful trial comparison, baseline
fungal burden and baseline CSF cryptococcal antigen titer values were extrapolated from one another
where they were not explicitly reported in the study, applying a correlation presented by Jarvis et al. (4).
We collated a variety of clinical trial outcomes based on those that were commonly reported across
trials of DAmB monotherapy: documented CSF sterility during trial follow-up, mortality at 2 weeks, and,
where possible, mortality at 10 weeks. Meta-analysis was performed on each outcome using a dose-
adjusted random-effects model to account for the baseline heterogeneity in the included studies. We
included dose as a moderator variable in the model to assess the degree to which it explained
heterogeneity in clinical outcomes (45). The resulting mixed-effects model took the form i  0 
1dosei  ui, where 0 and 1 are the model parameters intercept and dose, respectively; dosei is the
dose given in the ith study, assuming study-specific random effects; and ui  N(0, 	2), where 	2 is the
amount of residual heterogeneity among the true effects i that is not accounted for by dose. We
calculated to what extent dose as a moderator influenced the true average effect and estimated the
corresponding proportions of each outcome measure.
Monte Carlo simulation. Monte Carlo simulations were performed in Pmetrics (42). Model 2 was
used. Amphotericin B was administered on a milligram-per-kilogram basis and infused over 5.5 h. The
initial conditions of the central and peripheral compartments were set at a default value of zero. The
weight-based dosage of DAmB was converted to an absolute dosage by multiplying by the simulated
patient’s weight. This process served to mimic the bedside drug administration in the original clinical
trial, in which dosing was planned on a milligram-per-kilogram basis but the absolute dose that was
ultimately administered was determined by the patient’s weight.
Drug exposure was quantified using the DAmB AUC (9, 10, 46). The simulated AUC for each patient
was estimated 144 to 168 h post-therapy initiation. Simulations were performed to estimate the AUC that
resulted from dosages administered in clinical trials of DAmB monotherapy for which PD measures were
available—specifically, 0.4, 0.7, and 1.0 mg/kg q24h (5, 11, 13–15).
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Therapeutic drug monitoring (TDM) may be required to achieve optimal clinical outcomes in the setting of signifi-
cant pharmacokinetic variability, a situation that applies to a number of anti-mould therapies. The majority of
patients receiving itraconazole should routinely be managed with TDM. Voriconazole exhibits highly variable
inter-individual pharmacokinetics, and a trough concentration of 1.0–5.5 mg/L is widely accepted although it is
derived from relatively low-quality evidence. The case for TDM of posaconazole is currently in a state of flux fol-
lowing the introduction of a newer tablet formulation with improved oral bioavailability, but it may be indicated
when used for either prophylaxis or treatment of established disease. The novel broad-spectrum azole drug isa-
vuconazole does not currently appear to require TDM but ‘real-world’ data are awaited and TDM could be con-
sidered in selected clinical cases. For both polyene and echinocandin agents, there are insufficient data regarding
the relationship between serum concentrations and therapeutic outcomes to support the routine use of TDM.
A number of practical challenges to the implementation of TDM in the treatment of invasive mould infections re-
main unsolved. The delivery of TDM as a future standard of care will require real-time measurement of drug con-
centrations at the bedside and algorithms for dosage adjustment. Finally, measures of pharmacodynamic effect
are required to deliver therapy that is truly individualized.
Introduction
Dose is a notoriously poor measure of drug exposure, both in indi-
vidual patients and in larger patient populations. The use of a stand-
ard fixed regimen often results in considerable pharmacokinetic
variability. While it is possible to estimate pharmacokinetic variabil-
ity using population pharmacokinetic modelling approaches, the
sources of observed variance cannot generally be fully explained by
fixed effects (covariates) such as weight, height, ethnicity, pharma-
cogenetics and organ dysfunction. This limitation is further com-
pounded by the physiological changes that are associated with
various stages of illness. Thus, a fixed dosing strategy or a ‘one-size-
fits-all’ approach will always result in some patients experiencing
low drug exposure, with an increased probability of concentration-
dependent therapeutic failure, while others have higher exposures
than intended, placing them at increased risk of toxicity. In the
management of infections, the clinical consequences of this vari-
ability vary according to the drug–pathogen combination.
The rationale for therapeutic drug monitoring (TDM) of antifun-
gal therapies is the same as for any other therapeutic agent. First,
for TDM to be of potential benefit, the drug should have largely un-
predictable pharmacokinetic behaviour so that dose alone, or in
conjunction with covariates such as renal function or weight, is in-
adequate to predict safe and effective drug exposure. Second, the
drug should have a narrow therapeutic index so that under- or
over-exposure could render the treatment ineffective or toxic,
respectively. Third, the drug should have a defined concentration
range that is associated with a satisfactorily high probability of
both safety and efficacy.1 In general, the anti-Aspergillus triazoles
(i.e. itraconazole, voriconazole, posaconazole) and flucytosine fulfil
these criteria. In contrast, the echinocandins and amphotericin B
generally do not.2 An understanding of antifungal TDM has been
relatively mature for some time. Nevertheless, the arrival of new
therapeutic options (i.e. isavuconazole) will extend the debate until
further clinical evidence is gained.
Here, we review current knowledge regarding TDM of antifungal
agents.
Application of TDM to commonly used
antifungal agents
Itraconazole
Itraconazole was the first orally bioavailable antifungal agent with
activity against moulds such as Aspergillus species. It is indicated
for the treatment of oral and oesophageal candidiasis, prophylaxis
against fungal infections in the setting of prolonged neutropenia,
and for treatment of invasive aspergillosis and cryptococcosis in-
fections that are refractory to first-line therapy.3 The safety profile
of itraconazole is less favourable than fluconazole and it has been
associated with cardiotoxicity, gastrointestinal intolerance, neuro-
logical deficits and hepatitis.3,4 Itraconazole is available as oral
VC The Author 2017. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved.
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capsules, oral solution and an intravenous (iv) preparation, al-
though the latter is not available in the USA.
Itraconazole exhibits highly variable and non-linear pharmaco-
kinetics, the basis for which is multifactorial. Itraconazole solution
has an oral bioavailability that is 30% higher than capsules. The
absorption of itraconazole from capsules is largely dependent on
gastric acidity and as such, capsules should always be adminis-
tered with food or even an acidic beverage (e.g. cola).4–6
Itraconazole is extensively protein bound in plasma, highly lipo-
philic and only moderately water soluble.7 It undergoes oxidative
metabolism, primarily by the CYP3A4 isoenzyme, which the drug
also inhibits, and as a result drug–drug interactions are import-
ant.8–10 Alterations in hepatic metabolism may also contribute to
pharmacokinetic variability.2
Itraconazole was developed before the advent of modern phar-
macodynamic approaches. The pharmacodynamic drug exposure
target is quantified in terms of Cmin (i.e. trough concentration) ra-
ther than AUC (or AUC/MIC ratio). The Cmin is a relatively pragmatic
measure of drug exposure. The pharmacokinetic profile of itracon-
azole is relatively flat, meaning that deviations from true Cmin
values are unlikely to be clinically significant. A Cmin range of
0.5–1 mg/L, when measured using HPLC/mass spectrometry,11 is
generally used although this target is somewhat arbitrary.
Pharmacodynamic targets are based on studies performed in a
variety of clinical settings. In neutropenic patients receiving itra-
conazole for the prevention of invasive fungal infections, Cmin
,0.5 mg/L is associated with an increased likelihood of break-
through infections12–14 as well as a significantly higher mortality.14
When used for the treatment of oropharyngeal candidiasis, serum
itraconazole concentrations ,1 mg/L are predictive of therapeutic
failure.15 Clinical outcomes for patients with cryptococcal meningi-
tis and respiratory coccidioidomycosis are improved with higher
steady-state itraconazole concentrations.16 Finally, when itracon-
azole is administered in patients with invasive aspergillosis17 or
histoplasmosis,18 higher Cmin values tend to lead to better clinical
outcomes. Importantly, therapeutic targets for TDM of itracon-
azole were derived in an era before triazole resistance emerged in
Aspergillus. Such practice is illustrative of the limitations that result
from setting pharmacodynamic targets without accounting for
the susceptibility of the target organism. The appropriate Cmin tar-
get for the treatment of Aspergillus with non-wild-type MICs is un-
known,11 although the majority of isolates with common
resistance mechanisms tend to have very high MIC values and are
unlikely to be treatable with dosage escalation and a well-
demonstrated upper toxicity boundary.4
The majority of patients receiving itraconazole should routinely
be managed with TDM. The rationale for this is 5-fold: (i) high
inherent pharmacokinetic variability of all itraconazole formula-
tions; (ii) evidence of clinically relevant drug exposure–response re-
lationships (as summarized above); (iii) evidence of drug
exposure–toxicity relationships;19 (iv) potential for drug–drug inter-
actions;8–10 and (v) potential issues with compliance given the un-
palatability of itraconazole suspension.4,11 The accumulation of
itraconazole occurs slowly and target trough concentrations are
only reached after 7–15 days of dosing.20 These estimates are fur-
ther complicated by overt non-linear pharmacokinetics in at least
some patients, who experience early toxicity due to high Cmin val-
ues. Therapeutic Cmin values can only be confidently achieved with
the use of an oral loading dose or use of an iv formulation,
although this is a relatively uncommon scenario with the advent of
new antifungal agents.21 A suggested strategy for TDM of itracon-
azole is to measure the trough concentration after the first week of
therapy and then at regular intervals (e.g. every 1–2 weeks) ac-
cording to the clinical context (e.g. when interacting drugs are
started or discontinued, or if there are concerns about gastrointes-
tinal absorption or compliance). Cmin should be re-estimated
5–7 days following dose adjustment to ensure that target concen-
trations have been achieved.11
Voriconazole
Voriconazole is a structural congener of fluconazole that has a
broader spectrum of antifungal activity but maintains the high oral
bioavailability of fluconazole.22 It is indicated for the treatment of
invasive aspergillosis, invasive candidiasis exhibiting fluconazole
resistance and infections caused by Scedosporium spp. and
Fusarium spp.3 Voriconazole can be used for the prevention of in-
vasive fungal diseases in HSCT recipients.23,24 Voriconazole is avail-
able as a tablet, an oral suspension, and a powder for infusion.3
Voriconazole exhibits highly variable inter-individual pharmaco-
kinetics.25 This variability can be attributed to many factors, includ-
ing pharmacogenetic polymorphisms, drug–drug interactions,
altered gastrointestinal absorption, inflammation and body
weight.26 Voriconazole undergoes extensive hepatic metabolism
via CYP3A4, CYP2C9 and CYP2C19. Important pharmacogenetic
determinants of clearance in CYP2C19 are responsible for ethnic
differences in pharmacokinetics.27 Voriconazole exhibits classical
non-linear (Michaelis–Menten) pharmacokinetics in adults as a re-
sult of saturable clearance.26 In contrast, young children display
linear pharmacokinetics and have higher weight-corrected clear-
ance28 and higher weight-based dosages (9 mg/kg twice daily) are
required to achieve pharmacodynamic targets that are associated
with therapeutic success.29 There are scant data from neonates
and considerable uncertainty about the appropriate regimen in
this setting.30 Voriconazole is not widely used in this population be-
cause Aspergillus is such an uncommon pathogen.
The British Society for Medical Mycology (BSMM) recommends a
voriconazole Cmin target for TDM of between 1.0 and 5.5 mg/L
when the drug is used to treat established invasive infection.11 This
target is widely accepted although it is derived from relatively low-
quality evidence, based on studies that were limited by the diffi-
culty of estimating voriconazole exposure in individual patients
and in controlling for confounding factors that may have an im-
pact upon clinical outcome.11 The majority of studies assessing the
utility of voriconazole TDM have been relatively small, were gener-
ally conducted at a single centre and are retrospective, and the
methodological approaches were somewhat variable.26,31 Two
meta-analyses suggest that a target voriconazole concentration
of 1.0 mg/L is predictive of clinical success,26,32 although the
more recent of these reported some uncertainty about this esti-
mate.26 For prophylactic use, the target concentration for TDM is
less clear. The achievement of serum voriconazole concentrations
within the therapeutic range does not appear to predict successful
prophylaxis when using absence of breakthrough invasive fungal
infection and/or fungal colonization as the outcome measure.26
If the MIC of the invading pathogen is known, the recommended
target for TDM is a Cmin/MIC ratio of 2.0–5.0 (when the MIC is meas-
ured according to CLSI methodology). This has been demonstrated
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using an experimental pharmacodynamic model33 and in a retro-
spective study.34
Changes in voriconazole concentration occur more quickly than
those of itraconazole and posaconazole. Initial serum sampling for
TDM is recommended within the first 2–5 days of therapy. If clear-
ance mechanisms are saturated in a particular patient, the initial
level may not predict future concentrations, so subsequent sam-
pling should be performed.11,22 This strategy also applies to dose
adjustments, initiation or discontinuation of interacting drugs, and
changes in clinical circumstances. The timing of repeat sampling
to determine voriconazole concentrations is difficult to define
rigorously. If a patient is unstable or critically unwell and there is
some uncertainty about voriconazole concentrations, then repeat
sampling may be warranted every 3–5 days. In other circum-
stances, less intensive monitoring may be appropriate.
Posaconazole
Posaconazole has broad antifungal activity against medically im-
portant fungal pathogens including Candida spp., Aspergillus spp.,
Cryptococcus neoformans and the Mucorales.35 It is licensed for
use in fusariosis as salvage therapy; in invasive aspergillosis that is
refractory or intolerant to first-line agents; for chromoblastomyco-
sis and mycetoma when there is resistance and/or intolerance of
itraconazole; and for coccidioidomycosis where there is resistance
to, or intolerance of amphotericin, itraconazole or fluconazole.3
Posaconazole is available as a solid tablet, an oral suspension and
an iv formulation.
Posaconazole is structurally similar to itraconazole. It is highly
protein bound and widely distributed in tissues.36 Posaconazole
suspension exhibits linear pharmacokinetics with daily doses up to
800 mg, beyond which further dose increases do not result in pro-
portional increases in drug exposure.37 It has a Tmax of 5 h. The oral
bioavailability of posaconazole suspension is increased in an acidic
environment and in the presence of food.37,38 The long terminal
half-life of posaconazole (34 h) means that steady-state serum
concentrations are only achieved after 1 week.11 Metabolism is pri-
marily by glucuronidation rather than oxidation. Posaconazole in-
hibits CYP3A4 activity, and as such has a number of clinically
relevant drug–drug interactions.39
The case for TDM of posaconazole is currently in a state of flux
following introduction of a newer tablet formulation, which has
improved oral bioavailability. TDM of posaconazole may be indi-
cated when used for either prophylaxis or treatment of established
disease. Cmin should be measured 7 days after initiation of therapy
or a dosage adjustment. When posaconazole suspension is used,
TDM is particularly indicated if there are concerns about gastro-
intestinal absorption and if there is uncertainty about compliance.
The oral bioavailability of posaconazole tablets and capsules is bet-
ter than the suspension although considerable variability is still
seen,40 suggesting that TDM should be considered. The tablet and
oral suspension formulations of posaconazole are not considered
interchangeable due to different dosing and pharmacokinetics.41
For patients with established disease, the probability of a clinical
response increases with increasing drug exposure.42–44 For salvage
therapy, target trough concentrations should be .1.0 mg/L,
though this does not incorporate an estimate of MIC.11
Isavuconazole
Isavuconazole is a novel broad-spectrum azole drug with activity
against yeasts, moulds and dimorphic fungi including Aspergillus
spp., Mucorales, Candida spp. and Cryptococcus spp.45–47 It has
been approved by the EMA and the FDA for treatment of invasive
aspergillosis, and by the EMA for invasive mucormycosis in cases
where amphotericin B is inappropriate.45 Isavuconazole is admin-
istered as a prodrug (isavuconazonium sulphate) and is available
in both oral and iv formulations.48
Isuvaconazole has been shown to be non-inferior to voricon-
azole for the treatment of invasive disease caused by Aspergillus
spp. and other filamentous fungi in a Phase III, randomized con-
trolled trial.49 A multicentre, double-blind Phase II trial has demon-
strated non-inferiority of isavuconazole versus fluconazole for the
treatment of uncomplicated oesophageal candidiasis.50 In the
treatment of mucormycosis, the efficacy of isavuconazole is simi-
lar to that of amphotericin B and the former is well tolerated.51
Isavuconazole displays high oral bioavailability (nearly 100%), is
relatively rapidly absorbed with a Cmax of 2–3 h after oral adminis-
tration, and is highly protein bound (98%).52 It undergoes hep-
atic metabolism and has a long half-life (130 h). Accordingly, a
loading dose of 200 mg isavuconazole is given three times a day
for 2 days, followed by a maintenance dose of 200 mg once daily,
with the aim of reaching steady-state concentrations at day 3.53
Dose adjustment is not required in renal impairment.52 Relative to
other azole antifungals, the pharmacokinetics of isavuconazole
are predictable46,54 and is linear up to dosages of 600 mg/day.
Isavuconazole is better tolerated than voriconazole with statistic-
ally fewer visual, skin or subcutaneous tissue and hepatobiliary
disorders.49
The case for TDM of isavuconazole is uncertain at the present
time. Analysis of clinical trial data does not reveal any relationship
between various measures of drug exposure (e.g. AUC, Cmin) and
efficacy endpoints (all-cause mortality, clinical response) or safety
endpoints, although this information is only available in abstract
form at present.55 It is important to recognize that these analyses
were performed on the Phase III clinical trial using an optimized
regimen. Consequently, there is little opportunity to observe
concentration-dependent clinical failures and therefore identify a
threshold for TDM. Whether the same conclusion holds with more
‘real world’ data remains to be seen. TDM could be considered in
selected clinical cases where drug exposure needs to be confirmed
(e.g. severe gut disease from graft-versus-host disease where oral
absorption may be problematic, treatment of central nervous sys-
tem disease, or treatment of a non-wild-type fungal pathogen).
TDM may also be indicated in circumstances where there is cur-
rently little information (e.g. dosing in children or adolescents).
Concentrations of isavuconazole can be currently determined
in a small number of reference laboratories in Europe but materials
are available for units that are interested in developing an assay.
There are no algorithms that have been developed to adjust dos-
age and we are not aware of any clinical experience. One consider-
ation that is particularly pertinent to dosage adjustment of
isavuconazole is that although concentrations will begin to change
immediately after the dose or dosing interval is amended, the im-
pact of changes will not be fully apparent for 4 weeks (the time to
a new steady state), after which many clinically relevant issues will
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Flucytosine
Flucytosine therapy is a standard-of-care for cryptococcal menin-
gitis. Flucytosine is a pyrimidine analogue that has no intrinsic anti-
fungal activity, but which is taken up by susceptible fungal cells
and deaminated to the active metabolite, 5-fluorouracil (5-FU), by
the fungal enzyme cytosine deaminase.56 5-FU is further con-
verted to metabolites that inhibit fungal RNA and DNA synthesis.57
5-FU is active against most Candida spp. and C. neoformans and
has some activity against Aspergillus spp. Administration of flu-
cytosine should always be combined with other antifungal agents
because of the significant risk of resistance acquisition when used
as monotherapy.56 It is indicated as an adjunct to amphotericin
for the treatment of some cases of severe systemic candidiasis
and is a routine component of induction therapy for cryptococcal
meningitis.3
Flucytosine displays excellent bioavailability (90%) following
oral administration. Protein binding is negligible (2%–4%).58
Flucytosine readily penetrates the blood–brain barrier and
achieves effective concentrations in the vitreous, peritoneal and
synovial fluid, making it valuable for the treatment of deep
Candida infections that are otherwise refractory to first-line
agents.11,57,59 Since hepatic metabolism is minimal and .90% of
the drug is excreted unchanged in urine, dose reduction is required
in renal impairment.11,60 In patients with normal renal function,
Cmax is reached within 1–2 h at steady state. The half-life is 3–4 h in
patients with normal renal function but this can increase to several
days in those with renal impairment or anuria.61
Flucytosine exhibits significant inter-patient pharmacokinetic
variability.62 A precise target range for serum concentrations of flu-
cytosine for TDM is not universally agreed. Recommendations
from the BSMM are based on in vitro evidence that yeasts exposed
to trough concentrations ,20–40 mg/L develop resistance, and
that peak concentrations .100 mg/L are associated with myelo-
toxicity and hepatotoxicity.63,64 The impact of trough level on clin-
ical outcomes is unknown. Moreover, target concentrations for
flucytosine in combination with other antifungal agents are not
defined. Published data on TDM of flucytosine has revealed alarm-
ingly infrequent achievement of concentrations in this putative
therapeutic range, with two studies from the UK revealing ,20%
of concentrations within range,62,65 and a further study achieving
only 64.3% of concentrations within range.66
TDM is standard of care for the use of flucytosine. Serum con-
centrations should be determined: at 72 h post-therapy initiation;
after dose adjustment; if there is uncertain compliance with oral
therapy; and if there are clinical or laboratory signs of toxicity. The
BSMM recommends an upwards dose adjustment of 50% if levels
are sub-therapeutic.11
Polyenes
The polyenes comprise amphotericin B deoxycholate, licensed for
systemic fungal infections; liposomal amphotericin B, licensed for
severe or deep mycoses where toxicity precludes the use of con-
ventional amphotericin B, for infection in febrile neutropenic pa-
tients unresponsive to broad-spectrum antifungals and for
aspergillosis; and amphotericin B lipid complex, for severe invasive
candidiasis and systemic fungal infections refractory to conven-
tional amphotericin or where toxicity precludes its use.3
Despite over 50 years of clinical use of amphotericin B deoxy-
cholate, and 20 years use of liposomal amphotericin B and ampho-
tericin B lipid complex, relatively little is understood about
the pharmacology of amphotericin B and the requirement for
TDM.67–69 The Cmax and AUC/MIC ratio are recognized as the indi-
ces that predict clinical response.70 However, there is currently in-
sufficient evidence to support the routine use of TDM for
polyenes.71
Echinocandins
The echinocandin class comprises anidulafungin, caspofungin and
micafungin. These drugs inhibit synthesis of 1,3-b-D-glucan, an es-
sential component of the fungal cell wall.72 Anidulafungin is indi-
cated for the treatment of invasive candidiasis. Caspofungin can
additionally be used to treat invasive aspergillosis and systemic
fungal infections in neutropenic patients. Micafungin is licensed for
the treatment of invasive and oesophageal candidiasis, and for
prophylaxis in the neutropenic phase of bone marrow transplant-
ation.3 The echinocandins offer potential for use against azole-
resistant fungal pathogens.72
All echinocandins have low oral bioavailability and are only
available for parenteral use.3,72 They exhibit linear pharmacokinet-
ics following iv administration, and distribute into tissues. CNS
penetration is possible but only with use of higher dosages than
are licensed for the treatment of bloodstream infection.72,73 Drug
interactions are less clinically important for the echinocandins
than for other agents as they are weak substrates for, and do not
inhibit, cytochrome P450 enzymes. Neither are they substrates for
the P-glycoprotein transport systems.72,74 As is the case with the
polyenes, there are insufficient data regarding the relationship be-
tween echinocandin serum concentrations and therapeutic out-
comes to support the routine use of TDM for these agents.11,72
Advancing the field: what are the
immediate challenges for individualized
antifungal therapy?
Much has been written about antifungal TDM, and the current
state of knowledge is relatively stable. Several guidelines have
been developed. What then are the remaining challenges to en-
sure TDM becomes a practical and more widely used adjunct to
the routine use of antifungal agents?
Challenge 1. Measuring drug concentrations at
the bedside
In many institutions, the turnaround time for antifungal drug
measurement is too slow to be clinically helpful. Measurement re-
quires relatively expensive equipment and highly trained labora-
tory personnel. TDM services are often centralized, leading to
delays in transportation and reporting. A radical change in ap-
proach is required to enable measurement of drug concentrations
at the bedside or in the clinic. This, in turn, would allow rapid modi-
fications to the antifungal regimen which would be expected to
provide a far more significant clinical benefit than waiting a week
or longer, as is currently often the case.
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Challenge 2. Development of algorithms for
dosage adjustment
There is a distinct lack of published guidance on how to adjust the
dosage of antifungal agents in response to a level that is outside a
specified therapeutic range. Some authors suggest changing the
dose by 50%. Even for agents with relatively simple pharmacology
(e.g. fluconazole and flucytosine), such an approach is crude
at best. We have for some time been developing software that en-
ables precise calculation of the regimen that is required to shift
a patient from their current state to a new, safer and more effect-
ive state. Our approach uses a multiple model approach
(BestDose), which is a natural extension of the non-parametric
adaptive grid algorithms developed by the Laboratory of Applied
Pharmacokinetics in Los Angeles. Other approaches are certainly
possible, although the complex pharmacology of almost all anti-
fungal agents (e.g. non-linear pharmacokinetics) is an obstacle to
the use of simple dosage calculators based on simple covariates.
Furthermore, the problem of extreme variability in pharmacokinet-
ics becomes significantly heightened in special populations such
as neonates and children.
The development of software (or other dosage selection tools)
is not trivial. Safe use will require expansion of the currently limited
pool of clinicians who are well trained in clinical pharmacology. In
addition, there are significant regulatory hurdles to ensure that
software developed in academic settings fulfils the necessary
standards for use in patients. Nevertheless, we are clear that this is
the only path forward. Taking time and effort to measure drug
concentrations in the laboratory with a coefficient of variation
,10% and then guessing the dosage seems haphazard at the very
least, and in our view is completely unacceptable for clinical
practice.
Challenge 3. Real-time pharmacodynamic monitoring in
patients with invasive mould disease
Current paradigms of drug concentration measurement and dos-
age adjustment are somewhat crude and counter to notions of
truly individualized therapy. Considerable energy has been ex-
pended on developing population pharmacokinetic models that
estimate drug exposure in individual patients with a high degree of
precision. Interpretation of the result is then made with reference
to a concentration target range that is constructed from a popula-
tion of patients (usually determined using logistic regression mod-
els or classification and regression tree analysis). Such an
approach is necessarily a violation of any principle of individualized
dosing, whereby a patient should receive the right dose for their
given disease. Some patients will require more drug, others will re-
quire less. Consider the differences in a patient who has been neu-
tropenic for 6 weeks and has disseminated aspergillosis with bulky
disease near the mediastinum and a small CNS lesion on CT, com-
pared with a patient who received an allogeneic transplant 120
days ago and is well and currently an outpatient, but has a small
nodule on a chest CT. Clearly, these patients are different and re-
quire different intensities of therapy. Yet, a TDM laboratory will re-
port the same range for antifungal therapy and dosage
adjustment.
Recently, we have been investigating the use of galacto-
mannan (GM) to follow the pharmacodynamic effect of antifungal
therapy. This is not necessarily a new concept. While much early
work on GM focused on its role as a diagnostic modality, there are
many reports that suggest that high unremitting GM levels are
associated with poor clinical outcomes, including death.75–78 Thus,
circulating GM is a means by which patients can ‘tell’ their phys-
ician how much drug they need, without recourse to therapeutic
ranges that are constructed from populations of patients.
Accordingly, a patient with unremittingly high GM levels needs
more drug, regardless of the measured plasma drug concentration
and whether it is deemed ‘therapeutic’. If this is not possible be-
cause of toxicity, or if dosage escalation and an increase in serum
concentration does not result in normalization of the biomarker,
then a second drug needs to be added or the therapy needs to be
changed altogether. Such an approach constitutes true individual-
ized therapy. Both a fixed dosing strategy and a therapeutic con-
centration range is a ‘one-size-fits-all’ approach, and neither is
consistent with any notion of individualized antifungal therapy.
This is also an argument for the development of biomarkers
with prognostic value that can be used to follow the disease
course. Medical mycology is full of such possibilities, some of which
are already established (e.g. use of quantitative cerebrospinal fluid
counts of 1,3-b-D-glucan to monitor therapy for cryptococcal men-
ingitis).79 Most fungi produce a myriad of secondary metabolites
that can potentially be used to track the effect of antifungal ther-
apy, and the same could apply to transcriptomic and metabolomic
approaches as they are further developed. Volumetric radiological
analyses are a further extension of this idea.
Conclusion
Much remains to be done to ensure that patients with rapidly
advancing life-threatening fungal infections are treated in an opti-
mal manner. Such challenges include the development of meth-
ods to measure plasma concentrations of antifungal agents at the
bedside in a timely manner, algorithms to enable rapid and precise
dosage adjustment, and mechanisms by which the treatment of
infection can be followed and managed in real-time. The last point
remains an important challenge to enable true individualized ther-
apy for patients with invasive fungal diseases.
Funding
This Supplement was funded by Basilea Pharmaceutica International Ltd,
Basel, Switzerland. Editorial support was provided by a freelance medical
writer (C. Dunstall) with funding from Basilea.
Transparency declarations
W. H. has received research funding from Pfizer, Gilead, Astellas, AiCuris,
Amplyx, Spero Therapeutics and F2G, and acted as a consultant and/or
given talks for Pfizer, Basilea, Astellas, F2G, Nordic Pharma, Medicines
Company, Amplyx, Mayne Pharma, Spero Therapeutics, Auspherix, Cardeas
and Pulmocide. K. E. S. has no conflicts of interest to declare.
This article forms part of a Supplement sponsored by Basilea
Pharmaceutica International Ltd, Basel, Switzerland.
Author contributions









/jac/article-abstract/72/suppl_1/i12/3074192 by  katstott@
liverpool.ac.uk on 26 Septem
ber 2019
References
1 Schumacher G. Introduction to therapeutic drug monitoring. In: G
Schumacher, ed. Therapeutic Drug Monitoring. East Norwalk, CT: Appleton
and Lange, 1995; 1–17.
2 Lewis RE. Antifungal therapeutic drug monitoring. Curr Fungal Infect Rep
2010; 4: 158–67.
3 Joint Formulary Committee. British National Formulary (online). London:
BMJ Group and Pharmaceutical Press, 2016. https://www.bnf.org/products/
bnf-online/.
4 Lestner J, Hope WW. Itraconazole: an update on pharmacology and clin-
ical use for treatment of invasive and allergic fungal infections. Expert Opin
Drug Metab Toxicol 2013; 9: 911–26.
5 Van de Velde VJ, Van Peer AP, Heykants JJ et al. Effect of food on the
pharmacokinetics of a new hydroxypropyl-b-cyclodextrin formulation of itra-
conazole. Pharmacotherapy 1996; 16: 424–8.
6 Abuhelwa AY, Mudge S, Hayes D et al. Population in vitro-in vivo correlation
model linking gastrointestinal transit time, pH, and pharmacokinetics: itra-
conazole as a model drug. Pharm Res 2016; 33: 1782–94.
7 Lass-Flörl C. Triazole antifungal agents in invasive fungal infections: a com-
parative review. Drugs 2011; 71: 2405–19.
8 Andes D, Azie N, Yang H et al. Drug-drug interaction associated with mold-
active triazoles among hospitalized patients. Antimicrob Agents Chemother
2016; 60: 3398–406.
9 Liu L, Bello A, Dresser MJ et al. Best practices for the use of itraconazole as
a replacement for ketoconazole in drug-drug interaction studies. J Clin
Pharmacol 2016; 56: 143–51.
10 Dodds-Ashley E. Management of drug and food interactions with azole
antifungal agents in transplant recipients. Pharmacotherapy 2010; 30:
842–54.
11 Ashbee HR, Barnes RA, Johnson EM et al. Therapeutic drug monitoring
(TDM) of antifungal agents: guidelines from the British Society for Medical
Mycology. J Antimicrob Chemother 2014; 69: 1162–76.
12 Boogaerts MA, Verhoef GE, Zachee P et al. Antifungal prophylaxis with
itraconazole in prolonged neutropenia: correlation with plasma levels.
Mycoses 1989; 32 Suppl 1: 103–8.
13 Tricot G, Joosten E, Boogaerts MA et al. Ketoconazole vs. itraconazole for
antifungal prophylaxis in patients with severe granulocytopenia: preliminary
results of two nonrandomized studies. Rev Infect Dis 1987; 9 Suppl 1: S94–9.
14 Glasmacher A, Hahn C, Leutner C et al. Breakthrough invasive fungal in-
fections in neutropenic patients after prophylaxis with itraconazole. Mycoses
1999; 42: 443–51.
15 Cartledge JD, Midgely J, Gazzard BG. Itraconazole solution: higher serum
drug concentrations and better clinical response rates than the capsule for-
mulation in acquired immunodeficiency syndrome patients with candidosis.
J Clin Pathol 1997; 50: 477–80.
16 Sharkey PK, Rinaldi MG, Dunn JF et al. High-dose itraconazole in the treat-
ment of severe mycoses. Antimicrob Agents Chemother 1991; 35: 707–13.
17 Denning DW, Tucker RM, Hanson LH et al. Itraconazole in opportunistic
mycoses: cryptococcosis and aspergillosis. J Am Acad Dermatol 1990; 23:
602–7.
18 Wheat J, Hafner R, Korzun AH et al. Itraconazole treatment of dissemi-
nated histoplasmosis in patients with the acquired immunodeficiency syn-
drome. AIDS Clinical Trial Group. Am J Med 1995; 98: 336–42.
19 Lestner JM, Roberts SA, Moore CB et al. Toxicodynamics of itraconazole:
implications for therapeutic drug monitoring. Clin Infect Dis 2009; 49: 928–30.
20 Hardin TC, Graybill JR, Fetchick R et al. Pharmacokinetics of itraconazole
following oral administration to normal volunteers. Antimicrob Agents
Chemother 1988; 32: 1310–3.
21 Willems L, van der Geest R, de Beule K. Itraconazole oral solution and
intravenous formulations: a review of pharmacokinetics and pharmaco-
dynamics. J Clin Pharm Ther 2001; 26: 159–69.
22 Theuretzbacher U, Ihle F, Derendorf H. Pharmacokinetic/pharmacody-
namic profile of voriconazole. Clin Pharmacokinet 2006; 45: 649–63.
23 Wingard JR, Carter SL, Walsh TJ et al. Randomized, double-blind trial of
fluconazole versus voriconazole for prevention of invasive fungal infection
after allogeneic hematopoietic cell transplantation. Blood 2010; 116:
5111–8.
24 Marks DI, Pagliuca A, Kibbler CC et al. Voriconazole versus itraconazole for
antifungal prophylaxis following allogeneic haematopoietic stem-cell trans-
plantation. Br J Haematol 2011; 155: 318–27.
25 Hope WW. Population pharmacokinetics of voriconazole in adults.
Antimicrob Agents Chemother 2012; 56: 526–31.
26 Luong M-L, Al-Dabbagh M, Groll AH et al. Utility of voriconazole thera-
peutic drug monitoring: a meta-analysis. J Antimicrob Chemother 2016; 71:
1786–99.
27 Hyland R, Jones BC, Smith DA. Identification of the cytochrome p450
enzymes involved in the N-oxidation of voriconazole. Drug Metab Dispos
2003; 31: 540–7.
28 Walsh TJ, Karlsson MO, Driscoll T et al. Pharmacokinetics and safety of
intravenous voriconazole in children after single- or multiple-dose adminis-
tration. Antimicrob Agents Chemother 2004; 48: 2166–72.
29 Friberg LE, Ravva P, Karlsson MO et al. Integrated population pharmacoki-
netic analysis of voriconazole in children, adolescents, and adults. Antimicrob
Agents Chemother 2012; 56: 3032–42.
30 Kadam RS, Van Den Anker JN. Pediatric clinical pharmacology of voricon-
azole: role of pharmacokinetic/pharmacodynamic modeling in pharmaco-
therapy. Clin Pharmacokinet 2016; 55: 1031–43.
31 Elewa H, El-Mekaty E, El-Bardissy A et al. Therapeutic drug monitoring of
voriconazole in the management of invasive fungal infections: a critical re-
view. Clin Pharmacokinet 2015; 54: 1223–35.
32 Hamada Y, Seto Y, Yago K, Kuroyama M. Investigation and threshold of
optimum blood concentration of voriconazole: a descriptive statistical meta-
analysis. J Infect Chemother 2012; 18: 501–7.
33 Jeans AR, Howard SJ, Al-Nakeeb Z et al. Combination of voriconazole and
anidulafungin for treatment of triazole-resistant Aspergillus fumigatus in an
in vitro model of invasive pulmonary aspergillosis. Antimicrob Agents
Chemother 2012; 56: 5180–5.
34 Troke PF, Hockey HP, Hope WW. Observational study of the clinical effi-
cacy of voriconazole and its relationship to plasma concentrations in patients.
Antimicrob Agents Chemother 2011; 55: 4782–8.
35 Sabatelli F, Patel R, Mann PA et al. In vitro activities of posaconazole, flu-
conazole, itraconazole, voriconazole, and amphotericin B against a large col-
lection of clinically important molds and yeasts. Antimicrob Agents
Chemother 2006; 50: 2009–15.
36 Ezzet F, Wexler D, Courtney R et al. Oral bioavailability of posaconazole in
fasted healthy subjects: comparison between three regimens and basis for
clinical dosage recommendations. Clin Pharmacokinet 2005; 44: 211–20.
37 Courtney R, Pai S, Laughlin M et al. Pharmacokinetics, safety, and toler-
ability of oral posaconazole administered in single and multiple doses in
healthy adults. Antimicrob Agents Chemother 2003; 47: 2788–95.
38 Courtney R, Wexler D, Radwanski E et al. Effect of food on the relative bio-
availability of two oral formulations of posaconazole in healthy adults. Br J
Clin Pharmacol 2004; 57: 218–22.
39 Niwa T, Imagawa Y, Yamazaki H. Drug interactions between nine antifun-
gal agents and drugs metabolized by human cytochromes P450. Curr Drug
Metab 2014; 15: 651–79.
40 Krishna G, Ma L, Martinho M et al. Single-dose phase I study to evalu-
ate the pharmacokinetics of posaconazole in new tablet and capsule







/jac/article-abstract/72/suppl_1/i12/3074192 by  katstott@
liverpool.ac.uk on 26 Septem
ber 2019
formulations relative to oral suspension. Antimicrob Agents Chemother 2012;
56: 4196–201.
41 European Medicines Agency. EMA Warns That Noxafil Tablets and Oral
Suspension Have Different Doses and Are Not Interchangeable. EMA/
425762/2016. http://www.ema.europa.eu/docs/en_GB/document_library/
Press_release/2016/06/WC500209313.pdf.
42 Cattaneo C, Panzali A, Passi A et al. Serum posaconazole levels during
acute myeloid leukaemia induction therapy: correlations with breakthrough
invasive fungal infections. Mycoses 2015; 58: 362–7.
43 Dolton MJ, Ray JE, Chen SC et al. Multicenter study of posaconazole thera-
peutic drug monitoring: exposure-response relationship and factors affecting
concentration. Antimicrob Agents Chemother 2012; 56: 5503–10.
44 Walsh TJ, Raad I, Patterson TF et al. Treatment of invasive aspergillosis
with posaconazole in patients who are refractory to or intolerant of conven-
tional therapy: an externally controlled trial. Clin Infect Dis 2007; 44: 2–12.
45 Rybak JM, Marx KR, Nishimoto AT et al. Isavuconazole: pharmacology,
pharmacodynamics, and current clinical experience with a new triazole anti-
fungal agent. Pharmacotherapy 2015; 35: 1037–51.
46 Miceli MH, Kauffman CA. Isavuconazole: a new broad-spectrum triazole
antifungal agent. Clin Infect Dis 2015; 61: 1558–65.
47 McCormack PL. Isavuconazonium: first global approval. Drugs 2015; 75:
817–22.
48 Pettit NN, Carver PL. Isavuconazole: a new option for the management of
invasive fungal infections. Ann Pharmacother 2015; 49: 825–42.
49 Maertens JA, Raad II, Marr KA et al. Isavuconazole versus voriconazole
for primary treatment of invasive mould disease caused by Aspergillus and
other filamentous fungi (SECURE): a phase 3, randomised-controlled, non-in-
feriority trial. Lancet 2016; 387: 760–9.
50 Viljoen J, Azie N, Schmitt-Hoffmann AH et al. A phase 2, randomized,
double-blind, multicenter trial to evaluate the safety and efficacy of three
dosing regimens of isavuconazole compared with fluconazole in patients
with uncomplicated esophageal candidiasis. Antimicrob Agents Chemother
2015; 59: 1671–9.
51 Marty FM, Ostrosky-Zeichner L, Cornely OA et al. Isavuconazole treat-
ment for mucormycosis: a single-arm open-label trial and case-control ana-
lysis. Lancet Infect Dis 2016; 16: 828–37.
52 Girmenia C. New generation azole antifungals in clinical investigation.
Expert Opin Investig Drugs 2009; 18: 1279–95.
53 European Medicines Agency. Cresemba Assessment Report. EMA
596950/2015. http://www.ema.europa.eu/docs/en_GB/document_library/
EPAR_-_Public_assessment_report/human/002734/WC500196130.pdf.
54 Schmitt-Hoffmann A, Roos B, Maares J et al. Multiple-dose pharmacokin-
etics and safety of the new antifungal triazole BAL4815 after intravenous in-
fusion and oral administration of its prodrug, BAL8557, in healthy volunteers.
Antimicrob Agents Chemother 2006; 50: 286–93.
55 Kaindl T, Engelhardt M, Townsend R et al. Intra-subject variability and
exposure-response relationship of isavuconazole in the phase 3 SECURE
study in patients with invasive mould disease caused by Aspergillus spp. and
other filamentous fungi. Abstract O424. Presented at European Society of
Clinical Microbiology and Infectious Diseases (ECCMID) 26th Congress, 9–12
April 2016, Amsterdam, Netherlands.
56 Polak A, Scholer HJ. Mode of action of 5-fluorocytosine and mechanisms
of resistance. Chemotherapy 1975; 21: 113–30.
57 Vermes A, Guchelaar HJ, Dankert J. Flucytosine: a review of its pharma-
cology, clinical indications, pharmacokinetics, toxicity and drug interactions.
J Antimicrob Chemother 2000; 46: 171–9.
58 Block ER, Bennett JE, Livoti LG et al. Flucytosine and amphotericin B:
hemodialysis effects on the plasma concentration and clearance. Studies in
man. Ann Intern Med 1974; 80: 613–7.
59 Cutler RE, Blair AD, Kelly MR. Flucytosine kinetics in subjects with normal
and impaired renal function. Clin Pharmacol Ther 1978; 24: 333–42.
60 Goodwin ML, Drew RH. Antifungal serum concentration monitoring: an
update. J Antimicrob Chemother 2008; 61: 17–25.
61 Block ER, Bennett JE. Pharmacological studies with 5-fluorocytosine.
Antimicrob Agents Chemother 1972; 1: 476–82.
62 Pasqualotto AC, Howard SJ, Moore CB et al. Flucytosine therapeutic moni-
toring: 15 years experience from the UK. J Antimicrob Chemother 2007; 59:
791–3.
63 Normark S, Schonebeck J. In vitro studies of 5-fluorocytosine resistance
in Candida albicans and Torulopsis glabrata. Antimicrob Agents Chemother
1972; 2: 114–21.
64 Stamm AM, Diasio RB, Dismukes WE et al. Toxicity of amphotericin B plus
flucytosine in 194 patients with cryptococcal meningitis. Am J Med 1987; 83:
236–42.
65 Soltani M, Tobin CM, Bowker KE et al. Evidence of excessive concentra-
tions of 5-flucytosine in children aged below 12 years: a 12-year review of
serum concentrations from a UK clinical assay reference laboratory. Int J
Antimicrob Agents 2006; 28: 574–7.
66 Petersen D, Demertzis S, Freund M et al. Individualization of 5-fluorocyto-
sine therapy. Chemotherapy 1994; 40: 149–56.
67 Saravolatz LD, Ostrosky-Zeichner L, Marr KA et al. Amphotericin B: time
for a new ‘gold standard’. Clin Infect Dis 2003; 37: 415–25.
68 Stone NR, Bicanic T, Salim R, Hope W. Liposomal amphotericin B
(AmBisomeVR ): a review of the pharmacokinetics, pharmacodynamics, clinical
experience and future directions. Drugs 2016; 76: 485–500.
69 Rapp RP, Gubbins PO, Evans ME. Amphotericin B lipid complex. Ann
Pharmacother 1997; 31: 1174–86.
70 Andes D, Stamsted T, Conklin R. Pharmacodynamics of amphotericin B in
a neutropenic-mouse disseminated-candidiasis model. Antimicrob Agents
Chemother 2001; 45: 922–6.
71 Andes D, Pascual A, Marchetti O. Antifungal therapeutic drug monitor-
ing: established and emerging indications. Antimicrob Agents Chemother
2009; 53: 24–34.
72 Chen SC, Slavin MA, Sorrell TC. Echinocandin antifungal drugs in fungal in-
fections: a comparison. Drugs 2011; 71: 11–41.
73 Reminiac F, Sonneville R, Massias L et al. Very-high-dose caspofungin
combined with voriconazole to treat central nervous system aspergillosis:
substantial penetration of caspofungin into cerebrospinal fluid. Antimicrob
Agents Chemother 2014; 58: 3568–9.
74 Dowell JA, Knebel W, Ludden T et al. Population pharmacokinetic analysis
of anidulafungin, an echinocandin antifungal. J Clin Pharmacol 2004; 44:
590–8.
75 Miceli MH, Grazziutti ML, Woods G et al. Strong correlation between serum
aspergillus galactomannan index and outcome of aspergillosis in patients
with hematological cancer: clinical and research implications. Clin Infect Dis
2008; 46: 1412–22.
76 Woods G, Miceli MH, Grazziutti ML et al. Serum Aspergillus galacto-
mannan antigen values strongly correlate with outcome of invasive aspergil-
losis: a study of 56 patients with hematologic cancer. Cancer 2007; 110:
830–4.
77 Maertens J, Buve K, Theunissen K et al. Galactomannan serves as a surro-
gate endpoint for outcome of pulmonary invasive aspergillosis in neutropenic
hematology patients. Cancer 2009; 115: 355–62.
78 Nouér SA, Nucci M, Kumar NS et al. Earlier response assessment in inva-
sive aspergillosis based on the kinetics of serum Aspergillus galactomannan:
proposal for a new definition. Clin Infect Dis 2011; 53: 671–6.
79 Salvatore CM, Chen TK, Toussi SS et al. (1!3)-b-D-glucan in cerebrospinal
fluid as a biomarker for Candida and Aspergillus infections of the central ner-








/jac/article-abstract/72/suppl_1/i12/3074192 by  katstott@
liverpool.ac.uk on 26 Septem
ber 2019
